TWI835048B - 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法 - Google Patents
利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法 Download PDFInfo
- Publication number
- TWI835048B TWI835048B TW111100455A TW111100455A TWI835048B TW I835048 B TWI835048 B TW I835048B TW 111100455 A TW111100455 A TW 111100455A TW 111100455 A TW111100455 A TW 111100455A TW I835048 B TWI835048 B TW I835048B
- Authority
- TW
- Taiwan
- Prior art keywords
- alkyl
- group
- optionally substituted
- heteroaryl
- alkenyl
- Prior art date
Links
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 title claims abstract description 224
- 230000027455 binding Effects 0.000 title claims abstract description 184
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 139
- 201000011510 cancer Diseases 0.000 title claims abstract description 72
- 239000005557 antagonist Substances 0.000 title abstract description 103
- 238000000034 method Methods 0.000 title abstract description 50
- 229940124647 MEK inhibitor Drugs 0.000 claims abstract description 135
- 238000011282 treatment Methods 0.000 claims abstract description 90
- 230000001965 increasing effect Effects 0.000 claims abstract description 22
- 125000000217 alkyl group Chemical group 0.000 claims description 213
- 125000001072 heteroaryl group Chemical group 0.000 claims description 160
- 229910052739 hydrogen Inorganic materials 0.000 claims description 129
- 125000003342 alkenyl group Chemical group 0.000 claims description 115
- 125000003118 aryl group Chemical group 0.000 claims description 110
- 125000000623 heterocyclic group Chemical group 0.000 claims description 95
- 125000005843 halogen group Chemical group 0.000 claims description 94
- 239000001257 hydrogen Substances 0.000 claims description 91
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 87
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 82
- 150000001875 compounds Chemical class 0.000 claims description 77
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 71
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims description 70
- -1 -NHS(O) 2 R 8 Chemical group 0.000 claims description 69
- 125000000304 alkynyl group Chemical group 0.000 claims description 68
- 229910052799 carbon Inorganic materials 0.000 claims description 68
- 210000004027 cell Anatomy 0.000 claims description 68
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 67
- 150000002431 hydrogen Chemical class 0.000 claims description 66
- 239000000427 antigen Substances 0.000 claims description 63
- 108091007433 antigens Proteins 0.000 claims description 63
- 102000036639 antigens Human genes 0.000 claims description 63
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 62
- 150000003839 salts Chemical class 0.000 claims description 59
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 47
- 125000003107 substituted aryl group Chemical group 0.000 claims description 44
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims description 43
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 43
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims description 42
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims description 41
- 125000001188 haloalkyl group Chemical group 0.000 claims description 41
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 37
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 36
- 239000012453 solvate Substances 0.000 claims description 35
- 230000004044 response Effects 0.000 claims description 34
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 33
- 239000012634 fragment Substances 0.000 claims description 33
- 229910052757 nitrogen Inorganic materials 0.000 claims description 33
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 32
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 30
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 28
- 238000006467 substitution reaction Methods 0.000 claims description 28
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 27
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims description 26
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims description 26
- 239000003814 drug Substances 0.000 claims description 26
- 125000003545 alkoxy group Chemical group 0.000 claims description 22
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 22
- 229910052717 sulfur Inorganic materials 0.000 claims description 22
- 230000000694 effects Effects 0.000 claims description 21
- 125000005842 heteroatom Chemical group 0.000 claims description 21
- 230000036737 immune function Effects 0.000 claims description 21
- 229920006395 saturated elastomer Polymers 0.000 claims description 20
- 230000035772 mutation Effects 0.000 claims description 19
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 18
- 229910052760 oxygen Inorganic materials 0.000 claims description 18
- 230000004913 activation Effects 0.000 claims description 17
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 16
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 16
- 201000001441 melanoma Diseases 0.000 claims description 16
- 125000005415 substituted alkoxy group Chemical group 0.000 claims description 16
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 claims description 15
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 claims description 15
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims description 15
- 210000004443 dendritic cell Anatomy 0.000 claims description 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 14
- 229960003301 nivolumab Drugs 0.000 claims description 14
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims description 14
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 13
- 230000002708 enhancing effect Effects 0.000 claims description 13
- 125000004432 carbon atom Chemical group C* 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 12
- 229910052731 fluorine Inorganic materials 0.000 claims description 12
- 229910052736 halogen Inorganic materials 0.000 claims description 12
- 125000001424 substituent group Chemical group 0.000 claims description 12
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 12
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 11
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 11
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 11
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 11
- 230000003213 activating effect Effects 0.000 claims description 11
- 125000003282 alkyl amino group Chemical group 0.000 claims description 11
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 11
- 125000002837 carbocyclic group Chemical group 0.000 claims description 11
- 150000002367 halogens Chemical class 0.000 claims description 11
- 239000003112 inhibitor Substances 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 11
- 230000019491 signal transduction Effects 0.000 claims description 11
- 230000002459 sustained effect Effects 0.000 claims description 11
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 10
- 125000004104 aryloxy group Chemical group 0.000 claims description 9
- 125000004429 atom Chemical group 0.000 claims description 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 9
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 8
- 150000001412 amines Chemical class 0.000 claims description 8
- 230000006044 T cell activation Effects 0.000 claims description 7
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 7
- 239000000460 chlorine Chemical group 0.000 claims description 7
- 229910052801 chlorine Inorganic materials 0.000 claims description 7
- 150000002148 esters Chemical class 0.000 claims description 7
- 230000035800 maturation Effects 0.000 claims description 7
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 7
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 7
- 230000035755 proliferation Effects 0.000 claims description 7
- 210000002966 serum Anatomy 0.000 claims description 7
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 6
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 claims description 6
- 206010069755 K-ras gene mutation Diseases 0.000 claims description 6
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 6
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 claims description 6
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 6
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 5
- 102000003814 Interleukin-10 Human genes 0.000 claims description 5
- 108090000174 Interleukin-10 Proteins 0.000 claims description 5
- 108090001007 Interleukin-8 Proteins 0.000 claims description 5
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 5
- 239000011737 fluorine Chemical group 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 4
- 125000005092 alkenyloxycarbonyl group Chemical group 0.000 claims description 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 4
- 125000003277 amino group Chemical group 0.000 claims description 4
- 125000002393 azetidinyl group Chemical group 0.000 claims description 4
- 125000004122 cyclic group Chemical class 0.000 claims description 4
- 230000001461 cytolytic effect Effects 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 102200055464 rs113488022 Human genes 0.000 claims description 4
- 102100035793 CD83 antigen Human genes 0.000 claims description 3
- 102100030708 GTPase KRas Human genes 0.000 claims description 3
- 206010066476 Haematological malignancy Diseases 0.000 claims description 3
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims description 3
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 claims description 3
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 3
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims description 3
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 3
- 229910052794 bromium Inorganic materials 0.000 claims description 3
- 230000002860 competitive effect Effects 0.000 claims description 3
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 3
- 230000008595 infiltration Effects 0.000 claims description 3
- 238000001764 infiltration Methods 0.000 claims description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 claims description 2
- 102100036242 HLA class II histocompatibility antigen, DQ alpha 2 chain Human genes 0.000 claims description 2
- 101000930801 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 2 chain Proteins 0.000 claims description 2
- 102000043129 MHC class I family Human genes 0.000 claims description 2
- 108091054437 MHC class I family Proteins 0.000 claims description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
- 125000005090 alkenylcarbonyl group Chemical group 0.000 claims description 2
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims description 2
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims description 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 2
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 claims description 2
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 claims description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 2
- 150000001721 carbon Chemical group 0.000 claims description 2
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 claims description 2
- 238000002513 implantation Methods 0.000 claims description 2
- 230000037452 priming Effects 0.000 claims description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 25
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 14
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 13
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 13
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims 9
- BPXYEYJNCXITEY-UHFFFAOYSA-N diazonio(trifluoromethoxy)azanide Chemical compound FC(F)(F)ON=[N+]=[N-] BPXYEYJNCXITEY-UHFFFAOYSA-N 0.000 claims 6
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 6
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 5
- 125000005865 C2-C10alkynyl group Chemical group 0.000 claims 5
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims 4
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims 4
- 125000004434 sulfur atom Chemical group 0.000 claims 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 2
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 1
- 206010057248 Cell death Diseases 0.000 claims 1
- 125000004946 alkenylalkyl group Chemical group 0.000 claims 1
- 125000002355 alkine group Chemical group 0.000 claims 1
- 230000009089 cytolysis Effects 0.000 claims 1
- 125000005265 dialkylamine group Chemical group 0.000 claims 1
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 claims 1
- 230000006662 intracellular pathway Effects 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 230000000007 visual effect Effects 0.000 claims 1
- 230000005847 immunogenicity Effects 0.000 abstract description 6
- 230000005851 tumor immunogenicity Effects 0.000 abstract description 6
- 238000011284 combination treatment Methods 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 139
- 102000004196 processed proteins & peptides Human genes 0.000 description 136
- 229920001184 polypeptide Polymers 0.000 description 134
- 229960002271 cobimetinib Drugs 0.000 description 49
- BSMCAPRUBJMWDF-KRWDZBQOSA-N cobimetinib Chemical compound C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F BSMCAPRUBJMWDF-KRWDZBQOSA-N 0.000 description 49
- 230000004614 tumor growth Effects 0.000 description 29
- 241001529936 Murinae Species 0.000 description 26
- 239000012636 effector Substances 0.000 description 25
- 108060003951 Immunoglobulin Proteins 0.000 description 24
- 239000003795 chemical substances by application Substances 0.000 description 24
- 102000018358 immunoglobulin Human genes 0.000 description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 23
- 230000006870 function Effects 0.000 description 23
- 230000011664 signaling Effects 0.000 description 22
- 241000699670 Mus sp. Species 0.000 description 20
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 18
- 239000003981 vehicle Substances 0.000 description 18
- 201000010099 disease Diseases 0.000 description 17
- 230000002829 reductive effect Effects 0.000 description 17
- 108010038807 Oligopeptides Proteins 0.000 description 16
- 102000015636 Oligopeptides Human genes 0.000 description 16
- 230000000139 costimulatory effect Effects 0.000 description 16
- LVHMCPRJISQGAK-UHFFFAOYSA-N 3-(2-fluoro-4-iodoanilino)-n-(2-hydroxyethoxy)furo[3,2-c]pyridine-2-carboxamide Chemical compound OCCONC(=O)C=1OC2=CC=NC=C2C=1NC1=CC=C(I)C=C1F LVHMCPRJISQGAK-UHFFFAOYSA-N 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 230000003993 interaction Effects 0.000 description 15
- 210000004881 tumor cell Anatomy 0.000 description 15
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 13
- 238000002560 therapeutic procedure Methods 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 102000015696 Interleukins Human genes 0.000 description 12
- 108010063738 Interleukins Proteins 0.000 description 12
- 230000036961 partial effect Effects 0.000 description 12
- 239000002253 acid Substances 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 11
- 230000000259 anti-tumor effect Effects 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 102000005962 receptors Human genes 0.000 description 11
- 108020003175 receptors Proteins 0.000 description 11
- 108010087819 Fc receptors Proteins 0.000 description 10
- 102000009109 Fc receptors Human genes 0.000 description 10
- 238000005259 measurement Methods 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 230000009467 reduction Effects 0.000 description 10
- 229940024606 amino acid Drugs 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 9
- 239000002585 base Substances 0.000 description 9
- 238000002648 combination therapy Methods 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 230000001404 mediated effect Effects 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 8
- 108020001507 fusion proteins Proteins 0.000 description 8
- 102000037865 fusion proteins Human genes 0.000 description 8
- 229940047122 interleukins Drugs 0.000 description 8
- 239000003446 ligand Substances 0.000 description 8
- 230000037361 pathway Effects 0.000 description 8
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 7
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 7
- 108091008874 T cell receptors Proteins 0.000 description 7
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 7
- 230000004071 biological effect Effects 0.000 description 7
- 230000004927 fusion Effects 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 150000007523 nucleic acids Chemical class 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 6
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
- 239000002246 antineoplastic agent Substances 0.000 description 6
- 230000000903 blocking effect Effects 0.000 description 6
- 230000004940 costimulation Effects 0.000 description 6
- 229940127089 cytotoxic agent Drugs 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 238000011725 BALB/c mouse Methods 0.000 description 5
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 5
- 206010061818 Disease progression Diseases 0.000 description 5
- OVBPIULPVIDEAO-LBPRGKRZSA-N Folic acid Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 5
- 239000012981 Hank's balanced salt solution Substances 0.000 description 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 5
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 5
- 238000011374 additional therapy Methods 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 125000002619 bicyclic group Chemical group 0.000 description 5
- 230000003915 cell function Effects 0.000 description 5
- 238000007405 data analysis Methods 0.000 description 5
- 230000005750 disease progression Effects 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 229910052740 iodine Inorganic materials 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 108010082117 matrigel Proteins 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 238000001308 synthesis method Methods 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 208000031648 Body Weight Changes Diseases 0.000 description 4
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 4
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 4
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 4
- 102000004890 Interleukin-8 Human genes 0.000 description 4
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- 102000038030 PI3Ks Human genes 0.000 description 4
- 108091007960 PI3Ks Proteins 0.000 description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical group C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000004579 body weight change Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000011278 co-treatment Methods 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 150000001924 cycloalkanes Chemical class 0.000 description 4
- 230000001086 cytosolic effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000004064 dysfunction Effects 0.000 description 4
- 210000004408 hybridoma Anatomy 0.000 description 4
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 4
- 125000001041 indolyl group Chemical group 0.000 description 4
- 108091008042 inhibitory receptors Proteins 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- 229910052698 phosphorus Inorganic materials 0.000 description 4
- 210000001236 prokaryotic cell Anatomy 0.000 description 4
- 125000006413 ring segment Chemical group 0.000 description 4
- 238000009097 single-agent therapy Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 239000013589 supplement Substances 0.000 description 4
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- 229910052720 vanadium Inorganic materials 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 229910052727 yttrium Inorganic materials 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 102000019034 Chemokines Human genes 0.000 description 3
- 108010012236 Chemokines Proteins 0.000 description 3
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 3
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 3
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 3
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 108010073807 IgG Receptors Proteins 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
- 102000018697 Membrane Proteins Human genes 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 3
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 3
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 3
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 229930012538 Paclitaxel Natural products 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 description 3
- DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 230000007503 antigenic stimulation Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 230000007969 cellular immunity Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 229960004679 doxorubicin Drugs 0.000 description 3
- 239000003797 essential amino acid Substances 0.000 description 3
- 235000020776 essential amino acid Nutrition 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 229960002949 fluorouracil Drugs 0.000 description 3
- 229960000304 folic acid Drugs 0.000 description 3
- 235000019152 folic acid Nutrition 0.000 description 3
- 239000011724 folic acid Substances 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 3
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 3
- 125000005647 linker group Chemical group 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 3
- 229960000485 methotrexate Drugs 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 3
- 229960001756 oxaliplatin Drugs 0.000 description 3
- 229960001592 paclitaxel Drugs 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 229940127557 pharmaceutical product Drugs 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- HXCHCVDVKSCDHU-PJKCJEBCSA-N s-[(2r,3s,4s,6s)-6-[[(2r,3s,4s,5r,6r)-5-[(2s,4s,5s)-5-(ethylamino)-4-methoxyoxan-2-yl]oxy-4-hydroxy-6-[[(2s,5z,9r,13e)-9-hydroxy-12-(methoxycarbonylamino)-13-[2-(methyltrisulfanyl)ethylidene]-11-oxo-2-bicyclo[7.3.1]trideca-1(12),5-dien-3,7-diynyl]oxy]-2-m Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-PJKCJEBCSA-N 0.000 description 3
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229940054269 sodium pyruvate Drugs 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 210000000115 thoracic cavity Anatomy 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 3
- 229960004528 vincristine Drugs 0.000 description 3
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 3
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 3
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 2
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 2
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical class C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 125000004398 2-methyl-2-butyl group Chemical group CC(C)(CC)* 0.000 description 2
- 125000004918 2-methyl-2-pentyl group Chemical group CC(C)(CCC)* 0.000 description 2
- 125000004922 2-methyl-3-pentyl group Chemical group CC(C)C(CC)* 0.000 description 2
- 125000004917 3-methyl-2-butyl group Chemical group CC(C(C)*)C 0.000 description 2
- 125000004919 3-methyl-2-pentyl group Chemical group CC(C(C)*)CC 0.000 description 2
- 125000004921 3-methyl-3-pentyl group Chemical group CC(CC)(CC)* 0.000 description 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 125000004920 4-methyl-2-pentyl group Chemical group CC(CC(C)*)C 0.000 description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 2
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 2
- 241000219198 Brassica Species 0.000 description 2
- 235000003351 Brassica cretica Nutrition 0.000 description 2
- 235000003343 Brassica rupestris Nutrition 0.000 description 2
- 108010037003 Buserelin Proteins 0.000 description 2
- PYMDEDHDQYLBRT-DRIHCAFSSA-N Buserelin acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 PYMDEDHDQYLBRT-DRIHCAFSSA-N 0.000 description 2
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 2
- 108010092160 Dactinomycin Proteins 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 2
- 108060006698 EGF receptor Proteins 0.000 description 2
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 2
- 108010021468 Fc gamma receptor IIA Proteins 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- 108700012941 GNRH1 Proteins 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000840258 Homo sapiens Immunoglobulin J chain Proteins 0.000 description 2
- 101001117312 Homo sapiens Programmed cell death 1 ligand 2 Proteins 0.000 description 2
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 2
- 102000009490 IgG Receptors Human genes 0.000 description 2
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 2
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 2
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 2
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 2
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 2
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 2
- 102100029571 Immunoglobulin J chain Human genes 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 2
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 2
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 2
- 108010000817 Leuprolide Proteins 0.000 description 2
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 230000005723 MEK inhibition Effects 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical class C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 2
- 208000037581 Persistent Infection Diseases 0.000 description 2
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical group C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000020385 T cell costimulation Effects 0.000 description 2
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 2
- 108010050144 Triptorelin Pamoate Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 2
- 229960003437 aminoglutethimide Drugs 0.000 description 2
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical class C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940046836 anti-estrogen Drugs 0.000 description 2
- 230000001833 anti-estrogenic effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- QZPQTZZNNJUOLS-UHFFFAOYSA-N beta-lapachone Chemical compound C12=CC=CC=C2C(=O)C(=O)C2=C1OC(C)(C)CC2 QZPQTZZNNJUOLS-UHFFFAOYSA-N 0.000 description 2
- 229960000997 bicalutamide Drugs 0.000 description 2
- GPRLTFBKWDERLU-UHFFFAOYSA-N bicyclo[2.2.2]octane Chemical compound C1CC2CCC1CC2 GPRLTFBKWDERLU-UHFFFAOYSA-N 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229960005064 buserelin acetate Drugs 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229930195731 calicheamicin Natural products 0.000 description 2
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 229940001468 citrate Drugs 0.000 description 2
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 2
- 229960000684 cytarabine Drugs 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 2
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 2
- OQALFHMKVSJFRR-UHFFFAOYSA-N dityrosine Chemical compound OC(=O)C(N)CC1=CC=C(O)C(C=2C(=CC=C(CC(N)C(O)=O)C=2)O)=C1 OQALFHMKVSJFRR-UHFFFAOYSA-N 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- VLCYCQAOQCDTCN-UHFFFAOYSA-N eflornithine Chemical compound NCCCC(N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-UHFFFAOYSA-N 0.000 description 2
- 229960001904 epirubicin Drugs 0.000 description 2
- ITSGNOIFAJAQHJ-BMFNZSJVSA-N esorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)C[C@H](C)O1 ITSGNOIFAJAQHJ-BMFNZSJVSA-N 0.000 description 2
- 229950002017 esorubicin Drugs 0.000 description 2
- 239000000328 estrogen antagonist Substances 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229960002258 fulvestrant Drugs 0.000 description 2
- CHPZKNULDCNCBW-UHFFFAOYSA-N gallium nitrate Chemical compound [Ga+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O CHPZKNULDCNCBW-UHFFFAOYSA-N 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 108010037896 heparin-binding hemagglutinin Proteins 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 102000048776 human CD274 Human genes 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 229960001101 ifosfamide Drugs 0.000 description 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 2
- 229960002411 imatinib Drugs 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 230000006058 immune tolerance Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 125000003454 indenyl group Chemical class C1(C=CC2=CC=CC=C12)* 0.000 description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 2
- 238000006317 isomerization reaction Methods 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 229960004891 lapatinib Drugs 0.000 description 2
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 2
- 229960004338 leuprorelin Drugs 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 229960004961 mechlorethamine Drugs 0.000 description 2
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 2
- 229960001428 mercaptopurine Drugs 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 229960001156 mitoxantrone Drugs 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 235000010460 mustard Nutrition 0.000 description 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 2
- QZGIWPZCWHMVQL-UIYAJPBUSA-N neocarzinostatin chromophore Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1O[C@@H]1C/2=C/C#C[C@H]3O[C@@]3([C@@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(O)C=CC2=C(C)C=C(OC)C=C12 QZGIWPZCWHMVQL-UIYAJPBUSA-N 0.000 description 2
- 108010068617 neonatal Fc receptor Proteins 0.000 description 2
- 229960002653 nilutamide Drugs 0.000 description 2
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 229940116315 oxalic acid Drugs 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229960002340 pentostatin Drugs 0.000 description 2
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 229960004622 raloxifene Drugs 0.000 description 2
- 102000016914 ras Proteins Human genes 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 2
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 2
- CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- PVYJZLYGTZKPJE-UHFFFAOYSA-N streptonigrin Chemical compound C=1C=C2C(=O)C(OC)=C(N)C(=O)C2=NC=1C(C=1N)=NC(C(O)=O)=C(C)C=1C1=CC=C(OC)C(OC)=C1O PVYJZLYGTZKPJE-UHFFFAOYSA-N 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 239000011593 sulfur Chemical group 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 229960001603 tamoxifen Drugs 0.000 description 2
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical class C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 229960001196 thiotepa Drugs 0.000 description 2
- 229940019375 tiludronate Drugs 0.000 description 2
- 229960003087 tioguanine Drugs 0.000 description 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 2
- 229960004824 triptorelin Drugs 0.000 description 2
- 229910052721 tungsten Inorganic materials 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- JXLYSJRDGCGARV-CFWMRBGOSA-N vinblastine Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-CFWMRBGOSA-N 0.000 description 2
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 2
- 229960004355 vindesine Drugs 0.000 description 2
- 229960004276 zoledronic acid Drugs 0.000 description 2
- NNJPGOLRFBJNIW-HNNXBMFYSA-N (-)-demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- WDQLRUYAYXDIFW-RWKIJVEZSA-N (2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-4-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1 WDQLRUYAYXDIFW-RWKIJVEZSA-N 0.000 description 1
- YXTKHLHCVFUPPT-YYFJYKOTSA-N (2s)-2-[[4-[(2-amino-5-formyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid;(1r,2r)-1,2-dimethanidylcyclohexane;5-fluoro-1h-pyrimidine-2,4-dione;oxalic acid;platinum(2+) Chemical compound [Pt+2].OC(=O)C(O)=O.[CH2-][C@@H]1CCCC[C@H]1[CH2-].FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 YXTKHLHCVFUPPT-YYFJYKOTSA-N 0.000 description 1
- VESKBLGTHHPZJF-QNWVGRARSA-N (2s)-2-amino-5-[[(2r)-2-amino-3-[2-[bis[bis(2-chloroethyl)amino]phosphoryloxy]ethylsulfonyl]propanoyl]-[(r)-carboxy(phenyl)methyl]amino]-5-oxopentanoic acid Chemical compound ClCCN(CCCl)P(=O)(N(CCCl)CCCl)OCCS(=O)(=O)C[C@H](N)C(=O)N(C(=O)CC[C@H](N)C(O)=O)[C@@H](C(O)=O)C1=CC=CC=C1 VESKBLGTHHPZJF-QNWVGRARSA-N 0.000 description 1
- CGMTUJFWROPELF-YPAAEMCBSA-N (3E,5S)-5-[(2S)-butan-2-yl]-3-(1-hydroxyethylidene)pyrrolidine-2,4-dione Chemical compound CC[C@H](C)[C@@H]1NC(=O)\C(=C(/C)O)C1=O CGMTUJFWROPELF-YPAAEMCBSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- MWFQFKZIHPJXGE-IZZNHLLZSA-N (5r)-3-[(1s)-1-(6-cyclopropyl-1h-benzimidazol-2-yl)-2-phenylethyl]-5-[4-(2-hydroxyethoxy)phenyl]imidazolidine-2,4-dione Chemical compound C1=CC(OCCO)=CC=C1[C@@H]1C(=O)N([C@@H](CC=2C=CC=CC=2)C=2NC3=CC=C(C=C3N=2)C2CC2)C(=O)N1 MWFQFKZIHPJXGE-IZZNHLLZSA-N 0.000 description 1
- JTPVYFFBXWIZNV-XZOQPEGZSA-N (5r)-3-[(1s)-2-(4-fluorophenyl)-1-(6-iodo-1h-benzimidazol-2-yl)ethyl]-5-[4-(2-hydroxyethoxy)phenyl]imidazolidine-2,4-dione Chemical compound C1=CC(OCCO)=CC=C1[C@@H]1C(=O)N([C@@H](CC=2C=CC(F)=CC=2)C=2NC3=CC=C(I)C=C3N=2)C(=O)N1 JTPVYFFBXWIZNV-XZOQPEGZSA-N 0.000 description 1
- HPANRIOFRGTCGN-IMDCKVJKSA-N (5r)-3-[(1s,2s)-1-(6-ethynyl-1h-benzimidazol-2-yl)-2-phenylpropyl]-5-[4-(2-hydroxyethoxy)phenyl]imidazolidine-2,4-dione Chemical compound C1([C@H]2NC(=O)N(C2=O)[C@@H]([C@@H](C)C=2C=CC=CC=2)C=2NC3=CC=C(C=C3N=2)C#C)=CC=C(OCCO)C=C1 HPANRIOFRGTCGN-IMDCKVJKSA-N 0.000 description 1
- RZMQKHIWAWLIMU-DPMMWBKBSA-N (5r)-5-[4-(2-hydroxyethoxy)phenyl]-3-[(1r,2r)-1-(6-iodo-1h-benzimidazol-2-yl)-2-methoxypropyl]imidazolidine-2,4-dione Chemical compound C1([C@H]2NC(=O)N(C2=O)[C@@H]([C@@H](C)OC)C=2NC3=CC=C(I)C=C3N=2)=CC=C(OCCO)C=C1 RZMQKHIWAWLIMU-DPMMWBKBSA-N 0.000 description 1
- JNFBYDYNRXYRAI-BJKOFHAPSA-N (5r)-5-[4-(2-hydroxyethoxy)phenyl]-3-[(1s)-1-(6-iodo-1h-benzimidazol-2-yl)-2-(4-methoxyphenyl)ethyl]imidazolidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1C[C@@H](C=1NC2=CC=C(I)C=C2N=1)N1C(=O)[C@@H](C=2C=CC(OCCO)=CC=2)NC1=O JNFBYDYNRXYRAI-BJKOFHAPSA-N 0.000 description 1
- WLHWSBSAMRHILK-MOPGFXCFSA-N (5r)-5-[4-(2-hydroxyethoxy)phenyl]-3-[(1s)-1-(6-iodo-1h-benzimidazol-2-yl)-2-methylpropyl]imidazolidine-2,4-dione Chemical compound C1([C@H]2NC(=O)N(C2=O)[C@@H](C(C)C)C=2NC3=CC=C(I)C=C3N=2)=CC=C(OCCO)C=C1 WLHWSBSAMRHILK-MOPGFXCFSA-N 0.000 description 1
- JISLFBCBBAFGNU-XZOQPEGZSA-N (5r)-5-[4-(2-hydroxyethoxy)phenyl]-3-[(1s)-1-(6-iodo-1h-benzimidazol-2-yl)-2-phenylethyl]imidazolidine-2,4-dione Chemical compound C1=CC(OCCO)=CC=C1[C@@H]1C(=O)N([C@@H](CC=2C=CC=CC=2)C=2NC3=CC=C(I)C=C3N=2)C(=O)N1 JISLFBCBBAFGNU-XZOQPEGZSA-N 0.000 description 1
- DTZHXOMYCIHJFP-LEWJYISDSA-N (5r)-5-[4-(2-hydroxyethoxy)phenyl]-3-[(1s)-1-(6-iodo-1h-benzimidazol-2-yl)-2-thiophen-2-ylethyl]imidazolidine-2,4-dione Chemical compound C1=CC(OCCO)=CC=C1[C@@H]1C(=O)N([C@@H](CC=2SC=CC=2)C=2NC3=CC=C(I)C=C3N=2)C(=O)N1 DTZHXOMYCIHJFP-LEWJYISDSA-N 0.000 description 1
- JMHJIPPJIFRYLW-GHEQTVGYSA-N (5r)-5-[4-(2-hydroxyethoxy)phenyl]-3-[(1s,2s)-1-(6-iodo-1h-benzimidazol-2-yl)-2-phenylpropyl]imidazolidine-2,4-dione Chemical compound C1([C@H]2NC(=O)N(C2=O)[C@@H]([C@@H](C)C=2C=CC=CC=2)C=2NC3=CC(I)=CC=C3N=2)=CC=C(OCCO)C=C1 JMHJIPPJIFRYLW-GHEQTVGYSA-N 0.000 description 1
- AESVUZLWRXEGEX-DKCAWCKPSA-N (7S,9R)-7-[(2S,4R,5R,6R)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione iron(3+) Chemical compound [Fe+3].COc1cccc2C(=O)c3c(O)c4C[C@@](O)(C[C@H](O[C@@H]5C[C@@H](N)[C@@H](O)[C@@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO AESVUZLWRXEGEX-DKCAWCKPSA-N 0.000 description 1
- JXVAMODRWBNUSF-KZQKBALLSA-N (7s,9r,10r)-7-[(2r,4s,5s,6s)-5-[[(2s,4as,5as,7s,9s,9ar,10ar)-2,9-dimethyl-3-oxo-4,4a,5a,6,7,9,9a,10a-octahydrodipyrano[4,2-a:4',3'-e][1,4]dioxin-7-yl]oxy]-4-(dimethylamino)-6-methyloxan-2-yl]oxy-10-[(2s,4s,5s,6s)-4-(dimethylamino)-5-hydroxy-6-methyloxan-2 Chemical compound O([C@@H]1C2=C(O)C=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C2[C@@H](O[C@@H]2O[C@@H](C)[C@@H](O[C@@H]3O[C@@H](C)[C@H]4O[C@@H]5O[C@@H](C)C(=O)C[C@@H]5O[C@H]4C3)[C@H](C2)N(C)C)C[C@]1(O)CC)[C@H]1C[C@H](N(C)C)[C@H](O)[C@H](C)O1 JXVAMODRWBNUSF-KZQKBALLSA-N 0.000 description 1
- INAUWOVKEZHHDM-PEDBPRJASA-N (7s,9s)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7-[(2r,4s,5s,6s)-5-hydroxy-6-methyl-4-morpholin-4-yloxan-2-yl]oxy-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.N1([C@H]2C[C@@H](O[C@@H](C)[C@H]2O)O[C@H]2C[C@@](O)(CC=3C(O)=C4C(=O)C=5C=CC=C(C=5C(=O)C4=C(O)C=32)OC)C(=O)CO)CCOCC1 INAUWOVKEZHHDM-PEDBPRJASA-N 0.000 description 1
- RCFNNLSZHVHCEK-IMHLAKCZSA-N (7s,9s)-7-(4-amino-6-methyloxan-2-yl)oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound [Cl-].O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)C1CC([NH3+])CC(C)O1 RCFNNLSZHVHCEK-IMHLAKCZSA-N 0.000 description 1
- NOPNWHSMQOXAEI-PUCKCBAPSA-N (7s,9s)-7-[(2r,4s,5s,6s)-4-(2,3-dihydropyrrol-1-yl)-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione Chemical compound N1([C@H]2C[C@@H](O[C@@H](C)[C@H]2O)O[C@H]2C[C@@](O)(CC=3C(O)=C4C(=O)C=5C=CC=C(C=5C(=O)C4=C(O)C=32)OC)C(=O)CO)CCC=C1 NOPNWHSMQOXAEI-PUCKCBAPSA-N 0.000 description 1
- IEXUMDBQLIVNHZ-YOUGDJEHSA-N (8s,11r,13r,14s,17s)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(O)CCCO)[C@@]2(C)C1 IEXUMDBQLIVNHZ-YOUGDJEHSA-N 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- RKUNBYITZUJHSG-FXUDXRNXSA-N (S)-atropine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@H]3CC[C@@H](C2)N3C)=CC=CC=C1 RKUNBYITZUJHSG-FXUDXRNXSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- KEIFWROAQVVDBN-UHFFFAOYSA-N 1,2-dihydronaphthalene Chemical class C1=CC=C2C=CCCC2=C1 KEIFWROAQVVDBN-UHFFFAOYSA-N 0.000 description 1
- FONKWHRXTPJODV-DNQXCXABSA-N 1,3-bis[2-[(8s)-8-(chloromethyl)-4-hydroxy-1-methyl-7,8-dihydro-3h-pyrrolo[3,2-e]indole-6-carbonyl]-1h-indol-5-yl]urea Chemical compound C1([C@H](CCl)CN2C(=O)C=3NC4=CC=C(C=C4C=3)NC(=O)NC=3C=C4C=C(NC4=CC=3)C(=O)N3C4=CC(O)=C5NC=C(C5=C4[C@H](CCl)C3)C)=C2C=C(O)C2=C1C(C)=CN2 FONKWHRXTPJODV-DNQXCXABSA-N 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
- MYBLAOJMRYYKMS-RTRLPJTCSA-N 1-(2-chloroethyl)-1-nitroso-3-[(3r,4r,5s,6r)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea Chemical compound OC[C@H]1OC(O)[C@H](NC(=O)N(CCCl)N=O)[C@@H](O)[C@@H]1O MYBLAOJMRYYKMS-RTRLPJTCSA-N 0.000 description 1
- LEIHLFODGVRBMK-UHFFFAOYSA-N 1-[6-(4-bromo-2-chloroanilino)-7-fluoro-3-methylbenzimidazol-5-yl]-2-hydroxyethanone Chemical compound OCC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl LEIHLFODGVRBMK-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical group C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- BTOTXLJHDSNXMW-POYBYMJQSA-N 2,3-dideoxyuridine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(=O)NC(=O)C=C1 BTOTXLJHDSNXMW-POYBYMJQSA-N 0.000 description 1
- KEQTWHPMSVAFDA-UHFFFAOYSA-N 2,3-dihydro-1h-pyrazole Chemical compound C1NNC=C1 KEQTWHPMSVAFDA-UHFFFAOYSA-N 0.000 description 1
- BOMZMNZEXMAQQW-UHFFFAOYSA-N 2,5,11-trimethyl-6h-pyrido[4,3-b]carbazol-2-ium-9-ol;acetate Chemical compound CC([O-])=O.C[N+]1=CC=C2C(C)=C(NC=3C4=CC(O)=CC=3)C4=C(C)C2=C1 BOMZMNZEXMAQQW-UHFFFAOYSA-N 0.000 description 1
- FFMBYMANYCDCMK-UHFFFAOYSA-N 2,5-dihydro-1h-imidazole Chemical compound C1NCN=C1 FFMBYMANYCDCMK-UHFFFAOYSA-N 0.000 description 1
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical class OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 1
- QCXJFISCRQIYID-IAEPZHFASA-N 2-amino-1-n-[(3s,6s,7r,10s,16s)-3-[(2s)-butan-2-yl]-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-10-propan-2-yl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-4,6-dimethyl-3-oxo-9-n-[(3s,6s,7r,10s,16s)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propa Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N=C2C(C(=O)N[C@@H]3C(=O)N[C@H](C(N4CCC[C@H]4C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]3C)=O)[C@@H](C)CC)=C(N)C(=O)C(C)=C2O2)C2=C(C)C=C1 QCXJFISCRQIYID-IAEPZHFASA-N 0.000 description 1
- FDAYLTPAFBGXAB-UHFFFAOYSA-N 2-chloro-n,n-bis(2-chloroethyl)ethanamine Chemical compound ClCCN(CCCl)CCCl FDAYLTPAFBGXAB-UHFFFAOYSA-N 0.000 description 1
- VNBAOSVONFJBKP-UHFFFAOYSA-N 2-chloro-n,n-bis(2-chloroethyl)propan-1-amine;hydrochloride Chemical compound Cl.CC(Cl)CN(CCCl)CCCl VNBAOSVONFJBKP-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- CTRPRMNBTVRDFH-UHFFFAOYSA-N 2-n-methyl-1,3,5-triazine-2,4,6-triamine Chemical class CNC1=NC(N)=NC(N)=N1 CTRPRMNBTVRDFH-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- PWMYMKOUNYTVQN-UHFFFAOYSA-N 3-(8,8-diethyl-2-aza-8-germaspiro[4.5]decan-2-yl)-n,n-dimethylpropan-1-amine Chemical compound C1C[Ge](CC)(CC)CCC11CN(CCCN(C)C)CC1 PWMYMKOUNYTVQN-UHFFFAOYSA-N 0.000 description 1
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 description 1
- MJGPONXTQSTIRD-HNNXBMFYSA-N 3-[(1s)-1-(6-iodo-1h-benzimidazol-2-yl)-2-phenylethyl]imidazolidine-2,4-dione Chemical compound C([C@@H](C=1NC2=CC=C(C=C2N=1)I)N1C(NCC1=O)=O)C1=CC=CC=C1 MJGPONXTQSTIRD-HNNXBMFYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- JVQIKJMSUIMUDI-UHFFFAOYSA-N 3-pyrroline Chemical compound C1NCC=C1 JVQIKJMSUIMUDI-UHFFFAOYSA-N 0.000 description 1
- 125000004364 3-pyrrolinyl group Chemical group [H]C1=C([H])C([H])([H])N(*)C1([H])[H] 0.000 description 1
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 description 1
- MCGBIXXDQFWVDW-UHFFFAOYSA-N 4,5-dihydro-1h-pyrazole Chemical compound C1CC=NN1 MCGBIXXDQFWVDW-UHFFFAOYSA-N 0.000 description 1
- CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 description 1
- DODQJNMQWMSYGS-QPLCGJKRSA-N 4-[(z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-phenylbut-1-en-2-yl]phenol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 DODQJNMQWMSYGS-QPLCGJKRSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- 125000001826 4H-pyranyl group Chemical group O1C(=CCC=C1)* 0.000 description 1
- AGARBPGXQVNMHR-UHFFFAOYSA-N 5-(2-fluoro-4-iodoanilino)-n-(2-hydroxyethoxy)imidazo[1,5-a]pyrazine-6-carboxamide Chemical compound OCCONC(=O)C=1N=CC2=CN=CN2C=1NC1=CC=C(I)C=C1F AGARBPGXQVNMHR-UHFFFAOYSA-N 0.000 description 1
- AWWCYHAGTSTCON-VIFPVBQESA-N 5-(2-fluoro-4-iodoanilino)-n-[(2s)-2-hydroxypropoxy]imidazo[1,5-a]pyrazine-6-carboxamide Chemical compound C[C@H](O)CONC(=O)C=1N=CC2=CN=CN2C=1NC1=CC=C(I)C=C1F AWWCYHAGTSTCON-VIFPVBQESA-N 0.000 description 1
- ZYWKPZACNZQFED-JTQLQIEISA-N 5-(2-fluoro-4-iodoanilino)-n-[(2s)-2-hydroxypropoxy]imidazo[1,5-a]pyridine-6-carboxamide Chemical compound C[C@H](O)CONC(=O)C=1C=CC2=CN=CN2C=1NC1=CC=C(I)C=C1F ZYWKPZACNZQFED-JTQLQIEISA-N 0.000 description 1
- FTDJLZBVBJFFLS-UHFFFAOYSA-N 5-(2-fluoro-4-iodoanilino)-n-methylimidazo[1,5-a]pyrazine-6-carboxamide Chemical compound CNC(=O)C=1N=CC2=CN=CN2C=1NC1=CC=C(I)C=C1F FTDJLZBVBJFFLS-UHFFFAOYSA-N 0.000 description 1
- AFYJIBRYUGHWME-UHFFFAOYSA-N 5-(4-bromo-2-fluoroanilino)-8-fluoroimidazo[1,5-a]pyridine-6-carboxylic acid Chemical compound OC(=O)C=1C=C(F)C2=CN=CN2C=1NC1=CC=C(Br)C=C1F AFYJIBRYUGHWME-UHFFFAOYSA-N 0.000 description 1
- LLRLRUIBHBDFLL-UHFFFAOYSA-N 5-(4-bromo-2-fluoroanilino)-n-(2-hydroxyethoxy)imidazo[1,5-a]pyrazine-6-carboxamide Chemical compound OCCONC(=O)C=1N=CC2=CN=CN2C=1NC1=CC=C(Br)C=C1F LLRLRUIBHBDFLL-UHFFFAOYSA-N 0.000 description 1
- HNZBXMLVSVFHSO-UHFFFAOYSA-N 5-(4-bromo-2-fluoroanilino)-n-(2-hydroxyethoxy)imidazo[1,5-a]pyridine-6-carboxamide Chemical compound OCCONC(=O)C=1C=CC2=CN=CN2C=1NC1=CC=C(Br)C=C1F HNZBXMLVSVFHSO-UHFFFAOYSA-N 0.000 description 1
- SQHIOHMMNQAUAP-UHFFFAOYSA-N 5-(4-bromo-2-fluoroanilino)-n-(cyclopropylmethoxy)imidazo[1,5-a]pyrazine-6-carboxamide Chemical compound FC1=CC(Br)=CC=C1NC1=C(C(=O)NOCC2CC2)N=CC2=CN=CN12 SQHIOHMMNQAUAP-UHFFFAOYSA-N 0.000 description 1
- QSYZJPFCSFJLLQ-VIFPVBQESA-N 5-(4-bromo-2-fluoroanilino)-n-[(2s)-2-hydroxypropoxy]imidazo[1,5-a]pyrazine-6-carboxamide Chemical compound C[C@H](O)CONC(=O)C=1N=CC2=CN=CN2C=1NC1=CC=C(Br)C=C1F QSYZJPFCSFJLLQ-VIFPVBQESA-N 0.000 description 1
- WLEYARYQOFIVMP-JTQLQIEISA-N 5-(4-bromo-2-fluoroanilino)-n-[(2s)-2-hydroxypropoxy]imidazo[1,5-a]pyridine-6-carboxamide Chemical compound C[C@H](O)CONC(=O)C=1C=CC2=CN=CN2C=1NC1=CC=C(Br)C=C1F WLEYARYQOFIVMP-JTQLQIEISA-N 0.000 description 1
- MJMOPUIFKLDPSI-UHFFFAOYSA-N 5-(4-cyclopropyl-2-fluoroanilino)-n-(2-hydroxyethoxy)imidazo[1,5-a]pyridine-6-carboxamide Chemical compound OCCONC(=O)C=1C=CC2=CN=CN2C=1NC(C(=C1)F)=CC=C1C1CC1 MJMOPUIFKLDPSI-UHFFFAOYSA-N 0.000 description 1
- XHHGPLBYQFIILA-UHFFFAOYSA-N 5-[6-(4-bromo-2-methylanilino)-7-fluoro-3h-benzimidazol-5-yl]-1,3,4-oxadiazol-2-amine Chemical compound CC1=CC(Br)=CC=C1NC(C(=C1)C=2OC(N)=NN=2)=C(F)C2=C1NC=N2 XHHGPLBYQFIILA-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- CNSGKPJYNOLBMT-UHFFFAOYSA-N 6-(2,4-dichloroanilino)-7-fluoro-n-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Cl)C=C1Cl CNSGKPJYNOLBMT-UHFFFAOYSA-N 0.000 description 1
- XAAPQRFIXGDKPZ-UHFFFAOYSA-N 6-(4-bromo-2-chloroanilino)-7-fluoro-3-methylbenzimidazole-5-carboxylic acid Chemical compound OC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl XAAPQRFIXGDKPZ-UHFFFAOYSA-N 0.000 description 1
- MEDYRLZHKMRQBE-UHFFFAOYSA-N 6-(4-bromo-2-chloroanilino)-7-fluoro-n-(2-hydroxyethoxy)-3-(oxan-2-ylmethyl)benzimidazole-5-carboxamide Chemical compound C1=NC=2C(F)=C(NC=3C(=CC(Br)=CC=3)Cl)C(C(=O)NOCCO)=CC=2N1CC1CCCCO1 MEDYRLZHKMRQBE-UHFFFAOYSA-N 0.000 description 1
- JVPMEEQIGAMTTE-UHFFFAOYSA-N 6-(4-bromo-2-chloroanilino)-7-fluoro-n-(2-hydroxyethoxy)-3-(oxolan-2-ylmethyl)benzimidazole-5-carboxamide Chemical compound C1=NC=2C(F)=C(NC=3C(=CC(Br)=CC=3)Cl)C(C(=O)NOCCO)=CC=2N1CC1CCCO1 JVPMEEQIGAMTTE-UHFFFAOYSA-N 0.000 description 1
- UBEOBEUUUKHITB-UHFFFAOYSA-N 6-(4-bromo-2-chloroanilino)-7-fluoro-n-(2-hydroxyethoxy)-3h-benzimidazole-5-carboxamide Chemical compound OCCONC(=O)C1=CC=2NC=NC=2C(F)=C1NC1=CC=C(Br)C=C1Cl UBEOBEUUUKHITB-UHFFFAOYSA-N 0.000 description 1
- HVUPVWYURYMZHF-UHFFFAOYSA-N 6-(4-bromo-2-chloroanilino)-n-(2,3-dihydroxypropoxy)-7-fluoro-3-methylbenzimidazole-5-carboxamide Chemical compound OCC(O)CONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl HVUPVWYURYMZHF-UHFFFAOYSA-N 0.000 description 1
- KHNUMHAPGZJGJD-UHFFFAOYSA-N 6-(4-bromo-2-chloroanilino)-n-(cyclopropylmethoxy)-7-fluoro-3h-benzimidazole-5-carboxamide Chemical compound C1CC1CONC(=O)C1=CC=2NC=NC=2C(F)=C1NC1=CC=C(Br)C=C1Cl KHNUMHAPGZJGJD-UHFFFAOYSA-N 0.000 description 1
- DHZGVPNAMLHFJL-UHFFFAOYSA-N 6-(4-bromo-2-methylanilino)-n-(cyclopropylmethoxy)-7-fluoro-3h-benzimidazole-5-carboxamide Chemical compound CC1=CC(Br)=CC=C1NC(C(=C1)C(=O)NOCC2CC2)=C(F)C2=C1N=CN2 DHZGVPNAMLHFJL-UHFFFAOYSA-N 0.000 description 1
- ZRPLSUDCQQGCSE-UHFFFAOYSA-N 6-(N-bromo-2-fluoroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide Chemical compound OCCONC(=O)C1=CC2=C(N=CN2C)C(=C1N(C1=C(C=CC=C1)F)Br)F ZRPLSUDCQQGCSE-UHFFFAOYSA-N 0.000 description 1
- WYXSYVWAUAUWLD-SHUUEZRQSA-N 6-azauridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=N1 WYXSYVWAUAUWLD-SHUUEZRQSA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- FGTGVNVJPGUWKH-UHFFFAOYSA-N 8-fluoro-5-(2-fluoro-4-iodoanilino)-n-(2-hydroxyethoxy)imidazo[1,5-a]pyridine-6-carboxamide Chemical compound OCCONC(=O)C=1C=C(F)C2=CN=CN2C=1NC1=CC=C(I)C=C1F FGTGVNVJPGUWKH-UHFFFAOYSA-N 0.000 description 1
- MFCMEJVQRSMYOM-UHFFFAOYSA-N 8-fluoro-5-(2-fluoro-4-iodoanilino)imidazo[1,5-a]pyridine-6-carboxylic acid Chemical compound OC(=O)C=1C=C(F)C2=CN=CN2C=1NC1=CC=C(I)C=C1F MFCMEJVQRSMYOM-UHFFFAOYSA-N 0.000 description 1
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 1
- FUXVKZWTXQUGMW-FQEVSTJZSA-N 9-Aminocamptothecin Chemical compound C1=CC(N)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 FUXVKZWTXQUGMW-FQEVSTJZSA-N 0.000 description 1
- HDZZVAMISRMYHH-UHFFFAOYSA-N 9beta-Ribofuranosyl-7-deazaadenin Natural products C1=CC=2C(N)=NC=NC=2N1C1OC(CO)C(O)C1O HDZZVAMISRMYHH-UHFFFAOYSA-N 0.000 description 1
- YCIPQJTZJGUXND-UHFFFAOYSA-N Aglaia odorata Alkaloid Natural products C1=CC(OC)=CC=C1C1(C(C=2C(=O)N3CCCC3=NC=22)C=3C=CC=CC=3)C2(O)C2=C(OC)C=C(OC)C=C2O1 YCIPQJTZJGUXND-UHFFFAOYSA-N 0.000 description 1
- CEIZFXOZIQNICU-UHFFFAOYSA-N Alternaria alternata Crofton-weed toxin Natural products CCC(C)C1NC(=O)C(C(C)=O)=C1O CEIZFXOZIQNICU-UHFFFAOYSA-N 0.000 description 1
- 108020000948 Antisense Oligonucleotides Chemical class 0.000 description 1
- 229940088872 Apoptosis inhibitor Drugs 0.000 description 1
- 102000014654 Aromatase Human genes 0.000 description 1
- 108010078554 Aromatase Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 229940125431 BRAF inhibitor Drugs 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 description 1
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- MBABCNBNDNGODA-LTGLSHGVSA-N Bullatacin Natural products O=C1C(C[C@H](O)CCCCCCCCCC[C@@H](O)[C@@H]2O[C@@H]([C@@H]3O[C@H]([C@@H](O)CCCCCCCCCC)CC3)CC2)=C[C@H](C)O1 MBABCNBNDNGODA-LTGLSHGVSA-N 0.000 description 1
- KGGVWMAPBXIMEM-JQFCFGFHSA-N Bullatacinone Natural products O=C(C[C@H]1C(=O)O[C@H](CCCCCCCCCC[C@H](O)[C@@H]2O[C@@H]([C@@H]3O[C@@H]([C@@H](O)CCCCCCCCCC)CC3)CC2)C1)C KGGVWMAPBXIMEM-JQFCFGFHSA-N 0.000 description 1
- KGGVWMAPBXIMEM-ZRTAFWODSA-N Bullatacinone Chemical compound O1[C@@H]([C@@H](O)CCCCCCCCCC)CC[C@@H]1[C@@H]1O[C@@H]([C@H](O)CCCCCCCCCC[C@H]2OC(=O)[C@H](CC(C)=O)C2)CC1 KGGVWMAPBXIMEM-ZRTAFWODSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- HZDRLJYKYREHKF-UHFFFAOYSA-N CS(=O)(=O)N(C1=CC=CC=C1F)C2=C(C=CC3=CN=CN32)C(=O)NOCCO Chemical compound CS(=O)(=O)N(C1=CC=CC=C1F)C2=C(C=CC3=CN=CN32)C(=O)NOCCO HZDRLJYKYREHKF-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- UJOBWOGCFQCDNV-UHFFFAOYSA-N Carbazole Natural products C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- SHHKQEUPHAENFK-UHFFFAOYSA-N Carboquone Chemical compound O=C1C(C)=C(N2CC2)C(=O)C(C(COC(N)=O)OC)=C1N1CC1 SHHKQEUPHAENFK-UHFFFAOYSA-N 0.000 description 1
- AOCCBINRVIKJHY-UHFFFAOYSA-N Carmofur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- XCDXSSFOJZZGQC-UHFFFAOYSA-N Chlornaphazine Chemical compound C1=CC=CC2=CC(N(CCCl)CCCl)=CC=C21 XCDXSSFOJZZGQC-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 229930188224 Cryptophycin Natural products 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-YMDCURPLSA-N D-galactopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-YMDCURPLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- XXGMIHXASFDFSM-UHFFFAOYSA-N Delta9-tetrahydrocannabinol Natural products CCCCCc1cc2OC(C)(C)C3CCC(=CC3c2c(O)c1O)C XXGMIHXASFDFSM-UHFFFAOYSA-N 0.000 description 1
- NNJPGOLRFBJNIW-UHFFFAOYSA-N Demecolcine Natural products C1=C(OC)C(=O)C=C2C(NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-UHFFFAOYSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- AUGQEEXBDZWUJY-ZLJUKNTDSA-N Diacetoxyscirpenol Chemical compound C([C@]12[C@]3(C)[C@H](OC(C)=O)[C@@H](O)[C@H]1O[C@@H]1C=C(C)CC[C@@]13COC(=O)C)O2 AUGQEEXBDZWUJY-ZLJUKNTDSA-N 0.000 description 1
- AUGQEEXBDZWUJY-UHFFFAOYSA-N Diacetoxyscirpenol Natural products CC(=O)OCC12CCC(C)=CC1OC1C(O)C(OC(C)=O)C2(C)C11CO1 AUGQEEXBDZWUJY-UHFFFAOYSA-N 0.000 description 1
- ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 description 1
- CYQFCXCEBYINGO-DLBZAZTESA-N Dronabinol Natural products C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@H]21 CYQFCXCEBYINGO-DLBZAZTESA-N 0.000 description 1
- 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 description 1
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 1
- 101710146529 Dual specificity mitogen-activated protein kinase kinase 2 Proteins 0.000 description 1
- 102100023266 Dual specificity mitogen-activated protein kinase kinase 2 Human genes 0.000 description 1
- 229930193152 Dynemicin Natural products 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- AFMYMMXSQGUCBK-UHFFFAOYSA-N Endynamicin A Natural products C1#CC=CC#CC2NC(C=3C(=O)C4=C(O)C=CC(O)=C4C(=O)C=3C(O)=C3)=C3C34OC32C(C)C(C(O)=O)=C(OC)C41 AFMYMMXSQGUCBK-UHFFFAOYSA-N 0.000 description 1
- SAMRUMKYXPVKPA-VFKOLLTISA-N Enocitabine Chemical compound O=C1N=C(NC(=O)CCCCCCCCCCCCCCCCCCCCC)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 SAMRUMKYXPVKPA-VFKOLLTISA-N 0.000 description 1
- 229930189413 Esperamicin Natural products 0.000 description 1
- 229940102550 Estrogen receptor antagonist Drugs 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 108010021472 Fc gamma receptor IIB Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- RFWVETIZUQEJEF-UHFFFAOYSA-N GDC-0623 Chemical compound OCCONC(=O)C=1C=CC2=CN=CN2C=1NC1=CC=C(I)C=C1F RFWVETIZUQEJEF-UHFFFAOYSA-N 0.000 description 1
- DEZZLWQELQORIU-RELWKKBWSA-N GDC-0879 Chemical compound N=1N(CCO)C=C(C=2C=C3CCC(/C3=CC=2)=N\O)C=1C1=CC=NC=C1 DEZZLWQELQORIU-RELWKKBWSA-N 0.000 description 1
- 241000237858 Gastropoda Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 1
- 108010075704 HLA-A Antigens Proteins 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101001014196 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 description 1
- 101001115402 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 2 Proteins 0.000 description 1
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 101001002709 Homo sapiens Interleukin-4 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010041012 Integrin alpha4 Proteins 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 102000003815 Interleukin-11 Human genes 0.000 description 1
- 108090000177 Interleukin-11 Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000003816 Interleukin-13 Human genes 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 102000003812 Interleukin-15 Human genes 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102000000646 Interleukin-3 Human genes 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 102000000743 Interleukin-5 Human genes 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 102000000704 Interleukin-7 Human genes 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 102000000585 Interleukin-9 Human genes 0.000 description 1
- 102100020880 Kit ligand Human genes 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- JLERVPBPJHKRBJ-UHFFFAOYSA-N LY 117018 Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCC3)=CC=2)C2=CC=C(O)C=C2S1 JLERVPBPJHKRBJ-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 229920001491 Lentinan Polymers 0.000 description 1
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 1
- 102100032352 Leukemia inhibitory factor Human genes 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- MEPSBMMZQBMKHM-UHFFFAOYSA-N Lomatiol Natural products CC(=C/CC1=C(O)C(=O)c2ccccc2C1=O)CO MEPSBMMZQBMKHM-UHFFFAOYSA-N 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 102100029205 Low affinity immunoglobulin gamma Fc region receptor II-b Human genes 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- VJRAUFKOOPNFIQ-UHFFFAOYSA-N Marcellomycin Natural products C12=C(O)C=3C(=O)C4=C(O)C=CC(O)=C4C(=O)C=3C=C2C(C(=O)OC)C(CC)(O)CC1OC(OC1C)CC(N(C)C)C1OC(OC1C)CC(O)C1OC1CC(O)C(O)C(C)O1 VJRAUFKOOPNFIQ-UHFFFAOYSA-N 0.000 description 1
- 229930126263 Maytansine Natural products 0.000 description 1
- 229920000877 Melamine resin Polymers 0.000 description 1
- VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 108010050619 Monokines Proteins 0.000 description 1
- 102000013967 Monokines Human genes 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101000746372 Mus musculus Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- KGTDRFCXGRULNK-UHFFFAOYSA-N Nogalamycin Natural products COC1C(OC)(C)C(OC)C(C)OC1OC1C2=C(O)C(C(=O)C3=C(O)C=C4C5(C)OC(C(C(C5O)N(C)C)O)OC4=C3C3=O)=C3C=C2C(C(=O)OC)C(C)(O)C1 KGTDRFCXGRULNK-UHFFFAOYSA-N 0.000 description 1
- 229930187135 Olivomycin Natural products 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- VREZDOWOLGNDPW-ALTGWBOUSA-N Pancratistatin Chemical compound C1=C2[C@H]3[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)[C@@H]3NC(=O)C2=C(O)C2=C1OCO2 VREZDOWOLGNDPW-ALTGWBOUSA-N 0.000 description 1
- VREZDOWOLGNDPW-MYVCAWNPSA-N Pancratistatin Natural products O=C1N[C@H]2[C@H](O)[C@H](O)[C@H](O)[C@H](O)[C@@H]2c2c1c(O)c1OCOc1c2 VREZDOWOLGNDPW-MYVCAWNPSA-N 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 108010057150 Peplomycin Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- HFVNWDWLWUCIHC-GUPDPFMOSA-N Prednimustine Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 HFVNWDWLWUCIHC-GUPDPFMOSA-N 0.000 description 1
- 101710094000 Programmed cell death 1 ligand 1 Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102100024924 Protein kinase C alpha type Human genes 0.000 description 1
- 101710109947 Protein kinase C alpha type Proteins 0.000 description 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Natural products C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- NSFWWJIQIKBZMJ-YKNYLIOZSA-N Roridin A Chemical compound C([C@]12[C@]3(C)[C@H]4C[C@H]1O[C@@H]1C=C(C)CC[C@@]13COC(=O)[C@@H](O)[C@H](C)CCO[C@H](\C=C\C=C/C(=O)O4)[C@H](O)C)O2 NSFWWJIQIKBZMJ-YKNYLIOZSA-N 0.000 description 1
- CIEYTVIYYGTCCI-UHFFFAOYSA-N SJ000286565 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(O)C(=O)C2=C1 CIEYTVIYYGTCCI-UHFFFAOYSA-N 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 229920000519 Sizofiran Polymers 0.000 description 1
- 108010039445 Stem Cell Factor Proteins 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- BXFOFFBJRFZBQZ-QYWOHJEZSA-N T-2 toxin Chemical compound C([C@@]12[C@]3(C)[C@H](OC(C)=O)[C@@H](O)[C@H]1O[C@H]1[C@]3(COC(C)=O)C[C@@H](C(=C1)C)OC(=O)CC(C)C)O2 BXFOFFBJRFZBQZ-QYWOHJEZSA-N 0.000 description 1
- 208000037913 T-cell disorder Diseases 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 108700011582 TER 286 Proteins 0.000 description 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- WFWLQNSHRPWKFK-UHFFFAOYSA-N Tegafur Chemical compound O=C1NC(=O)C(F)=CN1C1OCCC1 WFWLQNSHRPWKFK-UHFFFAOYSA-N 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- CGMTUJFWROPELF-UHFFFAOYSA-N Tenuazonic acid Natural products CCC(C)C1NC(=O)C(=C(C)/O)C1=O CGMTUJFWROPELF-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 description 1
- IWEQQRMGNVVKQW-OQKDUQJOSA-N Toremifene citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 IWEQQRMGNVVKQW-OQKDUQJOSA-N 0.000 description 1
- UMILHIMHKXVDGH-UHFFFAOYSA-N Triethylene glycol diglycidyl ether Chemical compound C1OC1COCCOCCOCCOCC1CO1 UMILHIMHKXVDGH-UHFFFAOYSA-N 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 description 1
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000012452 Xenomouse strains Methods 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- PVNFMCBFDPTNQI-UIBOPQHZSA-N [(1S,2R,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] acetate [(1S,2R,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] 3-methylbutanoate [(1S,2R,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] 2-methylpropanoate [(1S,2R,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] propanoate Chemical compound CO[C@@H]1\C=C\C=C(C)\Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(C)=O)[C@]2(C)OC2[C@H](C)[C@@H]2C[C@@]1(O)NC(=O)O2.CCC(=O)O[C@H]1CC(=O)N(C)c2cc(C\C(C)=C\C=C\[C@@H](OC)[C@@]3(O)C[C@H](OC(=O)N3)[C@@H](C)C3O[C@@]13C)cc(OC)c2Cl.CO[C@@H]1\C=C\C=C(C)\Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(=O)C(C)C)[C@]2(C)OC2[C@H](C)[C@@H]2C[C@@]1(O)NC(=O)O2.CO[C@@H]1\C=C\C=C(C)\Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(=O)CC(C)C)[C@]2(C)OC2[C@H](C)[C@@H]2C[C@@]1(O)NC(=O)O2 PVNFMCBFDPTNQI-UIBOPQHZSA-N 0.000 description 1
- SPJCRMJCFSJKDE-ZWBUGVOYSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] 2-[4-[bis(2-chloroethyl)amino]phenyl]acetate Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)C(=O)CC1=CC=C(N(CCCl)CCCl)C=C1 SPJCRMJCFSJKDE-ZWBUGVOYSA-N 0.000 description 1
- IFJUINDAXYAPTO-UUBSBJJBSA-N [(8r,9s,13s,14s,17s)-17-[2-[4-[4-[bis(2-chloroethyl)amino]phenyl]butanoyloxy]acetyl]oxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] benzoate Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4OC(=O)COC(=O)CCCC=1C=CC(=CC=1)N(CCCl)CCCl)C)CC2=CC=3OC(=O)C1=CC=CC=C1 IFJUINDAXYAPTO-UUBSBJJBSA-N 0.000 description 1
- IHGLINDYFMDHJG-UHFFFAOYSA-N [2-(4-methoxyphenyl)-3,4-dihydronaphthalen-1-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]methanone Chemical compound C1=CC(OC)=CC=C1C(CCC1=CC=CC=C11)=C1C(=O)C(C=C1)=CC=C1OCCN1CCCC1 IHGLINDYFMDHJG-UHFFFAOYSA-N 0.000 description 1
- XZSRRNFBEIOBDA-CFNBKWCHSA-N [2-[(2s,4s)-4-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1h-tetracen-2-yl]-2-oxoethyl] 2,2-diethoxyacetate Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)C(OCC)OCC)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 XZSRRNFBEIOBDA-CFNBKWCHSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 108010023617 abarelix Proteins 0.000 description 1
- AIWRTTMUVOZGPW-HSPKUQOVSA-N abarelix Chemical compound C([C@@H](C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 AIWRTTMUVOZGPW-HSPKUQOVSA-N 0.000 description 1
- 229960002184 abarelix Drugs 0.000 description 1
- 230000007488 abnormal function Effects 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 229940037127 actonel Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 229950004955 adozelesin Drugs 0.000 description 1
- BYRVKDUQDLJUBX-JJCDCTGGSA-N adozelesin Chemical compound C1=CC=C2OC(C(=O)NC=3C=C4C=C(NC4=CC=3)C(=O)N3C[C@H]4C[C@]44C5=C(C(C=C43)=O)NC=C5C)=CC2=C1 BYRVKDUQDLJUBX-JJCDCTGGSA-N 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 230000009824 affinity maturation Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 108700025316 aldesleukin Proteins 0.000 description 1
- 229940062527 alendronate Drugs 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- WYTGDNHDOZPMIW-RCBQFDQVSA-N alstonine Natural products C1=CC2=C3C=CC=CC3=NC2=C2N1C[C@H]1[C@H](C)OC=C(C(=O)OC)[C@H]1C2 WYTGDNHDOZPMIW-RCBQFDQVSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 229960002749 aminolevulinic acid Drugs 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229960001220 amsacrine Drugs 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- BBDAGFIXKZCXAH-CCXZUQQUSA-N ancitabine Chemical compound N=C1C=CN2[C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3OC2=N1 BBDAGFIXKZCXAH-CCXZUQQUSA-N 0.000 description 1
- 229950000242 ancitabine Drugs 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- SMWDFEZZVXVKRB-UHFFFAOYSA-N anhydrous quinoline Natural products N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 239000013059 antihormonal agent Substances 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940045687 antimetabolites folic acid analogs Drugs 0.000 description 1
- 239000002257 antimetastatic agent Substances 0.000 description 1
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
- 229940045688 antineoplastic antimetabolites pyrimidine analogues Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003418 antiprogestin Substances 0.000 description 1
- 239000000074 antisense oligonucleotide Chemical class 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 239000000158 apoptosis inhibitor Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940078010 arimidex Drugs 0.000 description 1
- 229940087620 aromasin Drugs 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000008003 autocrine effect Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 125000000477 aza group Chemical group 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 150000001541 aziridines Chemical class 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 208000013404 behavioral symptom Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 150000001555 benzenes Chemical class 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 125000002527 bicyclic carbocyclic group Chemical group 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229950008548 bisantrene Drugs 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 229950006844 bizelesin Drugs 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 229960005520 bryostatin Drugs 0.000 description 1
- MJQUEDHRCUIRLF-TVIXENOKSA-N bryostatin 1 Chemical compound C([C@@H]1CC(/[C@@H]([C@@](C(C)(C)/C=C/2)(O)O1)OC(=O)/C=C/C=C/CCC)=C\C(=O)OC)[C@H]([C@@H](C)O)OC(=O)C[C@H](O)C[C@@H](O1)C[C@H](OC(C)=O)C(C)(C)[C@]1(O)C[C@@H]1C\C(=C\C(=O)OC)C[C@H]\2O1 MJQUEDHRCUIRLF-TVIXENOKSA-N 0.000 description 1
- MUIWQCKLQMOUAT-AKUNNTHJSA-N bryostatin 20 Natural products COC(=O)C=C1C[C@@]2(C)C[C@]3(O)O[C@](C)(C[C@@H](O)CC(=O)O[C@](C)(C[C@@]4(C)O[C@](O)(CC5=CC(=O)O[C@]45C)C(C)(C)C=C[C@@](C)(C1)O2)[C@@H](C)O)C[C@H](OC(=O)C(C)(C)C)C3(C)C MUIWQCKLQMOUAT-AKUNNTHJSA-N 0.000 description 1
- MBABCNBNDNGODA-LUVUIASKSA-N bullatacin Chemical compound O1[C@@H]([C@@H](O)CCCCCCCCCC)CC[C@@H]1[C@@H]1O[C@@H]([C@H](O)CCCCCCCCCC[C@@H](O)CC=2C(O[C@@H](C)C=2)=O)CC1 MBABCNBNDNGODA-LUVUIASKSA-N 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 108700002839 cactinomycin Proteins 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229940088954 camptosar Drugs 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- YAYRGNWWLMLWJE-UHFFFAOYSA-L carboplatin Chemical compound O=C1O[Pt](N)(N)OC(=O)C11CCC1 YAYRGNWWLMLWJE-UHFFFAOYSA-L 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 229960002115 carboquone Drugs 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- XREUEWVEMYWFFA-CSKJXFQVSA-N carminomycin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XREUEWVEMYWFFA-CSKJXFQVSA-N 0.000 description 1
- 229930188550 carminomycin Natural products 0.000 description 1
- XREUEWVEMYWFFA-UHFFFAOYSA-N carminomycin I Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XREUEWVEMYWFFA-UHFFFAOYSA-N 0.000 description 1
- 229960003261 carmofur Drugs 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 229950001725 carubicin Drugs 0.000 description 1
- BBZDXMBRAFTCAA-AREMUKBSSA-N carzelesin Chemical class C1=2NC=C(C)C=2C([C@H](CCl)CN2C(=O)C=3NC4=CC=C(C=C4C=3)NC(=O)C3=CC4=CC=C(C=C4O3)N(CC)CC)=C2C=C1OC(=O)NC1=CC=CC=C1 BBZDXMBRAFTCAA-AREMUKBSSA-N 0.000 description 1
- 108010047060 carzinophilin Proteins 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 239000012627 chemopreventive agent Substances 0.000 description 1
- 229940124443 chemopreventive agent Drugs 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- 229940060038 chlorine Drugs 0.000 description 1
- 229950008249 chlornaphazine Drugs 0.000 description 1
- 229960001480 chlorozotocin Drugs 0.000 description 1
- ZYVSOIYQKUDENJ-WKSBCEQHSA-N chromomycin A3 Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1OC(C)=O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](O[C@@H]3O[C@@H](C)[C@H](OC(C)=O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@@H]1C[C@@H](O)[C@@H](OC)[C@@H](C)O1 ZYVSOIYQKUDENJ-WKSBCEQHSA-N 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 229960002286 clodronic acid Drugs 0.000 description 1
- HJKBJIYDJLVSAO-UHFFFAOYSA-L clodronic acid disodium salt Chemical compound [Na+].[Na+].OP([O-])(=O)C(Cl)(Cl)P(O)([O-])=O HJKBJIYDJLVSAO-UHFFFAOYSA-L 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- COFJBSXICYYSKG-OAUVCNBTSA-N cph2u7dndy Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 COFJBSXICYYSKG-OAUVCNBTSA-N 0.000 description 1
- 108010006226 cryptophycin Proteins 0.000 description 1
- PSNOPSMXOBPNNV-VVCTWANISA-N cryptophycin 1 Chemical compound C1=C(Cl)C(OC)=CC=C1C[C@@H]1C(=O)NC[C@@H](C)C(=O)O[C@@H](CC(C)C)C(=O)O[C@H]([C@H](C)[C@@H]2[C@H](O2)C=2C=CC=CC=2)C/C=C/C(=O)N1 PSNOPSMXOBPNNV-VVCTWANISA-N 0.000 description 1
- PSNOPSMXOBPNNV-UHFFFAOYSA-N cryptophycin-327 Natural products C1=C(Cl)C(OC)=CC=C1CC1C(=O)NCC(C)C(=O)OC(CC(C)C)C(=O)OC(C(C)C2C(O2)C=2C=CC=CC=2)CC=CC(=O)N1 PSNOPSMXOBPNNV-UHFFFAOYSA-N 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 229960005052 demecolcine Drugs 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000008716 dendritic activation Effects 0.000 description 1
- 230000004041 dendritic cell maturation Effects 0.000 description 1
- 229950003913 detorubicin Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- WVYXNIXAMZOZFK-UHFFFAOYSA-N diaziquone Chemical compound O=C1C(NC(=O)OCC)=C(N2CC2)C(=O)C(NC(=O)OCC)=C1N1CC1 WVYXNIXAMZOZFK-UHFFFAOYSA-N 0.000 description 1
- 229950002389 diaziquone Drugs 0.000 description 1
- 125000002720 diazolyl group Chemical group 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 125000005411 dithiolanyl group Chemical group S1SC(CC1)* 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 description 1
- 229930188854 dolastatin Natural products 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 229940115080 doxil Drugs 0.000 description 1
- 229940035863 doxorubicin liposome injection Drugs 0.000 description 1
- 229950004203 droloxifene Drugs 0.000 description 1
- 229960004242 dronabinol Drugs 0.000 description 1
- 229960005501 duocarmycin Drugs 0.000 description 1
- VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 description 1
- 229930184221 duocarmycin Natural products 0.000 description 1
- AFMYMMXSQGUCBK-AKMKHHNQSA-N dynemicin a Chemical compound C1#C\C=C/C#C[C@@H]2NC(C=3C(=O)C4=C(O)C=CC(O)=C4C(=O)C=3C(O)=C3)=C3[C@@]34O[C@]32[C@@H](C)C(C(O)=O)=C(OC)[C@H]41 AFMYMMXSQGUCBK-AKMKHHNQSA-N 0.000 description 1
- FSIRXIHZBIXHKT-MHTVFEQDSA-N edatrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CC(CC)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FSIRXIHZBIXHKT-MHTVFEQDSA-N 0.000 description 1
- 229950006700 edatrexate Drugs 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 229960002759 eflornithine Drugs 0.000 description 1
- 229940121647 egfr inhibitor Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 229950000549 elliptinium acetate Drugs 0.000 description 1
- 229940120655 eloxatin Drugs 0.000 description 1
- JOZGNYDSEBIJDH-UHFFFAOYSA-N eniluracil Chemical compound O=C1NC=C(C#C)C(=O)N1 JOZGNYDSEBIJDH-UHFFFAOYSA-N 0.000 description 1
- 229950010213 eniluracil Drugs 0.000 description 1
- 229950011487 enocitabine Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 1
- 229930013356 epothilone Natural products 0.000 description 1
- 150000003883 epothilone derivatives Chemical class 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- LJQQFQHBKUKHIS-WJHRIEJJSA-N esperamicin Chemical compound O1CC(NC(C)C)C(OC)CC1OC1C(O)C(NOC2OC(C)C(SC)C(O)C2)C(C)OC1OC1C(\C2=C/CSSSC)=C(NC(=O)OC)C(=O)C(OC3OC(C)C(O)C(OC(=O)C=4C(=CC(OC)=C(OC)C=4)NC(=O)C(=C)OC)C3)C2(O)C#C\C=C/C#C1 LJQQFQHBKUKHIS-WJHRIEJJSA-N 0.000 description 1
- 229960001842 estramustine Drugs 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- QCYAXXZCQKMTMO-QFIPXVFZSA-N ethyl (2s)-2-[(2-bromo-3-oxospiro[3.5]non-1-en-1-yl)amino]-3-[4-(2,7-naphthyridin-1-ylamino)phenyl]propanoate Chemical compound N([C@@H](CC=1C=CC(NC=2C3=CN=CC=C3C=CN=2)=CC=1)C(=O)OCC)C1=C(Br)C(=O)C11CCCCC1 QCYAXXZCQKMTMO-QFIPXVFZSA-N 0.000 description 1
- QSRLNKCNOLVZIR-KRWDZBQOSA-N ethyl (2s)-2-[[2-[4-[bis(2-chloroethyl)amino]phenyl]acetyl]amino]-4-methylsulfanylbutanoate Chemical compound CCOC(=O)[C@H](CCSC)NC(=O)CC1=CC=C(N(CCCl)CCCl)C=C1 QSRLNKCNOLVZIR-KRWDZBQOSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000005469 ethylenyl group Chemical group 0.000 description 1
- WHRIKZCFRVTHJH-UHFFFAOYSA-N ethylhydrazine Chemical compound CCNN WHRIKZCFRVTHJH-UHFFFAOYSA-N 0.000 description 1
- 229940009626 etidronate Drugs 0.000 description 1
- 229960005237 etoglucid Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 229940085363 evista Drugs 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229950011548 fadrozole Drugs 0.000 description 1
- 229940043168 fareston Drugs 0.000 description 1
- 229940087861 faslodex Drugs 0.000 description 1
- 229940087476 femara Drugs 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 150000002224 folic acids Chemical class 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 229940001490 fosamax Drugs 0.000 description 1
- 229960004783 fotemustine Drugs 0.000 description 1
- YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229940044658 gallium nitrate Drugs 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical class N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229960003690 goserelin acetate Drugs 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 102000046157 human CSF2 Human genes 0.000 description 1
- 102000055229 human IL4 Human genes 0.000 description 1
- 102000050156 human MAP2K1 Human genes 0.000 description 1
- 102000050154 human MAP2K2 Human genes 0.000 description 1
- 102000048362 human PDCD1 Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229940088013 hycamtin Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- KNOSIOWNDGUGFJ-UHFFFAOYSA-N hydroxysesamone Natural products C1=CC(O)=C2C(=O)C(CC=C(C)C)=C(O)C(=O)C2=C1O KNOSIOWNDGUGFJ-UHFFFAOYSA-N 0.000 description 1
- 229960003210 hyoscyamine Drugs 0.000 description 1
- 229930005342 hyoscyamine Natural products 0.000 description 1
- 229940015872 ibandronate Drugs 0.000 description 1
- 229940099279 idamycin Drugs 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000008073 immune recognition Effects 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- DBIGHPPNXATHOF-UHFFFAOYSA-N improsulfan Chemical compound CS(=O)(=O)OCCCNCCCOS(C)(=O)=O DBIGHPPNXATHOF-UHFFFAOYSA-N 0.000 description 1
- 229950008097 improsulfan Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229940125798 integrin inhibitor Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- AWJUIBRHMBBTKR-UHFFFAOYSA-N iso-quinoline Natural products C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 1
- GWVMLCQWXVFZCN-UHFFFAOYSA-N isoindoline Chemical group C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 description 1
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical class OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical group C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- CWPGNVFCJOPXFB-UHFFFAOYSA-N lapachol Chemical compound C1=CC=C2C(=O)C(=O)C(CC=C(C)C)=C(O)C2=C1 CWPGNVFCJOPXFB-UHFFFAOYSA-N 0.000 description 1
- SIUGQQMOYSVTAT-UHFFFAOYSA-N lapachol Natural products CC(=CCC1C(O)C(=O)c2ccccc2C1=O)C SIUGQQMOYSVTAT-UHFFFAOYSA-N 0.000 description 1
- 229940115286 lentinan Drugs 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000012035 limiting reagent Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- YROQEQPFUCPDCP-UHFFFAOYSA-N losoxantrone Chemical compound OCCNCCN1N=C2C3=CC=CC(O)=C3C(=O)C3=C2C1=CC=C3NCCNCCO YROQEQPFUCPDCP-UHFFFAOYSA-N 0.000 description 1
- 229950008745 losoxantrone Drugs 0.000 description 1
- 108010078259 luprolide acetate gel depot Proteins 0.000 description 1
- 229940087857 lupron Drugs 0.000 description 1
- RVFGKBWWUQOIOU-NDEPHWFRSA-N lurtotecan Chemical compound O=C([C@]1(O)CC)OCC(C(N2CC3=4)=O)=C1C=C2C3=NC1=CC=2OCCOC=2C=C1C=4CN1CCN(C)CC1 RVFGKBWWUQOIOU-NDEPHWFRSA-N 0.000 description 1
- 229950002654 lurtotecan Drugs 0.000 description 1
- XGVJWXAYKUHDOO-DANNLKNASA-N lycorine Chemical compound C1CN2CC3=CC=4OCOC=4C=C3[C@H]3[C@H]2C1=C[C@H](O)[C@H]3O XGVJWXAYKUHDOO-DANNLKNASA-N 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 150000002680 magnesium Chemical class 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- MQXVYODZCMMZEM-ZYUZMQFOSA-N mannomustine Chemical compound ClCCNC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CNCCCl MQXVYODZCMMZEM-ZYUZMQFOSA-N 0.000 description 1
- 229950008612 mannomustine Drugs 0.000 description 1
- 229940099262 marinol Drugs 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- QZIQJVCYUQZDIR-UHFFFAOYSA-N mechlorethamine hydrochloride Chemical compound Cl.ClCCN(C)CCCl QZIQJVCYUQZDIR-UHFFFAOYSA-N 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- 229960004296 megestrol acetate Drugs 0.000 description 1
- JDSHMPZPIAZGSV-UHFFFAOYSA-N melamine Chemical compound NC1=NC(N)=NC(N)=N1 JDSHMPZPIAZGSV-UHFFFAOYSA-N 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 description 1
- VJRAUFKOOPNFIQ-TVEKBUMESA-N methyl (1r,2r,4s)-4-[(2r,4s,5s,6s)-5-[(2s,4s,5s,6s)-5-[(2s,4s,5s,6s)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-4-(dimethylamino)-6-methyloxan-2-yl]oxy-2-ethyl-2,5,7,10-tetrahydroxy-6,11-dioxo-3,4-dihydro-1h-tetracene-1-carboxylat Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=C(O)C=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1C[C@H](O)[C@H](O)[C@H](C)O1 VJRAUFKOOPNFIQ-TVEKBUMESA-N 0.000 description 1
- QRMNENFZDDYDEF-GOSISDBHSA-N methyl (8s)-8-(bromomethyl)-2-methyl-4-(4-methylpiperazine-1-carbonyl)oxy-6-(5,6,7-trimethoxy-1h-indole-2-carbonyl)-7,8-dihydro-3h-pyrrolo[3,2-e]indole-1-carboxylate Chemical compound C1([C@H](CBr)CN(C1=C1)C(=O)C=2NC3=C(OC)C(OC)=C(OC)C=C3C=2)=C2C(C(=O)OC)=C(C)NC2=C1OC(=O)N1CCN(C)CC1 QRMNENFZDDYDEF-GOSISDBHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229960005485 mitobronitol Drugs 0.000 description 1
- 229960003539 mitoguazone Drugs 0.000 description 1
- MXWHMTNPTTVWDM-NXOFHUPFSA-N mitoguazone Chemical compound NC(N)=N\N=C(/C)\C=N\N=C(N)N MXWHMTNPTTVWDM-NXOFHUPFSA-N 0.000 description 1
- VFKZTMPDYBFSTM-GUCUJZIJSA-N mitolactol Chemical compound BrC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-GUCUJZIJSA-N 0.000 description 1
- 229950010913 mitolactol Drugs 0.000 description 1
- 229960000350 mitotane Drugs 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000002625 monoclonal antibody therapy Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- VEQIZIHLBKMCHW-GFCCVEGCSA-N n-[(2r)-2,3-dihydroxypropoxy]-5-(2-fluoro-4-iodoanilino)imidazo[1,5-a]pyridine-6-carboxamide Chemical compound OC[C@@H](O)CONC(=O)C=1C=CC2=CN=CN2C=1NC1=CC=C(I)C=C1F VEQIZIHLBKMCHW-GFCCVEGCSA-N 0.000 description 1
- BMNCEMNXUSPULU-SNVBAGLBSA-N n-[(2r)-2,3-dihydroxypropoxy]-8-fluoro-5-(2-fluoro-4-iodoanilino)imidazo[1,5-a]pyridine-6-carboxamide Chemical compound OC[C@@H](O)CONC(=O)C=1C=C(F)C2=CN=CN2C=1NC1=CC=C(I)C=C1F BMNCEMNXUSPULU-SNVBAGLBSA-N 0.000 description 1
- NJSMWLQOCQIOPE-OCHFTUDZSA-N n-[(e)-[10-[(e)-(4,5-dihydro-1h-imidazol-2-ylhydrazinylidene)methyl]anthracen-9-yl]methylideneamino]-4,5-dihydro-1h-imidazol-2-amine Chemical compound N1CCN=C1N\N=C\C(C1=CC=CC=C11)=C(C=CC=C2)C2=C1\C=N\NC1=NCCN1 NJSMWLQOCQIOPE-OCHFTUDZSA-N 0.000 description 1
- BLCLNMBMMGCOAS-UHFFFAOYSA-N n-[1-[[1-[[1-[[1-[[1-[[1-[[1-[2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amin Chemical compound C1CCC(C(=O)NNC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 BLCLNMBMMGCOAS-UHFFFAOYSA-N 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- XGXNTJHZPBRBHJ-UHFFFAOYSA-N n-phenylpyrimidin-2-amine Chemical class N=1C=CC=NC=1NC1=CC=CC=C1 XGXNTJHZPBRBHJ-UHFFFAOYSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229940086322 navelbine Drugs 0.000 description 1
- 238000009099 neoadjuvant therapy Methods 0.000 description 1
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 description 1
- 229960001420 nimustine Drugs 0.000 description 1
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 1
- SFDJOSRHYKHMOK-UHFFFAOYSA-N nitramide Chemical compound N[N+]([O-])=O SFDJOSRHYKHMOK-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- KGTDRFCXGRULNK-JYOBTZKQSA-N nogalamycin Chemical compound CO[C@@H]1[C@@](OC)(C)[C@@H](OC)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=C4[C@@]5(C)O[C@H]([C@H]([C@@H]([C@H]5O)N(C)C)O)OC4=C3C3=O)=C3C=C2[C@@H](C(=O)OC)[C@@](C)(O)C1 KGTDRFCXGRULNK-JYOBTZKQSA-N 0.000 description 1
- 229950009266 nogalamycin Drugs 0.000 description 1
- 229940085033 nolvadex Drugs 0.000 description 1
- ZCYXXKJEDCHMGH-UHFFFAOYSA-N nonane Chemical compound CCCC[CH]CCCC ZCYXXKJEDCHMGH-UHFFFAOYSA-N 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 1
- BKIMMITUMNQMOS-UHFFFAOYSA-N normal nonane Natural products CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- CZDBNBLGZNWKMC-MWQNXGTOSA-N olivomycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1)O[C@H]1O[C@@H](C)[C@H](O)[C@@H](OC2O[C@@H](C)[C@H](O)[C@@H](O)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@H](O)[C@H](OC)[C@H](C)O1 CZDBNBLGZNWKMC-MWQNXGTOSA-N 0.000 description 1
- 229950005848 olivomycin Drugs 0.000 description 1
- 229950011093 onapristone Drugs 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229940043515 other immunoglobulins in atc Drugs 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 229940046231 pamidronate Drugs 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- VREZDOWOLGNDPW-UHFFFAOYSA-N pancratistatine Natural products C1=C2C3C(O)C(O)C(O)C(O)C3NC(=O)C2=C(O)C2=C1OCO2 VREZDOWOLGNDPW-UHFFFAOYSA-N 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229960002621 pembrolizumab Drugs 0.000 description 1
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 1
- 229960005079 pemetrexed Drugs 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- QIMGFXOHTOXMQP-GFAGFCTOSA-N peplomycin Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCN[C@@H](C)C=1C=CC=CC=1)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C QIMGFXOHTOXMQP-GFAGFCTOSA-N 0.000 description 1
- 229950003180 peplomycin Drugs 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- NJBFOOCLYDNZJN-UHFFFAOYSA-N pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 description 1
- 229960000952 pipobroman Drugs 0.000 description 1
- NUKCGLDCWQXYOQ-UHFFFAOYSA-N piposulfan Chemical compound CS(=O)(=O)OCCC(=O)N1CCN(C(=O)CCOS(C)(=O)=O)CC1 NUKCGLDCWQXYOQ-UHFFFAOYSA-N 0.000 description 1
- 229950001100 piposulfan Drugs 0.000 description 1
- 229960001221 pirarubicin Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 1
- 229960001237 podophyllotoxin Drugs 0.000 description 1
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 150000003109 potassium Chemical class 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229960004694 prednimustine Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000003623 progesteronic effect Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 229940087463 proleukin Drugs 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- WOLQREOUPKZMEX-UHFFFAOYSA-N pteroyltriglutamic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(=O)NC(CCC(=O)NC(CCC(O)=O)C(O)=O)C(O)=O)C(O)=O)C=C1 WOLQREOUPKZMEX-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- DNXIASIHZYFFRO-UHFFFAOYSA-N pyrazoline Chemical compound C1CN=NC1 DNXIASIHZYFFRO-UHFFFAOYSA-N 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical compound OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 229940076788 pyruvate Drugs 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- UOWVMDUEMSNCAV-WYENRQIDSA-N rachelmycin Chemical compound C1([C@]23C[C@@H]2CN1C(=O)C=1NC=2C(OC)=C(O)C4=C(C=2C=1)CCN4C(=O)C1=CC=2C=4CCN(C=4C(O)=C(C=2N1)OC)C(N)=O)=CC(=O)C1=C3C(C)=CN1 UOWVMDUEMSNCAV-WYENRQIDSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229940089617 risedronate Drugs 0.000 description 1
- 229950004892 rodorubicin Drugs 0.000 description 1
- MBABCNBNDNGODA-WPZDJQSSSA-N rolliniastatin 1 Natural products O1[C@@H]([C@@H](O)CCCCCCCCCC)CC[C@H]1[C@H]1O[C@@H]([C@H](O)CCCCCCCCCC[C@@H](O)CC=2C(O[C@@H](C)C=2)=O)CC1 MBABCNBNDNGODA-WPZDJQSSSA-N 0.000 description 1
- IMUQLZLGWJSVMV-UOBFQKKOSA-N roridin A Natural products CC(O)C1OCCC(C)C(O)C(=O)OCC2CC(=CC3OC4CC(OC(=O)C=C/C=C/1)C(C)(C23)C45CO5)C IMUQLZLGWJSVMV-UOBFQKKOSA-N 0.000 description 1
- VHXNKPBCCMUMSW-FQEVSTJZSA-N rubitecan Chemical compound C1=CC([N+]([O-])=O)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VHXNKPBCCMUMSW-FQEVSTJZSA-N 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229930182947 sarcodictyin Natural products 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 229950001403 sizofiran Drugs 0.000 description 1
- 229940112726 skelid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 229950006315 spirogermanium Drugs 0.000 description 1
- ICXJVZHDZFXYQC-UHFFFAOYSA-N spongistatin 1 Natural products OC1C(O2)(O)CC(O)C(C)C2CCCC=CC(O2)CC(O)CC2(O2)CC(OC)CC2CC(=O)C(C)C(OC(C)=O)C(C)C(=C)CC(O2)CC(C)(O)CC2(O2)CC(OC(C)=O)CC2CC(=O)OC2C(O)C(CC(=C)CC(O)C=CC(Cl)=C)OC1C2C ICXJVZHDZFXYQC-UHFFFAOYSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 208000034223 susceptibility to 2 systemic lupus erythematosus Diseases 0.000 description 1
- AYUNIORJHRXIBJ-TXHRRWQRSA-N tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 description 1
- 229950007866 tanespimycin Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- RCINICONZNJXQF-XAZOAEDWSA-N taxol® Chemical compound O([C@@H]1[C@@]2(CC(C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-XAZOAEDWSA-N 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- 229960001674 tegafur Drugs 0.000 description 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
- 229940061353 temodar Drugs 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000002769 thiazolinyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000002053 thietanyl group Chemical group 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 229930192474 thiophene Chemical group 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- YFTWHEBLORWGNI-UHFFFAOYSA-N tiamiprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC(N)=NC2=C1NC=N2 YFTWHEBLORWGNI-UHFFFAOYSA-N 0.000 description 1
- 229950011457 tiamiprine Drugs 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- PXSOHRWMIRDKMP-UHFFFAOYSA-N triaziquone Chemical compound O=C1C(N2CC2)=C(N2CC2)C(=O)C=C1N1CC1 PXSOHRWMIRDKMP-UHFFFAOYSA-N 0.000 description 1
- 229960004560 triaziquone Drugs 0.000 description 1
- 229930013292 trichothecene Natural products 0.000 description 1
- 150000003327 trichothecene derivatives Chemical class 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- 229960001670 trilostane Drugs 0.000 description 1
- KVJXBPDAXMEYOA-CXANFOAXSA-N trilostane Chemical compound OC1=C(C#N)C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@@]32O[C@@H]31 KVJXBPDAXMEYOA-CXANFOAXSA-N 0.000 description 1
- NOYPYLRCIDNJJB-UHFFFAOYSA-N trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 1
- 229960001099 trimetrexate Drugs 0.000 description 1
- 229950000212 trioxifene Drugs 0.000 description 1
- 229950010147 troxacitabine Drugs 0.000 description 1
- RXRGZNYSEHTMHC-BQBZGAKWSA-N troxacitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)OC1 RXRGZNYSEHTMHC-BQBZGAKWSA-N 0.000 description 1
- HDZZVAMISRMYHH-LITAXDCLSA-N tubercidin Chemical compound C1=CC=2C(N)=NC=NC=2N1[C@@H]1O[C@@H](CO)[C@H](O)[C@H]1O HDZZVAMISRMYHH-LITAXDCLSA-N 0.000 description 1
- 239000003744 tubulin modulator Substances 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
- 229950009811 ubenimex Drugs 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 239000002525 vasculotropin inhibitor Substances 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- CILBMBUYJCWATM-PYGJLNRPSA-N vinorelbine ditartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC CILBMBUYJCWATM-PYGJLNRPSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229960001771 vorozole Drugs 0.000 description 1
- XLMPPFTZALNBFS-INIZCTEOSA-N vorozole Chemical compound C1([C@@H](C2=CC=C3N=NN(C3=C2)C)N2N=CN=C2)=CC=C(Cl)C=C1 XLMPPFTZALNBFS-INIZCTEOSA-N 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 229940053867 xeloda Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229950009268 zinostatin Drugs 0.000 description 1
- 229940002005 zometa Drugs 0.000 description 1
- FBTUMDXHSRTGRV-ALTNURHMSA-N zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 description 1
- 229960000641 zorubicin Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
本發明闡述包含PD-1軸結合拮抗劑及MEK抑制劑之組合治療及其使用方法,包括治療需要增強免疫原性之病況之方法,例如增強腫瘤免疫原性以供治療癌症。
Description
向T細胞提供兩種不同信號係抗原呈遞細胞(APC)對靜息T淋巴球進行淋巴球活化的廣泛接受之模型。Lafferty等人,Aust. J. Exp. Biol. Med. ScL 53: 27-42 (1975)。此模型進一步提供自身與非自身之區別及免疫耐受性。Bretscher等人,Science 169: 1042-1049 (1970);Bretscher, P.A., P.N.A.S. USA 96: 185-190 (1999);Jenkins等人,J. Exp. Med. 165: 302-319 (1987)。主要信號或抗原特異性信號係在識別主要組織相容性複合物(MHC)之背景下呈遞之外來抗原肽後經由T細胞受體(TCR)轉導。第二或共刺激信號係藉由抗原呈遞細胞(APC)上表現之共刺激分子遞送至T細胞,且誘導T細胞促進純系擴增、細胞介素分泌及效應子功能。Lenschow等人,Ann, Rev. Immunol. 14:233 (1996)。在不存在共刺激時,T細胞可變得對抗原刺激不反應,不發動有效免疫反應,且可進一步導致耗竭或對外來抗原之耐受性。
在雙信號模型中,T細胞接收正及負二級共刺激信號。對此等正及負信號之調控對於使宿主之保護性免疫反應最大化同時維持免疫耐受性並防止自體免疫至關重要。負二級信號似乎為誘導T細胞耐受性所必需,而正信號促進T細胞活化。儘管簡單雙信號模型仍向天然淋巴球提供有效解釋,但宿主之免疫反應係動態過程,且亦可將共刺激信號提供至暴露於抗原之T細胞。共刺激機制在治療上引人關注,此乃因已顯示,對共刺激信號之操作提供增強或終止基於細胞之免疫反應之手段。最近已發現,T細胞功能異常或無因變性與抑制性受體程式化死亡1多肽(PD-1)之經誘導且持續之表現同時發生。因此,治療靶向PD-1及經由與PD-1相互作用而發出信號之其他分子(例如程式化死亡配體1 (PD-L1)及程式化死亡配體2 (PD-L2))係倍受關注之領域。
PD-L1在許多癌症中過表現,且通常與差預後相關(Okazaki T等人,Intern. Immun. 2007 19(7):813)(Thompson RH等人,Cancer Res 2006, 66(7):3381)。有趣的是,大多數腫瘤浸潤性T淋巴球主要表現PD-1,此與正常組織中之T淋巴球及周邊血T淋巴球不同,從而指示上調腫瘤反應性T細胞上之PD-1可損害抗腫瘤免疫反應(Blood 2009 114(8): 1537)。此可歸因於以下事件:利用藉由PD-L1表現腫瘤細胞與PD-1表現T細胞相互作用介導之PD-L1信號傳導來減弱T細胞活化並逃避免疫監視(Sharpe等人,Nat Rev 2002)(Keir ME等人,2008 Annu. Rev. Immunol. 26:677)。因此,抑制PD-L1/PD-1相互作用可增強CD8+ T細胞介導之腫瘤殺傷。
人們已提出將抑制經由直接配體(例如,PD-L1、PD-L2)之PD-1軸信號傳導作為增強治療癌症之T細胞免疫(例如,腫瘤免疫)之手段。此外,已藉由抑制PD-L1與結合配偶體B7-1之結合觀察到對T細胞免疫之類似增強。此外,組合抑制PD-1信號傳導與在腫瘤細胞中失調之其他信號傳導途徑(例如MAPK途徑,「MEK」)可進一步增強治療功效。然而,最佳治療性治療將組合對PD-1受體/配體相互作用之阻斷與直接抑制腫瘤生長之藥劑,視情況進一步包括單獨藉由PD-1阻斷不提供之獨特免疫增強性質。業內仍需要此一治療、穩定、預防各種癌症及/或延遲其發展之最佳療法。
本文所揭示所有參考文獻、出版物及專利申請案之全文皆以引用方式併入本文中。
本發明闡述組合治療,其包含MEK抑制劑(其具有直接腫瘤靶向效應及免疫增強性質)及PD-1軸結合拮抗劑。
本文提供治療個體之癌症或減緩癌症進展之方法,其包含向該個體投與有效量之PD-1軸結合拮抗劑及MEK抑制劑。
本文亦提供PD-1軸結合拮抗劑之用途,其用於製造與MEK抑制劑組合治療個體之癌症或延遲其進展之藥劑。本文亦提供MEK抑制劑之用途,其用於製造與PD-1軸結合拮抗劑組合治療個體之癌症或延遲其進展之藥劑。本文亦提供PD-1軸結合拮抗劑及MEK抑制劑之用途,其用於製造用以治療個體之癌症或延遲其進展之藥劑。本文亦提供製造用以治療個體之癌症或延遲其進展之藥劑的方法,其特徵在於使用PD-1軸結合拮抗劑及MEK抑制劑。本文亦提供PD-1軸結合拮抗劑,其與MEK抑制劑組合用於治療個體之癌症或延遲其進展。本文亦提供MEK抑制劑,其與PD-1軸結合拮抗劑組合用於治療個體之癌症或延遲其進展。
所治療癌症可含有BRAF V600E突變、BRAF野生型、KRAS野生型或活化KRAS突變。癌症可係黑色素瘤、結腸直腸癌、非小細胞肺癌、卵巢癌、乳癌、前列腺癌、胰腺癌、血液惡性病或腎細胞癌。癌症可處於早期或處於晚期。在一些實施例中,所治療個體係人類。
在一些實施例中,治療使個體在停止治療後產生持續反應。在一些實施例中,治療使個體產生完全反應、部分反應或穩定疾病。
本文亦提供增強患有癌症之個體之免疫功能的方法,其包含投與有效量之PD-1軸結合拮抗劑及MEK抑制劑。在一些實施例中,個體係人類。
本文亦提供PD-1軸結合拮抗劑之用途,其用於製造與MEK抑制劑組合增強患有癌症之個體之免疫功能之藥劑。本文亦提供MEK抑制劑之用途,其用於製造與PD-1軸結合拮抗劑組合增強患有癌症之個體之免疫功能之藥劑。本文亦提供PD-1軸結合拮抗劑及MEK抑制劑之用途,其用於製造用以增強患有癌症之個體之免疫功能的藥劑。本文亦提供用於增強個體之免疫功能之藥劑的製造方法,其特徵在於使用PD-1軸結合拮抗劑及MEK抑制劑。本文亦提供PD-1軸結合拮抗劑,其與MEK抑制劑組合用於增強患有癌症之個體之免疫功能。本文亦提供MEK抑制劑,其與PD-1軸結合拮抗劑組合用於增強患有癌症之個體之免疫功能。在一些實施例中,個體係人類。
在一些實施例中,PD-1軸結合拮抗劑係PD-1結合拮抗劑、PD-L1結合拮抗劑或PD-L2結合拮抗劑。在一些實施例中,PD-1結合拮抗劑抑制PD-1與PD-L1結合及/或PD-1與PD-L2結合。在一些實施例中,PD-1結合拮抗劑係抗體(例如,本文所述抗體MDX-1106、CT-011及Merck 3745)、其抗原結合片段、免疫黏附素、融合蛋白或寡肽。在一些實施例中,PD-1結合拮抗劑係包含融合至Fc結構域之PD‑L2細胞外結構域的免疫黏附素(例如,本文所述AMP‑224)。在一些實施例中,PD-L1結合拮抗劑抑制PD‑L1與PD-1結合及/或PD-L1與B7-1結合。在一些實施例中,PD-L1結合拮抗劑係抗體(例如,本文所述抗體YW243.55.S70、MPDL3280A及MDX-1105)、其抗原結合片段、免疫黏附素、融合蛋白或寡肽。在一些實施例中,PD-L2結合拮抗劑抑制PD-L2與PD-1結合。在一些實施例中,PD-L2結合拮抗劑係抗體、其抗原結合片段、免疫黏附素、融合蛋白或寡肽。
在一些實施例中,MEK抑制劑係如下文所述式(I)、(II)、(III)、(IV)、(V)或(VI)之化合物或其醫藥上可接受之鹽或溶劑合物。
在一些實施例中,MEK抑制劑係MEK之競爭抑制劑。在一些實施例中,MEK抑制劑針對活化性KRAS突變之選擇性較高。在一些實施例中,MEK抑制劑係MEK之異位抑制劑。在一些實施例中,MEK抑制劑針對活化性BRAF突變之選擇性較高。在一些實施例中,MEK抑制劑係選自由以下組成之群:G02442104、G-38963、G02443714、G00039805及GDC-0973或其醫藥上可接受之鹽或溶劑合物。
在一些實施例中,連續或間歇地投與MEK抑制劑。在一些實施例中,在投與PD-1軸結合拮抗劑之前,與投與PD-1軸結合拮抗劑同時,或在投與PD-1軸結合拮抗劑之後投與MEK抑制劑。在一些實施例中,以不同投藥頻率投與MEK抑制劑及PD-1軸結合拮抗劑。
在另一態樣中,提供包含PD-1軸結合拮抗劑及/或MEK抑制劑之套組,其用於治療個體之癌症或延遲其進展或增強患有癌症之個體之免疫功能。套組可包含PD-1軸結合拮抗劑及包裝插頁,該包裝插頁包含使用PD-1軸結合拮抗劑與MEK抑制劑之組合來治療個體之癌症或延遲其進展或增強患有癌症之個體之免疫功能的說明書。套組可包含MEK抑制劑及包裝插頁,該包裝插頁包含使用MEK抑制劑與PD-1軸結合拮抗劑之組合來治療個體之癌症或延遲其進展或增強患有癌症之個體之免疫功能的說明書。套組可包含PD-1軸結合拮抗劑及MEK抑制劑以及包裝插頁,該包裝插頁包含使用PD-1軸結合拮抗劑及MEK抑制劑來治療個體之癌症或延遲其進展或增強患有癌症之個體之免疫功能的說明書。
[相關申請案之交互參照]
本申請案主張2011年8月1日提出申請之美國臨時申請案第61/574,406號之優先權益,其全部內容以引用方式併入本文中。
I. 一般技術本文所述或所提及之技術及程序通常為彼等熟習此項技術者所充分理解且通常採用,其中使用習用方法,例如闡述於以下文獻中之廣泛利用之方法:Sambrook等人,
Molecular Cloning: A. Laboratory Manual第3版(2001) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.;
Current Protocols in Molecular Biology(F.M. Ausubel等人編輯,(2003));叢書
Methods in Enzymology(Academic Press公司):
PCR 2: A Practical Approach(M.J. MacPherson, B.D. Hames及G.R. Taylor編輯(1995)), Harlow及Lane編輯(1988)
Antibodies, A Laboratory Manual,and
Animal Cell Culture(R.I. Freshney編輯(1987));
Oligonucleotide Synthesis(M.J. Gait編輯,1984);
Methods in Molecular Biology,Humana Press;
Cell Biology: A Laboratory Notebook(J.E.
Cellis編輯,1998) Academic Press;
Animal Cell Culture(R.I. Freshney)編輯,1987);
Introduction to Cell and Tissue Culture(J.P. Mather及P.E. Roberts, 1998) Plenum Press;
Cell and Tissue Culture: Laboratory Procedures(A. Doyle、LB. Griffiths及D.G. Newell編輯,1.993-8) J. Wiley and Sons;
Handbook of Experimental Immunology (D.M.Weir及C.C. Blackwell編輯);
Gene Transfer Vectors for Mammalian Cells(J.M. Miller及M.P. Calos編輯,1987);
PCR: The Polymerase Chain Reaction,(Mullis等人編輯,1994);
Current Protocols in Immunology(J.E. Coligan等人編輯,1991);
Short Protocols in Molecular Biology(Wiley and Sons, 1999);
Immunobiology(C.A. Janeway及P. Travers, 1997);
Antibodies(P. Finch, 1997);
Antibodies: A. Practical Approach(D. Catty.編輯,IRL Press, 1988-1989);
Monoclonal Antibodies: A Practical Approach(P. Shepherd及C. Dean編輯,Oxford University Press, 2000);
Using Antibodies: A Laboratory Manual(E. Harlow及D. Lane,Cold Spring Harbor Laboratory Press, 1999);
The Antibodies(M. Zanetti及J. D. Capra編輯,Harwood Academic Publishers, 1995);及
Cancer: Principles and Practice of Oncology(V.T. DeVita等人編輯,J.B. Lippincott公司,1993)。
II. 定義術語「
PD-1 軸結合拮抗劑」係抑制PD-1軸結合配偶體與其結合配偶體中之一或多者相互作用,以去除由PD-1信號傳導軸上之信號傳導引起之T細胞功能異常的分子,其中一個結果係恢復或增強T細胞功能(例如,增殖、產生細胞介素、殺傷靶T細胞)。本文所用PD-1軸結合拮抗劑包括PD-1結合拮抗劑、PD-L1結合拮抗劑及PD-L2結合拮抗劑。
術語「
PD-1 結合拮抗劑」係降低、阻斷、抑制、消除或干擾由PD-1與其結合配偶體(例如PD-L1、PD-L2)中之一或多者相互作用引起之信號轉導的分子。在一些實施例中,PD-1結合拮抗劑係抑制PD-1與其結合配偶體結合之分子。在具體態樣中,PD-l結合拮抗劑抑制PD-1與PD-L1及/或PD-L2結合。例如,PD-1結合拮抗劑包括抗PD-1抗體、其抗原結合片段、免疫黏附素、融合蛋白、寡肽及其他分子,該等分子降低、阻斷、抑制、消除或干擾由PD-1與PD-L1及/或PD-L2相互作用引起之信號轉導。在一個實施例中,PD-1結合拮抗劑降低藉由或經由PD-1之信號傳導所介導T淋巴球上表現之細胞表面蛋白介導的負共刺激信號,以使功能異常T細胞較少功能異常(例如,增強對抗原識別之效應子反應)。在一些實施例中,PD-1結合拮抗劑係抗PD-1抗體。在一具體態樣中,PD-1結合拮抗劑係本文所述MDX-1106。在另一具體態樣中,PD-1結合拮抗劑係本文所述Merck 3745。在另一具體態樣中,PD-1結合拮抗劑係本文所述CT-011。
術語「
PD-L1 結合拮抗劑」係降低、阻斷、抑制、消除或干擾由PD-L1與其結合配偶體(例如PD-1、B7-1)中之一或多者相互作用引起之信號轉導的分子。在一些實施例中,PD-L1結合拮抗劑係抑制PD-L1與其結合配偶體結合之分子。在具體態樣中,PD-L1結合拮抗劑抑制PD-L1與PD-1及/或B7-1結合。在一些實施例中,PD-L1結合拮抗劑包括抗PD-L1抗體、其抗原結合片段、免疫黏附素、融合蛋白、寡肽及其他分子,該等分子降低、阻斷、抑制、消除或干擾由PD-L1與其結合配偶體(例如PD-1、B7-1)中之一或多者相互作用引起之信號轉導。在一個實施例中,PD-L1結合拮抗劑降低藉由或經由PD-L1之信號傳導所介導T淋巴球上表現之細胞表面蛋白介導的負共刺激信號,以使功能異常T細胞較少功能異常(例如,增強對抗原識別之效應子反應)。在一些實施例中,PD-L1結合拮抗劑係抗PD-L1抗體。在一具體態樣中,抗PD-L1抗體係本文所述YW243.55.S70。在另一具體態樣中,抗PD-L1抗體係本文所述MDX-1105。在再一具體態樣中,抗PD-L1抗體係本文所述MPDL3280A。
術語「
PD-L2 結合拮抗劑」係降低、阻斷、抑制、消除或干擾由PD-L2與其結合配偶體(例如PD-1)中之一或多者相互作用引起之信號轉導的分子。在一些實施例中,PD‑L2結合拮抗劑係抑制PD-L2與其結合配偶體結合之分子。在具體態樣中,PD-L2結合拮抗劑抑制PD-L2與PD-1結合。在一些實施例中,PD-L2結合拮抗劑包括抗PD-L2抗體、其抗原結合片段、免疫黏附素、融合蛋白、寡肽及其他分子,該等分子降低、阻斷、抑制、消除或干擾由PD-L2與其結合配偶體(例如PD-1)中之一或多者相互作用引起之信號轉導。在一個實施例中,PD-L2結合拮抗劑降低藉由或經由PD-L2之信號傳導所介導T淋巴球上表現之細胞表面蛋白介導的負共刺激信號,以使功能異常T細胞較少功能異常(例如,增強對抗原識別之效應子反應)。在一些實施例中,PD-L2結合拮抗劑係免疫黏附素。
在免疫功能異常之背景下,術語「
功能異常」係指對抗原刺激之免疫反應性降低之狀態。該術語包括
耗竭及/或
無因變性之常見要素,其中可發生抗原識別,但隨後免疫反應不能控制感染或腫瘤生長。
本文所用術語「
功能異常的」亦包括對抗原識別不反應或無反應,具體而言,將抗原識別轉化成下游T細胞效應子功能(例如增殖、產生細胞介素(例如,IL-2)及/或殺傷靶T細胞)之能力受損。
術語「
無因變性」係指因經由T細胞受體遞送之信號不完全或不足(例如在不存在ras-活化時細胞內Ca
+2之增加)引起的對抗原刺激無反應性之狀態。T細胞無因變性亦可在不存在共刺激時在抗原刺激後產生,從而使細胞變得即使在共刺激之背景下亦對抗原之隨後活化不反應。無反應狀態通常可藉由介白素-2之存在來消除。無因變性T細胞不會經受純系擴增及/或不會獲得效應子功能。
術語「
耗竭」係指呈T細胞功能異常狀態之T細胞耗竭,該功能異常係因在許多慢性感染及癌症期間發生之持續TCR信號傳導產生。其與無反應性之區別在於其並非經由不完全或不充分信號傳導,而是自持續信號傳導產生。其係藉由差效應子功能、抑制受體之持續表現及與功能性效應子或記憶T細胞不同之轉錄狀態來界定。耗竭阻止對感染及腫瘤進行最佳控制。耗竭可由非固有負調控途徑(例如,免疫調控細胞介素)以及細胞固有負調控(共刺激)途徑(PD-1、B7-H3、B7-H4等)二者引起。
「
增強 T 細胞功能」意指誘導、引起或刺激T細胞具有持續或擴大之生物學功能或更新或再活化耗竭或無活性T細胞。增強T細胞功能之實例包括:相對於此等在干擾前之程度,增加之來自CD8
+T細胞之γ干擾素分泌、增加之增殖、增加之抗原反應性(例如,病毒、病原體或腫瘤清除)。在一個實施例中,增強程度係至少50%、或者60%、70%、80%、90%、100%、120%、150%、200%。熟習此項技術者已知量測此增強之方式。
「
T 細胞功能異常病症」係特徵在於對抗原刺激之反應性降低之T細胞病症或病況。在一特定實施例中,T細胞功能異常病症係具體而言與經由PD-1之信號傳導不當增加相關之病症。在另一實施例中,T細胞功能異常病症係T細胞無因變性或分泌細胞介素、增殖或執行細胞溶解活性之能力降低者。在一具體態樣中,反應性降低導致不能控制表現免疫原之病原體或腫瘤。特徵在於T細胞功能異常之T細胞功能異常病症之實例包括未解決(unresolved)之急性感染、慢性感染及腫瘤免疫。
「
腫瘤免疫」係指腫瘤逃避免疫識別及清除之過程。因此,作為治療概念,當此逃避減弱且免疫系統識別並攻擊腫瘤時,「治療」腫瘤免疫。腫瘤識別之實例包括腫瘤結合、腫瘤縮小及腫瘤清除。
「
免疫原性」係指特定物質激發免疫反應之能力。腫瘤具有免疫原性且增強腫瘤免疫原性有助於藉由免疫反應清除腫瘤細胞。增強腫瘤免疫原性之實例包括用抗PDL抗體及MEK抑制劑治療。
「
持續反應」係指對減緩停止治療後之腫瘤生長之持續效應。例如,與投與階段開始時之大小相比,腫瘤大小可保持相同或更小。在一些實施例中,持續反應之持續時間至少與治療持續時間相同,至少為治療持續時間長度之1.5X、2.0X、2.5X或3.0X。
術語「
抗體」包括單株抗體(包括具有免疫球蛋白Fc區之全長抗體)、具有多表位特異性之抗體組合物、多特異性抗體(例如,雙特異性抗體、雙鏈抗體及單鏈分子以及抗體片段(例如,Fab、F(ab')
2及Fv)。術語「
免疫球蛋白」(Ig)在本文中可與「
抗體」互換使用。
基本4鏈抗體單元係由兩條相同輕(L)鏈及兩條相同重(H)鏈構成之異四聚物糖蛋白。IgM抗體係由5個基本異四聚物單元以及稱為J鏈之額外多肽組成,且含有10個抗原結合位點,而IgA抗體包含2至5個基本4鏈單元,該等單元可與J鏈組合聚合而形成多價裝配物。在IgG情形下,該4鏈單元通常為約150,000道爾頓。每一L鏈藉由一個共價二硫鍵與H鏈連接,而兩條H鏈端視H鏈同種型而定藉由一或多個二硫鍵彼此連接。每一H鏈及L鏈亦可有規則地由鏈內二硫橋間隔開。每一H鏈在N末端處具有可變結構域(V
H),之後為3個恆定結構域(C
H)(對於每一α及γ鏈而言)及4個C
H結構域(對於μ及ε同種型而言)。每一L鏈在N末端具有可變結構域(V
L),之後在其另一端為恆定結構域(C
L)。V
L與V
H對準,而C
L與重鏈之第一恆定結構域(C
H1)對準。人們相信,特定胺基酸殘基在輕鏈可變結構域與重鏈可變結構域之間形成界面。V
H與V
L配對共同形成單抗原結合位點。關於不同類別抗體之結構及性質,例如,參見
Basic and Clinical Immunology,第8版,Daniel P. Sties、Abba I. Terr及Tristram G. Parsolw (編輯),Appleton & Lange, Norwatk, CT, 1994,第71頁及第6章。可基於恆定結構域之胺基酸序列將來自任何脊椎動物物種之L鏈分配為兩種明顯不同類型(稱為κ及λ)中之一者。端視重鏈(C
H)恆定結構域之胺基酸序列,可將免疫球蛋白分配為不同類別或同型物。免疫球蛋白有五類:IgA、IgD、IgE、IgG及IgM,其重鏈分別命名為α、δ、ε、γ及μ。可基於C
H序列及功能之相對較小差異將γ及α類別進一步劃分成亞類,例如人類表現以下列亞類:IgGl、IgG2A、IgG2B、IgG3、IgG4、IgAl及IgA2。
抗體之「
可變區」
或「
可變結構域」係指抗體重鏈或輕鏈之胺基末端結構域。重鏈及輕鏈之可變結構域可分別稱為「
VH」及「
VL」。該等結構域通常為抗體之最可變部分(相對於相同類別之其他抗體)且含有抗原結合位點。
術語「可變」係指抗體之間可變結構域之某些區段之序列差異極大的事實。V結構域介導抗原結合並界定特定抗體對其特定抗原之特異性。然而,可變性在整個可變結構域範圍內並不均勻分佈。而是,其在輕鏈可變結構域與重鏈可變結構域二者中均主要集中於三個稱為超變區(HVR)之區段上。可變結構域之保守程度較高之部分稱為框架區(FR)。天然重鏈及輕鏈之可變結構域各自包括4個由三個HVR連接之主要採用β薄片組態的FR區,該等HVR形成連接且在一些情況下形成β薄片結構之一部分的環。每一鏈中之HVR藉助FR保持緊密靠近,且與來自另一鏈之HVR一起促進形成抗體之抗原結合位點(參見Kabat等人
, Sequences of Immunological Interest,第5版,National Institutes of Health,Bethesda,MD (1991))。恆定結構域並不直接參與抗體與抗原之結合,但展現各種效應子作用,例如抗體參與抗體依賴性細胞毒性。
本文所用術語「
單株抗體」係指自實質上同源之抗體群體獲得之抗體,即除少量存在之可能天然突變及/或轉譯後修飾(異構化、醯胺化)外,構成該群體之個別抗體皆相同。單株抗體針對單個抗原性位點具有高度特異性。與包括針對不同決定子(表位)之不同抗體之多株抗體製劑相反,每一單株抗體針對抗原上之單一決定子簇。除特異性外,單株抗體之優勢亦在於其係藉由未受其他免疫球蛋白污染之雜交瘤培養來合成。修飾詞「單株」指示抗體特徵係自實質上同源之抗體群體獲得,且不應理解為需要藉由任一特定方法來產生抗體。例如,欲根據本發明使用之單株抗體可藉由多種技術製得,該等技術包括(例如),雜交瘤方法(例如,Kohler及Milstein.,
Nature,256:495-97 (1975);Hongo等人,
Hybridoma,14 (3): 253-260 (1995);Harlow等人,
Antibodies: A Laboratory Manual,(Cold Spring Harbor Laboratory Press,第2版,1988);Hammerling等人,
Monoclonal Antibodies and T-Cell Hybridomas563-681 (Elsevier, N.Y., 1981))、重組DNA方法(例如,參見美國專利第4,816,567號)、噬菌體展示技術(例如,參見Clackson等人,
Nature,352: 624-628 (1991);Marks等人,
J. Mol. Biol222: 581-597 (1992);Sidhu等人,
J. Mol Biol.338(2): 299-310 (2004);Lee等人,
J. Mol Biol340(5): 1073-1093 (2004);Fellouse,
Proc. Natl Acad Sci. USA101(34): 12467-12472 (2004);及Lee等人,
J. Immunol Methods284(1-2): 119-132 (2004)及在具有編碼人類免疫球蛋白序列之人類免疫球蛋白基因座或基因之部分或全部的動物中產生人類或人類樣抗體之技術(例如,參見WO 1998/24893;WO 1996/34096;WO 1996/33735;WO 1991/10741;Jakobovits等人,
Proc. Natl Acad. Sci. USA90: 2551 (1993);Jakobovits等人,
Nature362: 255-258 (1993);Bruggemann等人,
Year in Immunol7:33 (1993);美國專利第5,545,807號、第5,545,806號、第5,569,825號、第5,625,126號、第5,633,425號及第5,661,016號;Marks等人,
Bio/Technology10: 779-783 (1992);Lonberg等人,
Nature368: 856-859 (1994);Morrison,
Nature368: 812-813 (1994);Fishwild等人,
Nature Biotechnol14: 845-851 (1996);Neuberger,
Nature Biotechnol.14: 826 (1996);以及Lonberg及Huszar,
Intern. Rev. Immunol13: 65-93 (1995)。
術語「
裸抗體」係指未偶聯至細胞毒性部分或放射性標記之抗體。
術語「
全長抗體」
、「
完整抗體」
或「
全抗體」可互換使用來指呈實質上完整形式之抗體,而非抗體片段。具體而言,全抗體包括彼等具有重鏈及輕鏈且包括Fc區者。恆定結構域可為天然序列恆定結構域(例如人類天然序列恆定結構域)或其胺基酸序列變體。在一些情形下,完整抗體可具有一種或多種效應子功能。
「
抗體片段」包含完整抗體之一部分、較佳完整抗體之抗原結合及/或可變區。抗體片段之實例包括Fab、Fab'、F(ab')
2及Fv片段;雙鏈抗體;線性抗體(參見美國專利第5,641,870號之實例2;Zapata等人,
Protein Eng.
8(10): 1057-1062 [1995]);單鏈抗體分子;及自抗體片段形成之多特異性抗體。抗體經木瓜蛋白酶消化產生兩個稱為「Fab」片段之相同抗原結合片段及殘餘「Fc」片段,「Fc」片段之名稱反映了其易於結晶之能力。Fab片段係由整個L鏈以及H鏈之可變區結構域(V
H)及一條重鏈之第一恆定結構域(C
H1)組成。每一Fab片段就抗原結合而言係單價,即,其具有單個抗原結合位點。抗體經胃蛋白酶處理產生單個大F(ab')
2片段,該片段大致對應於兩個經二硫鍵連接之具有二價抗原結合活性之Fab片段,且仍然能夠交聯抗原。Fab'片段與Fab片段不同之處在於C
H1結構域之羧基末端具有幾個額外殘基,該等殘基包括一或多個來自抗體鉸鏈區之半胱胺酸。本文中Fab'-SH特指恆定結構域之一或多個半胱胺酸殘基具有游離硫醇基之Fab'。F(ab')
2抗體片段最初係作為在其間具有鉸鏈半胱胺酸之Fab'片段對產生。亦已知抗體片段之其他化學偶聯。
Fc片段包含藉由二硫鍵結合在一起之兩條H鏈之羧基末端部分。抗體之效應子功能係由Fc區中之序列確定,該區亦為藉由某些細胞類型上發現之Fc受體(FcR)識別。
「Fv」係含有完全抗原識別及結合位點之最小抗體片段。此片段係由一個重鏈可變區結構域與一個輕鏈可變區結構域呈緊密非共價締合形式之二聚物構成。該兩個結構域摺疊可產生6個超變環(自H鏈及L鏈分別產生3個環),該等超變環貢獻用於抗原結合之胺基酸殘基且賦予抗體以抗原結合特異性。然而,即使單一可變結構域(或Fv之一半,其僅包含3個對抗原具有特異性之HVR)亦具有識別並結合抗原之能力,但其親和力低於完整結合位點。
亦縮寫成「
sFv」或「
scFv」之「
單鏈 Fv」係包含連接至單一多肽鏈之V
H及V
L抗體結構域的抗體片段。較佳地,sFv多肽進一步包含在V
H與V
L結構域之間的多肽連接體,其使sFv能夠形成期望抗原結合結構。關於sFv之綜述,參見Pluckthun,
The Pharmacology of Monoclonal Antibodies,第113卷,Rosenburg及Moore編輯,Springer-Verlag,New York,第269-315頁(1994)。
本發明抗體之「
功能片段」包含完整抗體之一部分,該部分通常包括完整抗體之抗原結合或可變區或抗體之保留或具有經修飾FcR結合能力之Fc區。抗體片段之實例包括線性抗體、單鏈抗體分子及自抗體片段形成之多特異性抗體。
術語「雙鏈抗體」係指藉由以下方式製備之小抗體片段:用介於V
H與V
L結構域之間的短連接體(約5-10個殘基)構築sFv片段(參見前述段落),以便達成V結構域之鏈間而非鏈內配對,藉此產生二價片段,即,具有兩個抗原結合位點之片段。雙特異性雙鏈抗體係兩個「交叉」sFv片段之異源二聚物,其中兩種抗體之V
H及V
L結構域存在於不同多肽鏈上。雙鏈抗體更詳細地闡述於(例如) EP 404,097;WO 93/11161;Hollinger等人,
Proc. Natl. Acad. Sci. USA 90: 6444-6448 (1993)中。
本文中之單株抗體具體而言包括「嵌合」抗體(免疫球蛋白),其中重鏈及/或輕鏈之一部分與源自特定物種或屬於特定抗體類別或亞類之抗體的對應序列相同或同源,而鏈之其餘部分與源自另一物種或屬於另一抗體類別或亞類之抗體的對應序列相同或同源;以及此等抗體之片段,只要其展現期望生物活性即可(美國專利第4,816,567號;Morrison等人,
Proc. Natl. Acad. Sci. USA 81:6851-6855 (1984))。本文中之所關注嵌合抗體包括PRIMATIZED
®抗體,其中抗體之抗原結合區係源自藉由(例如)用所關注抗原對獼猴實施免疫所產生之抗體。本文所用「人類化抗體」係作為「嵌合抗體」亞組使用。
「人類化」形式之非人類(例如
,鼠類)抗體係含有最少量源自非人類免疫球蛋白之序列之嵌合抗體。在一個實施例中,人類化抗體係人類免疫球蛋白(接受者抗體),其中來自接受者HVR(下文所定義)之殘基由來自非人類物種(例如小鼠、大鼠、兔或非人類靈長類動物)HVR(供體抗體)之具有期望特異性、親和力及能力的殘基替代。在一些情形下,人類免疫球蛋白框架區(「FR」)殘基由對應非人類殘基替代。此外,人類化抗體可包含未在接受者抗體或供體抗體中發現之殘基。可作出該等修飾以進一步改善抗體性能,例如結合親和力。一般而言,人類化抗體將包含實質上全部至少一個且通常兩個可變結構域,其中全部或實質上全部超變環對應於非人類免疫球蛋白序列之超變環,且全部或實質上全部FR區係人類免疫球蛋白序列之FR區,但FR區可包括一或多個改良抗體性能(例如結合親和力、異構化、免疫原性等)之個別FR殘基取代。FR中之該等胺基酸取代之數目通常在H鏈中不超過6且L鏈中不超過3。人類化抗體視情況亦將包含免疫球蛋白恆定區(Fc)(通常為人類免疫球蛋白恆定區)之至少一部分。關於其他細節,例如,參見Jones等人,
Nature321:522-525 (1986);Riechmann等人,
Nature332:323-329 (1988);及Presta,
Curr. Op. Struct. Biol.2:593-596 (1992)。例如,亦參見Vaswani及Hamilton,
Ann. Allergy, Asthma & Immunol.1:105-115 (1998);Harris,
Biochem. Soc. Transactions23:1035-1038 (1995);Hurle及Gross,
Curr. Op. Biotech.5:428-433 (1994);及美國專利第6,982,321號及第7,087,409號。
「
人類抗體」係具有對應於由人類產生之抗體之胺基酸序列之胺基酸序列及/或使用用於製備如本文所揭示人類抗體之技術中之任一者製備的抗體。此人類抗體之定義明確排除包含非人類抗原結合殘基之人類化抗體。人類抗體可使用業內已知各種技術(包括噬菌體展示文庫)產生。Hoogenboom及Winter,
J. Mol. Biol,227:381 (1991);Marks等人,
J. Mol. Biol.,222:581 (1991)。闡述於以下文獻中之方法亦可用於製備人類單株抗體:Cole等人,
Monoclonal Antibodies and Cancer Therapy,Alan R. Liss,第77頁(1985);Boerner等人,
J. Immunol, 147(l):86-95 (1991)。亦參見van Dijk及van de Winkel,
Curr. Opin. Pharmacol, 5: 368-74 (2001)。人類抗體可藉由向轉基因動物投與抗原來製備,該等動物已經修飾從而因應抗原攻擊產生此等抗體,但其內源性基因座已失能,例如,經免疫xenomice (關於XENOMOUSE
TM技術,例如,參見美國專利第6,075,181號及第6,150,584號)。關於經由人類B細胞雜交瘤技術產生之人類抗體,例如,亦參見Li等人,
Proc. Natl. Acad. Sci. USA,
103:3557-3562 (2006)。
本文所用術語「
超變區」、「
HVR」或「
HV」係指抗體可變結構域中序列超變及/或結構上形成所定義環之區域。通常,抗體包含6個HVR;3個位於VH中(H1、H2、H3),且3個位於VL中(L1、L2、L3)。在天然抗體中,H3及L3展示6個HVR之大部分多樣性,且相信尤其H3在賦予抗體特異性方面發揮獨特作用。例如,參見Xu等人,
Immunity 13:37-45 (2000);Johnson及Wu,
Methods in Molecular Biology 248:1-25 (Lo編輯,Human Press, Totowa, NJ, 2003)。實際上,僅由重鏈組成之天然駱駝科抗體在不存在輕鏈下具有功能且穩定。例如,參見
Hamers-Casterman等人
, Nature 363:446-448 (1993);Sheriff等人,
Nature Struct. Biol. 3:733-736 (1996)。
本文使用且涵蓋多個HVR之描述。Kabat互補決定區(CDR)係基於序列可變性且使用最為廣泛(Kabat等人,
Sequences of Proteins of Immunological Interest,第5版,Public Health Service, National Institutes of Health, Bethesda, MD. (1991))。而Chothia指結構環之位置(Chothia及Lesk
J. Mol. Biol. 196:901-917 (1987))。AbM HVR代表Kabat HVR與Chothia結構環之間的折衷方案且用於Oxford Molecular之AbM抗體建模軟體中。「接觸」HVR係基於對可獲得複雜晶體結構之分析。來自該等HVR中每一者之殘基係如下所述。
HVR可包含如下「經延伸HVR」:VL中之24-36或24-34 (L1)、46-56或50-56 (L2)及89-97或89-96 (L3)及VH中之26-35 (H1)、50-65或49-65 (H2)及93-102、94-102或95-102 (H3)。對於該等定義中之每一者,根據Kabat等人(見上文)對可變結構域殘基編號。
表達「
如 Kabat 中之可變結構域殘基編號」或「
如 Kabat 中之胺基酸位置編號」及其變化形式係指用於Kabat等人(見上文)中之所彙編抗體之重鏈可變結構域或輕鏈可變結構域中的編號系統。使用此編號系統,實際線性胺基酸序列可含有較少或額外之對應於可變結構域FR或HVR之縮短或插入之胺基酸。例如,重鏈可變結構域可包括在H2之殘基52後之單胺基酸插入(根據Kabat編號之殘基52a)及重鏈FR殘基82後之插入殘基(例如,根據Kabat編號之殘基82a、82b及82c等)。可藉由將抗體序列之同源區與「標準」Kabat編號序列比對來確定給定抗體殘基之Kabat編號。
「
架構」或「
FR」殘基係彼等除本文所定義HVR殘基外之可變結構域殘基。
「
人類共有框架」或「
受體人類框架」係代表在所選人類免疫球蛋白VL或VH框架序列中最普遍存在之胺基酸殘基之框架。通常,所選人類免疫球蛋白VL或VH序列係來自可變結構域序列亞群。通常,序列亞群係如以下文獻中所述之亞群:Kabat等人,
Sequences of Proteins of Immunological Interest,第5版,Public Health Service, National Institutes of Health, Bethesda, MD (1991)。實例包括,對於VL而言,亞群可為如Kabat等人(見上文)中所述之亞群κI、κII、κIII或κIV。另外,對於VH而言,亞群可為如Kabat等人(見上文)中所述之亞群I、亞群II或亞群III。或者,人類共有框架可係源自上述特定殘基,例如當將供體框架序列與所收集不同人類框架序列比對而基於其與供體框架之同源性來選擇人類框架殘基時。「源自」人類免疫球蛋白框架或人類共有框架之受體人類框架可包含其相同胺基酸序列,或其可含有預先存在之胺基酸序列變化。在一些實施例中,預先存在之胺基酸變化數目係10或更少、9或更少、8或更少、7或更少、6或更少、5或更少、4或更少、3或更少或2或更少。
「
VH 亞群 III 共有框架」包含自Kabat等人(見上文)之可變重鏈亞群III中之胺基酸序列獲得之共有序列。在一個實施例中,VH亞群III共有框架胺基酸序列包含以下序列中每一者之至少一部分或全部:EVQLVESGGGLVQPGGSLRLSCAAS (HC-FR1)(SEQ ID NO:4)、WVRQAPGKGLEWV (HC-FR2)、(SEQ ID NO:5)、RFTISADTSKNTA YLQMNSLRAEDTAVYYCAR (HC-FR3、SEQ ID NO:6)、WGQGTLVT VSA (HC-FR4)、(SEQ ID NO:7)。
「
VL κ I 共有框架」包含自Kabat等人(見上文)之可變輕鏈I亞群中之胺基酸序列獲得之共有序列。在一個實施例中,VH亞群I共有框架胺基酸序列包含以下序列中每一者之至少一部分或全部:DIQMTQSPSSL SASVGDRVTITC (LC-FR1)(SEQ ID NO: 11)、WYQQKPGKAPKLLIY (LC-FR2) (SEQ ID NO: 12)、GVPSRFSGSGSGTDFTLTISSLQPEDFA TYYC (LC-FR3)(SEQ ID NO: 13)、FGQGTKVEIKR (LC-FR4)(SEQ ID NO: 14)。
在(例如) Fc區之指定位置處之「
胺基酸修飾」係指取代或缺失指定殘基或毗鄰指定殘基插入至少一個胺基酸殘基。「毗鄰」指定殘基插入意指在其一至兩個殘基內插入。插入可在指定殘基之N末端或C末端進行。本文中之較佳胺基酸修飾係取代。
「
親和力成熟」抗體係在一或多個HVR中具有一或多個改變者,該等改變可使抗體與抗原之親和力相對於不具有彼等改變之親代抗體有所改良。在一個實施例中,親和力成熟抗體與靶抗原具有毫微莫耳濃度或甚至皮莫耳濃度親和力。藉由業內已知程序產生親和力成熟抗體。例如,Marks等人,
Bio/Technology10:779-783 (1992)闡述藉由VH-及VL-結構域改組之親和力成熟。HVR及/或框架殘基之隨機誘變闡述於(例如)以下文獻中:Barbas等人
Proc Nat. Acad. Sci. USA91:3809-3813 (1994);Schier等人,
Gene169:147-155 (1995);Yelton等人,
J. Immunol.155: 1994-2004 (1995);Jackson等人,
J. Immunol.154(7):3310-9 (1995);及Hawkins等人,
J. Mol. Biol.226:889-896 (1992)。
本文所用術語「
特異性結合至」或「
對…
具有特異性」係指可量測且可再現之相互作用,例如靶標與抗體間之結合,其決定在異源性分子群體(包括生物分子)存在下靶標之存在。例如,特異性結合至靶標(其可係表位)之抗體係與其結合至其他靶標相比以更大親和力、親合力更容易地及/或以更長持續時間結合此靶標之抗體。在一個實施例中,抗體與無關靶標之結合程度小於抗體與靶標之結合之約10%,如藉由(例如)放射性免疫分析(RIA)所量測。在某些實施例中,特異性結合至靶標之抗體之解離常數(Kd)係≤1 μM、≤100 nM、≤10 nM、≤1 nM或≤0.1 nM。在某些實施例中,抗體特異性結合至蛋白質上在不同物種之蛋白質間保守之表位。在另一實施例中,特異性結合可包括(但不要求)排他性結合。
本文所用術語「免疫黏附素」表示組合異源蛋白質(「黏附素」)之結合特異性與免疫球蛋白恆定結構域之效應子功能的抗體樣分子。在結構上,免疫黏附素包含具有不同於抗體之抗原識別及結合位點之期望結合特異性的胺基酸序列(即,「異源」)與免疫球蛋白恆定結構域序列之融合物。免疫黏附素分子之黏附素部分通常為至少包含受體或配體結合位點之鄰接胺基酸序列。免疫黏附素中之免疫球蛋白恆定結構域序列可自任一免疫球蛋白獲得,例如IgG-1、IgG-2 (包括IgG2A及IgG2B)、IgG-3或IgG-4亞型、IgA(包括IgA-1及IgA-2)、IgE、IgD或IgM。Ig融合物較佳包括代替Ig分子內之至少一個可變區之本文所述多肽或抗體之結構域的取代。在尤佳實施例中,免疫球蛋白融合物包括IgG1分子之鉸鏈、CH2及CH3、或鉸鏈、CH1、CH2及CH3區。關於免疫球蛋白融合物之產生,亦參見1995年6月27日頒佈之美國專利第5,428,130號。例如,作為用於本文組合療法之第二藥劑之有用免疫黏附素包括多肽,該等多肽包含PD-L1或PD-L2之細胞外或PD-1結合部分或PD-1之細胞外或PD-L1或PD-L2結合部分與免疫球蛋白序列之恆定結構域之融合物,分別例如PD-L1 ECD-Fc、PD-L2 ECD-Fc及PD-1 ECD-Fc。Ig Fc與細胞表面受體之ECD之免疫黏附素組合有時稱為可溶性受體。
「 融合蛋白 」及
「 融合多肽 」係指兩個部分共價連接在一起之多肽,其中該等部分中之每一者係具有不同性質之多肽。該性質可係生物性質,例如活體外或活體內之活性。該性質亦可係簡單化學或物理性質,例如結合至靶分子、催化反應等。兩個部分可直接藉由單一肽鍵或經由肽連接體連接,但彼此處於閱讀框內。
「
PD-1 寡肽」
、「
PD-L1 寡肽」或「
PD-L2 寡肽」分別係較佳具體而言結合至PD-1、PD-L1或PD-L2負共刺激多肽之寡肽,分別包括受體、配體或信號傳導組份,如本文所述。此等寡肽可使用已知寡肽合成方法化學合成或可使用重組技術製備並純化。此等寡肽通常長度為至少約5個胺基酸,或者長度為至少約6個、7個、8個、9個、10個、11個、12個、13個、14個、15個、16個、17個、18個、19個、20個、21個、22個、23個、24個、25個、26個、27個、28個、29個、30個、31個、32個、33個、34個、35個、36個、37個、38個、39個、40個、41個、42個、43個、44個、45個、46個、47個、48個、49個、50個、51個、52個、53個、54個、55個、56個、57個、58個、59個、60個、61個、62個、63個、64個、65個
、66個
、67個
、68個、69個、70個、71個、72個、73個、74個、75個、76個、77個、78個、79個、80個、81個、82個、83個、84個、85個、86個、87個、88個、89個、90個、91個、92個、93個、94個、95個、96個、97個、98個、99個或100個胺基酸或更多。此等寡肽可使用熟知技術鑑別。就此而言,應注意,用於篩選能夠特異性結合至多肽靶標之寡肽之寡肽文庫的技術為業內所熟知(例如,參見美國專利第5,556,762號、第5,750,373號、第4,708,871號、第4,833,092號、第5,223,409號、第5,403,484號、第5,571,689號、第5,663,143號;PCT公開案第WO 84/03506號及第WO84/03564號;Geysen等人,
Proc. Natl. Acad. Sci. U.S.A., 81:3998-4002 (1984);Geysen等人,
Proc. Natl. Acad. Sci. U.S.A., 82:178-182 (1985);Geysen等人,
Synthetic Peptides as Antigens,130-149 (1986);Geysen等人,
J. Immunol. Meth., 102:259-274 (1987);Schoofs等人,
J. Immunol.
,
140:611-616 (1988), Cwirla, S. E.等人,
Proc. Natl Acad. Sci. USA, 87:6378 (1990);Lowman, H.B.等人,
Biochemistry, 30:10832 (1991);Clackson, T.等人,
Nature, 352: 624 (1991);Marks, J. D.等人,
J. Mol Biol, 222:581 (1991);Kang, A.S.等人,
Proc. Natl. Acad. Sci. USA, 88:8363 (1991)及Smith, G. P.,
Current Opin. Biotechnol., 2:668 (1991)。
「
阻斷性」抗體或「
拮抗性」抗體係抑制或降低所結合抗原之生物活性的抗體。在一些實施例中,阻斷性抗體或拮抗性抗體實質上或完全地抑制抗原之生物活性。本發明抗PD-L1抗體阻斷經由PD-1之信號傳導,以將T細胞之功能反應(例如,增殖、產生細胞介素、殺傷靶T細胞)自功能異常狀態恢復至抗原刺激。
「
激動性」
或活化性抗體係藉由所結合抗原增強或起始信號傳導之抗體。在一些實施例中,激動性抗體在不存在天然配體下引起或活化信號傳導。
本文中之術語「
Fc 區」用於界定免疫球蛋白重鏈之C末端區,包括天然序列Fc區及變體Fc區。儘管免疫球蛋白重鏈Fc區之邊界可有所變化,但通常將人類IgG重鏈Fc區界定為自Cys226位處之胺基酸殘基或自Pro230延伸至其羧基末端。Fc區之C末端離胺酸(根據EU編號系統之殘基447)可在(例如)抗體產生或純化期間或藉由重組改造編碼抗體重鏈之核酸去除。因此,完整抗體之組成可包含去除全部K447殘基之抗體群體、未去除K447殘基之抗體群體及具有含有及不含有K447殘基之抗體之混合物的抗體群體。用於本發明抗體中之適宜天然序列Fc區包括人類IgG1、IgG2 (IgG2A、IgG2B)、IgG3及IgG4。
「
Fc 受體」或「
FcR」闡述與抗體Fc區結合之受體。較佳FcR係天然序列人類FcR。此外,較佳FcR係結合IgG抗體者(γ受體)且包括FcγRI、FcγRII及FcγRIII亞類之受體,包括該等受體之等位基因變體及替代剪接形式,FcγRII受體包括FcγRIIA (「活化性受體」)及Fcγ RIIB (「抑制性受體」),其具有主要差異在於胞質結構域之類似胺基酸序列。活化性受體FcγRIIA在其胞質結構域中含有基於免疫受體酪胺酸之活化基序(ITAM)。抑制受體FcyRIIB在其胞質結構域中含有基於免疫受體酪胺酸之抑制基序(ITIM)(參見M. Daëron,
Annu. Rev. Immunol. 15; 203-234 (1997)。FcR綜述於Ravetch及Kinet,
Annu. Rev. Immunol. 9: 457-92 (1991);Capel等人,
Immunomethods 4: 25-34 (1994);及de Haas等人,
J. Lab. Clin. Med.
126 :330-41 (1995)中。本文中之術語「FcR」涵蓋其他FcR,包括彼等欲在將來鑑別者。
術語「
Fc 受體」或「
FcR」亦包括新生兒受體
FcRn,其負責將母體IgG轉移至胎兒。Guyer等人,
J. Immunol. 117: 587 (1976) and Kim等人,
J. Immunol. 24 :249 (1994)。業內已知量測與FcRn之結合之方法(例如,參見Ghetie及Ward,
Immunol. Today 18: (12): 592-8 (1997);Ghetie等人,
Nature Biotechnology
15(7): 637-40 (1997);Hinton等人,
J. Biol Chem. 279(8): 6213-6 (2004);WO 2004/92219 (Hinton等人)。可在(例如)表現人類FcRn之轉基因小鼠或經轉染人類細胞系中或在投與具有變體Fc區之多肽之靈長類動物中分析人類FcRn高親和力結合多肽與FcRn之活體內結合及血清半衰期。WO 2004/42072 (Presta)闡述改良或減少與FcR之結合之抗體變體。例如,亦參見Shields等人,
J. Biol. Chem. 9(2): 6591-6604 (2001)。
本文所用片語「
實質上減少」或「
實質上不同」表示兩個數值(通常一個值與分子相關且另一值與參考/比較分子相關)之間之足夠高差異度使得熟習此項技術者會認為該兩個值間之差異在藉由該等值(例如,Kd值)所量測生物學特性之背景下具有統計學顯著性。該兩個值間之差異係(例如)大於約10%、大於約20%、大於約30%、大於約40%及/或大於約50%,其隨參考/比較分子之值而變化。
本文所用術語「
實質上相似」或「
實質上相同」表示兩個數值(例如,一個值與本發明抗體相關且另一者與參考/比較抗體相關)之間之足夠高相似度使得熟習此項技術者會認為該兩個值間之差異在藉由該等值(例如,Kd值)所量測生物學特性之背景下具有較少或不具有生物學及/或統計學顯著性。該兩個值間之差異係(例如)小於約50%、小於約40%、小於約30%、小於約20%,及/或小於約10%,其隨參考/比較值而變化。
本文所用「載劑」包括在所用劑量及濃度下對所暴露細胞或哺乳動物無毒性之醫藥上可接受之載劑、賦形劑或穩定劑。通常,生理學上可接受之載劑係pH緩衝水溶液。生理學上可接受之載劑的實例包括緩衝液,例如磷酸鹽、檸檬酸鹽及其他有機酸;抗氧化劑,包括抗壞血酸,低分子量(小於約10個殘基)多肽;蛋白質,例如血清白蛋白、明膠或免疫球蛋白;親水性聚合物,例如聚乙烯吡咯啶酮;胺基酸,例如甘胺酸、麩醯胺酸、天冬醯胺、精胺酸或離胺酸;單糖、二糖及其他碳水化合物,包括葡萄糖、甘露糖或糊精;螯合劑,例如EDTA;糖醇,例如甘露糖醇或山梨糖醇;形成鹽之抗衡離子,例如鈉;及/或非離子型表面活性劑,例如TWEEN™、聚乙二醇(PEG)及PLURONICS™。
「
包裝插頁」係指通常包括在藥劑商業包裝中之說明書,其含有關於適應症、用法、劑量、投與、禁忌症、欲與包裝產品組合之其他藥劑及/或涉及此等藥劑使用之警告等的資訊。
本文所用術語「
治療」係指經設計以改變所治療個體或所處理細胞在臨床病理學進程期間之天然進程之臨床幹預。合意治療效應包括降低疾病進展速率、改善或減輕疾病狀態及緩解或改良預後。例如,若緩和或消除一或多種與癌症相關之症狀,則順利地「治療」個體,包括(但不限於)減少(或破壞)癌細胞增殖、降低自疾病引起之症狀、提高彼等罹患疾病者之生活品質、降低治療疾病所需其他藥劑之劑量、延遲疾病進展及/或延長個體存活。
本文所用「延遲疾病進展」意指推遲、阻礙、減緩、減慢、穩定及/或延緩疾病(例如癌症)發展。此延遲可具有不同時長,此端視所治療疾病及/或個體之病史而定。如熟習此項技術者所顯而易見,充分或顯著延遲實際上可涵蓋預防,此乃因該個體不會發生疾病。例如,可延遲晚期癌症,例如轉移發生。
「
有效量」係至少實現特定病症之可量測改良或預防所需之最低濃度。本文中之有效量可根據諸如以下等因素而變化:患者之疾病狀態、年齡、性別及重量以及抗體在個體中誘發期望反應之能力。有效量亦為治療有益效應勝過治療之任何毒性或有害效應的量。對於預防性應用而言,有益或期望結果包括諸如以下等結果:消除或降低疾病風險、減輕其嚴重程度或延遲其發作,該疾病包括疾病之生物化學、組織學及/或行為症狀、其在疾病發展期間呈現之併發症及中間病理學表型。對於治療性應用而言,有益或期望結果包括諸如以下等臨床結果:降低一或多種自疾病引起之症狀、提高彼等罹患疾病者之生活品質、降低治療疾病所需其他藥劑之劑量、經由(靶向)增強另一藥劑之效應、延遲疾病進展及/或延長存活。在癌症或腫瘤之情形下,藥物之有效量可具有以下效應:減少癌細胞數目;減小腫瘤大小;抑制(即,在一定程度上減緩且合意地終止)癌細胞浸潤至周邊器官中;抑制(即,在一定程度上減緩且合意地終止)腫瘤轉移;在一定程度上抑制腫瘤生長;及/或在一定程度上減輕一或多種與病症相關之症狀。有效量可以一或多次投與來施用。出於本發明之目的,藥物、化合物或醫藥組合物之有效量係足以直接或間接達成預防性或治療性治療之量。如在臨床背景下所理解,藥物、化合物或醫藥組合物之有效量可或可不結合另一藥物、化合物或醫藥組合物達成。因此,可認為「有效量」係在投與一或多種治療劑之背景下進行,且若結合一或多種其他藥劑可達成或達成合意結果,則可認為單一藥劑係以有效量給予。
本文所用「結合」係指投與一種治療形式與另一治療形式。同樣,「結合」係指在向個體投與另一治療形式之間、期間或之後投與一種治療形式。
本文所用「完全反應」或「CR」係指全部靶病灶消失;「部分反應」或「PR」係指靶病灶最長直徑(SLD)之總和減小至少30%,將基線SLD視為參考值;且「穩定疾病」或「SD」係指靶病灶未充分縮小至符合PR,且未充分增加至符合PD,將自治療開始時之最小SLD視為參考值。
本文所用「進展性疾病」或「PD」係指靶病灶之SLD增加至少20%,將自治療開始或存在一或多個新病灶時記錄之最小SLD視為參考值。
本文所用「無進展存活」(PFS)係指在治療期間及之後所治療疾病(例如,癌症)不會惡化之時長。無進展存活可包括患者已經歷完全反應或部分反應之時間量以及患者已經歷穩定疾病之時間量。
本文所用「總體反應率」(ORR)係指完全反應(CR)率與部分反應(PR)率之總和。
本文所用」總體存活率」係指群組中可在特定持續時間後存活之個體之百分比。
「化學治療劑」係用於治療癌症之化學化合物。化學治療劑之實例包括烷基化劑,例如噻替哌(thiotepa)及環磷醯胺(CYTOXAN®);磺酸烷基酯,例如白消安(busulfan)、英丙舒凡(improsulfan)及哌泊舒凡(piposulfan);氮雜環丙烷,例如苯得哌(benzodopa)、卡波醌(carboquone)、米得哌(meturedopa)及烏得哌(uredopa);伸乙基亞胺及甲基蜜胺,包括六甲蜜胺、三伸乙基嘧胺、三伸乙基磷醯胺、三伸乙基硫代磷醯胺及三伸乙基硫化磷醯胺;多聚乙醯(尤其布拉他辛(bullatacin)及布拉他辛酮(bullatacinone));δ‑9-四氫大麻酚(屈大麻酚、MARINOL®);β-拉帕醌(lapachone);拉帕醇(lapachol);秋水仙鹼;樺木酸;喜樹鹼(camptothecin)(包括合成類似物托泊替康(topotecan) (HYCAMTIN®)、CPT-11(伊立替康(irinotecan)、CAMPTOSAR®)、乙醯基喜樹鹼、莨菪素及9-胺基喜樹鹼);苔蘚蟲素(bryostatin);培美曲塞(pemetrexed);卡利司他汀(callystatin);CC-1065 (包括其阿多來新(adozelesin)、卡折來新(carzelesin)及比折來新(bizelesin)合成類似物);鬼臼毒素(podophyllotoxin);鬼臼酸;替尼泊苷(teniposide);念珠藻素(cryptophycin)(尤其念珠藻素1及念珠藻素8);多拉司他汀(dolastatin);多卡米星(duocarmycin)(包括合成類似物KW-2189及CB1-TM1);艾榴素(eleutherobin);水鬼蕉鹼(pancratistatin);TLK-286;CDP323、口服α-4整合素抑制劑;匍枝珊瑚醇(sarcodictyin);海綿抑制素(spongistatin);氮芥,例如瘤克寧錠(chlorambucil)、萘氮芥(chlornaphazine)、氯磷醯胺、雌莫司汀(estramustine)、異環磷醯胺、氮芥(mechlorethamine)、鹽酸氧氮芥、美法侖(melphalan)、新氮芥(novembichin)、苯乙酸氮芥膽甾醇酯(phenesterine)、潑尼氮芥(prednimustine)、曲磷胺、尿嘧啶氮芥;亞硝基脲,例如卡莫司汀(carmustine)、氯脲菌素(chlorozotocin)、福莫司汀(fotemustine)、洛莫司汀(lomustine)、尼莫司汀(nimustine)及(ranimnustine);抗生素,例如烯二炔抗生素(例如,卡奇黴素(calicheamicin),尤其卡奇黴素γ1I及卡奇黴素ωI 1(例如,參見Nicolaou等人,
Angew. Chem Intl. Ed. Engl.,33: 183-186 (1994));達內黴素(dynemicin),包括達內黴素A;埃斯波黴素(esperamicin);以及新製癌菌素發色團(neocarzinostatin chromophore)及有關色蛋白烯二炔抗生素發色團)、阿克拉黴素(aclacinomysin)、放線菌素(actinomycin)、安麯黴素(authramycin)、偶氮絲胺酸、博來黴素(bleomycin)、放線菌素c、卡拉比星(carabicin)、洋紅黴素(carminomycin)、嗜癌黴素(carzinophilin)、色黴素(chromomycin)、更生黴素(dactinomycin)、唐黴素(daunorubicin)、地托比星(detorubicin)、6-重氮基-5-側氧基‑L-正白胺基、阿黴素(doxorubicin)(包括ADRIAMYCIN®、嗎啉基-阿黴素、氰基嗎啉基-阿黴素、2-吡咯啉并-阿黴素、HCl阿黴素脂質體注射液(DOXIL®)及去氧阿黴素)、泛艾黴素(epirubicin)、依索比星(esorubicin)、艾達黴素(idarubicin)、麻西羅黴素(marcellomycin)、絲裂黴素(mitomycin)(例如絲裂黴素C)、黴酚酸、諾加黴素(nogalamycin)、橄欖黴素(olivomycin)、培洛黴素(peplomycin)、波弗黴素(potfiromycin)、嘌呤黴素、三鐵阿黴素(quelamycin)、羅多比星(rodorubicin)、鏈黑菌素(streptonigrin)、鏈脲菌素(streptozocin)、殺結核菌素(tubercidin)、烏苯美司(ubenimex)、淨司他汀(zinostatin)、佐柔比星(zorubicin);抗代謝劑,例如胺甲蝶呤(methotrexate)、吉西他濱(gemcitabine)(GEMZAR®)、替加氟(tegafur)(UFTORAL®)、卡培他濱(capecitabine) (XELODA®)、埃博黴素(epothilone)及5-氟尿嘧啶(5-FU);葉酸類似物,例如二甲葉酸、胺甲蝶呤、蝶羅呤(pteropterin)、三甲曲沙(trimetrexate);嘌呤類似物,例如氟達拉濱(fludarabine)、6-巰嘌呤、硫咪嘌呤(thiamiprine)、硫鳥嘌呤;嘧啶類似物,例如安西他濱(ancitabine)、阿紮胞苷(azacitidine)、6-阿紮尿苷(azauridine)、卡莫氟(carmofur)、阿糖胞苷(cytarabine)、二去氧尿苷、去氧氟尿苷、依諾他濱(enocitabine)、氟尿苷及伊馬替尼(imatinib)(2-苯基胺基嘧啶衍生物)以及其他c-Kit抑制劑;抗腎上腺劑,例如胺魯米特(aminoglutethimide)、米托坦(mitotane)、曲洛司坦(trilostane);葉酸補充劑,例如亞葉酸;醋葡醛內酯;醛磷醯胺;胺基酮戊酸;恩尿嘧啶(eniluracil);安吖啶(amsacrine);貝斯特布西(bestrabucil);比生群(bisantrene);依達曲沙(edatraxate);地磷醯胺(defofamine);秋水仙胺(demecolcine);地吖醌(diaziquone);依氟鳥胺酸(elfornithine);依利乙銨(elliptinium acetate);依託格魯(etoglucid);硝酸鎵;羥基脲;香菇多糖;氯尼達明(lonidainine);類美坦辛(maytansinoids),例如美坦辛(maytansine)及安絲菌素(ansamitocin);米托胍腙(mitoguazone);米托蒽醌(mitoxantrone);美得眠(mopidanmol);硝基胺;噴司他汀(pentostatin);蛋胺氮芥(phenamet);吡柔比星(pirarubicin);洛索蒽醌(losoxantrone);2-乙基醯肼;丙卡巴肼(procarbazine);PSK®多糖複合物(JHS Natural Products, Eugene, OR);丙亞胺;根黴素;西佐喃(sizofiran);鍺螺胺(spirogermanium);替奴佐酸(tenuazonic acid);三亞胺醌(triaziquone);2,2',2''-三氯三乙胺;單端孢黴烯(trichothecene)(尤其T-2毒素、疣孢菌素A (verracurin A)、桿孢菌素A (roridin A)及蛇形菌索(anguidine));烏拉坦(urethan);長春地辛)(vindesine)(ELDISINE®、FILDESIN®);達卡巴嗪(dacarbazine);甘露氮芥(mannomustine);二溴甘露醇(mitobronitol);二溴衛矛醇(mitolactol);哌泊溴烷(pipobroman);gacytosine;阿糖胞苷(「Ara-C」);噻替哌;類紫杉醇(taxoid),例如,太平洋紫杉醇(paclitaxel) (TAXOL®)、太平洋紫杉醇之經白蛋白改造之奈米粒子調配物(ABRAXANE™)及多西紫杉醇(doxetaxel)(TAXOTERE®);瘤克寧錠;6-硫鳥嘌呤;巰嘌呤;胺甲蝶呤;鉑類似物,例如順鉑(cisplatin)及卡鉑(carboplatin);長春鹼(vinblastine)(VELBAN®);鉑;依託泊苷(etoposide) (VP‑16);異環磷醯胺;米托蒽醌;長春新鹼(vincristine) (ONCOVIN®);奧沙利鉑(oxaliplatin);醛氫葉酸;長春瑞濱(vinorelbine)(NAVELBINE®);諾肖林(novantrone);依達曲沙(edatrexate);道諾黴素(daunomycin);胺基蝶呤(aminopterin);伊班膦酸鹽(ibandronate);拓撲異構酶抑制劑RFS 2000;二氟甲基鳥胺酸(DMFO);類視色素,例如視黃酸;上述藥劑中任一者之醫藥上可接受之鹽、酸或衍生物;以及上述藥劑中兩者或更多者之組合,例如環磷醯胺、阿黴素、長春新鹼及潑尼松龍(prednisolone)之組合療法之縮寫CHOP及利用與5-FU及醛氫葉酸組合之奧沙利鉑(ELOXATIN
TM)之治療方案的縮寫FOLFOX。
化學治療劑之其他實例包括對可促進癌症生長之激素之效應具有調控、降低、阻斷或抑制作用且通常呈系統性或全身性治療形式的抗激素劑。其可為激素本身。實例包括抗雌激素及選擇性雌激素受體調節劑(SERM),包括(例如)他莫昔芬(tamoxifen)(包括NOLVADEX®他莫昔芬)、雷洛昔芬(raloxifene)(EVISTA®)、屈洛昔芬(droloxifene)、4-羥基他莫昔芬、曲沃昔芬(trioxifene)、金洛昔芬(keoxifene)、LY117018、奧那司酮(onapristone)及托瑞米芬(toremifene) (FARESTON®);抗孕酮(anti-progesterone);雌激素受體下調劑(ERD);雌激素受體拮抗劑,例如氟維司群(fulvestrant)(FASLODEX®);可用於抑制或關閉卵巢之藥劑,例如,促黃體激素-釋放激素(LHRH)激動劑,例如乙酸亮丙瑞林(leuprolide acetate)(LUPRON®及ELIGARD®)、乙酸戈舍瑞林(goserelin acetate)、乙酸布舍瑞林(buserelin acetate)及曲普瑞林(triptorelin);抗雄激素,例如氟利坦(flutamide)、尼魯米特(nilutamide)及比卡魯胺(bicalutamide);及抑制芳香酶之芳香酶抑制劑,其調控腎上腺中雌激素之產生,例如,4(5)-咪唑、胺魯米特、乙酸甲地孕酮(megestrol acetate)(MEGASE®)、依西美坦(exemestane) (AROMASIN®)、福美司坦(formestanie)、法倔唑(fadrozole)、伏氯唑(vorozole)(RIVISOR®)、來曲唑(letrozole)(FEMARA®)及阿納曲唑(anastrozole)(ARIMIDEX®)。另外,化學治療劑之此定義包括雙膦酸鹽,例如氯膦酸鹽(clodronate)(例如,BONEFOS®或OSTAC®)、依替膦酸鹽(etidronate) (DIDROCAL®)、NE-58095、唑來膦酸(zoledronic acid)/唑來膦酸鹽(ZOMETA®)、阿倫膦酸鹽(alendronate) (FOSAMAX®)、帕米膦酸鹽(pamidronate)(AREDIA®)、替魯膦酸鹽(tiludronate)(SKELID®)或利塞膦酸鹽(risedronate)(ACTONEL®);以及曲沙他濱(troxacitabine) (1,3-二氧戊環核苷胞嘧啶類似物);反義寡核苷酸,尤其彼等抑制涉及黏附細胞增殖之信號傳導路徑中之基因表現者,例如,PKC-α、Raf、H-Ras及表皮生長因子受體(EGF-R);疫苗,例如THERATOPE®疫苗及基因療法疫苗,例如ALLOVECTIN®疫苗、LEUVECTIN®疫苗及VAXID®疫苗;拓撲異構酶1抑制劑(例如,LURTOTECAN®);抗雌激素,例如氟維司群;Kit抑制劑,例如伊馬替尼或EXEL-0862 (酪胺酸激酶抑制劑);EGFR抑制劑,例如埃羅替尼(erlotinib)或西妥昔單抗(cetuximab);抗VEGF抑制劑,例如貝伐單抗(bevacizumab);伊立替康;rmRH (例如,ABARELIX®);拉帕替尼(lapatinib)及二甲苯磺酸拉帕替尼(ErbB-2及EGFR雙酪胺酸激酶小分子抑制劑,亦稱為GW572016);17AAG (格爾德黴素(geldanamycin)衍生物,其係熱休克蛋白(Hsp) 90毒物)及上述藥劑中任一者之醫藥上可接受之鹽、酸或衍生物。
本文所用術語「
細胞介素」通常係指由一種細胞群體釋放之作為細胞間介質對另一細胞起作用或對產生蛋白之細胞具有自分泌效應的蛋白。此等細胞介素之實例包括淋巴因子、單核因子;介白素(「IL」),例如IL-1、IL-1α、IL‑2、IL-3,IL-4、IL-5、IL-6、IL-7、IL-8、IL-9、IL10、IL-11、IL-12、IL-13、IL-15、IL-17A-F、IL-18至IL-29 (例如IL-23)、IL-31,包括PROLEUKIN
®rIL-2;腫瘤壞死因子,例如TNF-α或TNF-β、TGF-β1-3;及其他多肽因子,包括白血病抑制因子(「LIF」)、睫狀神經營養因子(「CNTF」)、CNTF樣細胞介素(「CLC」)、心臟營養素(「CT」)及套組配體(「KL」)。
本文所用術語「趨化因子」係指具有選擇性地誘導趨化性及白血球活化之能力的可溶性因子(例如,細胞介素)。其亦觸發血管生成、發炎、傷口癒合及腫瘤形成過程。實例趨化因子包括IL-8,即鼠類角質細胞化學吸引劑(KC)之人類同源物。
除非上下文另外明確指出,否則本文及隨附申請專利範圍中所用單數形式「一」、「或」及「該」包括複數個參考物。
本文在提及「約」值或參數時,其包括(且描述)關於該值或參數本身之變化形式。例如,關於「約X」之描述包括對「X」之描述。
本文所用術語「烷基」係指1至12個碳原子之飽和直鏈或具支鏈鏈單價烴基團。烷基之實例包括(但不限於)甲基(Me、-CH
3)、乙基(Et、-CH
2CH
3)、1-丙基(n-Pr、正丙基、-CH
2CH
2CH
3)、2-丙基(i-Pr、異丙基、-CH(CH
3)
2)、1‑丁基(n-Bu、正丁基、-CH
2CH
2CH
2CH
3)、2-甲基-1-丙基(i-Bu、異丁基、-CH
2CH(CH
3)
2)、2-丁基(s-Bu、第二丁基、-CH(CH
3)CH
2CH
3)、2-甲基-2-丙基(t-Bu、第三丁基、-C(CH
3)
3)、1-戊基(正戊基、-CH
2CH
2CH
2CH
2CH
3)、2-戊基(-CH(CH
3)CH
2CH
2CH
3)、3-戊基(-CH(CH
2CH
3)
2)、2-甲基-2-丁基(-C(CH
3)
2CH
2CH
3)、3-甲基-2-丁基(‑CH(CH
3)CH(CH
3)
2)、3-甲基-1-丁基(-CH
2CH
2CH(CH
3)
2)、2-甲基-1-丁基(-CH
2CH(CH
3)CH
2CH
3)、1-己基(‑CH
2CH
2CH
2CH
2CH
2CH
3)、2-己基(-CH(CH
3)CH
2CH
2CH
2CH
3)、3-己基(-CH(CH
2CH
3)(CH
2CH
2CH
3))、2-甲基-2-戊基(‑C(CH
3)
2CH
2CH
2CH
3)、3-甲基-2-戊基(-CH(CH
3)CH(CH
3)
CH
2CH
3)、4-甲基-2-戊基(-CH(CH
3)CH
2CH(CH
3)
2)、3-甲基-3-戊基(-C(CH
3)(CH
2CH
3)
2)、2-甲基-3-戊基(-CH(CH
2CH
3)CH(CH
3)
2)、2,3-二甲基-2-丁基(-C(CH
3)
2CH(CH
3)
2)、3,3-二甲基-2-丁基-(-CH(CH
3)C(CH
3)
3
、1-庚基、1-辛基及諸如此類。
術語「烯基」係指具有至少一個不飽和位點(即碳-碳sp
2雙鍵)之2至12個碳原子之直鏈或具支鏈單價烴基,其中烯基包括具有「順」及「反」定向或另一選擇為「E」及「Z」定向之基團。實例包括(但不限於)乙烯基(ethylenyl或vinyl)(-CH=CH
2)、烯丙基(-CH
2CH=CH
2)及諸如此類。
術語「炔基」係指具有至少一個不飽和位點(即碳-碳sp三鍵)之2至12個碳原子之直鏈或具支鏈單價烴基。實例包括(但不限於)乙炔基(-C≡CH)、丙炔基(炔丙基、‑CH
2C≡CH)及諸如此類。
術語「碳環」、「碳環基」、「碳環環」及「環烷基」係指具有3至12個呈單環之碳原子或7至12個呈二環之碳原子之單價非芳香族飽和或部分不飽和環。具有7至12個原子之二環碳環可佈置呈(例如)二環[4,5]、[5,5]、[5,6]或[6,6]系統,且具有9或10個環原子之二環碳環可佈置呈二環[5,6]或[6,6]系統或橋接系統,例如二環[2.2.1]庚烷、二環[2.2.2]辛烷及二環[3.2.2]壬烷。單環碳環之實例包括(但不限於)環丙基、環丁基、環戊基、1-環戊-1-烯基、1-環戊‑2-烯基、1-環戊-3-烯基、環己基、1-環己-1-烯基、1-環己-2-烯基、1-環己-3-烯基、環己二烯基、環庚基、環辛基、環壬基、環癸基、環十一基、環十二基及諸如此類。
「芳基」意指藉由自母體芳香族環系統之單一碳原子去除一個氫原子獲得之6至18個碳原子的單價芳香族烴基。一些芳基在實例性結構中表示為「Ar」。芳基包括包含稠合至飽和、部分不飽和環或芳香族碳環或雜環環之芳香族環的二環基團。典型芳基包括(但不限於)衍生自苯(苯基)、經取代苯、萘、蒽、茚基、二氫茚基、1,2-二氫萘、1,2,3,4-四氫萘基及諸如此類之基團。
術語「雜環」、「雜環基」及「雜環環」在本文中可互換使用且係指具有3至18個環原子之飽和或部分不飽和(即在環內具有一或多個雙鍵及/或三鍵)碳環基團,其中至少一個環原子係選自氮、氧及硫之雜原子,其餘環原子為C,其中一或多個環原子視情況獨立地經一或多個下文所述取代基取代。雜環可係具有3至7個環成員(2至6個碳原子及1至4個雜原子選自N、O、P及S)之單環或具有7至10個環成員(4至9個碳原子及1至6個選自N、O、P及S之雜原子)之二環,例如:二環[4,5]、[5,5]、[5,6]或[6,6]系統。雜環環闡述於以下文獻中:Paquette,Leo A.「Principles of Modern Heterocyclic Chemistry」(W.A. Benjamin, New York, 1968),尤其第1、3、4、6、7及9章;「The Chemistry of Heterocyclic Compounds, A series of Monographs」(John Wiley & Sons,New York,1950年至今),尤其第13、14、16、19及28卷;及J. Am. Chem. Soc. 82:5566 (1960)。雜環環之實例包括(但不限於)吡咯啶基、四氫呋喃基、二氫呋喃基、四氫噻吩基、四氫吡喃基、二氫吡喃基、四氫噻喃基、六氫吡啶基、嗎啉基、硫嗎啉基、氧硫雜環己基、六氫吡嗪基、高六氫吡嗪基、氮雜環丁基、氧雜環丁基、硫雜環丁基、高六氫吡啶基、氧雜環庚基、硫雜環庚基、噁氮呯基、二氮呯基、硫氮呯基、2-吡咯啉基、3-吡咯啉基、二氫吲哚基、2H-吡喃基、4H-吡喃基、二氧雜環己基、1,3-二氧戊環基、吡唑啉基、二噻烷基、二硫戊環基、二氫吡喃基、二氫噻吩基、二氫呋喃基、吡唑啶基、咪唑啉基、咪唑啶基、3-氮雜二環[3.1.0]己基、3-氮雜二環[4.1.0]庚基及氮雜二環[2.2.2]己基。螺部分亦包括在此定義之範圍內。環原子經側氧基(=O)部分取代之雜環基團之實例係嘧啶酮基及1,1-二側氧基-硫嗎啉基。
術語「雜芳基」係指5員或6員環之單價芳香族基團,且包括5至18個原子之稠合環系統(其中至少一者係芳香族),該等原子含有一或多個獨立地選自氮、氧及硫之雜原子。雜芳基之實例係吡啶基(包括例如2-羥基吡啶基)、咪唑基、咪唑并吡啶基、嘧啶基(包括例如4-羥基嘧啶基)、吡唑基、三唑基、吡嗪基、四唑基、呋喃基、噻吩基、異噁唑基、噻唑基、噁唑基、異噻唑基、吡咯基、喹啉基、異喹啉基、吲哚基、苯并咪唑基、苯并呋喃基、啉基、吲哚基、吲嗪基、酞嗪基、嗒嗪基、三嗪基、異吲哚基、蝶啶基、嘌呤基、噁二唑基、三唑基、噻二唑基、呋呫基、苯并呋呫基、苯并苯硫基、苯并噻唑基、苯并噁唑基、喹唑啉基、喹噁啉基、萘啶基及呋喃并吡啶基。
倘若可能,則雜環或雜芳基可與碳(碳連接)或氮(氮連接)附接。例如且不加以限制,與碳鍵結之雜環或雜芳基可在以下位置處鍵結:吡啶之2、3、4、5或6位;嗒嗪之3、4、5或6位;嘧啶之2、4、5或6位;吡嗪之2、3、5或6位;呋喃、四氫呋喃、硫代呋喃、噻吩、吡咯或四氫吡咯之2、3、4或5位;噁唑、咪唑或噻唑之2、4或5位;異噁唑、吡唑或異噻唑之3、4或5位;氮雜環丙烷之2或3位;氮雜環丁烷之2、3或4位;喹啉之2、3、4、5、6、7或8位;或異喹啉之1、3、4、5、6、7或8位。
例如且不加以限制,與氮鍵結之雜環或雜芳基可在以下位置處鍵結:氮雜環丙烷、氮雜環丁烷、吡咯、吡咯啶、2-吡咯啉、3-吡咯啉、咪唑、咪唑啶、2-咪唑啉、3-咪唑啉、吡唑、吡唑啉、2-吡唑啉、3-吡唑啉、六氫吡啶、六氫吡嗪、吲哚、二氫吲哚或1H-吲唑之1位;異吲哚或異二氫吲哚之2位;嗎啉之4位及咔唑或β-哢啉之9位。
存在於雜芳基或雜環基中之雜原子包括氧化形式,例如N
+→O
-、S(O)及S(O)
2。
術語「鹵基」係指F、Cl、Br或I。
本文所用片語「醫藥上可接受之鹽」係指本發明化合物之醫藥上可接受之有機或無機鹽。實例性鹽包括(但不限於)硫酸鹽、檸檬酸鹽、乙酸鹽、草酸鹽、氯化物、溴化物、碘化物、硝酸鹽、硫酸氫鹽、磷酸鹽、酸式磷酸鹽、異菸酸鹽、乳酸鹽、水楊酸鹽、酸式檸檬酸鹽、酒石酸鹽、油酸鹽、鞣酸鹽、泛酸鹽、酒石酸氫鹽、抗壞血酸鹽、琥珀酸鹽、馬來酸鹽、龍膽酸鹽、富馬酸鹽、葡萄糖酸鹽、葡糖醛酸鹽、糖二酸鹽、甲酸鹽、苯甲酸鹽、麩胺酸鹽、甲磺酸鹽(methanesulfonate, mesylate)、乙磺酸鹽、苯磺酸鹽、對甲苯磺酸鹽及雙羥萘酸鹽(即,1,1'-亞甲基-雙-(2-羥基-3-萘酸鹽))、鹼金屬(例如鈉及鉀)鹽、鹼土金屬(例如鎂)鹽及銨鹽。醫藥上可接受之鹽可涉及包括另一分子,例如乙酸根離子、琥珀酸根離子或另一抗衡離子。抗衡離子可係穩定母體化合物上之電荷之任何有機或無機部分。此外,醫藥上可接受之鹽在其結構中可具有一個以上帶電原子。多個帶電原子為醫藥上可接受之鹽之一部分之情形可具有多個抗衡離子。因此,醫藥上可接受之鹽可具有一或多個帶電原子及/或一或多個抗衡離子。
若本發明化合物係鹼,則期望之醫藥上可接受之鹽可藉由業內可用之任何適宜方法製備,例如,用以下酸處理游離鹼:無機酸,例如鹽酸、氫溴酸、硫酸、硝酸、甲磺酸、磷酸及諸如此類;或有機酸,例如乙酸、馬來酸、琥珀酸、苦杏仁酸、富馬酸、丙二酸、丙酮酸、草酸、草酸、水楊酸、吡喃糖苷基酸(pyranosidyl acid)(例如葡糖醛酸或半乳糖醛酸)、α羥基酸(例如檸檬酸或酒石酸)、胺基酸(例如天冬胺酸或麩胺酸)、芳香族酸(例如苯甲酸或桂皮酸)、磺酸(例如對甲苯磺酸或乙磺酸)或諸如此類。
若本發明化合物係酸,則期望之醫藥上可接受之鹽可任何適宜方法製備,例如,用諸如以下等無機或有機鹼處理游離酸:胺(一級、二級或三級)、鹼金屬氫氧化物或鹼土金屬氫氧化物或諸如此類。適宜鹽之說明性實例包括(但不限於)源自以下之有機鹽:胺基酸(例如甘胺酸及精胺酸)、氨、一級、二級及三級胺及環狀胺(例如六氫吡啶、嗎啉及六氫吡嗪);及源自以下之無機鹽:鈉、鈣、鉀、鎂、錳、鐵、銅、鋅、鋁及鋰。
片語「醫藥上可接受之」指示物質或組合物必須在化學上及/或毒理學上與包含調配物之其他成份及/或用其治療之哺乳動物相容。
「溶劑合物」係指一或多種溶劑分子與本發明化合物之締合物或複合物。形成溶劑合物之溶劑之實例包括(但不限於)水、異丙醇、乙醇、甲醇、DMSO、乙酸乙酯、乙酸及乙醇胺。術語「水合物」係指溶劑分子為水之複合物。
應理解,本文所述本發明之態樣及變化形式包括「由態樣及變化形式組成」及/或「基本上由態樣及變化形式組成」。
III 方法在一個態樣中,本文提供治療個體之癌症或延遲其進展之方法,其包含向該個體投與有效量之PD-1軸結合拮抗劑及MEK抑制劑。在一些實施例中,治療使個體在停止治療後產生持續反應。
本發明方法可用於治療期望增強免疫原性(例如增加對癌症治療之腫瘤免疫原性)之病況。可治療多種癌症,或可延遲其進展,包括(但不限於)可含有BRAF V600E突變之癌症、可含有BRAF野生型之癌症、可含有KRAS野生型之癌症或可含有活化性KRAS突變之癌症。
在一些實施例中,個體患有黑色素瘤。黑色素瘤可處於早期或處於晚期。在一些實施例中,個體患有結腸直腸癌。結腸直腸癌可處於早期或處於晚期。在一些實施例中,個體患有非小細胞肺癌。非小細胞肺癌可處於早期或處於晚期。在一些實施例中,個體患有胰腺癌。胰腺癌可處於早期或晚期。在一些實施例中,個體患有血液惡性病。血液惡性病可處於早期或晚期。在一些實施例中,個體患有卵巢癌。卵巢癌可處於早期或處於晚期。在一些實施例中,個體患有乳癌。乳癌可處於早期或處於晚期。在一些實施例中,個體患有腎細胞癌。腎細胞癌可處於早期或處於晚期。
在一些實施例中,所治療個體係人類。
在另一態樣中,本文提供增強患有癌症之個體之免疫功能的方法,其包含投與有效量之PD-1軸結合拮抗劑及MEK抑制劑。
在一些實施例中,個體中之CD8 T細胞之初免、活化、增殖及/或細胞溶解活性相對於投與PD-1途徑拮抗劑及MEK抑制劑之前有所增強。在一些實施例中,CD8 T細胞初免之特徵在於CD8 T細胞中之CD44表現有所升高及/或細胞溶解活性有所增強。在一些實施例中,CD8 T細胞活化之特徵在於γ-IFN
+CD8 T細胞之頻率有所升高。在一些實施例中,CD8 T細胞係抗原特異性T細胞。在一些實施例中,抑制經由PD-L1表面表現之信號傳導之免疫逃避。
在一些實施例中,個體中之癌細胞之MHC I類抗原表現之表現相對於投與PD-1途徑拮抗劑及MEK抑制劑之前有所升高。
在一些實施例中,個體中之抗原呈遞細胞之成熟及活化相對於投與PD-1途徑拮抗劑及MEK抑制劑之前有所增強。在一些實施例中,其中抗原呈遞細胞係樹突狀細胞。在一些實施例中,抗原呈遞細胞之成熟之特徵在於CD83
+樹突狀細胞之頻率有所增加。在一些實施例中,抗原呈遞細胞之活化之特徵在於樹突狀細胞上CD80及CD86之表現有所升高。
在一些實施例中,個體之細胞介素IL-10及/或趨化因子IL-8 (鼠類KC之人類同源物)之血清濃度相對於投與抗PD‑L1抗體及MEK抑制劑之前有所降低。
在一些實施例中,癌症之T細胞浸潤程度有所升高。
在一些實施例中,本發明之組合療法包含投與PD-1軸結合拮抗劑及MEK抑制劑。PD-1軸結合拮抗劑及MEK抑制劑可以業內已知之任何適宜方式投與。例如,PD-1軸結合拮抗劑及MEK抑制劑可依序(在不同時間)或同時(在同一時間)投與。
在一些實施例中,連續投與MEK抑制劑。在一些實施例中,間歇地投與MEK抑制劑。在一些實施例中,在投與PD-1軸結合拮抗劑之前投與MEK抑制劑。在一些實施例中,與投與PD-1軸結合拮抗劑同時投與MEK抑制劑。在一些實施例中,在投與PD-1軸結合拮抗劑之後投與MEK抑制劑。
在一些實施例中,提供治療個體之癌症或延遲其進展之方法,其包含向該個體投與有效量之PD-1軸結合拮抗劑及MEK抑制劑,進一步包含投與其他療法。其他療法可係輻射療法、手術(例如,病灶切除術及乳房切除術)、化學療法、基因療法、DNA療法、病毒療法、RNA療法、免疫療法、骨髓移植、奈米療法、單株抗體療法或上述療法之組合。其他療法可呈輔助或新輔助療法形式。在一些實施例中,其他療法係投與小分子酶促抑制劑或抗轉移劑。在一些實施例中,其他療法係投與副效應限制劑(例如,意欲減少治療副效應之發作及/或減輕其嚴重程度之藥劑,例如抗嘔吐劑等)。在一些實施例中,其他療法係輻射療法。在一些實施例中,其他療法係手術。在一些實施例中,其他療法係輻射療法與手術之組合。在一些實施例中,其他療法係γ輻照。在一些實施例中,其他療法係靶向PI3K/AKT/mTOR途徑之療法、HSP90抑制劑、微管蛋白抑制劑、細胞凋亡抑制劑及/或化學預防劑。其他療法可係上文所述化學治療劑中之一或多者。
PD-1軸結合拮抗劑及MEK抑制劑可藉由相同投與路徑或藉由不同投與路徑投與。在一些實施例中,經以下方式投與PD-1軸結合拮抗劑:經靜脈內、經肌內、經皮下、經局部、經口、經皮、經腹膜內、經眶內、藉由植入、藉由吸入、經鞘內、經心室內或經鼻內。在一些實施例中,經以下方式投與MEK抑制劑:經靜脈內、經肌內、經皮下、經局部、經口、經皮、經腹膜內、經眶內、藉由植入、藉由吸入、經鞘內、經心室內或經鼻內。
可在該等方法中使用業內已知或上文所述PD-1軸結合拮抗劑及MEK抑制劑中之任一者。
PD-1 軸結合拮抗劑 本文提供治療個體之癌症或延遲其進展之方法,其包含向該個體投與有效量之PD-1軸結合拮抗劑及MEK抑制劑。例如,PD-1軸結合拮抗劑包括PD-1結合拮抗劑、PD-L1結合拮抗劑及PD-L2結合拮抗劑。「PD-1」之替代名稱包括CD279及SLEB2。「PD-L1」之替代名稱包括B7-H1、B7‑4、CD274及B7-H。「PD-L2」之替代名稱包括B7-DC、Btdc及CD273。在一些實施例中,PD-1、PD-L1及PD-L2係人類PD-1、PD-L1及PD-L2。
在一些實施例中,PD-1結合拮抗劑係抑制PD-1與其配體結合配偶體結合之分子。在一具體態樣中,PD-1配體結合配偶體係PD-L1及/或PD-L2。在另一實施例中,PD-L1結合拮抗劑係抑制PD-L1與其結合配偶體結合之分子。在具體態樣中,PD-L1結合配偶體係PD-1及/或B7-1。在另一實施例中,PD-L2結合拮抗劑係抑制PD-L2與其結合配偶體結合之分子。在具體態樣中,PD-L2結合配偶體係PD-1。拮抗劑可係抗體、其抗原結合片段、免疫黏附素、融合蛋白或寡肽。
在一些實施例中,PD-1結合拮抗劑係抗PD-1抗體(例如,人類抗體、人類化抗體或嵌合抗體)。在一些實施例中,抗PD-1抗體係選自由以下組成之群:MDX-1106、Merck 3475及CT-011。在一些實施例中,PD-1結合拮抗劑係免疫黏附素(例如,包含PD-L1或PD-L2之融合至恆定區(例如,免疫球蛋白序列之Fc區)之細胞外或PD-1結合部分的免疫黏附素。在一些實施例中,PD-1結合拮抗劑係AMP-224。在一些實施例中,PD-L1結合拮抗劑係抗PD‑L1抗體。在一些實施例中,抗PD-L1結合拮抗劑係選自由以下組成之群:YW243.55.S70、MPDL3280A及MDX-1105。MDX-1105(亦稱為BMS-936559係闡述於WO 2007/005874中之抗PD-L1抗體。抗體YW243.55.S70(分別顯示於SEQ ID No. 20及21中之重鏈及輕鏈可變區序列)係闡述於WO 2010/077634 A1中之抗PD-L1。MDX-1106(亦稱為MDX-1106-04、ONO-4538或BMS-936558)係闡述於WO2006/121168中之抗PD-1抗體。Merck 3745(亦稱為MK‑3475或SCH-900475)係闡述於WO2009/114335中之抗PD-1抗體。CT-011(亦稱為hBAT或hBAT-1)係闡述於WO2009/101611中之抗PD-1抗體。AMP-224 (亦稱為B7‑DCIg)係闡述於WO2010/027827及WO2011/066342中之PD-L2-Fc融合物可溶性受體。
在一些實施例中,抗PD-1抗體係MDX-1106。「MDX-1106」之替代名稱包括MDX-1106-04、ONO-4538、BMS-936558或尼沃魯單抗(Nivolumab)。在一些實施例中,抗PD-1抗體係尼沃魯單抗(CAS登記號:946414-94-4)。在又一實施例中,提供經分離抗PD-1抗體,其包含含有SEQ ID NO:22之重鏈可變區胺基酸序列之重鏈可變區及/或包含SEQ ID NO:23之輕鏈可變區胺基酸序列之輕鏈可變區。在又一實施例中,提供經分離抗PD-1抗體,其包含重鏈及/或輕鏈序列,其中:
(a)該重鏈序列與以下重鏈序列具有至少85%、至少90%、至少91%、至少92%、至少93%、至少94%、至少95%、至少96%、至少97%、至少98%、至少99%或100%序列一致性:
QVQLVESGGGVVQPGRSLRLDCKASGITFSNSGMHWVRQAPGKGLEWVAVIWYDGSKRYYADSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCATNDDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK (SEQ ID NO:22),或
(b)該輕鏈序列與以下輕鏈序列具有至少85%、至少90%、至少91%、至少92%、至少93%、至少94%、至少95%、至少96%、至少97%、至少98%、至少99%或100%序列一致性:
EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQSSNWPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO:23)。
用於本發明方法之抗PD-L1抗體之實例及其製備方法闡述於PCT專利申請案WO 2010/077634 A1中,該案件以引用方式併入本文中。
在一些實施例中,PD-1軸結合拮抗劑係抗PD-L1抗體。在一些實施例中,抗PD-L1抗體能夠抑制PD-L1與PD-1之間及/或PD-L1與B7-1之間之結合。在一些實施例中,抗PD-L1抗體係單株抗體。在一些實施例中,抗PD-L1抗體係選自由以下組成之群之抗體片段:Fab、Fab'-SH、Fv、scFv及(Fab')
2片段。在一些實施例中,抗PD-L1抗體係人類化抗體。在一些實施例中,抗PD-L1抗體係人類抗體。
用於本發明中之抗PD-L1抗體(包括含有此等抗體之組合物)(例如彼等闡述於WO 2010/077634 A1中者)可與MEK抑制劑組合用於治療癌症。在一些實施例中,抗PD-L1抗體包含含有SEQ ID NO:20之胺基酸序列之重鏈可變區及包含SEQ ID NO:21之胺基酸序列之輕鏈可變區。
在一個實施例中,抗PD-L1抗體含有重鏈可變區多肽包含HVR-H1、HVR-H2及HVR-H3序列,其中:
(a) HVR-H1序列係GFTFSX
1SWIH (SEQ ID NO: 1);
(b) HVR-H2序列係AWIX
2PYGGSX
3YYADSVKG (SEQ ID NO:2);
(c) HVR-H3序列係RHWPGGFDY (SEQ ID NO:3);
另外其中:X
1係D或G;X
2係S或L;X
3係T或S。
在一個具體態樣中,X
1係D;X
2係S且X
3係T。在另一態樣中,多肽進一步包含根據下式併置於HVR之間之可變區重鏈框架序列:(HC-FR1)-(HVR-H1)-(HC-FR2)-(HVR-H2)-(HC-FR3)-(HVR-H3)-(HC-FR4)。在再一態樣中,框架序列係源自人類共有框架序列。在又一態樣中,框架序列係VH亞群III共有框架。在又一態樣中,框架序列中之至少一者如下:
HC-FR1係EVQLVESGGGLVQPGGSLRLSCAAS (SEQ ID NO: 4)
HC-FR2係WVRQAPGKGLEWV (SEQ ID NO: 5)
HC-FR3係RFTISADTSKNTAYLQMNSLRAEDTAVYYCAR (SEQ ID NO:6)
HC-FR4係WGQGTLVTVSA (SEQ ID NO:7)。
在又一態樣中,重鏈多肽進一步與包含HVR-L1、HVR-L2及HVR-L3之可變區輕鏈組合,其中:
(a) HVR-L1序列係RASQX
4X
5X
6TX
7X
8A (SEQ ID NO. 8);
(b) HVR-L2序列係SASX
9LX
10S, (SEQ ID NO 9);
(c) HVR-L3序列係QQX
11X
12X
13X
14PX
15T (SEQ ID N O:10);
另外其中:X
4係D或V;X
5係V或I;X
6係S或N;X
7係A或F;X
8係V或L;X
9係F或T;X
10係Y或A;X
11係Y、G、F或S;X
12係L、Y、F或W;X
13係Y、N、A、T、G、F或I;X
14係H、V、P、T或I;X
15係A、W、R、P或T。
在又一態樣中,X
4係D;X
5係V;X
6係S;X
7係A;X
8係V;X
9係F;X
10係Y;X
11係Y;X
12係L;X
13係Y;X
14係H;X
15係A。在又一態樣中,輕鏈進一步包含根據下式併置於HVR之間之可變區輕鏈框架序列:(LC-FR1)-(HVR-L1)-(LC-FR2)-(HVR-L2)-(LC-FR3)-(HVR-L3)-(LC-FR4)。在又一態樣中,框架序列係源自人類共有框架序列。在又一態樣中,框架序列係VLκI共有框架。在又一態樣中,框架序列中之至少一者如下:
在另一實施例中,提供係包含重鏈及輕鏈可變區序列之經分離抗PD-L1抗體或抗原結合片段,其中:
(a)該重鏈包含HVR-H1、HVR-H2及HVR-H3,其中另外:
(b)該輕鏈包含HVR-L1、HVR-L2及HVR-L3,其中另外:
另外其中:X
1係D或G;X
2係S或L;X
3係T或S;X
4係D或V;X
5係V或I;X
6係S或N;X
7係A或F;X
8係V或L;X
9係F或T;X
10係Y或A;X
11係Y、G、F或S;X
12係L、Y、F或W;X
13係Y、N、A、T、G、F或I;X
14係H、V、P、T或I;X
15係A、W、R、P或T。
在一具體態樣中,X
1係D;X
2係S且X
3係T。在另一態樣中,X
4係D;X
5係V;X
6係S;X
7係A;X
8係V;X
9係F;X
10係Y;X
11係Y;X
12係L;X
13係Y;X
14係H;X
15係A。在又一態樣中,X
1係D;X
2係S且X
3係T,X
4係D;X
5係V;X
6係S;X
7係A;X
8係V;X
9係F;X
10係Y;X
11係Y;X
12係L;X
13係Y;X
14係H且X
15係A。
在又一態樣中,重鏈可變區包含一或多個如下併置於HVR之間之框架序列:(HC-FR1)-(HVR-H1)-(HC-FR2)-(HVR-H2)-(HC-FR3)-(HVR-H3)-(HC-FR4),且輕鏈可變區包含一或多個如下併置於HVR之框架序列:(LC-FR1)-(HVR-L1)-(LC-FR2)-(HVR-L2)-(LC-FR3)-(HVR-L3)-(LC-FR4)。在又一態樣中,框架序列係源自人類共有框架序列。在又一態樣中,重鏈框架序列係源自Kabat亞群I、II或III序列。在又一態樣中,重鏈框架序列係VH亞群III共有框架。在又一態樣中,一或多個重鏈框架序列如下:
在又一態樣中,輕鏈框架序列係源自Kabat κI、II、II或IV亞群序列。在又一態樣中,輕鏈框架序列係VL κI共有框架。在又一態樣中,一或多個輕鏈框架序列如下:
在又一具體態樣中,抗體進一步包含人類或鼠類恆定區。在又一態樣中,人類恆定區係選自由以下組成之群:IgG1、IgG2、IgG2、IgG3、IgG4。在又一具體態樣中,人類恆定區係IgG1。在又一態樣中,鼠類恆定區係選自由以下組成之群:IgG1、IgG2A、IgG2B、IgG3。在又一態樣中,鼠類恆定區係IgG2A。在又一具體態樣中,抗體具有經降低或最低效應子功能。在又一具體態樣中,最低效應子功能係自「無效應子之Fc突變」或無糖基化引起。在又一實施例中,無效應子之Fc突變係恆定區中之N297A或D265A/N297A取代。
在再一實施例中,提供包含重鏈及輕鏈可變區序列之抗PD-L1抗體,其中:
(a) 該重鏈進一步包含分別與GFTFSDSWIH (SEQ ID NO: 15)、AWISPYGGSTYYADSVKG (SEQ ID NO: 16)及RHWPGGFDY (SEQ ID NO:3)具有至少85%序列一致性之HVR-H1、HVR-H2及HVR-H3序列,或
(b) 該輕鏈進一步包含分別與RASQDVSTAVA (SEQ ID NO: 17)、SASFLYS (SEQ ID NO: 18)及QQYLYHPAT (SEQ ID NO: 19)具有至少85%序列一致性之HVR-L1、HVR-L2及HVR-L3序列。
在一具體態樣中,序列一致性係86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%或100%。在另一態樣中,重鏈可變區包含一或多個如下併置於HVR之間之框架序列:(HC-FR1)-(HVR-H1)-(HC-FR2)-(HVR-H2)-(HC-FR3)-(HVR-H3)-(HC-FR4),且輕鏈可變區包含一或多個如下併置於HVR之間之框架序列:(LC-FR1)-(HVR-L1)-(LC-FR2)-(HVR-L2)-(LC-FR3)-(HVR-L3)-(LC-FR4)。在再一態樣中,框架序列係源自人類共有框架序列。在又一態樣中,重鏈框架序列係源自Kabat亞群I、II或III序列。在又一態樣中,重鏈框架序列係VH亞群III共有框架。在又一態樣中,一或多個重鏈框架序列如下:
在又一態樣中,輕鏈框架序列係源自Kabat κI、II、II或IV亞群序列。在又一態樣中,輕鏈框架序列係VL κI共有框架。在又一態樣中,一或多個輕鏈框架序列如下:
在又一具體態樣中,抗體進一步包含人類或鼠類恆定區。在又一態樣中,人類恆定區係選自由以下組成之群:IgG1、IgG2、IgG2、IgG3、IgG4。在又一具體態樣中,人類恆定區係IgG1。在又一態樣中,鼠類恆定區係選自由以下組成之群:IgG1、IgG、IgG2B、IgG3。在又一態樣中,鼠類恆定區係IgG2A。在又一具體態樣中,抗體具有經降低或最低效應子功能。在又一具體態樣中,最低效應子功能係自「無效應子之Fc突變」或無糖基化引起。在又一實施例中,無效應子之Fc突變係恆定區中之N297A或D265A/N297A取代。
在又一實施例中,提供包含重鏈及輕鏈可變區序列之經分離抗PD-L1抗體,其中:
(a)該重鏈序列與以下重鏈序列具有至少85%序列一致性:EVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWVAWISPYGGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRHWPGGFDYWGQGTLVTVSA (SEQ ID NO:20),或
(b)該輕鏈序列與以下輕鏈序列具有至少85%序列一致性:DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYLYHPATFGQGTKVEIKR(SEQ ID NO:21)。
在一具體態樣中,序列一致性係86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%或100%。在另一態樣中,重鏈可變區包含一或多個如下併置於HVR之間之框架序列:(HC-FR1)-(HVR-H1)-(HC-FR2)-(HVR-H2)-(HC-FR3)-(HVR-H3)-(HC-FR4),且輕鏈可變區包含一或多個如下併置於HVR之間之框架序列:(LC-FR1)-(HVR-L1)-(LC-FR2)-(HVR-L2)-(LC-FR3)-(HVR-L3)-(LC-FR4)。在再一態樣中,框架序列係源自人類共有框架序列。在又一態樣中,重鏈框架序列係源自Kabat亞群I、II或III序列。在又一態樣中,重鏈框架序列係VH亞群III共有框架。在又一態樣中,一或多個重鏈框架序列如下:
在又一態樣中,輕鏈框架序列係源自Kabat κI、II、II或IV亞群序列。在又一態樣中,輕鏈框架序列係VL κI共有框架。在又一態樣中,一或多個輕鏈框架序列如下:
在又一具體態樣中,抗體進一步包含人類或鼠類恆定區。在又一態樣中,人類恆定區係選自由以下組成之群:IgG1、IgG2、IgG2、IgG3、IgG4。在又一具體態樣中,人類恆定區係IgG1。在又一態樣中,鼠類恆定區係選自由以下組成之群:IgG1、IgG2A、IgG2B、IgG3。在又一態樣中,鼠類恆定區係IgG2A。在又一具體態樣中,抗體具有經降低或最低效應子功能。在又一具體態樣中,最低效應子功能係自原核細胞中產生引起。在又一具體態樣中,最低效應子功能係自「無效應子之Fc突變」或無糖基化引起。在又一實施例中,無效應子之Fc突變係恆定區中之N297A或D265A/N297A取代。
在又一實施例中,提供包含重鏈及輕鏈可變區序列之經分離抗PD-L1抗體,其中:
(a)該重鏈序列與以下重鏈序列具有至少85%序列一致性:EVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWVAWISPYGGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRHWPGGFDYWGQGTLVTVSS (SEQ ID NO:24),或
(b)該輕鏈序列與以下輕鏈序列具有至少85%序列一致性:DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYLYHPATFGQGTKVEIKR(SEQ ID NO:21)。
在一具體態樣中,序列一致性係86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%或100%。在另一態樣中,重鏈可變區包含一或多個如下併置於HVR之間之框架序列:(HC-FR1)-(HVR-H1)-(HC-FR2)-(HVR-H2)-(HC-FR3)-(HVR-H3)-(HC-FR4),且輕鏈可變區包含一或多個如下併置於HVR之間之框架序列:(LC-FR1)-(HVR-L1)-(LC-FR2)-(HVR-L2)-(LC-FR3)-(HVR-L3)-(LC-FR4)。在再一態樣中,框架序列係源自人類共有框架序列。在又一態樣中,重鏈框架序列係源自Kabat亞群I、II或III序列。在又一態樣中,重鏈框架序列係VH亞群III共有框架。在又一態樣中,一或多個重鏈框架序列如下:
在又一態樣中,輕鏈框架序列係源自Kabat κI、II、II或IV亞群序列。在又一態樣中,輕鏈框架序列係VL κI共有框架。在又一態樣中,一或多個輕鏈框架序列如下:
在又一具體態樣中,抗體進一步包含人類或鼠類恆定區。在又一態樣中,人類恆定區係選自由以下組成之群:IgG1、IgG2、IgG2、IgG3、IgG4。在又一具體態樣中,人類恆定區係IgG1。在又一態樣中,鼠類恆定區係選自由以下組成之群:IgG1、IgG2A、IgG2B、IgG3。在又一態樣中,鼠類恆定區係IgG2A。在又一具體態樣中,抗體具有經降低或最低效應子功能。在又一具體態樣中,最低效應子功能係自原核細胞中產生引起。在又一具體態樣中,最低效應子功能係自「無效應子之Fc突變」或無糖基化引起。在又一實施例中,無效應子之Fc突變係恆定區中之N297A或D265A/N297A取代。
在再一實施例中,抗PD-1抗體係MPDL3280A。在又一實施例中,提供經分離抗PD-1抗體,其包含含有SEQ ID NO:24之重鏈可變區胺基酸序列之重鏈可變區及/或包含SEQ ID NO:25之輕鏈可變區胺基酸序列之輕鏈可變區。在又一實施例中,提供經分離抗PD-1抗體,其包含重鏈及/或輕鏈序列,其中:
(a)該重鏈序列與以下重鏈序列具有至少85%、至少90%、至少91%、至少92%、至少93%、至少94%、至少95%、至少96%、至少97%、至少98%、至少99%或100%序列一致性:
EVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWVAWISPYGGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRHWPGGFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK(SEQ ID NO:26),或
(b)該輕鏈序列與以下輕鏈序列具有至少85%、至少90%、至少91%、至少92%、至少93%、至少94%、至少95%、至少96%、至少97%、至少98%、至少99%或100%序列一致性:
DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYLYHPATFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 27)。
在又一實施例中,本發明提供包含上述抗PD-L1抗體中之任一者與至少一種醫藥上可接受之載劑組合之組合物。
在又一實施例中,提供編碼抗PD-L1抗體之輕鏈或重鏈可變區序列之經分離核酸,其中:
(a) 該重鏈進一步包含分別與GFTFSDSWIH (SEQ ID NO: 15)、AWISPYGGSTYYADSVKG (SEQ ID NO: 16)及RHWPGGFDY (SEQ ID NO:3)具有至少85%序列一致性之HVR-H1、HVR-H2及HVR-H3序列,且
(b) 該輕鏈進一步包含分別與RASQDVSTAVA (SEQ ID NO: 17)、SASFLYS (SEQ ID NO: 18)及QQYLYHPAT (SEQ ID NO: 19)具有至少85%序列一致性之HVR-L1、HVR-L2及HVR-L3序列。
在一具體態樣中,序列一致性係86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%或100%。在態樣中,重鏈可變區包含一或多個如下併置於HVR之間之框架序列:(HC-FR1)-(HVR-H1)-(HC-FR2)-(HVR-H2)-(HC-FR3)-(HVR-H3)-(HC-FR4),且輕鏈可變區包含一或多個如下併置於HVR之間之框架序列:(LC-FR1)-(HVR-L1)-(LC-FR2)-(HVR-L2)-(LC-FR3)-(HVR-L3)-(LC-FR4)。在再一態樣中,框架序列係源自人類共有框架序列。在又一態樣中,重鏈框架序列係源自Kabat亞群I、II或III序列。在又一態樣中,重鏈框架序列係VH亞群III共有框架。在又一態樣中,一或多個重鏈框架序列如下:
在又一態樣中,輕鏈框架序列係源自Kabat κI、II、II或IV亞群序列。在又一態樣中,輕鏈框架序列係VL κI共有框架。在又一態樣中,一或多個輕鏈框架序列如下:
在又一具體態樣中,本文所述抗體(例如抗PD-1抗體、抗PD-L1抗體或抗PD-L2抗體)進一步包含人類或鼠類恆定區。在又一態樣中,人類恆定區係選自由以下組成之群:IgG1、IgG2、IgG2、IgG3、IgG4。在又一具體態樣中,人類恆定區係IgG1。在又一態樣中,鼠類恆定區係選自由以下組成之群:IgG1、IgG2A、IgG2B、IgG3。在又一態樣中,鼠類恆定區係IgG2A。在又一具體態樣中,抗體具有經降低或最低效應子功能。在又一具體態樣中,最低效應子功能係自原核細胞中產生引起。在又一具體態樣中,最低效應子功能係自「無效應子之Fc突變」或無糖基化引起。在又一態樣中,無效應子之Fc突變係恆定區中之N297A或D265A/N297A取代。
在又一態樣中,本文提供編碼本文所述任一抗體之核酸。在一些實施例中,核酸進一步包含適於表現編碼前文所述抗PD-L1、抗PD-1或抗PD-L2抗體中任一者之核酸的載體。在又一具體態樣中,該載體進一步包含適於表現該核酸之宿主細胞。在又一具體態樣中,宿主細胞係真核細胞或原核細胞。在又一具體態樣中,真核細胞係哺乳動物細胞,例如中國倉鼠卵巢(CHO)。
抗體或其抗原結合片段可使用業內已知方法製得,例如,藉由包含以下步驟之方法製得:在適於產生此抗體或片段之條件下培養含有編碼前文所述抗PD-L1、抗PD-1或抗PD-L2抗體中任一者或抗原-結合片段之核酸(呈適於表現之形式)的宿主細胞並回收該抗體或片段。
在又一實施例中,本發明提供包含如本文所提供抗PD‑L1、抗PD-1或抗PD-L2抗體或其抗原結合片段及至少一種醫藥上可接受之載劑的組合物。在一些實施例中,投與個體之抗PD-L1、抗PD-1或抗PD-L2抗體或其抗原結合片段係包含一或多種醫藥上可接受之載劑之組合物。可使用本文所述或業內已知之任一醫藥上可接受之載劑。
MEK 抑制劑 本發明提供治療個體之癌症或減緩癌症進展之方法,其包含投與有效量之PD-1途徑拮抗劑及MEK抑制劑。期望任一已知MEK抑制劑,例如闡述於PCT專利申請案WO 03/077914 A1、WO 2005/121142 A1、WO 2007/044515 A1、WO 2008/024725 A1及WO 2009/085983 A1中之MEK抑制劑化合物,該等案件之內容以引用方式併入本文中。
在一些實施例中,MEK抑制劑係MEK之競爭抑制劑。在一些實施例中,MEK抑制劑針對活化性KRAS突變之選擇性較高。在一些實施例中,MEK抑制劑係MEK之異位抑制劑。在一些實施例中,MEK抑制劑針對活化性BRAF突變(例如,BRAF V600E突變)之選擇性較高。在一些實施例中,MEK抑制劑結合並抑制MEK1及/或MEK2之活性(例如人類MEK1及/或人類MEK2)。
在一些實施例中,MEK抑制劑係選自由以下組成之群之化合物:GDC-0973、G-38963、G02443714 (亦稱為「AS703206」)、G02442104 (亦稱為「GSK-1120212」)及G00039805 (亦稱為「AZD-6244」)或其醫藥上可接受之鹽或溶劑合物。
在一些實施例中,MEK抑制劑係式(I)化合物,
或其醫藥上可接受之鹽或溶劑合物,其中A、X、R
1、R
2、R
3、R
4、R
5、R
6及R
7係如群組A、群組B、群組C或群組D中所定義:
群組 A :A係視情況經1個、2個、3個或4個選自R
10、R
12、R
14、R
16及R
19之基團取代之伸芳基,其中R
10、R
12、R
14及R
16獨立地係氫、烷基、烯基、炔基、鹵基、鹵代烷氧基、羥基、烷氧基、胺基、烷基胺基、二烷基胺基、鹵代烷基、-NHS(O)
2R
8、-CN、-C(O)R
8、-C(O)OR
8、-C(O)NR
8R
8'及-NR
8C(O)R
8'且R
19係氫、烷基或烯基;
X係烷基、鹵基、鹵代烷基或鹵代烷氧基;
R
1、R
2、R
3、R
4、R
5及R
6獨立地係氫、鹵基、硝基、-NR
8R
8'、-OR
8、-NHS(O)
2R
8、-CN、-S(O)
mR
8、-S(O)
2NR
8R
8'、-C(O)R
8、-C(O)OR
8、-C(O)NR
8R
8'、-NR
8C(O)OR
8'、-NR
8C(O)NR
8'R
8''、-NR
8C(O)OR
8'、-NR
8C(O)R
8'、-CH
2N(R
25)(NR
25aR
25b)、-CH
2NR
25C(=NH)(NR
25aR
25b)、-CH
2NR
25C(=NH)(N(R
25a)(NO
2))、-CH
2NR
25C(=NH)(N(R
25a)(CN))、-CH
2NR
25C(=NH)(R
25)、-CH
2NR
25C(NR
25aR
25b)=CH(NO
2)、烷基、烯基、炔基、環烷基、雜芳基或雜環烷基;其中烷基、烯基、炔基、環烷基、雜芳基及雜環烷基獨立地視情況經1個、2個、3個、4個、5個、6個或7個獨立地選自以下之基團取代:鹵基、烷基、鹵代烷基、硝基、視情況經取代之環烷基、視情況經取代之雜環烷基、視情況經取代之芳基、視情況經取代之芳基烷基、視情況經取代之雜芳基、-OR
8、-NR
8R
8'、-NR
8S(O)
2R
9、-CN、-S(O)
mR
9、-C(O)R
8、-C(O)OR
8、-C(O)NR
8V
8'
、-NR
8C(O)NR
8'R
8''、-NR
8C(O)OR
8'及-NR
8C(O)R
8';或R
1及R
2中之一者與其所附接之碳一起、R
3及R
4與其所附接之碳一起以及R
5及R
6與其所附接之碳一起形成C(O)或C(=NOH);
m係0、1或2;
R
7係氫、鹵基或烷基;
每一R
8、R
8'及R
8''係獨立地選自氫、羥基、視情況經取代之烷氧基、烷基、烯基、炔基、芳基、環烷基、雜芳基及雜環烷基;其中烷基、烯基、炔基、芳基、環烷基、雜芳基及雜環烷基獨立地視情況經1個、2個、3個、4個或5個獨立地選自以下之基團取代:烷基、鹵基、羥基、羥基烷基、視情況經取代之烷氧基、烷氧基烷基、鹵代烷基、羧基、烷氧基羰基、烯氧基羰基、視情況經取代之環烷基、視情況經取代之環烷氧基羰基、視情況經取代之芳基、視情況經取代之芳氧基、視情況經取代之芳氧基羰基、視情況經取代之芳基烷基、視情況經取代之芳基烷氧基、視情況經取代之芳基烷氧基羰基、硝基、氰基、視情況經取代之雜環烷基、視情況經取代之雜芳基、-S(O)R
31(其中n係0、1或2且R
31係視情況經取代之烷基、視情況經取代之芳基、視情況經取代之雜環烷基或視情況經取代之雜芳基)、-NR
34SO
2R
34a(其中R
34係氫或烷基且R
34a係烷基、烯基、環烷基、芳基、雜芳基或雜環烷基)、-SO
2NR
35R
35a(其中R
35係氫或烷基且R
35a係烷基、烯基、環烷基、芳基、雜芳基或雜環烷基)、-NR
32C(O)R
32a(其中R
32係氫或烷基且R
32a係烷基、烯基、烷氧基或環烷基)、-NR
30R
30'(其中R
30及R
30'獨立地係氫、烷基或羥基烷基)及-C(O)NR
33R
33a(其中R
33係氫或烷基且R
33a係烷基、烯基、炔基或環烷基);且
每一R
9係獨立地選自烷基、烯基、炔基、芳基、環烷基、雜芳基及雜環烷基;其中烷基、烯基、炔基、芳基、環烷基、雜芳基及雜環烷基獨立地視情況經1個、2個、3個、4個或5個選自以下之基團取代:鹵基、羥基、烷基、鹵代烷基、鹵代烷氧基、胺基、烷基胺基及二烷基胺基;
群組 B :A係視情況經1個、2個、3個或4個選自以下之基團取代之伸雜芳基:R
10、R
12、R
14、R
16及R
19,其中R
10、R
12、R
14及R
16獨立地係氫、烷基、烯基、炔基、鹵基、鹵代烷氧基、羥基、烷氧基、氰基、胺基、烷基胺基、二烷基胺基、鹵代烷基、烷基磺醯基胺基、烷基羰基、烯基羰基、烷氧基羰基、烯氧基羰基、胺基羰基、烷基胺基羰基、二烷基胺基羰基或烷基羰基胺基;其中R
19係氫、烷基或烯基;且其中每一烷基及烯基單獨或作為R
10、R
12、R
14、R
16及R
19內另一基團之一部分獨立地視情況經鹵基、羥基或烷氧基取代;
X係烷基、鹵基、鹵代烷基或鹵代烷氧基;
R
1、R
2、R
3、R
4、R
3及R
6獨立地係氫、鹵基、硝基、-NR
8R
8'、-OR
8、-NHS(O)
2R
8、-CN、-S(O)
mR
8、-S(O)
2NR
8R
8'、-C(O)R
8、-C(O)OR
8、-C(O)NR
8R
8'、-NR
8C(O)OR
8'、-NR
8C(O)NR
8'R
8''、-NR
8C(O)OR
8'、-NR
8C(O)R
8'、-CH
2N(R
25)(NR
25aR
25b)、-CH
2NR
25C(=NH)(NR
25aR
25b)、-CH
2NR
25C(=NH)(N(R
25a)(NO
2))、-CH
2NR
25C(NH)(N(R
25a)(CN))、-CH
2NR
25C(=NH)(R
25)、-CH
2NR
25C(NR
25aR
25b)=CH(NO
2)、烷基、烯基、炔基、環烷基、雜芳基或雜環烷基,其中烷基、烯基、炔基、環烷基、雜芳基及雜環烷基獨立地視情況經1個、2個、3個、4個、5個、6個或7個獨立地選自以下之基團取代:鹵基、烷基、鹵代烷基、硝基、視情況經取代之環烷基、視情況經取代之雜環烷基、視情況經取代之芳基、視情況經取代之芳基烷基、視情況經取代之雜芳基、-OR
8、-NR
8R
8'、-NR
8S(O)
2R
9、-CN、-S(O)
mR
9、-C(O)R
8、-C(O)OR
8、-C(O)NR
8R
8'、-NR
8C(O)NR
8'R
8''、-NR
8C(O)OR
8'及-NR
8C(O)R
8';或R
1及R
2中之一者與其所附接之碳一起、R
3及R
4與其所附接之碳一起以及R
5及R
6與其所附接之碳一起形成C(O)或C(=NOH);
m係1或2;
R
7係氫、鹵基或烷基;且
每一R
8、R
8'及R
8''係獨立地選自氫、羥基、視情況經取代之烷氧基、烷基、鹵代烷基、烯基、炔基、芳基、環烷基、雜芳基及雜環烷基,其中烷基、烯基、炔基、芳基、環烷基、雜芳基及雜環烷基獨立地視情況經1個、2個、3個、4個或5個獨立地選自以下之基團取代:烷基、鹵基、羥基、羥基烷基、視情況經取代之烷氧基、烷氧基烷基、鹵代烷基、羧基、羧基酯、硝基、氰基、-S(O)
nR
31(其中n係0、1或2且R
31係視情況經取代之烷基、視情況經取代之芳基、視情況經取代之環烷基、視情況經取代之雜環烷基或視情況經取代之雜芳基)、-NR
36S(O)
2R
36a(其中R
36係氫、烷基或烯基且R
36a係烷基、烯基、視情況經取代之芳基、視情況經取代之環烷基、視情況經取代之雜環烷基或視情況經取代之雜芳基)、-S(O)
2NR
37R
37a(其中R
37係氫、烷基或烯基且R
37a係烷基、烯基、視情況經取代之芳基、視情況經取代之環烷基、視情況經取代之雜環烷基或視情況經取代之雜芳基)、視情況經取代之環烷基、視情況經取代之雜環烷基、視情況經取代之芳基、視情況經取代之芳基烷基、視情況經取代之芳氧基、視情況經取代之芳基烷氧基、視情況經取代之雜芳基、-NHC(O)R
32(其中R
32係烷基、烯基、烷氧基或環烷基)及-NR
30R
30'(其中R
30及R
30'獨立地係氫、烷基或羥基烷基)及-C(O)NHR
33(其中R
33係烷基、烯基、炔基或環烷基);
群組 C :A係
其中R
10係氫、烷基、烯基、炔基、鹵基、鹵代烷氧基、羥基、烷氧基、胺基、烷基胺基、二烷基胺基、鹵代烷基、-NHS(O)
2R
8、-CN、-C(O)R
8、-C(O)OR
8、-C(O)NR
8R
8'及-NR
8C(O)R
8';
R
10a係氫、烷基或烯基;
Y
1係=CH-或=N-;
X係烷基、鹵基、鹵代烷基或鹵代烷氧基;
R
1、R
2、R
3、R
4、R
5及R
6獨立地係氫、鹵基、硝基、‑NR
8R
8'、-OR
8、-NHS(O)
2R
8、-CN、-S(O)
mR
8、-S(O)
2NR
8R
8'、-C(O)R
8、-C(O)OR
8、-C(O)NR
8R
8'、-NR
8C(O)OR
8'、-NR
8C(O)NR
8'R
8''、-NR
8C(O)OR
8'、-NR
8C(O)R
8'、-CH
2N(R
25)NR
25aR
25b)、-CH
2NR
25C(=NH)(NR
25aR
25b)、-CH
2NR
25C(=NH)(N(R
25a)(NO
2))、-CH
2NR
25C(=NH)(N(R
25a)(CN))、-CH
2NR
25C(=NH)(R
25)、-CH
2NR
25C(NR
25aR
25b)=CH(NO
2)、烷基、烯基、炔基、環烷基、雜芳基或雜環烷基,其中烷基、烯基、炔基、環烷基、雜芳基及雜環烷基獨立地視情況經1個、2個、3個、4個、5個、6個或7個獨立地選自以下之基團取代:鹵基、烷基、鹵代烷基、硝基、視情況經取代之環烷基、視情況經取代之雜環烷基、視情況經取代之芳基、視情況經取代之芳基烷基、視情況經取代之雜芳基、-OR
8、-NR
8R
8'、-NR
8S(O)
2R
9、-CN、-S(O)
mR
9、-C(O)R
8、-C(O)OR
8、-C(O)NR
8R
8'
、-NR
8C(O)NR
8'R
8''、-NR
8C(O)OR
8'及-NR
8C(O)R
8';或R
1及R
2中之一者與其附接之碳一起、R
3及R
4與其所附接之碳一起以及R
5及R
6與其所附接之碳一起形成C(O)或C(NOH);
m係1或2;
R
7係氫、鹵基或烷基;且
每一R
8、R
8'及R
8''係獨立地選自氫、羥基、視情況經取代之烷氧基、烷基、鹵代烷基、烯基、炔基、芳基、環烷基、雜芳基及雜環烷基,其中烷基、烯基、炔基、芳基、環烷基、雜芳基及雜環烷基獨立地視情況經1個、2個、3個、4個或5個獨立地選自以下之基團取代:烷基、鹵基、羥基、羥基烷基、視情況經取代之烷氧基、烷氧基烷基、鹵代烷基、羧基、羧基酯、硝基、氰基、-S(O)
nR
31(其中n係0、1或2且R
31係視情況經取代之烷基、視情況經取代之芳基、視情況經取代之環烷基、視情況經取代之雜環烷基或視情況經取代之雜芳基)、‑NR
36S(O)
2R
36a(其中R
36係氫、烷基或烯基且R
36a係烷基、烯基、視情況經取代之芳基、視情況經取代之環烷基、視情況經取代之雜環烷基或視情況經取代之雜芳基)、-S(O)
2NR
37R
37a(其中R
37係氫、烷基或烯基且R
37a係烷基、烯基、視情況經取代之芳基、視情況經取代之環烷基、視情況經取代之雜環烷基或視情況經取代之雜芳基)、視情況經取代之環烷基、視情況經取代之雜環烷基、視情況經取代之芳基、視情況經取代之芳基烷基、視情況經取代之芳氧基、視情況經取代之芳基烷氧基、視情況經取代之雜芳基、-NHC(O)R
32(其中R
32係烷基、烯基、烷氧基或環烷基)及-NR
30R
30'(其中R
30及R
30'獨立地係氫、烷基或羥基烷基)及-C(O)NHR
33(其中R
33係烷基、烯基、炔基或環烷基);或
群組 D :A係
R
40及R
40a獨立地係氫或烷基;
X係烷基、鹵基、鹵代烷基或鹵代烷氧基;
R
1、R
2、R
3、R
4、R
5及R
6獨立地係氫、鹵基、硝基、-NR
8R
8'、-OR
8、-NHS(O)
2R
8、-CN、-S(O)
mR
8、-S(O)
2NR
8R
8'、-C(O)R
8、-C(O)OR
8、-C(O)NR
8R
8'、-NR
8C(O)OR
8'、-NR
8C(O)NR
8'R
8''、-NR
8C(O)OR
8'、-NR
8C(O)R
8'、-CH
2N(R
25)(NR
25aR
25b)、-CH
2NR
25C(=NH)(NR
25aR
25b)、-CH
2NR
25C(=NH)(N(R
25a)(NO
2))、-CH
2NR
25C(=NH)(N(R
25a)(CN))、-CH
2NR
25C(=NH)(R
25)、-CH
2NR
25C(NR
25aR
25b)=CH(NO
2)、烷基、烯基、炔基、環烷基、雜芳基或雜環烷基,其中烷基、烯基、炔基、環烷基、雜芳基及雜環烷基獨立地視情況經1個、2個、3個、4個、5個、6個或7個獨立地選自以下之基團取代:鹵基、烷基、鹵代烷基、硝基、視情況經取代之環烷基、視情況經取代之雜環烷基、視情況經取代之芳基、視情況經取代之芳基烷基、視情況經取代之雜芳基、-OR
8、-NR
8R
8'、-NR
8S(O)
2R
9、-CN、-S(O)
mR
9、-C(O)R
8、-C(O)OR
8、-C(O)NR
8R
8'、-NR
8C(O)NR
8'R
8''、-NR
8C(O)OR
8'及-NR
8C(O)R
8';或R
1及R
2中之一者與其所附接之碳一起、R
3及R
4與其所附接之碳一起以及R
5及R
6與其所附接之碳一起形成C(O)或C(NOH);
m係1或2;
R
7係氫、鹵基或烷基;且
R
8、R
8'及R
8''係獨立地選自氫、羥基、視情況經取代之烷氧基、烷基、鹵代烷基、烯基、炔基、芳基、環烷基、雜芳基及雜環烷基,其中烷基、烯基、炔基、芳基、環烷基、雜芳基及雜環烷基獨立地視情況經1個、2個、3個、4個或5個獨立地選自以下之基團取代:烷基、鹵基、羥基、羥基烷基、視情況經取代之烷氧基、烷氧基烷基、鹵代烷基、羧基、羧基酯、硝基、氰基、‑S(O)
nR
31(其中n係0、1或2且R
31係視情況經取代之烷基、視情況經取代之芳基、視情況經取代之環烷基、視情況經取代之雜環烷基或視情況經取代之雜芳基)、‑NR
36S(O)
2R
36a(其中R
36係氫、烷基或烯基且R
36a係烷基、烯基、視情況經取代之芳基、視情況經取代之環烷基、視情況經取代之雜環烷基或視情況經取代之雜芳基)、-S(O)
2NR
37R
37a(其中R
37係氫、烷基或烯基且R
37a係烷基、烯基、視情況經取代之芳基、視情況經取代之環烷基、視情況經取代之雜環烷基或視情況經取代之雜芳基)、視情況經取代之環烷基、視情況經取代之雜環烷基、視情況經取代之芳基、視情況經取代之芳基烷基、視情況經取代之芳氧基、視情況經取代之芳基烷氧基、視情況經取代之雜芳基、-NHC(O)R
32(其中R
32係烷基、烯基、烷氧基或環烷基)及-NR
30R
30'(其中R
30及R
30'獨立地係氫、烷基或羥基烷基)及-C(O)NHR
33(其中R
33係烷基、烯基、炔基或環烷基)。
在一些變化形式中,式(I)之MEK抑制劑化合物係群組A之化合物,其具有式I(a)或I(b):
或其醫藥上可接受之鹽或溶劑合物,其中變量係如針對式(I)群組A所定義或如WO 2007/044515 A1中所定義,該案件以引用方式併入本文中。
在一些變化形式中,式(I)之MEK抑制劑化合物係群組B之化合物,其具有式I(c)、I(d)、I(e)、I(f)、I(g)、I(h)、I(i)、I(j)、I(k)、I(m)、I(n)、I(o)、I(p)、I(q)、I(r)、I(s)、I(u)、I(v)、I(w)、I(x)、I(cc)或I(dd):
或其醫藥上可接受之鹽或溶劑合物,其中變量係如針對式(I)群組B所定義或如WO 2007/044515 A1中所定義,該案件以引用方式併入本文中。
在一些變化形式中,式(I)之MEK抑制劑化合物係群組C之化合物,其具有式I(y)或I(z):
或其醫藥上可接受之鹽或溶劑合物,其中變量係如針對式(I)群組C所定義或如WO 2007/044515 A1中所定義,該案件以引用方式併入本文中。
在一些變化形式中,式(I)之MEK抑制劑化合物係群組D之化合物,其具有式I(aa)或I(bb):
或其醫藥上可接受之鹽或溶劑合物,其中變量係如針對式(I)群組D所定義或如WO 2007/044515 A1中所定義,該案件以引用方式併入本文中。
在一些實施例中,式(I)之MEK抑制劑化合物係選自如WO 2007/044515 A1第71-144頁之表1中所列示之化合物1至362 (本文中統稱為式I物質)之化合物或其醫藥上可接受之鹽或溶劑合物。
本文亦涵蓋如WO 2007/044515 A1中所述式(I)之任何變化形式,該案件以引用方式併入本文中。式(I)化合物或其任何變化形式可使用業內已知方法(例如,闡述於WO 2007/044515 A1中之合成方法)合成,該案件以引用方式併入本文中。
除非本文另有定義,否則用於描述式(I)化合物之術語應理解為具有與WO 2007/044515 A1中所定義相同之含義。
在一些實施例中,MEK抑制劑係式(II)化合物:
或其醫藥上可接受之鹽或溶劑合物,其中:
Z
1係CR
1或N;
Z
2係CR
2或N;
Z
3係CR
3或N;
Z
4係CR
4或N;
其中Z
1、Z
2、Z
3及Z
4中之一或兩者係N;
R
1、R
2、R
3及R
4係獨立地選自H、鹵基、CN、CF
3、-OCF
3、-NO
2
、-(CR
14R
15)
nC(=Y)R
11、-(CR
14R
15)
nC(=Y)OR
11、-(CR
14R
15)
nC(=Y)NR
11R
12、-(CR
14R
15)
nNR
11R
12、-(CR
14R
15)
nOR
11、-(CR
14R
15)
nSR
11、-(CR
14R
15)
nNR
12C(=Y)R
11、-(CR
14R
15)
nNR
12C(=Y)OR
11、-(CR
14R
15)
nNR
13C(=Y)NR
11R
12、-(CR
14R
15)
nNR
12SO
2R
11、-(CR
14R
15)
nOC(=Y)R
11、-(CR
14R
15)
nOC(=Y)OR
11、-(CR
14R
15)
nOC(=Y)NR
11R
12、-(CR
14R
15)
nOS(O)
2(OR
11)、-(CR
14R
15)
n=OP(=Y)(OR
11)(OR
12)、-(CR
14R
15)
nOP(OR
11)(OR
12)、-(CR
14R
15)
nS(O)R
11、-(CR
l4R
15)
nS(O)
2R
11、-(CR
14R
15)
nS(O)
2NR
11R
12、-(CR
14R
15)
nS(O)(OR
11)、-(CR
14R
15)
nS(O)
2(OR
11)、-(CR
14R
15)
nSC(=Y)R
11、-(CR
14R
15)
nSC(=Y)OR
11、-(CR
14R
15)
nSC(=Y)NR
11R
12、C
1-C
12烷基、C
2-C
8烯基、C
2-C
8炔基、碳環基、雜環基、芳基及雜芳基;
W係
或
;
R
5及R
6係獨立地選自H或C
1-C
12烷基;
X
1係選自R
11、-OR
11、-NR
11R
12、-S(O)R
11及-S(O)
2R
11;當X
1係R
11或-OR
11時,X
1之R
11或-OR
11及-R
5視情況與其所附接之氮原子一起形成具有0至2個選自O、S及N之其他雜原子之4至7員飽和或不飽和環,其中該環視情況經一或多個選自以下之基團取代:鹵基、CN、CF
3、-OCF
3、-NO
2、側氧基、-Si(C
1-C
6烷基)、-(CR
19R
20)
nC(=Y')R
16、-(CR
19R
20)
n
C(=Y')OR
16、-(CR
19R
20)
nC(=Y')NR
16R
17、-(CR
19R
20)
nNR
16R
17、-(CR
19R
20)
nOR
16、-(CR
19R
20)
n-SR
16、-(CR
19R
20)
nNR
16C(=Y')R
17、-(CR
19R
20)
nNR
16C(=Y')OR
17、-(CR
19R
20)
nNR
18C(=Y')NR
16R
17、-(CR
19R
20)
nNR
17SO
2R
16、-(CR
19R
20)
nOC(=Y')R
16、-(CR
19R
20)
nOC(=Y')OR
16
、-(CR
19R
20)
nOC(=Y')NR
16R
17、-(CR
19R
20)
nOS(O)
2(OR
16)、-(CR
19R
20)
nOP(=Y')(OR
16)(OR
17)、-(CR
19R
20)
nOP(OR
16)(OR
17)、-(CR
19R
20)
nS(O)R
16、-(CR
19R
20)
nS(O)
2R
16、-(CR
19R
20)
nS(O)
2NR
16R
17、-(CR
19R
20)
nS(O)(OR
16)、-(CR
19R
20)
nS(O)
2(OR
16)、-(CR
19R
20)
nSC(=Y')R
16
、-(CR
19R
20)
nSC(=Y')OR
16、-(CR
19R
20)
nSC(=Y')NR
16R
17及R
21;
X
2係選自碳環基、雜環基、芳基及雜芳基;
R
11、R
12及R
13獨立地係H、C
1-C
12烷基、C
2-C
8烯基、C
2-C
8炔基、碳環基、雜環基、芳基或雜芳基,
或R
11及R
12與其所附接之氮一起形成具有0至2個選自O、S及N之雜原子之3至8員飽和、不飽和或芳香族環,其中該環視情況經一或多個選自以下之基團取代:鹵基、CN、CF
3、-OCF
3、-NO
2、C
1-C
6烷基、-OH、-SH、-O(C
1-C
6烷基)、-S(C
1-C
6烷基)、-NH
2、-NH(C
1-C
6烷基)、-N(C
1-C
6烷基)
2、-SO
2(C
1-C
6烷基)、-CO
2H、-CO
2(C
1-C
6烷基)、‑C(O)NH
2、-C(O)NH(C
1-C
6烷基)、-C(O)N(C
1-C
6烷基)
2、-N(C
1-C
6烷基)C(O)(C
1-C
6烷基)、-NHC(O)(C
1-C
6烷基)、-NHSO
2(C
1-C
6烷基)、-N(C
1-C
6烷基)SO
2(C
1-C
6烷基)、-SO
2NH
2、-SO
2NH(C
1-C
6烷基)、-SO
2N(C
1-C
6烷基)
2、-OC(O)NH
2、-OC(O)NH(C
1-C
6烷基)、-OC(O)N(C
1-C
6烷基)
2、-OC(O)O(C
1-C
6烷基)、-NHC(O)NH(C
1-C
6烷基)、‑NHC(O)N(C
1-C
6烷基)
2、-N(C
1-C
6烷基)C(O)NH(C
1-C
6烷基)、-N(C
1-C
6烷基)C(O)N(C
1-C
6烷基)
2、-NHC(O)NH (C
1-C
6烷基)、-NHC(O)N(C
1-C
6烷基)
2、-NHC(O)O(C
1-C
6烷基)及-N(C
1-C
6烷基)C(O)O(C
1-C
6烷基);
R
14及R
15係獨立地選自H、C
1-C
12烷基、芳基、碳環基、雜環基及雜芳基;
m及n係獨立地選自0、1、2、3、4、5或6;
Y獨立地係O、NR
11或S;
其中R
1、R
2、R
3、R
4、R
5、R
6、X
1、X
2、R
11、R
12、R
13、R
14及R
15中之每一該烷基、烯基、炔基、碳環基、雜環基、芳基及雜芳基獨立地視情況經一或多個獨立地選自以下之基團取代:鹵基、CN、CF
3、-OCF
3、-NO
2、側氧基、-Si(C
1-C
6烷基)、-(CR
19R
20)
nC(=Y')R
16、-(CR
19R
20)
nC(=Y')OR
16、-(CR
19R
20)
nC(=Y')NR
16R
17、-(CR
19R
20)
nNR
16R
17
、-(CR
19R
20)
nOR
16、-(CR
19R
20)
n-SR
16、-(CR
19R
20)
nNR
16C(=Y')R
17
、-(CR
19R
20)
nNR
16C(=Y')OR
17、-(CR
19R
20)
nNR
18C(=Y')NR
16R
17
、-(CR
19R
20)
nNR
17SO
2R
16、-(CR
19R
20)
nOC(=Y')R
16、-(CR
19R
20)
n
OC(=Y')OR
16、-(CR
19R
20)
nOC(=Y')NR
16R
17、-(CR
19R
20)
nOS(O)
2(OR
16)
、-(CR
19R
20)
nOP(=Y')(OR
16)(OR
17)、-(CR
19R
20)
nOP(OR
16)(OR
17)、-(CR
19R
20)
nS(O)R
16、-(CR
19R
20)
nS(O)
2R
16、-(CR
19R
20)
nS(O)
2NR
16R
17、-(CR
19R
20)
nS(O)(OR
16)、-(CR
19R
20)
nS(O)
2(OR
16)、-(CR
19R
20)
nSC(=Y')R
16
、-(CR
19R
20)
nSC(=Y')OR
16、-(CR
19R
20)
nSC(=Y')NR
16R
17及R
21;
每一R
16、R
17及R
18獨立地係H、C
1-C
12烷基、C
2-C
8烯基、C
2-C
8炔基、碳環基、雜環基、芳基或雜芳基,其中該烷基、烯基、炔基、碳環基、雜環基、芳基或雜芳基視情況經一或多個選自以下之基團取代:鹵基、側氧基、CN、-OCF
3、CF
3、-NO
2、C
1-C
6烷基、-OH、-SH、-O(C
1-C
6烷基)、-S(C
1-C
6烷基)、-NH
2、-NH(C
1-C
6烷基)、-N(C
1-C
6烷基)
2、-SO
2(C
1-C
6烷基)、-CO
2H、-CO
2(C
1-C
6烷基)、‑C(O)NH
2、-C(O)NH(C
1-C
6烷基)、-C(O)N(C
1-C
6烷基)
2、-N(C
1-C
6烷基)C(O)(C
1-C
6烷基)、-NHC(O)(C
1-C
6烷基)、-NHSO
2(C
1-C
6烷基)、-N(C
1-C
6烷基)SO
2(C
1-C
6烷基)、-SO
2NH
2、-SO
2NH(C
1-C
6烷基)、-SO
2N(C
1-C
6烷基)
2、-OC(O)NH
2、-OC(O)NH(C
1-C
6烷基)、-OC(O)N(C
1-C
6烷基)
2、-OC(O)O(C
1-C
6烷基)、-NHC(O)NH(C
1-C
6烷基)、‑NHC(O)N(C
1-C
6烷基)
2、-N(C
1-C
6烷基)C(O)NH(C
1-C
6烷基)、-N(C
1-C
6烷基)C(O)N(C
1-C
6烷基)
2、-NHC(O)NH (C
1-C
6烷基)、-NHC(O)N(C
1-C
6烷基)
2、-NHC(O)O(C
1-C
6烷基)及-N(C
1-C
6烷基)C(O)O(C
1-C
6烷基);
或R
16及R
17與其所附接之氮一起形成具有0至2個選自O、S及N之雜原子之3至8員飽和、不飽和或芳香族環,其中該環視情況經一或多個選自以下之基團取代:鹵基、CN、-OCF
3、CF
3、-NO
2、C
1-C
6烷基、-OH、-SH、-O(C
1-C
6烷基)、-S(C
1-C
6烷基)、-NH
2、-NH(C
1-C
6烷基)、-N(C
1-C
6烷基)
2、-SO
2(C
1-C
6烷基)、-CO
2H、-CO
2(C
1-C
6烷基)、‑C(O)NH
2、-C(O)NH(C
1-C
6烷基)、-C(O)N(C
1-C
6烷基)
2、-N(C
1-C
6烷基)C(O)(C
1-C
6烷基)、-NHC(O)(C
1-C
6烷基)、-NHSO
2(C
1-C
6烷基)、-N(C
1-C
6烷基)SO
2(C
1-C
6烷基)、-SO
2NH
2、-SO
2NH(C
1-C
6烷基)、-SO
2N(C
1-C
6烷基)
2、-OC(O)NH
2、-OC(O)NH(C
1-C
6烷基)、-OC(O)N(C
1-C
6烷基)
2、-OC(O)O(C
1-C
6烷基)、-NHC(O)NH(C
1-C
6烷基)、‑NHC(O)N(C
1-C
6烷基)
2、-N(C
1-C
6烷基)C(O)NH(C
1-C
6烷基)、-N(C
1-C
6烷基)C(O)N(C
1-C
6烷基)
2、-NHC(O)NH (C
1-C
6烷基)、-NHC(O)N(C
1-C
6烷基)
2、-NHC(O)O(C
1-C
6烷基)及-N(C
1-C
6烷基)C(O)O(C
1-C
6烷基);
R
19及R
20獨立地選自H、C
1-C
12烷基、-(CH
2)
n-芳基、‑(CH
2)
n-碳環基、-(CH
2)
n-雜環基及-(CH
2)
n-雜芳基;
R
21係C
1-C
12烷基、C
2-C
8烯基、C
2-C
8炔基、碳環基、雜環基、芳基或雜芳基,其中R
21中之每一成員視情況經一或多個選自以下之基團取代:鹵基、CN、-OCF
3、CF
3、‑NO
2、C
1-C
6烷基、-OH、-SH、-O(C
1-C
6烷基)、‑S(C
1-C
6烷基)、-NH
2、-NH(C
1-C
6烷基)、-N(C
1-C
6烷基)
2、-SO
2(C
1-C
6烷基)、-CO
2H、-CO
2(C
1-C
6烷基)、‑C(O)NH
2、-C(O)NH(C
1-C
6烷基)、-C(O)N(C
1-C
6烷基)
2、-N(C
1-C
6烷基)C(O)(C
1-C
6烷基)、-NHC(O)(C
1-C
6烷基)、-NHSO
2(C
1-C
6烷基)、-N(C
1-C
6烷基)SO
2(C
1-C
6烷基)、-SO
2NH
2、-SO
2NH(C
1-C
6烷基)、-SO
2N(C
1-C
6烷基)
2、-OC(O)NH
2
、-OC(O)NH(C
1-C
6烷基)、-OC(O)N(C
1-C
6烷基)
2、-OC(O)O(C
1-C
6烷基)、-NHC(O)NH(C
1-C
6烷基)、‑NHC(O)N(C
1-C
6烷基)
2、-N(C
1-C
6烷基)C(O)NH(C
1-C
6烷基)、-N(C
1-C
6烷基)C(O)N(C
1-C
6烷基)
2、-NHC(O)NH (C
1-C
6烷基)、-NHC(O)N(C
1-C
6烷基)
2、-NHC(O)O(C
1-C
6烷基)及-N(C
1-C
6烷基)C(O)O(C
1-C
6烷基);
每一Y'獨立地係O、NR
22或S;且
R
22係H或C
1-C
12烷基。
在一些變化形式中,式(II)之MEK抑制劑化合物係以下各式之化合物:式(II-1-a)、(II-1-b)、(II-1-c)、(II-1-d)、(II-1-e)、(II-1-f)、(II-1-g)、(II-1-h)、(II-1-i)、(II-2-a)、(II-2-b)、(II-2-c)、(II-2-d)、(II-2-e)、(II-2-f)、(II-2-g)、(II-2-h)、(II-2-i)、(II-3-a)、(II-3-b)、(II-3-c)、(II-3-d)、(II-3-e)、(II-3-f)、(II-3-g)、(II-3-h)或(II-3-i):
或其醫藥上可接受之鹽或溶劑合物,其中變量係如針對式(II)所定義或如WO 2008/024725 A1中所定義,該案件以引用方式併入本文中。
在一些實施例中,式(II)之MEK抑制劑化合物係選自WO 2008/024725 A1中之實例5至18、20至102、105至109、111至118、120至133、136至149及151至160之化合物(本文中統稱為式II物質)之化合物或其醫藥上可接受之鹽或溶劑合物。該等化合物在實例8a或8b中所述分析(MEK活性分析)中展現小於10 μM之IC
50。該等化合物中之大多數展現小於5 μM之IC
50。參見WO 2008/024725 A1中之第62頁。
亦涵蓋闡述於WO 2008/024725 A1 (其以引用方式併入本文中)中之MEK抑制劑化合物(及/或其溶劑合物及鹽),例如,式(II)(在例如WO 2008/024725 A1中第3頁命名為式I)之氮雜-苯并呋喃化合物及其變化形式,如WO 2008/024725 A1中所述。式(II)化合物可使用業內已知方法(例如,闡述於WO 2008/024725 A1中之合成方法)合成,該案件以引用方式併入本文中。
在一些實施例中,MEK抑制劑係式(III)化合物:
或其醫藥上可接受之鹽或溶劑合物,其中:
Z
1係CR
1或N;
R
1係H、C
1-C
3烷基、鹵基、CF
3、CHF
2、CN、OR
A或NR
AR
A;
R
1'係H、C
1-C
3烷基、鹵基、CF
3、CHF
2、CN、OR
A或NR
AR
A;
其中每一R
A獨立地係H或C
1-C
3烷基;
Z
2係CR
2或N;
Z
3係CR
3或N;前提為同時Z
1、Z
2及Z
3中僅一者可為N;
R
2及R
3係獨立地選自H、鹵基、CN、CF
3、-OCF
3、-NO
2、-(CR
14R
15)
nC(=Y')R
11、-(CR
14R
15)
nC(=Y')OR
11、-(CR
14R
15)
nC(=Y')NR
11R
12
、-(CR
14R
15)
nNR
11R
12、-(CR
14R
15)
nOR
11、-(CR
14R
15)
nSR
11、-(CR
14R
15)
nNR
12C(=Y')R
11、-(CR
14R
15)
nNR
12C(=Y')OR
11、-(CR
14R
15)
nNR
13C(=Y')NR
11R
12、-(CR
14R
15)
nNR
12SO
2R
11、-(CR
14R
15)
nOC(=Y')R
11、-(CR
14R
15)
nOC(=Y')OR
11、-(CR
14R
15)
nOC(=Y')NR
11R
12、-(CR
14R
15)
nOS(O)
2(OR
11)、-(CR
14R
15)
nOP(=Y')(OR
11)(OR
12)、-(CR
14R
15)
nOP(OR
11)(OR
12)、-(CR
14R
15)
nS(O)R
11、-(CR
14R
15)
nS(O)
2R
11、-(CR
14R
15)
nS(O)
2NR
11R
12、-(CR
14R
15)
nS(O)(OR
11)、-(CR
14R
15)
nS(O)
2(OR
11)、-(CR
14R
15)
nSC(=Y')R
11
、-(CR
14R
15)
nSC(=Y')OR
11、-(CR
14R
15)
nSC(=Y')NR
11R
12、C
1-C
12烷基、C
2-C
8烯基、C
2-C
8炔基、碳環基、雜環基、芳基及雜芳基;
R
4係H、C
1-C
6烷基或C
3-C
4碳環基;
Y係W-C(O)-或W;
W係
或
;
R
5係H或C
1-C
12烷基;
X
1係選自R
11'及-OR
11';當X
1係R
11'時,X
1視情況與R
5及其所結合之氮原子一起形成具有0至2個選自O、S及N之其他雜原子之4至7員飽和或不飽和環,其中該環視情況經一或多個選自以下之基團取代:鹵基、CN、CF
3、-OCF
3、-NO
2、側氧基、-(CR
19R
20)
nC(=Y')R
16、-(CR
19R
20)
nC(=Y')OR
16、-(CR
19R
20)
nC(=Y')NR
16R
17、-(CR
19R
20)
nNR
16R
17
、-(CR
19R
20)
nOR
16、-(CR
19R
20)
n-SR
16、-(CR
19R
20)
nNR
16C(=Y')R
17、-(CR
19R
20)
nNR
16C(=Y')OR
17、-(CR
19R
20)
nNR
18C(=Y')NR
16R
17、-(CR
19R
20)
nNR
17SO
2R
16、-(CR
19R
20)
nOC(=Y')OR
16、-(CR
19R
20)
nOC(=Y')OR
16
、-(CR
19R
20)
nOC(=Y')NR
16R
17、-(CR
19R
20)
nOS(O)
2(OR
16)、
-(CR
19R
20)
nOP(=Y')(OR
16)(OR
17)、-(CR
19R
20)
nOP(OR
16)(OR
17)、
-(CR
19R
20)
nS(O)R
16、-(CR
19R
20)
nS(O)
2R
16、-(CR
19R
20)
nS(O)
2NR
16R
17、-(CR
19R
20)
nS(O)(OR
16)、-(CR
19R
20)
nS(O)
2(OR
16)、-(CR
19R
20)
nSC(=Y')R
16
、-(CR
19R
20)
nSC(=Y')OR
16、-(CR
19R
20)
nSC(=Y')NR
16R
17及R
21;
每一R
11'獨立地係H、C
1-C
12烷基、C
2-C
8烯基、C
2-C
8炔基、碳環基、雜環基、芳基或雜芳基;
R
11、R
12及R
13獨立地係H、C
1-C
12烷基、C
2-C
8烯基、C
2-C
8炔基、碳環基、雜環基、芳基或雜芳基,
或R
11及R
12與其所附接之氮一起形成具有0至2個選自O、S及N之雜原子之3至8員飽和、不飽和或芳香族環,其中該環視情況經一或多個選自以下之基團取代:鹵基、CN、CF
3、-OCF
3、-NO
2、C
1-C
6烷基、-OH、-SH、-O(C
1-C
6烷基)、-S(C
1-C
6烷基)、-NH
2、-NH(C
1-C
6烷基)、-N(C
1-C
6烷基)
2、-SO
2(C
1-C
6烷基)、-CO
2H、-CO
2(C
1-C
6烷基)、‑C(O)NH
2、-C(O)NH(C
1-C
6烷基)、-C(O)N(C
1-C
6烷基)
2、-N(C
1-C
6烷基)C(O)(C
1-C
6烷基)、-NHC(O)(C
1-C
6烷基)、-NHSO
2(C
1-C
6烷基)、-N(C
1-C
6烷基)SO
2(C
1-C
6烷基)、-SO
2NH
2、-SO
2NH(C
1-C
6烷基)、-SO
2N(C
1-C
6烷基)
2、-OC(O)NH
2、-OC(O)NH(C
1-C
6烷基)、-OC(O)N(C
1-C
6烷基)
2、-OC(O)O(C
1-C
6烷基)、-NHC(O)NH(C
1-C
6烷基)、‑NHC(O)N(C
1-C
6烷基)
2、-N(C
1-C
6烷基)C(O)NH(C
1-C
6烷基)、-N(C
1-C
6烷基)C(O)N(C
1-C
6烷基)
2、-NHC(O)NH (C
1-C
6烷基)、-NHC(O)N(C
1-C
6烷基)
2、-NHC(O)O(C
1-C
6烷基)及-N(C
1-C
6烷基)C(O)O(C
1-C
6烷基);
R
14及R
15係獨立地選自H、C
1-C
12烷基、芳基、碳環基、雜環基及雜芳基;
W'係
其中
係
每一X
2獨立地係O、S或NR
9;
每一R
7係獨立地選自H、鹵基、CN、CF
3、-OCF
3、-NO
2
、-(CR
14R
15)
nC(=Y')R
11、-(CR
14R
15)
nC(=Y')OR
11、-(CR
14R
15)
nC(=Y')NR
11R
12
、-(CR
14R
15)
nNR
11R
12、-(CR
14R
15)
nOR
11、-(CR
14R
15)
nSR
11
、-(CR
14R
15)
nNR
12C(=Y')R
11、-(CR
14R
15)
nNR
12C(=Y')OR
11、
-(CR
14R
15)
nNR
13C(=Y')NR
11R
12、-(CR
14R
15)
nNR
12SO
2R
11、
-(CR
14R
15)
nOC(=Y')R
11、-(CR
14R
15)
nOC(=Y')OR
11、
-(CR
14R
15)
nOC(=Y')NR
11R
12、-(CR
14R
15)
nOS(O)
2(OR
11)、
-(CR
14R
15)
nOP(=Y')(OR
11)(OR
12)、-(CR
14R
15)
nOP(OR
11)(OR
12)、
-(CR
14R
15)
nS(O)R
11、-(CR
14R
15)
nS(O)
2R
11、-(CR
14R
15)
nS(O)
2NR
11R
12
、-(CR
14R
15)
nS(O)(OR
11)、-(CR
14R
15)
nS(O)
2(OR
11)、-(CR
14R
15)
n
SC(=Y')R
11、-(CR
14R
15)
nSC(=Y')OR
11、-(CR
14R
15)
nSC(=Y')NR
11R
12
、C
1-C
12烷基、C
2-C
8烯基、C
2-C
8炔基、碳環基、雜環基、芳基及雜芳基;
每一R
8係獨立地選自C
1-C
12烷基、芳基、碳環基、雜環基及雜芳基;
R
9係選自H、-(CR
14R
15)
nC(=Y')R
11、-(CR
14R
15)
nC(=Y')OR
11
、-(CR
14R
15)
nC(=Y')NR
11R
12、-(CR
14R
15)
qNR
11R
12、-(CR
14R
15)
qOR
11
、-(CR
14R
15)
qSR
11、-(CR
14R
15)
qNR
12C(=Y')R
11、-(CR
14R
15)
qNR
12C(=Y')OR
11
、-(CR
14R
15)
qNR
13C(=Y')NR
11R
12、-(CR
14R
15)
qNR
12SO
2R
11、
-(CR
14R
15)
qOC(=Y')R
11、-(CR
14R
15)
qOC(=Y')OR
11、
-(CR
14R
15)
qOC(=Y')NR
11R
12、-(CR
14R
15)
qOS(O)
2(OR
11)、
-(CR
14R
15)
qOP(=Y')(OR
11)(OR
12)、-(CR
14R
15)
qOP(OR
11)(OR
12)、
-(CR
14R
15)
nS(O)R
11、-(CR
14R
15)
nS(O)
2R
11、-(CR
14R
15)
nS(O)
2NR
11R
12、C
1-C
12烷基、C
2-C
8烯基、C
2-C
8炔基、碳環基、雜環基、芳基及雜芳基;
R
10係H、C
1-C
6烷基或C
3-C
4碳環基;
X
4係
;
R
6係H、鹵基、C
1-C
6烷基、C
2-C
8烯基、C
2-C
8炔基、碳環基、雜芳基、雜環基、-OCF
3、-NO
2、-Si(C
1-C
6烷基)、-(CR
19R
20)
nNR
16R
17、-(CR
19R
20)
nOR
16或-(CR
19R
20)
n-SR
16;
R
6'係H、鹵基、C
1-C
6烷基、碳環基、CF
3、-OCF
3、-NO
2、-Si(C
1-C
6烷基)、-(CR
19R
20)
nNR
16R
17、-(CR
19R
20)
nOR
16、-(CR
19R
20)
n-SR
16、C
2-C
8烯基、C
2-C
8炔基、雜環基、芳基或雜芳基;
p係0、1、2或3;
n係0、1、2或3;
q係2或3;
其中R
1、R
2、R
3、R
4、R
5、R
6、R
6'、R
7、R
8、R
9、R
10、R
11、R
11'、R
12、R
13、R
14、R
15及R
A中之每一該烷基、烯基、炔基、碳環基、雜環基、芳基及雜芳基獨立地視情況經一或多個獨立地選自以下之基團取代:鹵基、CN、CF
3、-OCF
3、-NO
2、側氧基、-Si(C
1-C
6烷基)
、‑(CR
19R
20)
nC(=Y')R
16、-(CR
19R
20)
nC(=Y')OR
16、-(CR
19R
20)
nC(=Y')NR
16R
17
、-(CR
19R
20)
nNR
16R
17、-(CR
19R
20)
nOR
16、-(CR
19R
20)
nSR
16、
-(CR
19R
20)
nNR
16C(=Y')R
17、-(CR
19R
20)
nNR
16C(=Y')OR
17、
-(CR
19R
20)
nNR
18C(=Y')NR
16R
17、-(CR
19R
20)
nNR
17SO
2R
16、
-(CR
19R
20)
nOC(=Y')R
16、-(CR
19R
20)
nOC(=Y')OR
16、-(CR
19R
20)
nOC(=Y')NR
16R
17、-(CR
19R
20)
nOS(O)
2(OR
16)、
-(CR
19R
20)
nOP(=Y')(OR
16)(OR
17)、-(CR
19R
20)
nOP(OR
16)(OR
17)、
-(CR
19R
20)
nS(O)R
16、-(CR
19R
20)
nS(O)
2R
16、-(CR
19R
20)
nS(O)
2NR
16R
17、-(CR
19R
20)
nS(O)(OR
16)、-(CR
19R
20)
nS(O)
2(OR
16)、-(CR
19R
20)
nSC(=Y')R
16
、-(CR
19R
20)
nSC(=Y')OR
16、-(CR
19R
20)
nSC(=Y')NR
16R
17及R
21;
每一R
16、R
17及R
18獨立地係H、C
1-C
12烷基、C
2-C
8烯基、C
2-C
8炔基、碳環基、雜環基、芳基或雜芳基,其中該烷基、烯基、炔基、碳環基、雜環基、芳基或雜芳基視情況經一或多個選自以下之基團取代:鹵基、CN、-OCF
3、CF
3、-NO
2、C
1-C
6烷基、-OH、-SH、-O(C
1-C
6烷基)、‑S(C
1-C
6烷基)、-NH
2、-NH(C
1-C
6烷基)、-N(C
1-C
6烷基)
2、-SO
2(C
1-C
6烷基)、-CO
2H、-CO
2(C
1-C
6烷基)、‑C(O)NH
2、-C(O)NH(C
1-C
6烷基)、-C(O)N(C
1-C
6烷基)
2、-N(C
1-C
6烷基)C(O)(C
1-C
6烷基)、-NHC(O)(C
1-C
6烷基)、-NHSO
2(C
1-C
6烷基)、-N(C
1-C
6烷基)SO
2(C
1-C
6烷基)、-SO
2NH
2、-SO
2NH(C
1-C
6烷基)、-SO
2N(C
1-C
6烷基)
2、-OC(O)NH
2、-OC(O)NH(C
1-C
6烷基)、-OC(O)N(C
1-C
6烷基)
2、-OC(O)O(C
1-C
6烷基)、-NHC(O)NH(C
1-C
6烷基)、‑NHC(O)N(C
1-C
6烷基)
2、-N(C
1-C
6烷基)C(O)NH(C
1-C
6烷基)、-N(C
1-C
6烷基)C(O)N(C
1-C
6烷基)
2、-NHC(O)NH (C
1-C
6烷基)、-NHC(O)N(C
1-C
6烷基)
2、-NHC(O)O(C
1-C
6烷基)及-N(C
1-C
6烷基)C(O)O(C
1-C
6烷基);
或R
16及R
17與其所附接之氮一起形成具有0至2個選自O、S及N之雜原子之3至8員飽和、不飽和或芳香族環,其中該環視情況經一或多個選自以下之基團取代:鹵基、CN、-OCF
3、CF
3、-NO
2、C
1-C
6,烷基、-OH、-SH、-O(C
1-C
6烷基)、-S(C
1-C
6烷基)、-NH
2、-NH(C
1-C
6烷基)、-N(C
1-C
6烷基)
2、-SO
2(C
1-C
6烷基)、-CO
2H、-CO
2(C
1-C
6烷基)、‑C(O)NH
2、-C(O)NH(C
1-C
6烷基)、-C(O)N(C
1-C
6烷基)
2、-N(C
1-C
6烷基)C(O)(C
1-C
6烷基)、-NHC(O)(C
1-C
6烷基)、-NHSO
2(C
1-C
6烷基)、-N(C
1-C
6烷基)SO
2(C
1-C
6烷基)、-SO
2NH
2、-SO
2NH(C
1-C
6烷基)、-SO
2N(C
1-C
6烷基)
2、-OC(O)NH
2、-OC(O)NH(C
1-C
6烷基)、-OC(O)N(C
1-C
6烷基)
2、-OC(O)O(C
1-C
6烷基)、-NHC(O)NH(C
1-C
6烷基)、‑NHC(O)N(C
1-C
6烷基)
2、-N(C
1-C
6烷基)C(O)NH(C
1-C
6烷基)、-N(C
1-C
6烷基)C(O)N(C
1-C
6烷基)
2、-NHC(O)NH (C
1-C
6烷基)、-NHC(O)N(C
1-C
6烷基)
2、-NHC(O)O(C
1-C
6烷基)及-N(C
1-C
6烷基)C(O)O(C
1-C
6烷基);
R
19及R
20獨立地選自H、C
1-C
12烷基、-(CH
2)
n-芳基、‑(CH
2)
n-碳環基、-(CH
2)
n-雜環基及-(CH
2)
n-雜芳基;
R
21係C
1-C
12烷基、C
2-C
8烯基、C
2-C
8炔基、碳環基、雜環基、芳基或雜芳基、其中R
21中之每一成員視情況經一或多個選自以下之基團取代:鹵基、側氧基、CN、‑OCF
3、CF
3、-NO
2、C
1-C
6烷基、-OH、-SH、-O(C
1-C
6烷基)、-S(C
1-C
6烷基)、-NH
2、-NH(C
1-C
6烷基)、-N(C
1-C
6烷基)
2、-SO
2(C
1-C
6烷基)、-CO
2H、-CO
2(C
1-C
6烷基)、‑C(O)NH
2、-C(O)NH(C
1-C
6烷基)、-C(O)N(C
1-C
6烷基)
2、-N(C
1-C
6烷基)C(O)(C
1-C
6烷基)、-NHC(O)(C
1-C
6烷基)、-NHSO
2(C
1-C
6烷基)、-N(C
1-C
6烷基)SO
2(C
1-C
6烷基)、-SO
2NH
2、-SO
2NH(C
1-C
6烷基)、-SO
2N(C
1-C
6烷基)
2、-OC(O)NH
2、-OC(O)NH(C
1-C
6烷基)、-OC(O)N(C
1-C
6烷基)
2、-OC(O)O(C
1-C
6烷基)、-NHC(O)NH(C
1-C
6烷基)、‑NHC(O)N(C
1-C
6烷基)
2、-N(C
1-C
6烷基)C(O)NH(C
1-C
6烷基)、-N(C
1-C
6烷基)C(O)N(C
1-C
6烷基)
2、-NHC(O)NH (C
1-C
6烷基)、-NHC(O)N(C
1-C
6烷基)
2、-NHC(O)O(C
1-C
6烷基)及-N(C
1-C
6烷基)C(O)O(C
1-C
6烷基);
每一Y'獨立地係O、NR
22或S;且
R
22係H或C
1-C
12烷基。
在一些變化形式中,式(III)之MEK抑制劑化合物具有式(III-a)或(III-b):
或其醫藥上可接受之鹽或溶劑合物,其中變量係如針對式(III)所定義或如WO 2009/085983 A1中所定義,該案件以引用方式併入本文中。
在一些實施例中,式(III)之MEK抑制劑化合物係選自表1中所列示化合物之化合物或其醫藥上可接受之鹽或溶劑合物。
表 1
表1中之化合物對應於WO 2009/085983 A1中之實例5至25。化合物(III)-5-(III)-20及(III)-22-(III)-24在闡述於實例8b中之分析(MEK活性分析)中展現小於0.5 μM之IC
50。該等化合物中之一些展現小於0.1 μM之IC
50。化合物(III)-21及(HI)-25展現小於10 μM之IC
50。參見WO 2009/085983 A1中之第49頁。
亦涵蓋闡述於WO 2009/085983 A1 (其以引用方式併入本文中)中之MEK抑制劑化合物(及/或其溶劑合物及鹽),例如,式(III)(例如WO 2009/085983 A1中第3頁命名為式I)之咪唑并吡啶化合物及其變化形式,如WO 2009/085983 A1中所述。式(III)化合物可使用業內已知方法(例如,闡述於WO 2009/085983 A1中之合成方法)合成,該案件以引用方式併入本文中。
在一些實施例中,MEK抑制劑係式(IV)化合物,
或其醫藥上可接受之鹽或溶劑合物,其中多個變量係如WO 03/077914 A1中第4至9頁之式I或WO 03/077914 A1中所述任何適用變化形式所定義,該案件以引用方式併入本文中。
在一些變化形式中,式(IV)之MEK抑制劑化合物係式(IV-a)、(IV-b)、(IV-c)或(IV-d)之化合物:
或其醫藥上可接受之鹽或溶劑合物,其中多個變量係如WO 03/077914 A1中第10至13頁之分別式II、III、IIIa及IIIb或WO 03/077914 A1中所述任何適用變化形式所定義,該案件以引用方式併入本文中。
在一些實施例中,式(IV)之MEK抑制劑化合物係選自由以下組成之群之化合物:
7-氟-6-(4-溴-2-甲基-苯基胺基)-3H-苯并咪唑-5-甲酸環丙基甲氧基-醯胺;
6-(4-溴-2-氯-苯基胺基)-7-氟-3H-苯并咪唑-5-甲酸環丙基甲氧基-醯胺;
6-(4-溴-2-氯-苯基胺基)-7-氟-3-甲基-3H-苯并咪唑-5-甲酸(2-羥基-乙氧基)-醯胺;
6-(4-溴-2-氯-苯基胺基)-7-氟-3-甲基-3H-苯并咪唑-5-甲酸(2,3-二羥基-丙氧基)-醯胺;
6-(4-溴-2-氯-苯基胺基)-7-氟-3-(四氫-吡喃-2-基甲基)-3H-苯并咪唑-5-甲酸(2-羥基-乙氧基)-醯胺;
[6-(5-胺基-[1,3,4]噁二唑-2-基)-4-氟-1H-苯并咪唑-5-基]-(4-溴-2-甲基-苯基)-胺;
1-[6-(4-溴-2-氯-苯基胺基)-7-氟-3-甲基-3H-苯并咪唑-5-基]-2-羥基-乙酮;
l-[6-(4-溴-2-氯-苯基胺基)-7-氟-3H-苯并咪唑-5-基]-2-甲氧基乙酮;
6-(4-溴-2-氯-苯基胺基)-7-氟-3-甲基-3H-苯并咪唑-5-甲酸(2-羥基-1,1-二甲基-乙氧基)-醯胺;
6-(4-溴-2-氯-苯基胺基)-7-氟-3-(四氫-呋喃-2-基甲基)-3H-苯并咪唑-5-甲酸(2-羥基-乙氧基)-醯胺;
6-(4-溴-2-氯-苯基胺基)-7-氟-3H-苯并咪唑-5-甲酸(2-羥基-乙氧基)-醯胺;
6-(-溴-2-氟-苯基胺基)-7-氟-3-甲基-3H-苯并咪唑-5-甲酸(2-羥基-乙氧基)-醯胺;及
6-(2,4-二氯-苯基胺基)-7-氟-3-甲基-3H-苯并咪唑-5-甲酸(2-羥基-乙氧基)-醯胺;
或其醫藥上可接受之鹽或溶劑合物。
本文亦涵蓋如WO 03/077914 A1中所述式(IV)之任何變化形式,該案件以引用方式併入本文中。式(IV)化合物或其任何變化形式可使用業內已知方法(例如,闡述於WO 03/077914 A1中之合成方法)合成,該案件以引用方式併入本文中。在一些實施例中,MEK抑制劑係式(V)化合物,
或其醫藥上可接受之鹽或溶劑合物,其中多個變量係如WO 2005/121142 A1中第6至10頁之式[I]或WO 2005/121142 A1中所述任何適用變化形式所定義,該案件以引用方式併入本文中。
亦涵蓋如WO 2005/121142 A1中所述式(V)之任何變化形式,例如闡述於WO 2005/121142 A1中之個別MEK抑制劑化合物,例如,表1中之實例1-1至1-343、表2中之實例2-1及2-2、表3中之實例3-1至3-9、表4中之實例4-1至4-148。式(V)化合物或其任何變化形式可使用業內已知方法(例如闡述於WO 2005/121142 A1中之合成方法)合成,該案件以引用方式併入本文中。
在一些實施例中,MEK抑制劑係式(VI)化合物,
或其醫藥上可接受之鹽或酯,其中:
R1係選自由以下組成之群:溴、碘、乙炔基、環烷基、烷氧基、氮雜環丁基、乙醯基、雜環基、氰基、直鏈烷基及具支鏈烷基;
R2係選自由氫、氯、氟及烷基組成之群;
R3係選自由氫、氯及氟組成之群;
R4係選自由氫、視情況經取代之芳基、烷基及環烷基組成之群;
R5係選自由氫及
組成之群;
其中R6係選自由以下組成之群:羥基、烷氧基、環烷基、視情況經取代之烷基、視情況經取代之芳基及視情況經取代之雜芳基;
R7及R8係獨立選自由氫及視情況經取代之烷基組成之群;
或R6及R7可一起形成環烷基且R8係氫。
在一些變化形式中,MEK抑制劑化合物具有式(VI)或其醫藥上可接受之鹽或酯,其中多個變量係如WO 2007/096259 A1中之式I或WO 2007/096259 A1中第4至10頁所述任何適用變化形式所定義,該案件以引用方式併入本文中。其他所涵蓋MEK抑制劑係WO 2007/096259 A1中之實例1至182中所述之化合物,該案件以引用方式併入本文中。
在一些實施例中,式(VI)之MEK抑制劑化合物係選自由以下組成之群之化合物:
(2S,3S)-N-(4-溴-苯基)-2-[(R)-4-(4-甲氧基-苯基)-2,5-二側氧基-咪唑啶-1-基]-3-苯基-丁醯胺;
(2S,3S)-N-(4-碘-苯基)-2-[(R)-4-(4-甲氧基-苯基)-2,5-二側氧基-咪唑啶-1-基]-3-苯基-丁醯胺;
(2S,3S)-N-(2-氟-4-碘-苯基)-2-{(R)-4-[4-(2-羥基-乙氧基)-苯基]-2,5-二側氧基-咪唑啶-1-基}-3-苯基-丁醯胺;
(2S,3S)-N-(4-乙炔基-2-氟-苯基)-2-{(R)-4-[4-(2-羥基-乙氧基)-苯基]-2,5-二側氧基-咪唑啶-1-基}-3-苯基-丁醯胺;
(2R,3S)-N-(4-乙炔基-2-氟-苯基)-2-{(R)-4-[4-(2-羥基-乙氧基)-苯基]-2,5-二側氧基-咪唑啶-1-基)-3-苯基-丁醯胺;
(2S,3S)-N-(2-氯-4-碘-苯基)-2-{(R)-4-[4-(2-羥基-乙氧基)-苯基]-2,5-二側氧基-咪唑啶-1-基}-3-苯基-丁醯胺;
(2S,3S)-2-{(R)-4-[4-(2-羥基-乙氧基)-苯基]-2,5-二側氧基-咪唑啶-1-基}-N-(4-碘-2-甲基-苯基)-3-苯基-丁醯胺;
(2S,3S)-N-(2-氯-4-碘-苯基)-2-{(R)-4-[4-((R)-2,3-二羥基-丙氧基)-苯基]-2,5-二側氧基-咪唑啶-1-基}-3-苯基-丁醯胺;
(2S,3S)-N-(2-氯-4-碘-苯基)-2-{(R)-4-[4-((S)-2,3-二羥基-丙氧基)-苯基]-2,5-二側氧基-咪唑啶-1-基}-3-苯基-丁醯胺;
(2S,3S)-2-{(R)-2,5-二側氧基-4-[4-(2-側氧基-2-吡咯啶-1-基-乙氧基)-苯基]-咪唑啶-1-基}-N-(2-氟-4-碘-苯基)-3-苯基-丁醯胺;
(2S,3S)-2-((R)-2,5-二側氧基-4-噻吩-3-基-咪唑啶-1-基)-N-(4-碘-苯基)-3-苯基-丁醯胺;
(S)-2-[(R)-4-(2,3-二氫-苯并[1,4]二噁英-6-基)-2,5-二側氧基-咪唑啶-1-基]-N-(2-氟-4-碘-苯基)-3-苯基-丙醯胺;
(S)-2-[(R)-4-(4-乙醯基胺基-苯基)-2,5-二側氧基-咪唑啶-1-基]-N-(2-氟-4-碘-苯基)-3-苯基-丙醯胺;
(4-{(R)-1-[(1S,2S)-1-(2-氟-4-碘-苯基胺基甲醯基)-2-苯基-丙基]-2,5-二側氧基-咪唑啶-4-基}-苯氧基甲基)-膦酸二甲酯;
(2S,3S)-N-(2-氟-4-碘-苯基)-2-((R)-4-異丙基-2,5-二側氧基-咪唑啶-1-基)-3-苯基-丁醯胺;
(S)-N-(2-氟-4-碘-苯基)-2-{(R)-4-[4-(2-羥基-乙氧基)-苯基]-2,5-二側氧基-咪唑啶-1-基}-3-甲基-丁醯胺;
(S)-N-(2-氟-4-碘-苯基)-2-[(R)-4-(4-甲氧基-苯基)-2,5-二側氧基-咪唑啶-1-基]-3-鄰-甲苯基-丙醯胺;
(S)-N-(2-氟-4-碘-苯基)-2-[(R)-4-(4-甲氧基-苯基)-2,5-二側氧基-咪唑啶-1-基]-3-間-甲苯基-丙醯胺;
(S)-N-(2-氟-4-碘-苯基)-2-[(R)-4-(4-甲氧基-苯基)-2,5-二側氧基-咪唑啶-1-基]-3-對-甲苯基-丙醯胺;及
(S)-N-(4-環丙基-2-氟-苯基)-3-(4-氟-苯基)-2-{(R)-4-[4-(2-羥基-1-羥基甲基-乙氧基)-苯基]-2,5-二側氧基-咪唑啶-1-基}-丙醯胺;
或其醫藥上可接受之鹽或酯。
在一些實施例中,MEK抑制劑係式(VII)化合物,
或其醫藥上可接受之鹽或酯,其中:
R1係選自由鹵素、乙炔基及環烷基組成之群;
R2係選自由氫及CH(R3)(R4)組成之群;
R3係選自由以下組成之群:低碳烷基、低碳烷氧基、視情況經取代之芳基及視情況經取代之雜芳基;
R4係選自由氫及低碳烷基組成之群;
R5係氫或與R2以及R2及R5所附接之碳一起形成低碳環烷基;且
R6係選自由以下組成之群:氫、低碳烷基、低碳環烷基、視情況經取代之芳基及視情況經取代之雜芳基。
在一些變化形式中,MEK抑制劑化合物具有式(VI)或其醫藥上可接受之鹽或酯,其中變量係如WO 2009/021887 A1中之式I或WO 2009/021887 A1中第4至5頁所述任何適用變化形式所定義,該案件以引用方式併入本文中。其他所涵蓋MEK抑制劑係2009/021887 A1中之實例1至21中所述之化合物,該案件以引用方式併入本文中。
在一些實施例中,式(VI)之MEK抑制劑化合物係選自由以下組成之群之化合物:
(R)-5-[4-(2-羥基-乙氧基)-苯基]-3-[(S)-1-(6-碘-1H-苯并咪唑-2-基)-2-苯基-乙基]-咪唑啶-2,4-二酮;
(R)-5-[4-(2-羥基-乙氧基)-苯基]-3-(5-碘-1H-苯并咪唑-2-基甲基)-咪唑啶-2,4-二酮;
(R)-5-[4-(2-羥基-乙氧基)-苯基]-3-[(S)-1-(5-碘-1H-苯并咪唑-2-基)-2-甲基-丙基]-咪唑啶-2,4-二酮;
(R)-5-[4-(2-羥基-乙氧基)-苯基]-3-[(1R,2R)-1-(5-碘-1H-苯并咪唑-2-基)-2-甲氧基-丙基]-咪唑啶-2,4-二酮;
3-[(S)-1-(5-碘-1H-苯并咪唑-2-基)-2-苯基-乙基]-咪唑啶-2,4-二酮;其與三氟乙酸之化合物;
(R)-3-[(S)-2-(4-氟-苯基)-1-(5-碘-1H-苯并咪唑-2-基)-乙基]-5-[4-(2-羥基-乙氧基)-苯基]-咪唑啶-2,4-二酮;
(R)-5-[4-(2-羥基-乙氧基)-苯基]-3-[(S)-1-(5-碘-1H-苯并咪唑-2-基)-2-(4-甲氧基-苯基)-乙基]-咪唑啶-2,4-二酮;
(R)-5-[4-(2-羥基-乙氧基)-苯基]-3-[(S)-1-(5-碘-1H-苯并咪唑-2-基)-2-噻吩-2-基-乙基]-咪唑啶-2,4-二酮;
(R)-3-[(1S,2S)-1-(6-碘-1H-苯并咪唑-2-基)-2-苯基-丙基]-5-苯基-咪唑啶-2,4-二酮;
(R)-3-[(1S,2S)-1-(6-碘-1H-苯并咪唑-2-基)-2-苯基-丙基]-5-(4-甲氧基-苯基)-咪唑啶-2,4-二酮;
(R)-5-[4-(2-羥基-乙氧基)-苯基]-3-[(lS,2S)-1-(6-碘-1H-苯并咪唑-2-基)-2-苯基-丙基]-咪唑啶-2,4-二酮;
(R)-3-[(1S,2S)-1-(6-碘-1H-苯并咪唑-2-基)-2-苯基-丙基]-5-[4-(2-甲氧基-乙氧基)-苯基]-咪唑啶-2,4-二酮;
2-(4-{(R)-1-[(1S,2S)-1-(6-碘-1H-苯并咪唑-2-基)-2-苯基-丙基]-2,5-二側氧基-咪唑啶-4-基}-苯氧基)-N,N-二甲基-乙醯胺;
N,N-雙-(2-羥基-乙基)-2-(4-{(R)-1-[(1S,2S)-1-(6-碘-1H-苯并咪唑-2-基)-2-苯基-丙基]-2,5-二側氧基-咪唑啶-4-基}-苯氧基)-乙醯胺;
(R)-3-[(1S,2S)-1-(5-碘-1H-苯并咪唑-2-基)-2-苯基-丙基]-5-異丙基-咪唑啶-2,4-二酮;
(R)-5-環己基-3-[(1S,2S)-1-(5-碘-1H-苯并咪唑-2-基)-2-苯基-丙基]-咪唑啶-2,4-二酮;
(R)-5-[4-(2-羥基-乙氧基)-苯基]-3-[l-(5-碘-1H-苯并咪唑-2-基)-環丙基]-咪唑啶-2,4-二酮;
(R)-3-[(1S,2S)-1-6-溴-1H-苯并咪唑-2-基)-2-苯基-丙基]-5-[4-(2-羥基-乙氧基)-苯基]-咪唑啶-2,4-二酮;
(R)-3-[(S)-1-(5-環丙基-1H-苯并咪唑-2-基)-2-苯基-乙基]-5-[4-(2-羥基-乙氧基)-苯基]-咪唑啶-2,4-二酮;
(R)-3-[(S)-1-(5-乙炔基-1H-苯并咪唑-2-基)-2-苯基-乙基]-5-[4-(2-羥基-乙氧基)-苯基]-咪唑啶-2,4-二酮;及
(R)-3-[(1S,2S)-1-(5-乙炔基-1H-苯并咪唑-2-基)-2-苯基-丙基]-5-[4-(2-羥基-乙氧基)-苯基]-咪唑啶-2,4-二酮;
或其醫藥上可接受之鹽或溶劑合物組合。
在一些實施例中,MEK抑制劑係選自由以下組成之群之化合物:GDC-0973 (甲酮, [3,4-二氟-2-[(2-氟-4-碘苯基)胺基]苯基][3-羥基-3-(2S)-2-六氫吡啶基-1-氮雜環丁基]-)、G-38963、G02443714、G02442104及G00039805或其醫藥上可接受之鹽或溶劑合物。
IV 套組在另一態樣中,提供包含PD-L1軸結合拮抗劑及/或MEK抑制劑之套組,其用於治療個體之癌症或延遲其進展或增強患有癌症之個體之免疫功能。在一些實施例中,套組包含PD-1軸結合拮抗劑及包裝插頁,該包裝插頁包含使用PD-1軸結合拮抗劑與MEK抑制劑之組合來治療個體之癌症或延遲其進展或增強患有癌症之個體之免疫功能的說明書。在一些實施例中,套組包含MEK抑制劑及包裝插頁,該包裝插頁包含使用MEK抑制劑與PD-1軸結合拮抗劑之組合來治療個體之癌症或延遲其進展或增強患有癌症之個體之免疫功能的說明書。在一些實施例中,套組包含PD-1軸結合拮抗劑及MEK抑制劑以及包裝插頁,該包裝插頁包含使用PD-1軸結合拮抗劑及MEK抑制劑來治療個體之癌症或延遲其進展或增強患有癌症之個體之免疫功能的說明書。可在套組中包括本文所述PD-1軸結合拮抗劑及/或MEK抑制劑中之任一者。
在一些實施例中,套組包含含有本文所述PD-1軸結合拮抗劑及MEK抑制劑中之一或多者之容器。適宜容器包括(例如)瓶、小瓶(例如,雙室小瓶)、注射器(例如單室或雙室注射器)及試管。容器可自諸如玻璃或塑膠等多種材料形成。在一些實施例中,套組可包含標記(例如,在容器上或伴隨容器提供)或包裝插頁。標記或包裝插頁可指示,其中所含化合物可用於或意欲用於治療個體之癌症或延遲其進展或用於增強患有癌症之個體之免疫功能。套組可進一步包含自商業及用戶角度考慮所期望之其他材料,包括其他緩衝液、稀釋劑、過濾器、針及注射器。
實例
可藉由參考以下實例進一步理解本發明,該等實例係以說明方式提供且不意欲具有限制性。
實例 1 : MEK 抑制劑增強腫瘤細胞系上之 MHC I 表現為確定用MEK抑制劑(MEKi)處理是否增強腫瘤細胞之免疫原性,分析用MEK抑制劑GDC-0973及G-38963處理之腫瘤細胞系上MHC-I之表面表現。簡言之,用1微莫耳濃度MEKi GDC-0973或G-38963、BRAF抑制劑(BRAFi) GDC-0879或DMSO媒劑將人類黑色素瘤細胞系(Malme-3M、A2058、A375、HS294T、SK23、SKMEL-28、537 Mel、RPMI-795)及人類結腸直腸細胞系(Colo 320 DM、Colo 205、WiDr、Colo 741、RKO、DLD-1、HM7、HCT-15)處理24小時。在處理後,用針對HLA-A、B、C之抗體將細胞染色用於表面MHC I類表現以供後續FACS分析。所示數據係針對用MEKi GDC-0973治療。使用經標記同種型匹配抗體來測定非特異性染色程度。數據分析及直方圖之構築顯示,與媒劑處理細胞相比,MEKi處理細胞中MHC-I之細胞表面表現上調(圖1A)。相比之下,與媒劑處理細胞相比,BRAFi處理細胞中MHC-I之細胞表面表現未上調(圖2)。該等結果顯示,黑色素瘤與結腸直腸腫瘤細胞二者中MHC-I之細胞表面表現增強係專一性之MEK抑制,且並非歸因於RAS/RAF/MEK信號傳導途徑之全面抑制。
為確定用MEK抑制劑(MEKi)處理是否與人類腫瘤細胞類似可增強小鼠腫瘤細胞之免疫原性,分析經過MEKi GDC-0973處理之小鼠腫瘤細胞系上MHC-I之表面表現。簡言之,用MEKi GDC-0973、G-38963或媒劑處理小鼠黑色素瘤細胞系(MC38及B16.F10)及小鼠結腸直腸細胞系(CT26)。簡言之,用1微莫耳濃度MEK抑制劑或DMSO媒劑對照刺激細胞24小時。在處理後,用針對MHC-I (H-2D)之抗體對細胞進行表面染色,並藉由後續FACS分析來分析表現。使用經標記同種型匹配抗體來測定非特異性染色程度。數據分析及直方圖之構築顯示,與媒劑處理細胞相比,MEKi處理細胞(所示數據係針對MEKi GDC-0973)中MHC-I之細胞表面表現上調(圖1B)。該等結果顯示,不管小鼠或人類來源,在整個若干黑色素瘤及結腸直腸腫瘤細胞系中出現MHC-I之細胞表面表現均增強。
為確定MHC-I之細胞表面表現增強是否特屬於腫瘤細胞,分析MEKi處理對人類周邊血液單核細胞(PMBC)上之MHC-I表現之效應。簡言之,首先用等體積室溫PBS稀釋,且隨後覆蓋至填充蔗聚糖(Ficoll)之Leucosep管(Greiner Bio-One)上,自全血中分離PMBCS。離心後,將PBMC界面洗滌兩次,且再懸浮於培養基(RPMI-1640,其含有10%胎牛血清、20 μM HEPES、55 μM 2-巰基乙醇、50 μg/ml建他黴素(gentamicin)及來自Gibco之以下補充物之1:100稀釋物:Gluta-MAX、丙酮酸鈉、青黴素(penicillin)/鏈黴素(streptomycin)及非必需胺基酸)中。將細胞以4×10
6個/孔平鋪於6孔板中,總共4 ml/孔。添加1 μM或3 μM MEK抑制劑GDC-0973。24小時後收穫細胞,且將其分配至96孔V形底板中,以供FACS染色。用以下抗體(全部來自BD Biosciences,依1:10,保持在冰上30分鐘)將細胞染色:CD3-FITC、HLA-ABC-PE、CD4-APC、CD19-FITC及CD14-FITC。納入碘化丙啶以排除死細胞。在BD FACSCaliber流式細胞儀上運行試樣且使用FlowJo軟體(Tree Star公司)分析數據。數據分析及直方圖之構築顯示,與媒劑處理細胞相比,用1 μM MEKi GDC-0973或3 μM MEKi GDC-0973處理之CD4+ T細胞(圖3A)、CD8+ T細胞(圖3B)、B細胞(圖3C)或單核球(圖3D)中MHC-I之細胞表面表現未上調。該等結果顯示,藉由MEK抑制劑處理使MHC-I之細胞表面表現增強特屬於腫瘤細胞。
實例 2 : 共刺激信號使 T 細胞對 MEK 抑制劑所致之 TCR 信號傳導失活具有抗性最近研究已顯示,MEK抑制劑處理損害T淋巴球功能(Boni等人,
Cancer Res.,70(13), 2010)。為確認MEK抑制劑處理損害CD8+ T細胞,用MEKi與T細胞刺激信號之組合處理T細胞且分析T細胞增殖。簡言之,依照製造商說明書使用StemCell Technologies人類CD8 RosetteSep自全血純化人類CD8+ T細胞。一式三份將經純化細胞以200,000個/孔平鋪於96孔U形底板中,其中每孔具有200,000個抗CD3或抗CD3/抗CD28 Dynabead (Invitrogen)。自10 μM至0.001 μM滴加10倍之MEK抑制劑GDC-0973及G-38963,以使得最終培養物濃度係0.5% DMSO,總體積為200 μl/孔。培養基係RPMI-1640,其含有10%胎牛血清、20 μM HEPES、55 μM 2-巰基乙醇、50 μg/ml建他黴素及以下補充物之1:100稀釋物:Gibco: Gluta-MAX、丙酮酸鈉、青黴素/鏈黴素及非必需胺基酸。48小時時,用1 μCi/孔3H-胸苷對各孔實施脈衝處理且再培養16小時,隨後冷凍並收穫。數據分析顯示,與未受刺激T細胞(空心圓)相比,用抗CD3處理CD8+ T細胞刺激T細胞活化(實心三角形)。在所有所測試MEKi濃度下,用兩種不同MEK抑制劑處理T細胞降低抗CD3之刺激效應(實心圓、實心正方形),其中在0.01 μM
MEKi處理下幾乎完全抑制T細胞受體誘導之增殖(圖4A)。相比之下,在MEKi處理之T細胞中用抗CD3及抗CD28進行共刺激(實心圓、實心正方形)足以克服MEKi對T細胞活化之抑制效應(圖4B)。該等意外結果顯示以下新發現,MEKi處理對TCR信號傳導之抑制可藉由提供足夠T細胞共刺激來克服,該共刺激係由抗原呈遞細胞(例如B細胞、巨噬細胞及樹突狀細胞)提供至T細胞。
不受理論限制,吾人認為共刺激之關鍵組份為PI3激酶之活化且係由CD28經由PI3K p85亞單位與其胞質YMNM基序之締合來提供。PD-1經由其與SHP2之相互作用阻礙PI3K之活性。因此,阻斷PD1軸可使PI3激酶去抑制,從而增強T細胞共刺激並提供克服MEKi對T細胞活化之抑制效應之手段。PD-1/-LI阻斷係用於在諸如B7.1及B7.2等共刺激配體之表現通常在(例如)多數腫瘤或腫瘤微環境中受到限制時之條件下增強共刺激。組合MEKi與PD1軸之阻斷應藉由經由MEKi上調腫瘤MHC I增強TCR對Ag之識別(增強信號I)及藉由經由PD1/PDL1阻斷減輕對PI3K之抑制(增強信號2)來增強腫瘤特異性T細胞免疫。
實例 3 : MEK 抑制劑特異性增強樹突狀細胞之成熟及活化為確定MEK抑制劑治療是否藉由刺激樹突狀細胞(DC)特異性增強腫瘤免疫原性,用增加濃度之MEKi GDC-0973、MEKi GDC-38963或BRAFi GDC-0879與針對DC共刺激分子CD40之抗體組合處理單核球源樹突狀細胞。簡言之,依照製造商說明書使用StemCell Technologies人類單核球RosetteSep自全血純化人類單核球。將約0.5-1.0×10
6個/ml單核球(存於50 ng/ml人類GM-CSF及100 ng/ml人類IL-4中)接種於T175燒瓶中並保持總共7天,且每2天更換一半培養基。然後收穫細胞且將其以100,000個細胞/孔平鋪於含有或不含有1 μg/ml Pfizer抗CD40之96孔平底板中。自10 μM至0.001 μM滴加10倍之MEK抑制劑及BRAF抑制劑,以使得最終培養物濃度係0.5% DMSO,總體積為200 μl/孔。48小時後,收穫細胞且將其轉移至96孔V形底板中。首先使細胞經Fc-受體(Miltenyi)阻斷且隨後使用以下抗體(來自BD Biosciences,以1:10,在冰上保持30分鐘)染色:HLA-DR、-DP、-DQ-FITC、HLA-ABC-PE、CD83-APC、CD14-FITC、CD80-PE及CD86-APC。納入碘化丙啶以排除死細胞。在BD FACSCaliber流式細胞儀上運行試樣且使用FlowJo軟體(Tree Star公司)分析數據。數據分析及直方圖之構築顯示,與媒劑處理細胞相比,經1 μM MEKi GDC-0973處理之細胞中表現成熟標記物CD83 (圖5A)、MHC-II (圖5B)及共刺激分子CD86 (圖5C)之細胞頻率有所增加。相比之下,經1 μM BRAFi處理之DC中該等DC表面活化標記物之細胞表面表現未上調且與媒劑處理細胞類似。此外,增加濃度之MEKi G-38963 (實心正方形)或MEKi GDC-0973 (實心圓)以濃度依賴方式增強表現該等DC成熟及活化表面標記物之DC之頻率(圖5D-5F)。相比之下,BRAFi (實心三角形)治療不會增強抗CD40共刺激效應。該等新結果顯示,DC之增強成熟及活化係特屬於MEK抑制劑治療且並非歸因於RAS/RAF/MEK信號傳導途徑之一般抑制。此外,MEKi以濃度依賴方式增強經抗CD40共刺激之人類單核球源DC之活化,從而指示,MEKi可對DC具有免疫調節效應。
實例 4 : 用 MEK 抑制劑及抗 PD-L1 抗體共治療降低促進腫瘤生長之細胞介素之血清濃度由於有以下新觀察結果:在共刺激因子存在下MEKi治療增強T細胞及DC活化,因此與抗PD-L1抗體組合使用MEKi G-38963來確定MEKi是否可增強抗PD-L1抗體治療之抗腫瘤效應並調節帶腫瘤動物之細胞介素濃度。用於該等實驗中之抗PD-L1抗體係針對人類PD-L1之PRO314483 (批號59554.96),且識別人類PD-L1與鼠類PD-L1二者。簡言之,在治療後7天,將小鼠麻醉且經眶後抽取血清。使用BioRad Bio-Plex分析來分析細胞介素之血清濃度,且確定,免疫抑制性細胞介素IL-10在黑色素瘤(圖6A)與結腸直腸(圖6C)腫瘤二者之活體內模型中顯著降低。單獨利用抗PD-L1抗體或MEKi治療使IL-10濃度有所降低,但藉由用MEKi及抗PD-L1抗體共治療使其顯著降低。此外,鼠類趨化因子KC (已知在腫瘤進展中發揮作用之人類趨化因子IL-8之同源物)之血清濃度在黑色素瘤(圖6B)與結腸直腸(圖6D)腫瘤二者之活體內模型中亦顯著降低,其中藉由用MEKi及抗PD-L1抗體共治療誘導最顯著降低。該等結果指示,抗PD-L1抗體及MEKi之組合治療抑制促進腫瘤生長之細胞介素之釋放。
實例 5 : MEK 抑制增強抗 PD-L1 抗體在活體內結腸直腸腫瘤中之抗腫瘤活性為確定MEKi是否增強抗PD-L1抗體之抗腫瘤效應,利用組合治療來治療結腸直腸腫瘤之小鼠模型。簡言之,用腫瘤細胞經皮下接種小鼠且使其生長腫瘤。當帶腫瘤小鼠達到200 mm
3(圖7A)或450 mm
3(圖7B)之平均腫瘤體積時,將小鼠隨機分配至4個治療組中之一者。1組:每週3次經腹膜內接受10 mg/kg同種型對照抗體(抗gp120、PRO67181、PUR編號20455)且持續3週,且每天一次經口接受MCT對照媒劑且持續21天;2組:每週3次經腹膜內接受10 mg/kg抗PD-L1抗體PRO314483 (批號59554.96)且持續3週;3組:每週3次經腹膜內接受10 mg/kg同種型對照抗體(抗gp120、PRO67181、PUR編號20455)且持續3週,且每天一次經口接受75 mg/kg MEKi G-38963且持續21天;4組:每週3次經腹膜內接受10 mg/kg抗PD-L1抗體PRO314483 (批號59554.96)且持續3週,且每天一次經口接受75 mg/kg MEKi G-38963且持續21天。監測小鼠之腫瘤生長及體重變化。在早期(圖7A)或晚期(圖7B)幹預中用抗PD-L1抗體PRO314483 (批號5944.96)阻斷PD-L1作為單一藥劑療法預防腫瘤生長高度有效。在早期或晚期幹預中用MEKi G-38963治療作為單一藥劑療法預防腫瘤生長亦高度有效且與抗PD-L1抗體治療相當。在早期幹預與晚期幹預二者中,用抗PD-L1抗體及MEKi組合治療顯著抑制腫瘤生長且比單獨抗PD-L1抗體或MEKi治療顯著更有效。此外,在腫瘤生長早期進行共治療不僅顯著減小腫瘤體積且亦顯示持續反應。早期幹預產生維持至少92天之約60%完全反應。該等結果指示,MEKi增強PD-L1阻斷之抗腫瘤活性且因此與抗PD-L1抗體協同作用以抑制腫瘤生長。
為進一步確定MEKi是否增強抗PD-L1抗體之抗腫瘤效應,在兩種不同研究中使用不同MEK抑制劑(MEKi GDC-0973)利用組合治療來治療結腸直腸腫瘤之小鼠模型。
對於第一研究而言,在雌性BALB/c小鼠之單側胸區中經皮下接種100,000個存於100 μL HBSS:基質膠中之CT26鼠類結腸直腸細胞。當小鼠達到約200 mm
3之平均腫瘤體積時,在第0實驗天將其隨機分配至9個不同治療組中之一者且在第1實驗天起始治療。10只小鼠之群組每天一次經口給予以下200 μl之體積之藥劑且持續21天:1組接受MCT媒劑;2組接受0.5 mg/kg GDC-0973;3組接受1.0 mg/kg GDC-0973;4組接受2.0 mg/kg GDC-0973;5組接受3.0 mg/kg GDC-0973;6組接受4.0 mg/kg GDC-0973;7組接受5.0 mg/kg GDC-0973;8組接受6.0 mg/kg GDC-0973;且9組接受7.5 mg/kg GDC-0973。
對於第二研究而言,在雌性BALB/c小鼠之單側胸區中經皮下接種100,000個存於100 μL HBSS:基質膠中之CT26鼠類結腸直腸細胞。當小鼠達到約200 mm
3之平均腫瘤體積時,在第0實驗天將其隨機分配至6個不同治療組中之一者且在第1實驗天起始治療。10只小鼠之群組給予以下藥劑:1組每天一次經口接受200 μL體積之MCT媒劑且持續21天,且每週3次經腹膜內接受10 mg/kg同種型對照抗體(抗gp120、PRO67181、PUR編號20455);2組每天一次經口接受7.5 mg/kg GDC-0973且持續21天;3組每週3次經腹膜內接受10 mg/kg抗PD-L1抗體PRO314483 (批號5944.96);4組每週3次經腹膜內接受10 mg/kg抗PD-L1抗體PRO314483 (批號5944.96),且每天一次經口接受1.0 mg/kg GDC-0973且持續21天;5組每週3次經腹膜內接受10 mg/kg抗PD-L1抗體PRO314483 (批號5944.96),且每天一次經口接受3.0 mg/kg GDC-0973且持續21天;且6組每週3次經腹膜內接受10 mg/kg抗PD-L1抗體PRO314483 (批號5944.96),且每天一次經口接受6.0 mg/kg GDC-0973且持續21天。抗PD-L1抗體PRO314483 (批號5944.96)係含有MPDL3280A之人類可變區及IgG2A之鼠類恆定區之反向嵌合體,其在恆定區中具有無效應子之Fc D265A/N297A取代。
對於兩種研究而言,每週監測小鼠之腫瘤生長及體重變化2至3次且保持研究持續時間。對於腫瘤生長之量測而言,使用UltraCal-IV卡尺(型號54-10-111;Fred V. Fowler公司;Newton, MA)量測腫瘤體積,其中長度及寬度量測彼此垂直,且使用下式計算腫瘤體積:
腫瘤體積(mm
3)=(長度×寬度
2)×0.5
對於體重之量測而言,使用Adventura Pro AV812天平(Ohaus公司;Pine Brook, NJ)對小鼠稱重。使用下式計算體重變化%:
體重變化(%)=[(重量
新一天-重量
第 0 天)/重量
第 0 天]×100
使用R 2.9.2版(R Development Core Team 2008;R Foundation for Statistical Computing;Vienna, Austria)分析數據,且使用nlme軟體包3.1-96版(Pinheiro J等人,
R package version 3.2009, 1-96)在R內擬合混合模型。在Prism Mac 5.0b版(GraphPad軟體公司;La Jolla, CA)中實施繪圖。使用混合建模方法來分析自相同動物隨時間重複量測之腫瘤體積(Pinheiro J等人,
Statistics and Computing,Springer. 2010)。此方法同時應對重複量測與因可在統計學上分類為隨機缺失(MAR)之原因所致之研究結束前之適度丟失。將log
2(體積)隨時間及劑量之固定效應變化建模成主要效應及自然三次回歸樣條基(時間)與自動測定之自然樣條基(劑量)之相互作用的總和。假定截距及生長率(斜率)隨動物而隨機變化。使用下式將作為對照治療組之百分比之腫瘤生長抑制(TGI%)計算為有關對照之各別治療組/天之擬合曲線下面積(AUG)之百分比,同時對照治療小鼠仍在研究中:
TGI%=100×(1-AUC
劑量/AUC
媒劑)
完全反應(CR)定義為在研究期間之任何時間個別動物之腫瘤體積低於檢測限(LOD)。部分反應(PR)定義為在研究期間之任何時間個別動物腫瘤體積降低其初始腫瘤體積之50%。總體反應率(ORR)定義為完全及部分反應之總和。
至進展5×之時間(TTP5×)定義為群組之擬合腫瘤體積(基於上述混合建模分析)超過5倍起始體積之時間(天)(舍入為最接近的半天)且報告為該群組之TTP5×。亦採用線性混合效應分析來分析自相同動物隨時間重複量測之體重變化。
用增加濃度之MEKi GDC-0973治療以最低抑制抑制腫瘤生長,如藉由7.5 mg/kg GDC-0973治療組在治療後20天所顯示(圖8A,表2)。
表 2.因MEKi GDC-0973之劑量增加而增加之TGI
與單獨用抗PD-L1抗體或MEKi GDC-0973治療相比,用抗PD-L1抗體及MEKi GDC-0973組合治療顯示在較長時段內腫瘤生長降低增強(圖8B,表3)。此外,與單獨使用較高劑量濃度(7.5 mg/kg)之MEKi GDC-0973時相比,當與抗PD-L1抗體組合使用時,較低劑量濃度(1 mg/kg、3 mg/kg及6 mg/kg)之MEKi GDC-0973可更有效地抑制腫瘤生長(圖8A及B,表3)。
表 3.抗PD-L1抗體及MEKi GDC-0973組合治療之有效性
實施進一步研究以確定其他MEK抑制劑(G02443714、G02442104及G00039805)在結腸直腸腫瘤之小鼠模型中用於組合治療時是否亦增強抗PD-L1抗體之抗腫瘤效應。
對於用MEK抑制劑G02443714組合治療而言,在雌性BALB/c小鼠之單側胸區中經皮下接種100,000個存於100 μL HBSS:基質膠中之CT26鼠類結腸直腸細胞。當小鼠達到約200 mm
3之平均腫瘤體積時,在第0實驗天將其隨機分配至4個不同治療組中之一者且在第1實驗天起始治療。10小鼠之群組給予以下藥劑:1組每天一次經口接受200 μL體積之MCT媒劑且保持21天,且每週3次經腹膜內接受10 mg/kg同種型對照抗體(抗gp120、PRO67181、PUR編號20455);2組每天一次經口接受25 mg/kg G02443714且保持21天;3組每週3次經腹膜內接受10 mg/kg抗PD-L1抗體PRO314483 (批號5944.96);且4組每週3次經腹膜內接受10 mg/kg抗PD-L1抗體PRO314483 (批號5944.96),且每天一次經口接受25 mg/kg G02443714且保持21天。在投與抗PD-L1及/或同種型對照抗體前4小時,藉由管飼經口投施G02443714以及經口媒劑(MCT)。
對於用MEK抑制劑G02442104組合治療而言,在雌性BALB/c小鼠之單側胸區中經皮下接種100,000個存於100 μL HBSS:基質膠中之CT26鼠類結腸直腸細胞。當小鼠達到約200 mm
3之平均腫瘤體積時,在第0實驗天將其隨機分配至4個不同治療組中之一者且在第1實驗天起始治療。10小鼠之群組給予以下藥劑:1組每天一次經口接受200 μL體積之MCT媒劑且保持21天,且每週3次經腹膜內接受10 mg/kg同種型對照抗體(抗gp120、PRO67181、PUR編號20455);2組每天一次經口接受25 mg/kg G02442104且保持21天;3組每週3次經腹膜內接受10 mg/kg抗PD-L1抗體PRO314483 (批號5944.96);且4組每週3次經腹膜內接受10 mg/kg抗PD-L1抗體PRO314483 (批號5944.96),且每天一次經口接受25 mg/kg G02442104且保持21天。在投與抗PD-L1及/或同種型對照抗體前4小時,藉由管飼經口投施G02442104以及經口媒劑(MCT)。
對於用MEK抑制劑G00039805組合治療而言,在雌性BALB/c小鼠之單側胸區中經皮下接種100,000個存於100 μL HBSS:基質膠中之CT26鼠類結腸直腸細胞。當小鼠達到約200 mm
3之平均腫瘤體積時,在第0實驗天將其隨機分配至4個不同治療組中之一者且在第1實驗天起始治療。10小鼠之群組給予以下藥劑:1組每天一次經口接受200 μL體積之MCT媒劑且保持21天,且每週3次經腹膜內接受10 mg/kg同種型對照抗體(抗gp120、PRO67181、PUR編號20455);2組每天一次經口接受100 mg/kg G00039805且保持21天;3組每週3次經腹膜內接受10 mg/kg抗PD-L1抗體PRO314483 (批號5944.96);且4組每週3次經腹膜內接受10 mg/kg抗PD-L1抗體PRO314483 (批號5944.96),且每天一次經口接受100 mg/kg G00039805且保持21天。在投與抗PD-L1及/或同種型對照抗體前4小時,藉由管飼經口投施G00039805以及經口媒劑(MCT)。
對於利用G02443714、G02442104或G00039805進行之3種組合研究而言,每週監測小鼠之腫瘤生長及體重變化2至3次且保持研究持續時間。對於腫瘤生長之量測而言,使用UltraCal-IV卡尺(型號54-10-111;Fred V. Fowler公司;Newton, MA)量測腫瘤體積,其中長度及寬度量測彼此垂直,且使用以式計算腫瘤體積:
腫瘤體積(mm
3)=(長度×寬度
2)×0.5
對於體重之量測而言,使用Adventura Pro AV812天平(Ohaus公司;Pine Brook, NJ)對小鼠稱重。使用下式計算體重變化%:
體重變化(%)=[(重量
新一天-重量
第 0 天)/重量
第 0 天]×100
使用R 2.9.2版(R Development Core Team 2008;R Foundation for Statistical Computing;Vienna, Austria)分析數據,且使用nlme軟體包3.1-96版(Pinheiro J等人,
R package version 3.2009, 1-96)在R內擬合混合模型。在Prism Mac 5.0b版(GraphPad軟體公司;La Jolla, CA)中實施繪圖。使用混合建模方法來分析自相同動物隨時間重複量測之腫瘤體積(Pinheiro J等人,
Statistics and Computing,Springer. 2010)。此方法同時應對重複量測與因可在統計學上分類為隨機缺失(MAR)之原因所致之研究結束前之適度丟失。將log
2(體積)隨時間及劑量之固定效應變化建模成主要效應及自然三次回歸樣條基(以時間計)與自動測定之自然樣條基(以劑量計)之相互作用的總和。假定截距及生長率(斜率)隨動物而隨機變化。使用下式將作為對照治療組之百分比之腫瘤生長抑制(TGI%)計算為有關對照之各別治療組/天之擬合曲線下面積(AUC)之百分比,同時對照治療小鼠仍在研究中:
TGI%=100×(1-AUC
劑量/AUC
媒劑)
完全反應(CR)定義為在研究期間之任何時間個別動物之腫瘤體積低於檢測限(LOD)。部分反應(PR)定義為在研究期間之任何時間個別動物腫瘤體積降低其初始腫瘤體積之50%。總體反應率(ORR)定義為完全及部分反應之總和。
至進展5×之時間(TTP5×)定義為群組之擬合腫瘤體積(基於上述混合建模分析)超過5倍起始體積之時間(天)(舍入為最接近的半天)且報告為該群組之TTP5×。亦採用線性混合效應分析來分析自相同動物隨時間重複量測之體重變化。
與單獨用抗PD-L1抗體或G02443714治療相比,用抗PD‑L1抗體及G02443714組合治療在較長時段內使腫瘤生長降低增強,其中在第18天觀察到20%部分反應(圖9)。與單獨用抗PD-L1抗體或MEKi G02442104治療相比,用抗PD-L1抗體及G02442104組合治療亦在較長時段內使腫瘤生長降低增強,其中在第37.5天觀察到40%部分反應及10%完全反應(圖10)。另外,與單獨用抗PD-L1抗體或MEKi G00039805治療相比,用抗PD-L1抗體及G00039805組合治療在較長時段內使腫瘤生長降低增強,其中在第22天觀察到30%部分反應(圖11)。總之,該等結果顯示,多種MEK抑制劑可增強抗PD-L1抗體抑制腫瘤生長之抗腫瘤活性。
實例 6 : MEK 抑制增強抗 PD-L1 抗體在活體內黑色素瘤腫瘤中之抗腫瘤活性為確定MEKi是否增強抗PD-L1抗體之抗腫瘤效應,利用組合治療來治療黑色素瘤腫瘤之小鼠模型。簡言之,用腫瘤細胞經皮下接種小鼠且使其生長腫瘤。當帶腫瘤小鼠達到100-200 mm
3之平均腫瘤體積時,將小鼠隨機分配至4個治療組中之一者。1組:每週3次經腹膜內接受10 mg/kg同種型對照抗體(抗gp 120、PRO67181、PUR編號20455)且持續3週,且每天一次經口接受MCT對照媒劑且持續21天;2組:每週3次經腹膜內接受10 mg/kg抗PD-L1抗體PRO314483 (批號59554.96)且持續3週;3組:每週3次經腹膜內接受10 mg/kg同種型對照抗體(抗gp120、PRO67181、PUR編號20455)且保持3週,且每天一次經口接受75 mg/kg MEKi G-38963且保持21天;4組:每週3次經腹膜內接受10 mg/kg抗PD-L1抗體PRO314483 (批號59554.96)且保持3週,且每天一次經口接受75 mg/kg MEKi G-38963且保持21天。監測小鼠之腫瘤生長及體重變化。在Cloudman S91 (圖12)黑色素瘤腫瘤中用抗PD-L1抗體PRO314483 (批號59554.96)阻斷PD-L1作為單一藥劑療法預防腫瘤生長有效。用MEKi G-38963治療作為單一藥劑療法預防腫瘤生長(圖12)亦高度有效且與抗PD-L1抗體治療相當。在兩種黑色素瘤細胞系中用抗PD-L1抗體及MEKi組合治療顯著抑制腫瘤生長。相比之下,化學治療劑Temodar當與抗PD-L1抗體組合使用時,抑制抗PD-L1抗體之抗腫瘤活性(圖13)。當阻斷T細胞OX40共刺激分子之抗體與MEK抑制劑G-38963組合使用時,獲得類似結果(圖14)。該等結果指示,MEKi特異性增強PD-L1阻斷之抗腫瘤活性且因此與抗PD-L1抗體協同作用以抑制黑色素瘤腫瘤生長。
實例 7 : MEK 抑制劑獨立於 PDL1 抗體活性增加樹突狀細胞之活化先前研究已指示,MEK抑制可藉由下調表面PD-L1增大免疫功能,從而表明MEKi之效應經由PD-L1表現之改變介導。為確定增強之腫瘤免疫原性是否歸因於PD-L1表現對MEK活化之依賴性,比較在以下情形下樹突狀細胞之活化:當用單獨MEKi GDC-0973、單獨抗PD-L1抗體(由MPDL3280A之融合至小鼠IgG2a恆定序列之可變區構成之嵌合抗體,該等恆定序列含有Fc突變以預防與Fcγ受體之有效結合)或MEKi與抗PD-L1抗體組合治療時。簡言之,分離小鼠骨髓細胞且每10 cm具有40 ng/ml小鼠GM-CSF之非組織培養治療皿中接種2×10
6個/10 ml總體積且保持7天。每2至3天更換一半新鮮培養基。培養基係RPMI-1640,其含有10%胎牛血清、20 μM HEPES、55 μM 2-巰基乙醇、50 μg/ml建他黴素及以下補充物之1:100稀釋物:Gibco: Gluta-MAX、丙酮酸鈉、青黴素/鏈黴素及非必需胺基酸。在第7天,收穫全部細胞並洗滌,然後以100,000個細胞個/孔接種於96孔平底板中。以1 μM之最終濃度添加MEK抑制劑GDC-0973,以10 μg/ml添加抗PDL1人類/小鼠反相嵌合體或抗Ragweed小鼠IgG2a同種型對照(Genentech PUR 22251)。在以各為1 μg/ml之最終濃度添加至細胞中之前,在室溫下使抗CD40純系FGK-45 (Genentech批號68020-62)與山羊抗大鼠IgG Fc-γ-受體(Jackson ImmunoResearch)交聯1小時。在48小時刺激後,收穫細胞且將其轉移至96孔V形底板中。首先使試樣經Fc受體(來自BD Biosciences之經純化抗CD 16/CD32,5 μg/ml)阻斷且然後用I-A/I-E-FITC、H-2Db/H-2Kb-生物素(之後為抗生蛋白鏈菌素-PE (streptavidin-PE))、CD11c-APC、CD86-FITC及CD80-PE (全部來自BD Biosciences)染色。納入碘化丙啶以排除死細胞。在BD FACSCaliber流式細胞儀上運行試樣且使用FlowJo軟體(Tree Star公司)分析數據。單獨用功能阻斷性抗PD-L1抗體治療適度地增加MHC-I之DC表面表現(圖15A),然而,其不會誘導DC表面活化標記物MHC-II (圖15B)、CD80 (圖15C)或CD86 (圖15D)之表現。相比之下,MEKi治療增強MHC-II、CD80及CD86以及MHC-I表現。有趣的是,與單獨MEKi相比,MEKi及抗PD-LI抗體之組合治療不會改變DC表面活化標記物。添加共刺激抗CD40抗體時,獲得類似結果(圖15E-H)。該等新發現指示,MEKi獨立於其對PD-L1表現之效應誘導DC之活化。總之,該等結果顯示,MEKi藉由與抗PDL不同之機制增加腫瘤免疫原性且提供對組合MEKi與PD-L1阻斷以最佳增強抗腫瘤免疫之支持。
實例 8a : MEK 分析 (MEK 活性分析 )使用在昆蟲細胞中表現之組成性活化之人類突變體MEK1作為酶促活性源,該激酶在激酶分析中之最終濃度為62.5 nM。
使用大腸桿菌(
E.Coli)中產生之重組GST-ERK1作為受質,在50 μM ATP存在下實施30分鐘分析。使用由Cisbio供應之HTRF試劑檢測並定量受質之磷酸化。該等試劑係由偶聯至別藻藍蛋白(XL665)之抗GST抗體及偶聯至銪穴狀化合物之抗磷酸(Thr202/Tyr204) ERK抗體組成。抗磷酸抗體識別在Thr202及Tyr204上雙重磷酸化之ERK1。當兩種抗體均結合至ERK1時(即當受質經磷酸化時),在340 nm下激發後發生穴狀化合物至別藻藍蛋白之能量轉移,從而產生與所產生磷酸化受質之量成比例之發射螢光。使用多孔螢光計檢測螢光。
在添加分析緩衝液之前,在DMSO中稀釋化合物,且其在分析中之最終DMSO濃度係1%。
IC
50之定義為該指定化合物達到對照組之50%抑制性時之濃度。使用XLfit套裝軟體(2.0.5版)計算IC
50值。
實例 8b : MEK 分析 (MEK 活性分析 )使用在昆蟲細胞中表現之組成性活化之人類突變體MEK1作為酶促活性源,該激酶在激酶分析中之最終濃度為15 nM。
使用大腸桿菌中產生之重組GST-ERK1作為受質,在50 μM ATP存在下實施30分鐘分析。使用由Cisbio供應之HTRF試劑檢測並定量受質之磷酸化。該等試劑係由偶聯至別藻藍蛋白(XL665)之抗GST抗體及偶聯至銪穴狀化合物之抗磷酸(Thr202/Tyr204) ERK抗體組成。所用該等試劑之最終濃度分別為4 μg/ml及0.84 μg/ml。抗磷酸抗體識別在Thr202及Tyr204上雙重磷酸化之ERK1。當兩種抗體均結合至ERK1時(即當受質經磷酸化時),在340 nm下激發後發生穴狀化合物至別藻藍蛋白之能量轉移,從而產生與所產生磷酸化受質之量成比例之發射螢光。使用多孔螢光計檢測螢光。
在添加分析緩衝液之前,在DMSO中稀釋化合物且其在分析中之最終DMSO濃度係1%。
IC
50之定義為該指定化合物達到對照組之50%抑制性時之濃度。使用XLfit軟體包(2.0.5版)計算IC
50值。
所有所引用之專利、專利申請案、文件及論文之全部內容均以引用方式併入本文中。
Loop | Kabat | AbM | Chothia | 接觸 | |
L1 | L24-L34 | L24-L34 | L26-L32 | L30-L36 | |
L2 | L50-L56 | L50-L56 | L50-L52 | L46-L55 | |
L3 | L89-L97 | L89-L97 | L91-L96 | L89-L96 | |
H1 | H31-H35B | H26-H35B | H26-H32 | H30-H35B | (Kabat編號) |
H1 | H31-H35 | H26-H35 | H26-H32 | H30-H35 (Chothia編號) | |
H2 | H50-H65 | H50-H58 | H53-H55 | H47-H58 | |
H3 | H95-H102 | H95-H102 | H96-H101 | H93-H101 |
LC-FR1係DIQMTQSPSSLSASVGDRVTITC | (SEQ ID NO:11) |
LC-FR2係WYQQKPGKAPKLLIY | (SEQ ID NO:12) |
LC-FR3係GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC | (SEQ ID NO:13) |
LC-FR4係FGQGTKVEIKR | (SEQ ID NO: 14)。 |
(i)該HVR-H1序列係GFTFSX 1SWIH; | (SEQ ID NO:1) |
(ii)該HVR-H2序列係AWIX 2PYGGSX 3YYADSVKG | (SEQ ID NO: 2) |
(iii)該HVR-H3序列係RHWPGGFDY,且 | (SEQ ID NO: 3) |
(i)該HVR-L1序列係RASQX 4X 5X 6TX 7X 8A | (SEQIDNO:8) |
(ii)該HVR-L2序列係SASX 9LX 10S;且 | (SEQIDNO:9) |
(iii)該HVR-L3序列係QQX 11X 12X 13X 14PX 15T; | (SEQ ID NO: 10) |
HC-FR1 | EVQLVESGGGLVQPGGSLRLSCAAS | (SEQ ID NO:4) |
HC-FR2 | WVRQAPGKGLEWV | (SEQ ID NO:5) |
HC-FR3 | RFTISADTSKNTAYLQMNSLRAEDTAVYYCAR | (SEQ ID NO:6) |
HC-FR4 | WGQGTLVTVSA | (SEQ ID NO:7)。 |
LC-FR1 | DIQMTQSPSSLSASVGDRVTITC | (SEQ ID NO: 11) |
LC-FR2 | WYQQKPGKAPKLLIY | (SEQ ID NO: 12) |
LC-FR3 | GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC | (SEQ ID NO: 13) |
LC-FR4 | FGQGTKVEIKR | (SEQ ID NO:14) 。 |
HC-FR1 | EVQLVESGGGLVQPGGSLRLSCAAS | (SEQ ID NO: 4) |
HC-FR2 | WVRQAPGKGLEWV | (SEQ ID NO: 5) |
HC-FR3 | RFTISADTSKNTAYLQMNSLRAEDTAVYYCAR | (SEQ ID NO: 6) |
HC-FR4 | WGQGTLVTVSA | (SEQ ID NO:7)。 |
LC-FR1 | DIQMTQSPSSLSASVGDRVTITC | (SEQ ID NO: 11) |
LC-FR2 | WYQQKPGKAPKLLIY | (SEQ ID NO: 12) |
LC-FR3 | GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC | (SEQ ID NO: 13) |
LC-FR4 | FGQGTKVEIKR | (SEQ ID NO:14)。 |
HC-FR1 | EVQLVESGGGLVQPGGSLRLSCAAS | (SEQ ID NO:4) |
HC-FR2 | WVRQAPGKGLEWV | (SEQ ID NO: 5) |
HC-FR3 | RFTISADTSKNTAYLQMNSLRAEDTAVYYCAR | (SEQ ID NO:6) |
HC-FR4 | WGQGTLVTVSA | (SEQ ID NO:7)。 |
LC-FR1 | DIQMTQSPSSLSASVGDRVTITC | (SEQ ID NO: 11) |
LC-FR2 | WYQQKPGKAPKLLIY | (SEQ ID NO: 12) |
LC-FR3 | GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC | (SEQ ID NO:13) |
LC-FR4 | FGQGTKVEIKR | (SEQ ID NO:14)。 |
HC-FR1 | EVQLVESGGGLVQPGGSLRLSCAAS | (SEQ ID NO: 4) |
HC-FR2 | WVRQAPGKGLEWV | (SEQ ID NO:5) |
HC-FR3 | RFTISADTSKNTAYLQMNSLRAEDTAVYYCAR | (SEQ ID NO: 6) |
HC-FR4 | WGQGTLVTVSS | (SEQ ID NO:25)。 |
LC-FR1 | DIQMTQSPSSLSASVGDRVTITC | (SEQ ID NO: 11) |
LC-FR2 | WYQQKPGKAPKLLIY | (SEQ ID NO: 12) |
LC-FR3 | GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC | (SEQ ID NO: 13) |
LC-FR4 | FGQGTKVEIKR | (SEQ ID NO: 14)。 |
HC-FR1 | EVQLVESGGGLVQPGGSLRLSCAAS | (SEQ ID NO: 4) |
HC-FR2 | WVRQAPGKGLEWV | (SEQ ID NO: 5) |
HC-FR3 | RFTISADTSKNTAYLQMNSLRAEDTAVYYCAR | (SEQ ID NO: 6) |
HC-FR4 | WGQGTLVTVSA | (SEQ ID NO:7)。 |
LC-FR1 | DIQMTQSPSSLSASVGDRVTITC | (SEQ ID NO: 11) |
LC-FR2 | WYQQKPGKAPKLLIY | (SEQ ID NO: 12) |
LC-FR3 | GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC | (SEQ ID NO: 13) |
LC-FR4 | FGQGTKVEIKR | (SEQ ID NO:14)。 |
化合物編號 | 化學名稱 | 結構 | ||||
(III)-5 | 5-(2-氟-4-碘苯基胺基)-咪唑并[1,5-a]吡啶-6-甲酸(2-羥基乙氧基)-醯胺 | |||||
(III)-6 | 5-(2-氟-4-碘-苯基胺基)-咪唑并[1,5-a]吡啶-6-甲酸((R)-2,3-二羥基-丙氧基)-醯胺 | |||||
(III)-7 | 5-(2-氟-4-碘-苯基胺基)-咪唑并[1,5-a]吡啶-6-甲酸((S)-2-羥基-丙氧基)-醯胺 | |||||
(III)-8 | 5-(4-溴-2-氟苯基胺基)-咪唑并[1,5-a]吡啶-6-甲酸(2-羥基乙氧基)-醯胺 | |||||
(III)-9 | 5-(4-溴-2-氟-苯基胺基)-咪唑并[1,5-a]吡啶-6-甲酸((S)-2-羥基-丙氧基)-醯胺 | |||||
(III)-10 | 5-(4-溴-2-氟-苯基胺基)-8-氟-咪唑并[1,5-a]吡啶-6-甲酸((S)-2-羥基-丙氧基)- 醯胺 | |||||
(III)-11 | 8-氟-5-(2-氟-4-碘-苯基胺基)-咪唑并[1,5-a]吡啶-6-甲酸(2-羥基-乙氧基)-醯胺 | |||||
(III)-12 | 8-氟-5-(2-氟-4-碘-苯基胺基)-咪唑并[1,5-a]吡啶-6-甲酸(( R)-2,3-二羥基-丙氧基)-醯胺 | |||||
(III)-13 | 8-氟-5-(2-氟-4-碘-苯基胺基)-咪唑并[1,5-a]吡啶-6-甲酸((S)-2-羥基-丙氧基)- 醯胺 | |||||
(III)-14 | 5-(2-氟-甲烷磺醯基-苯基胺基)-咪唑并[1,5-a]吡啶-6-甲酸(2-羥基-乙氧基)-醯胺 | |||||
(III)-15 | 5-(2-氟-4-碘-苯基胺基)-咪唑并[1,5-a]吡嗪-6-甲酸(2-羥基-乙氧基)-醯胺 | |||||
(III)-16 | 5-(2-氟-4-碘-苯基胺基)-咪唑并[1,5-a]吡嗪-6-甲酸((S)-2-羥基-丙氧基)-醯胺 | |||||
(III)-17 | 5-(4-環丙基-2-氟-苯基胺基)-咪唑并[1,5-a]吡啶-6-甲酸(2-羥基-乙氧基)-醯胺 | |||||
(III)-18 | (R)- N-(2,3-二羥基丙氧基)-5-(2-氟-4-碘苯基胺基)咪唑并[1,5-a]吡嗪-6-甲醯胺 | |||||
(III)-19 | N-乙氧基-5-(2-氟-4-碘苯基胺基)咪唑并[l,5- a]吡嗪-6-甲醯胺 | |||||
(III)-20 | N-(環丙基甲氧基)-5-(2-氟-4-碘苯基胺基)咪唑并[1,5‑a]吡嗪-6-甲醯胺 | |||||
(III)-21 | 5-(2-氟-4-碘苯基胺基)-N-甲基咪唑并[1,5-a]吡嗪-6-甲醯胺 | |||||
(III)-22 | 5-(4-溴-2-氟苯基胺基)- N-(2-羥基-乙氧基)咪唑并[1,5-a]吡嗪-6-甲醯胺 | |||||
(III)-23 | (S)-5-(4-溴-2-氟苯基胺基)-N-(2-羥基-丙氧基)咪唑并[1,5- a]吡嗪-6-甲醯胺 | |||||
(III)-24 | (R)-5-(4-溴-2-氟苯基胺基)-N-(2,3-二羥基-丙氧基)咪唑并[1,5- a]吡嗪-6-甲醯胺 | |||||
(III)-25 | 5-(4-溴-2-氟苯基胺基)-N-(環丙基-甲氧基)咪唑并[1,5- a]吡嗪-6-甲醯胺 | |||||
治療 | TGI% |
媒劑 | 0 |
GDC-0973, 0.5 mg/kg | -8 |
GDC-0973, 1.0 mg/kg | -16 |
GDC-0973, 2.0 mg/kg | -21 |
GDC-0973, 3.0 mg/kg | -4 |
GDC-0973, 4.0 mg/kg | 27 |
GDC-0973, 5.0 mg/kg | 55 |
GDC-0973, 6.0 mg/kg | 72 |
GDC-0973, 7.5 mg/kg | 87 |
治療 | TGI% | TTP5× ( 天 ) | PR% | CR% |
對照 | 0 | 12 | 0 | 0 |
抗PD-L1抗體 | 78 | 24 | 20 | 0 |
GDC-0973, 7.5 mg/kg | 71 | 21.5 | 10 | 0 |
抗PD-L1抗體+GDC-0973, 1.0 mg/kg | 78 | 30 | 20 | 10 |
抗PD-L1抗體+GDC-0973, 3.0 mg/kg | 98 | 43 | 30 | 20 |
抗PD-L1抗體+GDC-0973, 6.0 mg/kg | 106 | 44.5 | 40 | 20 |
圖1顯示在用MEK抑制劑處理後,黑色素瘤及結腸直腸腫瘤細胞系上增強之MHC I表面表現。(A)直方圖顯示用MEK抑制劑處理之人類腫瘤細胞系之表面上增加之MHC I表現。(B)直方圖顯示用MEK抑制劑處理之小鼠腫瘤細胞系之表面上增加之MHC I表現。
圖2係直方圖,其顯示用BRAF抑制劑處理之人類黑色素瘤細胞系(其中8個細胞系中有5個係BRAF突變體;BRAF野生型細胞用星號指示)不會上調MHC I表面表現。
圖3顯示,用MEK抑制劑處理人類周邊血單核細胞不會上調MHC I表面表現。(A-D)直方圖顯示在MEK抑制劑處理後,CD4+ T細胞、CD8+ T細胞、B細胞或單核球中未改變之MHC I表面表現。
圖4顯示,儘管進行MEK抑制劑處理,但共刺激信號仍使T細胞具有反應性。(A) CD8
+T細胞含量圖顯示,MEK抑制劑處理降低通常藉由CD3刺激誘導之T細胞增殖及活化。(B) CD8
+T細胞圖顯示,CD3及CD28之共刺激足以克服MEK抑制劑處理之抑制效應。
圖5顯示,MEK抑制劑處理增強樹突狀細胞經抗CD40抗體刺激之成熟及活化。(A-C)直方圖顯示用抗CD40抗體刺激且用MEK或BRAF抑制劑處理之樹突狀細胞。MEK抑制劑增強DC活化,如藉由DC表面活化標記物CD83、MHC II及CD86之上調所證明。(D-F)經活化樹突狀細胞含量圖顯示,MEK抑制劑以劑量依賴方式增強DC活化。
圖6係顯示免疫抑制性及促腫瘤細胞介素之血清濃度在活體內癌症模型中降低之圖。(A及C)與單獨用抗PD-L1或MEK抑制劑治療相比,在用抗PD-L1抗體及MEK抑制劑共治療後7天,免疫抑制性細胞介素IL-10有所降低。(B及D)與單獨用抗PD-L1或MEK抑制劑治療相比,在用抗PD-L1抗體及MEK抑制劑共治療後,促腫瘤趨化因子KC有所降低。
圖7顯示,在活體內結腸直腸癌模型中,MEK抑制劑治療增強抗PD-L1抗體之抗腫瘤活性。(A)繪示用抗PD-L1抗體及MEK抑制劑共治療之腫瘤體積變化之圖顯示,與單獨抗PD-L1抗體或MEK抑制劑治療相比,早期腫瘤生長顯著降低及持續抗腫瘤效應。(B)繪示用抗PD-L1抗體及MEK抑制劑共治療之腫瘤體積變化之圖顯示,與單獨抗PD-L1抗體或MEK抑制劑治療相比,顯著抑制晚期腫瘤生長。
圖8係一系列圖,其顯示,MEK抑制劑劑量在與抗PD-L1抗體組合使用時對活體內結腸直腸癌模型中之治療更有效。(A)圖繪示腫瘤體積隨MEK抑制劑GDC-0973治療之劑量增加而減小。(B)圖繪示在投與與不同劑量之MEK抑制劑GDC-0973組合之抗PD-L1抗體後腫瘤體積之減小。Mpk指示毫克/公斤(mg/kg)。
圖9係顯示在活體內結腸直腸癌模型中用MEK抑制劑G02443714治療增強抗PD-L1抗體之抗腫瘤活性之圖。觀察到與單獨用抗PD-L1抗體或MEK抑制劑G02443714治療相比,用抗PD-L1抗體及MEK抑制劑組合治療促進腫瘤體積減小。
圖10係顯示在活體內結腸直腸癌模型中用MEK抑制劑G02442104治療增強抗PD-L1抗體之抗腫瘤活性之圖。觀察到與單獨用抗PD-L1抗體或MEK抑制劑G02442104治療相比,用抗PD-L1抗體及MEK抑制劑組合治療促進腫瘤體積減小。
圖11係顯示在活體內結腸直腸癌模型中用MEK抑制劑G00039805治療增強抗PD-L1抗體之抗腫瘤活性之圖。觀察到與單獨用抗PD-L1抗體或MEK抑制劑G00039805治療相比,用抗PD-L1抗體及MEK抑制劑組合治療促進腫瘤體積減小。
圖12顯示,在活體內黑色素瘤模型中,MEK抑制劑治療增強抗PD-L1抗體之抗腫瘤活性。繪示用抗PD-L1抗體及MEK抑制劑共治療之腫瘤體積變化之圖顯示,與單獨抗PD-L1抗體或MEK抑制劑治療相比,腫瘤生長顯著降低。
圖13係顯示在活體內黑色素瘤模型中用抗PD-L1抗體及化學治療劑Temodar共治療不會降低腫瘤生長之圖。因此,MEK抑制劑及抗PD-L1抗體之抗腫瘤效應具有特異性。
圖14係顯示在活體內結腸直腸模型中用抗OX40抗體及MEK抑制劑共治療不會降低腫瘤生長之圖。因此,MEK抑制劑及抗PD-L1抗體之抗腫瘤效應具有特異性。
圖15含有若干圖,其顯示MEK抑制劑獨立於抗PD-L1抗體治療增加樹突狀細胞之活化。(A)圖顯示,抗PD-L1抗體治療稍微增加MHC I表面表現。MEK抑制劑治療顯著增強MHCI表現,但與抗PD-L1抗體之共治療不會增強MEK抑制劑治療之效應。(B-D)圖顯示,抗PD-L1抗體治療不會增加樹突狀細胞活化標記物MHC II、CD80及CD86之表現。相比之下,MEK抑制劑治療顯著增強樹突狀細胞活化標記物之表現。與抗PD-L1抗體之共治療不會增強MEK抑制劑治療之效應。(E-H)圖顯示,用抗CD40抗體刺激樹突狀細胞不會改變MEK抑制劑及抗PD-L1共治療對樹突狀細胞活化之效應。
<![CDATA[<110> 美商建南德克公司(GENENTECH, INC.)]]> <![CDATA[<120> 利用PD-1軸結合拮抗劑及MEK抑制劑治療癌症之方法]]> <![CDATA[<130> TW109132965 ]]> <![CDATA[<150> US 61/574,406 ]]> <![CDATA[<151> 2011-08-01 ]]> <![CDATA[<160> 27]]> <![CDATA[<170> FastSEQ for Windows Version 4.0]]> <![CDATA[<210> 1]]> <![CDATA[<211> 10]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220> ]]> <![CDATA[<223> 合成構築體]]> <![CDATA[<220> ]]> <![CDATA[<221> VARIANT ]]> <![CDATA[<222> 6]]> <![CDATA[<223> Xaa = Asp或Gly]]> <![CDATA[<400> 1]]> Gly Phe Thr Phe Ser Xaa Ser Trp Ile His 1 5 10 <![CDATA[<210> 2]]> <![CDATA[<211> 18]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220> ]]> <![CDATA[<223> 合成構築體]]> <![CDATA[<220> ]]> <![CDATA[<221> VARIANT ]]> <![CDATA[<222> 4]]> <![CDATA[<223> Xaa = Ser或Leu]]> <![CDATA[<220> ]]> <![CDATA[<221> VARIANT ]]> <![CDATA[<222> 10]]> <![CDATA[<223> Xaa = Thr或Ser]]> <![CDATA[<400> 2]]> Ala Trp Ile Xaa Pro Tyr Gly Gly Ser Xaa Tyr Tyr Ala Asp Ser Val 1 5 10 15 Lys Gly <![CDATA[<210> 3]]> <![CDATA[<211> 9]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220> ]]> <![CDATA[<223> 合成構築體]]> <![CDATA[<400> 3]]> Arg His Trp Pro Gly Gly Phe Asp Tyr 1 5 <![CDATA[<210> 4]]> <![CDATA[<211> 25]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220> ]]> <![CDATA[<223> 合成構築體]]> <![CDATA[<400> 4]]> Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser 20 25 <![CDATA[<210> 5]]> <![CDATA[<211> 13]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220> ]]> <![CDATA[<223> 合成構築體]]> <![CDATA[<400> 5]]> Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 1 5 10 <![CDATA[<210> 6]]> <![CDATA[<211> 32]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220> ]]> <![CDATA[<223> 合成構築體]]> <![CDATA[<400> 6]]> Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr Leu Gln 1 5 10 15 Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg 20 25 30 <![CDATA[<210> 7]]> <![CDATA[<211> 11]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220> ]]> <![CDATA[<223> 合成構築體]]> <![CDATA[<400> 7]]> Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala 1 5 10 <![CDATA[<210> 8]]> <![CDATA[<211> 11]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220> ]]> <![CDATA[<223> 合成構築體]]> <![CDATA[<220> ]]> <![CDATA[<221> VARIANT ]]> <![CDATA[<222> 5]]> <![CDATA[<223> Xaa = Asp或Val]]> <![CDATA[<220> ]]> <![CDATA[<221> VARIANT ]]> <![CDATA[<222> 6]]> <![CDATA[<223> Xaa = Val或Ile]]> <![CDATA[<220> ]]> <![CDATA[<221> VARIANT ]]> <![CDATA[<222> 7]]> <![CDATA[<223> Xaa = Ser或Asn]]> <![CDATA[<220> ]]> <![CDATA[<221> VARIANT ]]> <![CDATA[<222> 9]]> <![CDATA[<223> Xaa = Ala或Phe]]> <![CDATA[<220> ]]> <![CDATA[<221> VARIANT ]]> <![CDATA[<222> 10]]> <![CDATA[<223> Xaa = Val或Leu]]> <![CDATA[<400> 8]]> Arg Ala Ser Gln Xaa Xaa Xaa Thr Xaa Xaa Ala 1 5 10 <![CDATA[<210> 9]]> <![CDATA[<211> 7]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220> ]]> <![CDATA[<223> 合成構築體]]> <![CDATA[<220> ]]> <![CDATA[<221> VARIANT ]]> <![CDATA[<222> 4]]> <![CDATA[<223> Xaa = Phe或Thr]]> <![CDATA[<220> ]]> <![CDATA[<221> VARIANT ]]> <![CDATA[<222> 6]]> <![CDATA[<223> Xaa = Tyr或Ala]]> <![CDATA[<400> 9]]> Ser Ala Ser Xaa Leu Xaa Ser 1 5 <![CDATA[<210> 10]]> <![CDATA[<211> 9]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220> ]]> <![CDATA[<223> 合成構築體]]> <![CDATA[<220> ]]> <![CDATA[<221> VARIANT ]]> <![CDATA[<222> 3]]> <![CDATA[<223> Xaa = Tyr, Gly, Phe或Ser]]> <![CDATA[<220> ]]> <![CDATA[<221> VARIANT ]]> <![CDATA[<222> 4]]> <![CDATA[<223> Xaa = Leu, Tyr, Phe或Trp]]> <![CDATA[<220> ]]> <![CDATA[<221> VARIANT ]]> <![CDATA[<222> 5]]> <![CDATA[<223> Xaa = Tyr, Asn, Ala, Thr, Gly, Phe或Ile]]> <![CDATA[<220> ]]> <![CDATA[<221> VARIANT ]]> <![CDATA[<222> 6]]> <![CDATA[<223> Xaa = His, Val, Pro, Thr或Ile]]> <![CDATA[<220> ]]> <![CDATA[<221> VARIANT ]]> <![CDATA[<222> 8]]> <![CDATA[<223> Xaa = Ala, Trp, Arg, Pro或Thr]]> <![CDATA[<400> 10]]> Gln Gln Xaa Xaa Xaa Xaa Pro Xaa Thr 1 5 <![CDATA[<210> 11]]> <![CDATA[<211> 23]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220> ]]> <![CDATA[<223> 合成構築體]]> <![CDATA[<400> 11]]> Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys 20 <![CDATA[<210> 12]]> <![CDATA[<211> 15]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220> ]]> <![CDATA[<223> 合成構築體]]> <![CDATA[<400> 12]]> Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr 1 5 10 15 <![CDATA[<210> 13]]> <![CDATA[<211> 32]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220> ]]> <![CDATA[<223> 合成構築體]]> <![CDATA[<400> 13]]> Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr 1 5 10 15 Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys 20 25 30 <![CDATA[<210> 14]]> <![CDATA[<211> 11]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220> ]]> <![CDATA[<223> 合成構築體]]> <![CDATA[<400> 14]]> Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg 1 5 10 <![CDATA[<210> 15]]> <![CDATA[<211> 10]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220> ]]> <![CDATA[<223> 合成構築體]]> <![CDATA[<400> 15]]> Gly Phe Thr Phe Ser Asp Ser Trp Ile His 1 5 10 <![CDATA[<210> 16]]> <![CDATA[<211> 18]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220> ]]> <![CDATA[<223> 合成構築體]]> <![CDATA[<400> 16]]> Ala Trp Ile Ser Pro Tyr Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val 1 5 10 15 Lys Gly <![CDATA[<210> 17]]> <![CDATA[<211> 11]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220> ]]> <![CDATA[<223> 合成構築體]]> <![CDATA[<400> 17]]> Arg Ala Ser Gln Asp Val Ser Thr Ala Val Ala 1 5 10 <![CDATA[<210> 18]]> <![CDATA[<211> 7]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220> ]]> <![CDATA[<223> 合成構築體]]> <![CDATA[<400> 18]]> Ser Ala Ser Phe Leu Tyr Ser 1 5 <![CDATA[<210> 19]]> <![CDATA[<211> 9]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220> ]]> <![CDATA[<223> 合成構築體]]> <![CDATA[<400> 19]]> Gln Gln Tyr Leu Tyr His Pro Ala Thr 1 5 <![CDATA[<210> 20]]> <![CDATA[<211> 118]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220> ]]> <![CDATA[<223> 合成構築體]]> <![CDATA[<400> 20]]> Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ser 20 25 30 Trp Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Trp Ile Ser Pro Tyr Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Arg His Trp Pro Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ala 115 <![CDATA[<210> 21]]> <![CDATA[<211> 108]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220> ]]> <![CDATA[<223> 合成構築體]]> <![CDATA[<400> 21]]> Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Val Ser Thr Ala 20 25 30 Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Leu Tyr His Pro Ala 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg 100 105 <![CDATA[<210> 22]]> <![CDATA[<211> 440]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220> ]]> <![CDATA[<223> 合成構築體]]> <![CDATA[<400> 22]]> Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Asp Cys Lys Ala Ser Gly Ile Thr Phe Ser Asn Ser 20 25 30 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Trp Tyr Asp Gly Ser Lys Arg Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Phe 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Thr Asn Asp Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser 100 105 110 Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser 115 120 125 Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp 130 135 140 Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr 145 150 155 160 Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr 165 170 175 Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys 180 185 190 Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp 195 200 205 Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala 210 215 220 Pro Glu Phe Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 225 230 235 240 Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val 245 250 255 Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val 260 265 270 Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln 275 280 285 Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln 290 295 300 Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly 305 310 315 320 Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro 325 330 335 Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr 340 345 350 Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser 355 360 365 Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr 370 375 380 Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr 385 390 395 400 Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe 405 410 415 Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys 420 425 430 Ser Leu Ser Leu Ser Leu Gly Lys 435 440 <![CDATA[<210> 23]]> <![CDATA[<211> 214]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220> ]]> <![CDATA[<223> 合成構築體]]> <![CDATA[<400> 23]]> Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45 Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro 65 70 75 80 Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Ser Ser Asn Trp Pro Arg 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 <![CDATA[<210> 24]]> <![CDATA[<211> 118]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220> ]]> <![CDATA[<223> 合成構築體]]> <![CDATA[<400> 24]]> Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ser 20 25 30 Trp Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Trp Ile Ser Pro Tyr Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Arg His Trp Pro Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser 115 <![CDATA[<210> 25]]> <![CDATA[<211> 11]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220> ]]> <![CDATA[<223> 合成構築體]]> <![CDATA[<400> 25]]> Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 1 5 10 <![CDATA[<210> 26]]> <![CDATA[<211> 448]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220> ]]> <![CDATA[<223> 合成構築體]]> <![CDATA[<400> 26]]> Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ser 20 25 30 Trp Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Trp Ile Ser Pro Tyr Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Arg His Trp Pro Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125 Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 130 135 140 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160 Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 165 170 175 Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190 Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 195 200 205 Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr 210 215 220 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 225 230 235 240 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 260 265 270 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Ala Ser Thr Tyr Arg Val Val 290 295 300 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 325 330 335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350 Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 405 410 415 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 <![CDATA[<210> 27]]> <![CDATA[<211> 214]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220> ]]> <![CDATA[<223> 合成構築體]]> <![CDATA[<400> 27]]> Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Val Ser Thr Ala 20 25 30 Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Leu Tyr His Pro Ala 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210
Claims (59)
- 一種有效量之抗PD-1抗體及MEK抑制劑之用途,其係用於製備用以治療個體之癌症或延遲其進展之包含該抗PD-1抗體之第一藥物及包含該MEK抑制劑之第二藥物,其中該MEK抑制劑係:a)式(I)化合物:
- 一種有效量之抗PD-1抗體之用途,其係用於製備用以治療個體之癌症或延遲其進展之藥物,其中該藥物係與MEK抑制劑組合使用,且其中該MEK抑制劑係如請求項1所定義者。
- 一種有效量之MEK抑制劑之用途,其係用於製備用以治療個體之癌症或延遲其進展之藥物,其中該藥物係與抗PD-1抗體組合使用,且其中該MEK抑制劑係如請求項1所定義者。
- 如請求項1至3中任一項之用途,其中該抗PD-1抗體係選自由以下組成之群:MDX-1106及Merck 3745。
- 如請求項1至3中任一項之用途,其中該MEK抑制劑係MEK之競爭抑制劑。
- 如請求項1至3中任一項之用途,其中該MEK抑制劑針對活化性KRAS突變之選擇性較高。
- 如請求項1至3中任一項之用途,其中該MEK抑制劑係MEK之異位抑制劑。
- 如請求項1至3中任一項之用途,其中該MEK抑制劑針對活化性BRAF突變之選擇性較高。
- 如請求項1至3中任一項之用途,其中該癌症含有BRAF V600E突變。
- 如請求項1至3中任一項之用途,其中該癌症含有BRAF野生型。
- 如請求項1至3中任一項之用途,其中該癌症含有KRAS野生型。
- 如請求項1至3中任一項之用途,其中該癌症含有活化性KRAS突變。
- 如請求項1至3中任一項之用途,其中該治療使該個體在停止該治療後產生持續反應。
- 如請求項1至3中任一項之用途,其中該MEK抑制劑係連續投與。
- 如請求項1至3中任一項之用途,其中該MEK抑制劑係間歇性投與。
- 如請求項1至3中任一項之用途,其中該MEK抑制劑係在該抗PD-1抗體之前投與。
- 如請求項1至3中任一項之用途,其中該MEK抑制劑係與該抗PD-1抗體同時投與。
- 如請求項1至3中任一項之用途,其中該MEK抑制劑係在該抗PD-1抗體之後投與。
- 如請求項1至3中任一項之用途,其中該個體患有結腸直腸癌。
- 如請求項1至3中任一項之用途,其中該個體患有黑色素瘤。
- 如請求項1至3中任一項之用途,其中該個體患有非小細胞肺癌。
- 如請求項1至3中任一項之用途,其中該個體患有卵巢癌。
- 如請求項1至3中任一項之用途,其中該個體患有乳癌。
- 如請求項1至3中任一項之用途,其中該個體患有胰腺癌。
- 如請求項1至3中任一項之用途,其中該個體患有血液惡性病。
- 如請求項1至3中任一項之用途,其中該個體患有腎細胞癌。
- 一種有效量之抗PD-1抗體及MEK抑制劑之用途,其係用於製備用以增強患有癌症之個體之免疫功能之包含該抗PD-1抗體之第一藥物及包含該MEK抑制劑之第二藥物,其中該MEK抑制劑係如請求項1所定義者。
- 一種有效量之抗PD-1抗體之用途,其係用於製備用以增強患有癌症之個體之免疫功能之藥物,其中該藥物係與MEK抑制劑組合使用,且其中該MEK抑制劑係如請求項1所定義者。
- 一種有效量之MEK抑制劑之用途,其係用於製備用以增強患有癌症之個體之免疫功能之藥物,其中該藥物係與抗PD-1抗體組合使用,且其中該MEK抑制劑係如請求項1所定義者。
- 如請求項28至30中任一項之用途,其中該個體中之CD8 T細胞之初免、活化、增殖及/或細胞溶解活性比投與該抗PD-1抗體及該MEK抑制劑之前增強。
- 如請求項31之用途,其中該CD8 T細胞活化之特徵在於相對於投與該抗PD-1抗體及該MEK抑制劑之前,γ-IFN+ CD8 T細胞之頻率有升高及/或細胞溶解活性有增強。
- 如請求項31之用途,其中CD8 T細胞之數目比使用該抗PD-1抗體及該MEK抑制劑之前升高。
- 如請求項31之用途,其中該CD8 T細胞係抗原特異性CD8 T細胞。
- 如請求項31之用途,其中在使用該抗PD-1抗體及該MEK抑制劑之前,該個體中之癌細胞選擇性地具有升高的MHC I類抗原表現。
- 如請求項35之用途,其中該個體之PBMC細胞不具有升高的MHC I類抗原之表現。
- 如請求項31之用途,其中該個體中之抗原呈遞細胞之成熟及活化比使用該抗PD-1抗體及該MEK抑制劑之前增強。
- 如請求項37之用途,其中該等抗原呈遞細胞係樹突狀細胞。
- 如請求項37之用途,其中該等抗原呈遞細胞之該成熟之特徵在於CD83+樹突狀細胞之頻率增加。
- 如請求項37之用途,其中該等抗原呈遞細胞之該活化之特徵在於樹突狀細胞上CD80及CD86之表現升高。
- 如請求項31之用途,其中該個體中IL-10及/或IL-8之血清濃度比投與該抗PD-1抗體及該MEK抑制劑之前降低。
- 如請求項31之用途,其中該癌症之T細胞浸潤程度升高。
- 如請求項28至30中任一項之用途,其中該癌細胞表面上之PD-L1被 抑制信號轉導至細胞內途徑。
- 如請求項1至3及28至30中任一項之用途,其中該抗PD-1抗體能夠抑制PD-1與PD-L1之間之結合、PD-1與PD-L2之間之結合,或PD-1與PD-L1及PD-L2二者之間之結合。
- 如請求項1至3及28至30中任一項之用途,其中該抗PD-1抗體係單株抗體。
- 如請求項1至3及28至30中任一項之用途,其中該抗PD-1抗體係選自由以下組成之群之抗體片段:Fab、Fab'-SH、Fv、scFv及(Fab')2片段。
- 如請求項1至3及28至30中任一項之用途,其中該抗PD-1抗體係人類化抗體。
- 如請求項1至3及28至30中任一項之用途,其中該抗PD-1抗體係人類抗體。
- 如請求項1至3及28至30中任一項之用途,其中該抗PD-1抗體包含含有SEQ ID NO:22之胺基酸序列之重鏈可變區及含有SEQ ID NO:23之胺基酸序列之輕鏈可變區。
- 如請求項1至3及28至30中任一項之用途,其中該抗PD-1抗體係經以 下方式投與:經靜脈內、經肌內、經皮下、經局部、經口、經皮、經腹膜內、經眶內、藉由植入、藉由吸入、經鞘內、經心室內或經鼻內。
- 如請求項1至3、28至30及56至58中任一項之用途,其中該抗PD-1抗體係MDX-1106。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161574406P | 2011-08-01 | 2011-08-01 | |
US61/574,406 | 2011-08-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW202216199A TW202216199A (zh) | 2022-05-01 |
TWI835048B true TWI835048B (zh) | 2024-03-11 |
Family
ID=46717934
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW109132965A TW202114735A (zh) | 2011-08-01 | 2012-08-01 | 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法 |
TW101127823A TWI654994B (zh) | 2011-08-01 | 2012-08-01 | 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法 |
TW111100455A TWI835048B (zh) | 2011-08-01 | 2012-08-01 | 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法 |
TW107113740A TW201840336A (zh) | 2011-08-01 | 2012-08-01 | 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW109132965A TW202114735A (zh) | 2011-08-01 | 2012-08-01 | 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法 |
TW101127823A TWI654994B (zh) | 2011-08-01 | 2012-08-01 | 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW107113740A TW201840336A (zh) | 2011-08-01 | 2012-08-01 | 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法 |
Country Status (27)
Country | Link |
---|---|
US (2) | US9724413B2 (zh) |
EP (1) | EP2739358B1 (zh) |
JP (3) | JP6238459B2 (zh) |
KR (2) | KR102049817B1 (zh) |
CN (1) | CN103842030B (zh) |
AR (2) | AR087405A1 (zh) |
AU (4) | AU2012290121B2 (zh) |
BR (2) | BR122022000334B1 (zh) |
CA (1) | CA2843595C (zh) |
CO (1) | CO6900118A2 (zh) |
CR (1) | CR20140034A (zh) |
EA (1) | EA026924B1 (zh) |
EC (1) | ECSP14013223A (zh) |
ES (1) | ES2708669T3 (zh) |
IL (2) | IL230647B (zh) |
MA (1) | MA35366B1 (zh) |
MX (2) | MX368257B (zh) |
MY (2) | MY170117A (zh) |
PE (2) | PE20141693A1 (zh) |
PH (1) | PH12018500365A1 (zh) |
PL (1) | PL2739358T3 (zh) |
SG (1) | SG10201606284UA (zh) |
TR (1) | TR201820873T4 (zh) |
TW (4) | TW202114735A (zh) |
UA (1) | UA117220C2 (zh) |
WO (1) | WO2013019906A1 (zh) |
ZA (1) | ZA201400612B (zh) |
Families Citing this family (353)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1539228B1 (en) | 2002-09-11 | 2010-12-29 | Genentech, Inc. | Novel composition and methods for the treatment of immune related diseases |
US20090258013A1 (en) | 2008-04-09 | 2009-10-15 | Genentech, Inc. | Novel compositions and methods for the treatment of immune related diseases |
DK2853269T3 (da) | 2008-05-19 | 2019-08-05 | Advaxis Inc | Dobbelt indgivelsessystem til heterologe antigener, der omfatter en rekombinant Listeria-stamme svækket ved mutation af dal/dat og deletion af ActA, der omfatter et nukleinsyremolekyle, der koder for et listeriolysin O-prostataspecifikt antigenfusionsprotein |
US9017660B2 (en) | 2009-11-11 | 2015-04-28 | Advaxis, Inc. | Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors |
US9650639B2 (en) | 2008-05-19 | 2017-05-16 | Advaxis, Inc. | Dual delivery system for heterologous antigens |
KR20210060670A (ko) | 2008-12-09 | 2021-05-26 | 제넨테크, 인크. | 항-pd-l1 항체 및 t 세포 기능을 향상시키기 위한 그의 용도 |
US10016617B2 (en) | 2009-11-11 | 2018-07-10 | The Trustees Of The University Of Pennsylvania | Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers |
CN103282048B (zh) | 2010-10-01 | 2017-05-17 | 宾夕法尼亚大学理事会 | 李斯特菌疫苗载体用于在寄生虫感染的个体中扭转免疫无应答的用途 |
CN103687611A (zh) | 2011-03-11 | 2014-03-26 | 阿德瓦希斯公司 | 基于李斯特菌属的佐剂 |
WO2012135571A1 (en) | 2011-04-01 | 2012-10-04 | Curis, Inc. | Phosphoinositide 3-kinase inhibitor with a zinc binding moiety |
EP2714937B1 (en) | 2011-06-03 | 2018-11-14 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
PE20141693A1 (es) | 2011-08-01 | 2014-11-24 | Genentech Inc | Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1e inhibidores de mek |
CN104427992B (zh) | 2012-01-25 | 2017-12-19 | 德那翠丝有限公司 | 生物标志物及使用溶瘤病毒和免疫调节剂的组合疗法 |
KR20140134695A (ko) | 2012-03-12 | 2014-11-24 | 어드박시스, 인크. | 리스테리아 백신 치료 후 억제 세포 기능 저해 |
CN112587671A (zh) * | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
US9682143B2 (en) | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
US20150231241A1 (en) | 2012-08-14 | 2015-08-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
KR20150127203A (ko) * | 2013-03-14 | 2015-11-16 | 제넨테크, 인크. | Mek 억제제 화합물과 her3/egfr 억제제 화합물의 조합물 및 사용 방법 |
US9302005B2 (en) | 2013-03-14 | 2016-04-05 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
WO2014151006A2 (en) * | 2013-03-15 | 2014-09-25 | Genentech, Inc. | Biomarkers and methods of treating pd-1 and pd-l1 related conditions |
CA2899577C (en) * | 2013-04-03 | 2023-10-17 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
JP6720075B2 (ja) * | 2013-05-31 | 2020-07-08 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | 癌のための併用療法 |
MA38643A1 (fr) | 2013-06-03 | 2017-10-31 | Novartis Ag | Combinaisons d'un anticorps anti-pd-l1 et d'un inhibiteur de mek et/ou d'un inhibiteur de braf |
WO2014204856A1 (en) * | 2013-06-17 | 2014-12-24 | Catabasis Pharmaceuticals, Inc. | Fatty acid anticancer derivatives and their uses |
ES2819209T3 (es) * | 2013-07-16 | 2021-04-15 | Hoffmann La Roche | Procedimientos de tratamiento del cáncer usando antagonistas de unión al eje de PD-1 e inhibidores de TIGIT |
AR097279A1 (es) | 2013-08-09 | 2016-03-02 | Actelion Pharmaceuticals Ltd | Derivados de benzimidazolil-metil urea como agonistas del receptor de alx |
WO2015026634A1 (en) | 2013-08-20 | 2015-02-26 | Merck Sharp & Dohme Corp. | Treating cancer with a combination of a pd-1 antagonist and dinaciclib |
AR097306A1 (es) | 2013-08-20 | 2016-03-02 | Merck Sharp & Dohme | Modulación de la inmunidad tumoral |
AR097584A1 (es) | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano |
PT3702373T (pt) * | 2013-09-13 | 2022-09-27 | Beigene Switzerland Gmbh | Anticorpos anti-pd1 e a sua utilização como agentes terapêuticos e de diagnóstico |
WO2015048312A1 (en) * | 2013-09-26 | 2015-04-02 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
BR112016006397B1 (pt) * | 2013-09-27 | 2024-01-16 | Genentech, Inc | Formulações de anticorpo de anti-pdl1, seu uso, artigo de fabricação e composição |
ES2714708T3 (es) | 2013-10-01 | 2019-05-29 | Mayo Found Medical Education & Res | Procedimientos para el tratamiento de cáncer en pacientes con niveles elevados de Bim |
WO2015088930A1 (en) * | 2013-12-10 | 2015-06-18 | Merck Sharp & Dohme Corp. | Immunohistochemical proximity assay for pd-1 positive cells and pd-ligand positive cells in tumor tissue |
JP6502959B2 (ja) | 2013-12-12 | 2019-04-17 | 上海恒瑞医薬有限公司 | Pd−1抗体、その抗原結合性断片及びそれらの医学的使用 |
AU2014364606A1 (en) * | 2013-12-17 | 2016-07-07 | Genentech, Inc. | Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists |
CA2933881A1 (en) * | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody |
WO2015094992A1 (en) | 2013-12-17 | 2015-06-25 | Merck Sharp & Dohme Corp. | Ifn-gamma gene signature biomarkers of tumor response to pd-1 antagonists |
EP3083692B1 (en) | 2013-12-17 | 2020-02-19 | F.Hoffmann-La Roche Ag | Methods of treating her2-positive cancers using pd-1 axis binding antagonists and anti-her2 antibodies |
EP3092255A4 (en) | 2014-01-10 | 2017-09-20 | Birdie Biopharmaceuticals Inc. | Compounds and compositions for treating egfr expressing tumors |
TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對pd-1的人類抗體 |
TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗pd-l1之人類抗體 |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
SG11201606428UA (en) | 2014-02-04 | 2016-09-29 | Incyte Corp | Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer |
MX2016010082A (es) | 2014-02-04 | 2016-10-07 | Pfizer | Combinacion de un antagonista de proteina de muerte programada 1 (pd-1) y un inhibidor del receptor del factor de crecimiento endotelial vascular (vegfr) para tratar cancer. |
ES2783026T3 (es) | 2014-02-04 | 2020-09-16 | Pfizer | Combinación de un antagonista de PD-1 y un agonista de 4-1BB para el tratamiento de cáncer |
JP6731346B2 (ja) * | 2014-02-10 | 2020-07-29 | メルク パテント ゲーエムベーハー | 標的TGFβ阻害 |
US20150259420A1 (en) | 2014-03-14 | 2015-09-17 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
WO2015148683A1 (en) * | 2014-03-26 | 2015-10-01 | Tocagen Inc. | A retroviral vector having immune-stimulating activity |
RU2016142476A (ru) | 2014-03-31 | 2018-05-07 | Дженентек, Инк. | Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40 |
US10302653B2 (en) | 2014-05-22 | 2019-05-28 | Mayo Foundation For Medical Education And Research | Distinguishing antagonistic and agonistic anti B7-H1 antibodies |
KR20170005492A (ko) | 2014-05-28 | 2017-01-13 | 아이데닉스 파마슈티칼스 엘엘씨 | 암의 치료를 위한 뉴클레오시드 유도체 |
EP3610924B1 (en) | 2014-06-06 | 2021-11-03 | Bristol-Myers Squibb Company | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof |
KR102130600B1 (ko) | 2014-07-03 | 2020-07-08 | 베이진 엘티디 | Pd-l1 항체와 이를 이용한 치료 및 진단 |
JP6760919B2 (ja) | 2014-07-09 | 2020-09-23 | バーディー バイオファーマシューティカルズ インコーポレイテッド | 腫瘍を治療するための抗pd−l1組み合わせ |
MX2017000419A (es) | 2014-07-11 | 2017-08-16 | Genentech Inc | Anticuerpos anti-pd-l1 y sus usos de diagnóstico. |
BR112017000672A2 (pt) * | 2014-07-15 | 2017-11-14 | Genentech Inc | composições para tratamento de câncer utilizando antagonistas de ligação de eixo pd-1 e inibidores de mek |
CA2955612C (en) | 2014-07-18 | 2022-05-17 | Advaxis, Inc. | Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancer |
NZ766356A (en) | 2014-07-22 | 2024-02-23 | Cb Therapeutics Inc | Anti-pd-1 antibodies |
US10517875B2 (en) | 2014-07-23 | 2019-12-31 | Mayo Foundation for Medical Engineering and Research | Targeting DNA-PKcs and B7-H1 to treat cancer |
SG11201700672YA (en) | 2014-08-05 | 2017-02-27 | MabQuest SA | Immunological reagents binding to pd-1 |
US9982052B2 (en) | 2014-08-05 | 2018-05-29 | MabQuest, SA | Immunological reagents |
NZ766660A (en) | 2014-08-05 | 2024-02-23 | Cb Therapeutics Inc | Anti-pd-l1 antibodies |
PT3177640T (pt) | 2014-08-08 | 2020-08-31 | Univ Leland Stanford Junior | Agentes pd-1 de alta afinidade e métodos de utilização |
CR20170096A (es) | 2014-08-12 | 2017-06-15 | Alligator Bioscience Ab | Tratamientos conjuntos con anticuerpos anti cd40 |
EP3070102A1 (en) * | 2015-03-18 | 2016-09-21 | F. Hoffmann-La Roche AG | Combination therapy of antibodies human cd40 activating antibodies and anti human pld-1 antibodies |
JP6586454B2 (ja) * | 2014-08-14 | 2019-10-02 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ヒトcd40を活性化する抗体とヒトpd−l1に対する抗体との併用療法 |
US10695426B2 (en) | 2014-08-25 | 2020-06-30 | Pfizer Inc. | Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer |
IL302218B1 (en) | 2014-08-28 | 2024-06-01 | Eisai R&D Man Co Ltd | Methods for the production of lanvotinib and its derivatives in a high degree of purity |
WO2016033555A1 (en) | 2014-08-28 | 2016-03-03 | Halozyme, Inc. | Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor |
CN112587672A (zh) * | 2014-09-01 | 2021-04-02 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-pd-l1结合物 |
US9535074B2 (en) | 2014-09-08 | 2017-01-03 | Merck Sharp & Dohme Corp. | Immunoassay for soluble PD-L1 |
RU2718914C2 (ru) | 2014-09-13 | 2020-04-15 | Новартис Аг | Сочетанные способы лечения с использованием ингибиторов alk |
EP3194440A1 (en) * | 2014-09-15 | 2017-07-26 | F. Hoffmann-La Roche AG | Methods of treating cancer using pd-1 axis binding antagonist and il-17 binding antagonists |
ES2825576T3 (es) | 2014-09-16 | 2021-05-17 | Innate Pharma | Neutralización de rutas inhibidoras en linfocitos |
ES2774448T3 (es) | 2014-10-03 | 2020-07-21 | Novartis Ag | Terapias de combinación |
MX2017004708A (es) | 2014-10-10 | 2017-10-12 | Idera Pharmaceuticals Inc | Tratamiento del cáncer con agonista de tlr9 con inhibidores de punto de control. |
RU2746804C2 (ru) | 2014-10-10 | 2021-04-21 | Иннейт Фарма | Блокада cd73 |
CR20170143A (es) | 2014-10-14 | 2017-06-19 | Dana Farber Cancer Inst Inc | Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas |
PL3207130T3 (pl) | 2014-10-14 | 2020-02-28 | Halozyme, Inc. | Kompozycje deaminazy adenozyny 2 (ada2), jej warianty i sposoby ich zastosowania |
EP3221360A1 (en) * | 2014-11-17 | 2017-09-27 | F. Hoffmann-La Roche AG | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
AU2015348657B2 (en) * | 2014-11-20 | 2021-06-10 | F. Hoffmann-La Roche Ag | Combination therapy of T cell activating bispecific antigen binding molecules CD3 ABD folate receptor 1 (FolRl) and PD-1 axis binding antagonists |
CN105669862A (zh) * | 2014-11-21 | 2016-06-15 | 上海中信国健药业股份有限公司 | 抗人pd-l1/kir双特异性抗体及其制备方法和应用 |
EP3226856A4 (en) * | 2014-12-02 | 2018-07-11 | Celgene Corporation | Combination therapies |
JP2017537929A (ja) * | 2014-12-05 | 2017-12-21 | ジェネンテック, インコーポレイテッド | Pd−1軸アンタゴニスト及びhpk1アンタゴニストを用いたがん治療のための方法及び組成物 |
EP3226688B1 (en) | 2014-12-05 | 2020-07-01 | Merck Sharp & Dohme Corp. | Tricyclic compounds as inhibitors of mutant idh enzymes |
US10086000B2 (en) | 2014-12-05 | 2018-10-02 | Merck Sharp & Dohme Corp. | Tricyclic compounds as inhibitors of mutant IDH enzymes |
WO2016089830A1 (en) | 2014-12-05 | 2016-06-09 | Merck Sharp & Dohme Corp. | Novel tricyclic compounds as inhibitors of mutant idh enzymes |
WO2016094377A1 (en) | 2014-12-09 | 2016-06-16 | Merck Sharp & Dohme Corp. | System and methods for deriving gene signature biomarkers of response to pd-1 antagonists |
WO2016100882A1 (en) | 2014-12-19 | 2016-06-23 | Novartis Ag | Combination therapies |
WO2016106160A1 (en) * | 2014-12-22 | 2016-06-30 | Enumeral Biomedical Holdings, Inc. | Methods for screening therapeutic compounds |
CN107208138A (zh) * | 2014-12-30 | 2017-09-26 | 豪夫迈·罗氏有限公司 | 用于癌症预后和治疗的方法和组合物 |
JP2016155776A (ja) * | 2015-02-24 | 2016-09-01 | 学校法人兵庫医科大学 | 抗腫瘍効果増強剤および抗腫瘍剤 |
DK3263106T3 (da) | 2015-02-25 | 2024-01-08 | Eisai R&D Man Co Ltd | Fremgangsmåde til undertrykkelse af bitterhed af quinolinderivat |
IL278423B2 (en) | 2015-02-26 | 2024-04-01 | Merck Patent Gmbh | Fidi-1 / Fidi-AL1 inhibitors for cancer treatment |
AU2015384801B2 (en) | 2015-03-04 | 2022-01-06 | Eisai R&D Management Co., Ltd. | Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer |
WO2016141209A1 (en) | 2015-03-04 | 2016-09-09 | Merck Sharp & Dohme Corp. | Combination of a pd-1 antagonist and eribulin for treating cancer |
SG11201707383PA (en) | 2015-03-13 | 2017-10-30 | Cytomx Therapeutics Inc | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof |
US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
EP3283882B1 (en) | 2015-04-17 | 2020-12-16 | Merck Sharp & Dohme Corp. | Blood-based biomarkers of tumor sensitivity to pd-1 antagonists |
AU2016252038B2 (en) * | 2015-04-20 | 2021-08-12 | Effector Therapeutics, Inc. | Inhibitors of immune checkpoint modulators for use in treating cancer and infections |
US20180134771A1 (en) * | 2015-05-07 | 2018-05-17 | Bioxcel Corporation | Novel immunomodulatory therapeutic strategies targeting tumors in cancer |
EP3297674B1 (en) * | 2015-05-22 | 2023-01-04 | Translational Drug Development Llc | Benzamide and active compound compositions and methods of use |
WO2016189055A1 (en) | 2015-05-27 | 2016-12-01 | Idenix Pharmaceuticals Llc | Nucleotides for the treatment of cancer |
JP6884111B2 (ja) * | 2015-05-29 | 2021-06-09 | ジェネンテック, インコーポレイテッド | 癌におけるpd−l1プロモーターのメチル化 |
EP3892284B1 (en) | 2015-05-29 | 2024-05-22 | Merck Sharp & Dohme LLC | Combination of a pd-1 antagonist and a cpg-c type oligonucleotide for treating cancer |
CN107849096B (zh) | 2015-05-30 | 2022-05-24 | 分子模板公司 | 去免疫化的志贺毒素a亚基支架和包含它们的细胞靶向分子 |
AU2016271101B2 (en) * | 2015-05-31 | 2021-04-01 | Curegenix Corporation | Combination compositions for immunotherapy |
EP3311841B1 (en) | 2015-06-16 | 2021-07-28 | PRISM BioLab Co., Ltd. | Anticancer agent |
WO2016205277A1 (en) | 2015-06-16 | 2016-12-22 | Merck Patent Gmbh | Pd-l1 antagonist combination treatments |
JP6996983B2 (ja) | 2015-06-16 | 2022-02-21 | ジェネンテック, インコーポレイテッド | 抗cll-1抗体及び使用方法 |
KR20180018538A (ko) * | 2015-06-17 | 2018-02-21 | 제넨테크, 인크. | Pd-1 축 결합 길항제 및 탁산을 사용하여 국소적 진행성 또는 전이성 유방암을 치료하는 방법 |
GB201511790D0 (en) | 2015-07-06 | 2015-08-19 | Iomet Pharma Ltd | Pharmaceutical compound |
EP3322987B1 (en) * | 2015-07-13 | 2021-09-08 | Biodesix, Inc. | Predictive test for melanoma patient benefit from pd-1 antibody drug and classifier development methods |
CN108368170B (zh) | 2015-07-13 | 2022-04-15 | 西托姆克斯治疗公司 | 抗pd-1抗体、可活化抗pd-1抗体及其使用方法 |
CN108136025B (zh) | 2015-07-16 | 2022-09-06 | 比奥克斯塞尔医疗股份有限公司 | 一种使用免疫调节治疗癌症的新颖方法 |
MX2017016844A (es) | 2015-07-16 | 2018-08-15 | Biokine Therapeutics Ltd | Composiciones y procedimientos para tratar cancer. |
DK3317301T3 (da) | 2015-07-29 | 2021-06-28 | Immutep Sas | Kombinationsterapier omfattende antistofmolekyler mod lag-3 |
EP4378957A2 (en) | 2015-07-29 | 2024-06-05 | Novartis AG | Combination therapies comprising antibody molecules to pd-1 |
WO2017019897A1 (en) | 2015-07-29 | 2017-02-02 | Novartis Ag | Combination therapies comprising antibody molecules to tim-3 |
WO2017024465A1 (en) * | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
WO2017027645A1 (en) | 2015-08-13 | 2017-02-16 | Merck Sharp & Dohme Corp. | Cyclic di-nucleotide compounds as sting agonists |
US11453697B1 (en) | 2015-08-13 | 2022-09-27 | Merck Sharp & Dohme Llc | Cyclic di-nucleotide compounds as sting agonists |
CN108348571B (zh) | 2015-09-03 | 2022-03-22 | 艾瑞朗医疗公司 | 拟肽大环化合物及其用途 |
MX2018003633A (es) | 2015-09-25 | 2018-08-01 | Genentech Inc | Anticuerpos anti-tigit y metodos de uso. |
AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
CN108602887B (zh) | 2015-10-02 | 2022-06-21 | 豪夫迈·罗氏有限公司 | 对共刺激性tnf受体特异性的双特异性抗体 |
RU2731202C2 (ru) | 2015-10-08 | 2020-08-31 | Макродженикс, Инк. | Комбинированная терапия для лечения рака |
US11130817B2 (en) | 2015-10-12 | 2021-09-28 | Innate Pharma | CD73 blocking agents |
WO2017075045A2 (en) | 2015-10-30 | 2017-05-04 | Mayo Foundation For Medical Education And Research | Antibodies to b7-h1 |
TW201722985A (zh) | 2015-11-02 | 2017-07-01 | 戊瑞治療有限公司 | Cd80胞外域多肽及其用於癌症治療 |
EP3370768B9 (en) | 2015-11-03 | 2022-03-16 | Janssen Biotech, Inc. | Antibodies specifically binding pd-1 and their uses |
CA3006930A1 (en) | 2015-12-03 | 2017-06-08 | Glaxosmithkline Intellectual Property Development Limited | Cyclic purine dinucleotides as modulators of sting |
WO2017098421A1 (en) | 2015-12-08 | 2017-06-15 | Glaxosmithkline Intellectual Property Development Limited | Benzothiadiazine compounds |
WO2017106062A1 (en) | 2015-12-15 | 2017-06-22 | Merck Sharp & Dohme Corp. | Novel compounds as indoleamine 2,3-dioxygenase inhibitors |
CN108495651A (zh) | 2015-12-17 | 2018-09-04 | 诺华股份有限公司 | 抗pd-1的抗体分子及其用途 |
GB201522309D0 (en) | 2015-12-17 | 2016-02-03 | Photocure Asa | Use |
GB201522311D0 (en) | 2015-12-17 | 2016-02-03 | Photocure Asa | Use |
CN106943596A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技(北京)有限公司 | 用于治疗肿瘤的抗-cd20组合 |
CN106943597A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技(北京)有限公司 | 用于治疗肿瘤的抗-egfr组合 |
CN106943598A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技(北京)有限公司 | 用于治疗肿瘤的抗-her2组合 |
KR20180097615A (ko) * | 2016-01-08 | 2018-08-31 | 에프. 호프만-라 로슈 아게 | Pd-1 축 결합 길항물질 및 항-cea/항-cd3 이중특이성 항체를 사용하는 cea-양성 암의 치료 방법 |
EP3405495B1 (en) | 2016-01-21 | 2021-02-24 | Innate Pharma | Neutralization of inhibitory pathways in lymphocytes |
EP3964529A1 (en) | 2016-01-22 | 2022-03-09 | Mabquest SA | Non-blocking pd1 specific antibodies |
US11214617B2 (en) | 2016-01-22 | 2022-01-04 | MabQuest SA | Immunological reagents |
US11710539B2 (en) | 2016-02-01 | 2023-07-25 | Biodesix, Inc. | Predictive test for melanoma patient benefit from interleukin-2 (IL2) therapy |
EP3426688A1 (en) | 2016-03-08 | 2019-01-16 | Innate Pharma | Siglec neutralizing antibodies |
WO2017153952A1 (en) | 2016-03-10 | 2017-09-14 | Glaxosmithkline Intellectual Property Development Limited | 5-sulfamoyl-2-hydroxybenzamide derivatives |
WO2017160599A1 (en) | 2016-03-14 | 2017-09-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of cd300b antagonists to treat sepsis and septic shock |
JP7137474B2 (ja) | 2016-03-15 | 2022-09-14 | メルサナ セラピューティクス,インコーポレイティド | NaPi2b標的化抗体-薬物コンジュゲート及びその使用方法 |
CA3016552A1 (en) * | 2016-03-15 | 2017-09-21 | Genentech, Inc. | Methods of treating cancers using pd-1 axis binding antagonists and anti-gpc3 antibodies |
WO2017165742A1 (en) | 2016-03-24 | 2017-09-28 | Millennium Pharmaceuticals, Inc. | Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments |
EP3433275A1 (en) | 2016-03-24 | 2019-01-30 | Millennium Pharmaceuticals, Inc. | Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments |
WO2017167921A1 (en) | 2016-03-30 | 2017-10-05 | Centre Léon-Bérard | Lymphocytes expressing cd73 in cancerous patient dictates therapy |
CN109608443B (zh) | 2016-04-07 | 2021-09-07 | 葛兰素史密斯克莱知识产权发展有限公司 | 用作蛋白质调节剂的杂环酰胺 |
EA201892128A1 (ru) | 2016-04-07 | 2019-04-30 | Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Гетероциклические амиды, полезные в качестве модуляторов |
RU2754452C2 (ru) | 2016-04-12 | 2021-09-02 | Эли Лилли Энд Компани | Комбинированная терапия ингибиторами notch и pi3k/mtor для применения в лечении рака |
AU2017248766A1 (en) | 2016-04-15 | 2018-11-01 | Genentech, Inc. | Methods for monitoring and treating cancer |
JP2019515035A (ja) * | 2016-04-27 | 2019-06-06 | ミラ ディーエックス, インコーポレイテッド | Krasバリアントがん患者の免疫ベースの処置 |
WO2017192874A1 (en) | 2016-05-04 | 2017-11-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Albumin-binding immunomodulatory compositions and methods of use thereof |
CA3023157A1 (en) | 2016-05-05 | 2017-11-09 | Glaxosmithkline Intellectual Property (No.2) Limited | Enhancer of zeste homolog 2 inhibitors |
TWI786044B (zh) | 2016-05-13 | 2022-12-11 | 美商再生元醫藥公司 | 藉由投予pd-1抑制劑治療皮膚癌之方法 |
AU2017268187A1 (en) * | 2016-05-20 | 2018-11-29 | Eli Lilly And Company | Combination therapy with notch and PD-1 or PD-L1 inhibitors |
US10851053B2 (en) | 2016-06-08 | 2020-12-01 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds |
AU2017279029A1 (en) | 2016-06-08 | 2018-12-20 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds as ATF4 pathway inhibitors |
CN109475536B (zh) | 2016-07-05 | 2022-05-27 | 百济神州有限公司 | 用于治疗癌症的PD-l拮抗剂和RAF抑制剂的组合 |
EP3487503A1 (en) | 2016-07-20 | 2019-05-29 | GlaxoSmithKline Intellectual Property Development Limited | Isoquinoline derivatives as perk inhibitors |
WO2018014260A1 (en) | 2016-07-20 | 2018-01-25 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
WO2018029124A1 (en) * | 2016-08-08 | 2018-02-15 | F. Hoffmann-La Roche Ag | Therapeutic and diagnostic methods for cancer |
US11701357B2 (en) | 2016-08-19 | 2023-07-18 | Beigene Switzerland Gmbh | Treatment of B cell cancers using a combination comprising Btk inhibitors |
CN109790220A (zh) | 2016-08-25 | 2019-05-21 | 豪夫迈·罗氏有限公司 | 与巨噬细胞激活剂组合的抗csf-1r抗体的间歇给药 |
CA3038671A1 (en) * | 2016-09-29 | 2018-04-05 | Genentech, Inc. | Combination therapy with a mek inhibitor, a pd-1 axis inhibitor, and a taxane |
RS62410B1 (sr) | 2016-10-04 | 2021-10-29 | Merck Sharp & Dohme | Benzo[b]tiofenska jedinjenja kao agonisti sting |
AU2017339856A1 (en) | 2016-10-06 | 2019-05-23 | Merck Patent Gmbh | Dosing regimen of avelumab for the treatment of cancer |
WO2018068201A1 (en) | 2016-10-11 | 2018-04-19 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against ctla-4 |
MX2019003994A (es) | 2016-10-14 | 2019-09-19 | Merck Sharp & Dohme | Combinacion de un antagonista de proteina de muerte programada-1 (pd-1) y eribulina para el tratamiento de cancer urotelial. |
EP4295918A3 (en) | 2016-11-02 | 2024-03-20 | Bristol-Myers Squibb Company | Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma |
WO2018089293A2 (en) | 2016-11-08 | 2018-05-17 | Qilu Puget Sound Biotherapeutics Corporation | Anti-pd1 and anti-ctla4 antibodies |
EP3541825A1 (en) | 2016-11-21 | 2019-09-25 | Idenix Pharmaceuticals LLC. | Cyclic phosphate substituted nucleoside derivatives for the treatment of liver diseases |
US11135307B2 (en) | 2016-11-23 | 2021-10-05 | Mersana Therapeutics, Inc. | Peptide-containing linkers for antibody-drug conjugates |
WO2018102536A1 (en) | 2016-11-30 | 2018-06-07 | Oncomed Pharmaceuticals, Inc. | Methods for treatment of cancer comprising tigit-binding agents |
CA3045241A1 (en) | 2016-12-01 | 2018-06-07 | Glaxosmithkline Intellectual Property Development Limited | Combination therapy |
JP2020511407A (ja) | 2016-12-01 | 2020-04-16 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | 併用療法 |
MX2019006331A (es) * | 2016-12-12 | 2019-07-12 | Genentech Inc | Métodos para tratar el cáncer usando anticuerpos anti-pd-l1 y antiandrógenos. |
EP3558360A1 (en) | 2016-12-22 | 2019-10-30 | F. Hoffmann-La Roche AG | Treatment of tumors with an anti-csf-1r antibody in combination with an anti-pd-l1 antibody after failure of anti-pd-l1/pd1 treatment |
CN108239149B (zh) * | 2016-12-25 | 2021-03-05 | 南京传奇生物科技有限公司 | 高亲和力、高特异性、多抗原识别表位的具有更高功能性的抗人pd-l1抗体 |
CN110291105B (zh) | 2017-01-05 | 2024-03-01 | 奈特里斯药物公司 | 导蛋白-1干扰药物和免疫检查点抑制剂药物的组合治疗 |
WO2018129301A1 (en) | 2017-01-05 | 2018-07-12 | Biodesix, Inc. | Method for identification of cancer patients with durable benefit from immunotherapy in overall poor prognosis subgroups |
WO2018137681A1 (en) | 2017-01-25 | 2018-08-02 | Beigene, Ltd. | Crystalline forms of (s) -7- (1- (but-2-ynoyl) piperidin-4-yl) -2- (4-phenoxyphenyl) -4, 5, 6, 7-tetrahy dropyrazolo [1, 5-a] pyrimidine-3-carboxamide, preparation, and uses thereof |
WO2018138684A1 (en) | 2017-01-27 | 2018-08-02 | Janssen Biotech, Inc. | Cyclic dinucleotides as sting agonists |
EP3573718B1 (en) | 2017-01-27 | 2022-06-01 | Janssen Biotech, Inc. | Cyclic dinucleotides as sting agonists |
US20200023071A1 (en) | 2017-02-06 | 2020-01-23 | Innate Pharma | Immunomodulatory antibody drug conjugates binding to a human mica polypeptide |
IL308805A (en) | 2017-02-21 | 2024-01-01 | Regeneron Pharma | Anti-PD-1 antibodies for the treatment of lung cancer |
CN108503691B (zh) * | 2017-02-25 | 2021-07-23 | 复旦大学 | 一种人pd-l1蛋白高亲和性肽及其应用 |
BR112019017738A2 (pt) | 2017-02-27 | 2020-04-07 | Glaxosmithkline Ip Dev Ltd | combinação, composição farmacêutica, uso de uma combinação ou composição farmacêutica, método para tratar câncer em um humano, e, composto |
TW201834697A (zh) | 2017-02-28 | 2018-10-01 | 美商梅爾莎納醫療公司 | Her2標靶抗體-藥物結合物之組合療法 |
US20200150125A1 (en) | 2017-03-12 | 2020-05-14 | Yeda Research And Development Co., Ltd. | Methods of diagnosing and prognosing cancer |
WO2018167780A1 (en) | 2017-03-12 | 2018-09-20 | Yeda Research And Development Co. Ltd. | Methods of prognosing and treating cancer |
MX2019010848A (es) | 2017-03-16 | 2019-10-30 | Innate Pharma | Composiciones y procedimientos para el tratamiento del cancer. |
SG11201909064RA (en) | 2017-03-30 | 2019-10-30 | Merck Patent Gmbh | Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer |
US11603407B2 (en) | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
CN108794467A (zh) | 2017-04-27 | 2018-11-13 | 博笛生物科技有限公司 | 2-氨基-喹啉衍生物 |
WO2018201014A1 (en) | 2017-04-28 | 2018-11-01 | Five Prime Therapeutics, Inc. | Methods of treatment with cd80 extracellular domain polypeptides |
US11466047B2 (en) | 2017-05-12 | 2022-10-11 | Merck Sharp & Dohme Llc | Cyclic di-nucleotide compounds as sting agonists |
EP3625260A1 (en) | 2017-05-16 | 2020-03-25 | Bristol-Myers Squibb Company | Treatment of cancer with anti-gitr agonist antibodies |
JP2020522486A (ja) | 2017-06-01 | 2020-07-30 | サイトメックス セラピューティクス インコーポレイテッド | 活性化可能抗pdl1抗体、およびその使用方法 |
WO2018225093A1 (en) | 2017-06-07 | 2018-12-13 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds as atf4 pathway inhibitors |
JP2020523018A (ja) | 2017-06-09 | 2020-08-06 | プロビデンス ヘルス アンド サービシーズ−オレゴン | がんの処置のための腫瘍反応性ヒトt細胞の同定のためのcd39およびcd103の使用 |
WO2018225033A1 (en) | 2017-06-09 | 2018-12-13 | Glaxosmithkline Intellectual Property Development Limited | Combination therapy |
WO2018232725A1 (en) | 2017-06-23 | 2018-12-27 | Birdie Biopharmaceuticals, Inc. | PHARMACEUTICAL COMPOSITIONS |
CA3066518A1 (en) | 2017-06-26 | 2019-01-03 | Beigene, Ltd. | Immunotherapy for hepatocellular carcinoma |
CN110896634A (zh) | 2017-07-03 | 2020-03-20 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为atf4抑制剂用于治疗癌症和其它疾病的2-(4-氯苯氧基)-n-((1-(2-(4-氯苯氧基)乙炔氮杂环丁烷-3-基)甲基)乙酰胺衍生物和相关化合物 |
JP2020525513A (ja) | 2017-07-03 | 2020-08-27 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | 癌および他の疾患を治療するためのatf4阻害剤としてのn−(3−(2−(4−クロロフェノキシ)アセトアミドビシクロ[1.1.1]ペンタン−1−イル)−2−シクロブタン−1−カルボキサミド誘導体および関連化合物 |
EP3652208A1 (en) | 2017-07-10 | 2020-05-20 | Innate Pharma | Siglec-9-neutralizing antibodies |
WO2019016174A1 (en) | 2017-07-18 | 2019-01-24 | Institut Gustave Roussy | METHOD FOR ASSESSING RESPONSE TO TARGETING DRUG PD-1 / PDL-1 MEDICINES |
WO2019021208A1 (en) | 2017-07-27 | 2019-01-31 | Glaxosmithkline Intellectual Property Development Limited | USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS |
EP3661498A4 (en) | 2017-08-04 | 2021-04-21 | Merck Sharp & Dohme Corp. | BENZO [B] THIOPHEN STING ANTAGONISTS FOR CANCER TREATMENT |
US11312772B2 (en) | 2017-08-04 | 2022-04-26 | Merck Sharp & Dohme Corp. | Combinations of PD-1 antagonists and benzo [b] thiophene STING agonists for cancer treatment |
TW201922721A (zh) | 2017-09-07 | 2019-06-16 | 英商葛蘭素史克智慧財產發展有限公司 | 化學化合物 |
WO2019053617A1 (en) | 2017-09-12 | 2019-03-21 | Glaxosmithkline Intellectual Property Development Limited | CHEMICAL COMPOUNDS |
BR112020006780A2 (pt) | 2017-10-05 | 2020-10-06 | Glaxosmithkline Intellectual Property Development Limited | moduladores do estimulador de genes do interferon (sting) |
TW201927771A (zh) | 2017-10-05 | 2019-07-16 | 英商葛蘭素史密斯克藍智慧財產發展有限公司 | 可作為蛋白質調節劑之雜環醯胺及其使用方法 |
CN111542539B (zh) | 2017-10-06 | 2023-10-20 | 先天制药公司 | 通过cd39/cd73轴恢复t细胞活性 |
CN109663130B (zh) * | 2017-10-13 | 2021-06-29 | 江苏恒瑞医药股份有限公司 | Pd-1抗体和mek抑制剂联合在制备治疗肿瘤的药物中的用途 |
SG11202003486UA (en) | 2017-10-19 | 2020-05-28 | Debiopharm Int Sa | Combination product for the treatment of cancer |
EP3703692A4 (en) | 2017-11-01 | 2021-04-28 | Merck Sharp & Dohme Corp. | NEW SUBSTITUTED TETRAHYDROQUINOLINE COMPOUNDS USED AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS |
TWI815829B (zh) | 2017-11-14 | 2023-09-21 | 美商默沙東有限責任公司 | 作為吲哚胺2,3-二氧酶(ido)抑制劑之新穎經取代二芳基化合物 |
US11498904B2 (en) | 2017-11-14 | 2022-11-15 | Merck Sharp & Dohme Llc | Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors |
WO2019099838A1 (en) | 2017-11-16 | 2019-05-23 | Novartis Ag | Combination therapies |
WO2019104289A1 (en) | 2017-11-27 | 2019-05-31 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepine antibody conjugates |
CN111801334B (zh) | 2017-11-29 | 2023-06-09 | 百济神州瑞士有限责任公司 | 使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤 |
CN108165536A (zh) * | 2017-12-11 | 2018-06-15 | 浙江大学 | 一种重组溶瘤痘苗病毒及其制备方法与应用 |
ES2927194T3 (es) | 2017-12-15 | 2022-11-03 | Janssen Biotech Inc | Dinucleótidos cíclicos como agonistas de STING |
EP3727401A4 (en) | 2017-12-20 | 2022-04-06 | Merck Sharp & Dohme Corp. | CYCLIC DINUCLEOTIDE COMPOUNDS USED AS STING AGONISTS |
WO2019126691A1 (en) | 2017-12-21 | 2019-06-27 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepine antibody conjugates |
CA3082280A1 (en) | 2017-12-28 | 2019-07-04 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against tigit |
KR20200106921A (ko) * | 2018-01-10 | 2020-09-15 | 어레이 바이오파마 인크. | 암을 치료하기 위한 방법 및 조합 요법 |
WO2019137541A1 (en) | 2018-01-15 | 2019-07-18 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against pd-1 |
KR20200128014A (ko) | 2018-01-31 | 2020-11-11 | 셀진 코포레이션 | 입양 세포 요법 및 체크포인트 억제제를 이용한 병용 요법 |
US20210353614A1 (en) | 2018-03-14 | 2021-11-18 | Merck Patent Gmbh | Compounds and uses thereof to treat tumors in a subject |
US10793557B2 (en) | 2018-04-03 | 2020-10-06 | Merck Sharp & Dohme Corp. | Sting agonist compounds |
US11702430B2 (en) | 2018-04-03 | 2023-07-18 | Merck Sharp & Dohme Llc | Aza-benzothiophene compounds as STING agonists |
WO2019193541A1 (en) | 2018-04-06 | 2019-10-10 | Glaxosmithkline Intellectual Property Development Limited | Bicyclic aromatic ring derivatives of formula (i) as atf4 inhibitors |
WO2019193540A1 (en) | 2018-04-06 | 2019-10-10 | Glaxosmithkline Intellectual Property Development Limited | Heteroaryl derivatives of formula (i) as atf4 inhibitors |
US11542505B1 (en) | 2018-04-20 | 2023-01-03 | Merck Sharp & Dohme Llc | Substituted RIG-I agonists: compositions and methods thereof |
CA3099079A1 (en) | 2018-05-04 | 2019-11-07 | Merck Patent Gmbh | Combined inhibition of pd-1/pd-l1, tgf.beta. and dna-pk for the treatment of cancer |
RU2020136057A (ru) | 2018-05-04 | 2022-05-04 | Толлиз | Лиганды tlr3, которые активируют как эпителиальные, так и миелоидные клетки |
KR20210005617A (ko) * | 2018-05-07 | 2021-01-14 | 젠맵 에이/에스 | 항-pd-1 항체와 항-조직 인자 항체-약물 접합체의 조합을 사용하여 암을 치료하는 방법 |
GB201807924D0 (en) | 2018-05-16 | 2018-06-27 | Ctxt Pty Ltd | Compounds |
MA52777A (fr) | 2018-05-24 | 2021-04-14 | Janssen Biotech Inc | Agents de liaison psma et utilisations correspondantes |
EP3810109A4 (en) | 2018-05-31 | 2022-03-16 | Peloton Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR INHIBITING CD73 |
EP3810116B1 (en) | 2018-05-31 | 2023-11-15 | Merck Sharp & Dohme LLC | Novel substituted [1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors |
KR20210029158A (ko) | 2018-06-03 | 2021-03-15 | 람카프 바이오 베타 엘티디. | Ceacam5 및 cd47에 대한 이중특이성 항체 |
CN111867630B (zh) | 2018-06-17 | 2023-10-13 | 上海健信生物医药科技有限公司 | 靶向cldn18.2的抗体、双特异性抗体、adc和car及其应用 |
SG11202012435UA (en) | 2018-06-18 | 2021-01-28 | Innate Pharma | Compositions and methods for treating cancer |
EP3819313A4 (en) | 2018-07-03 | 2021-09-01 | L&L Biopharma Co., Ltd. | BISPECIFIC ANTIBODIES AND ITS USE |
JP2021528988A (ja) * | 2018-07-04 | 2021-10-28 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 新規の二重特異性アゴニスト4−1bb抗原結合分子 |
US20210253528A1 (en) | 2018-07-09 | 2021-08-19 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds |
AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
JP7340591B2 (ja) | 2018-07-11 | 2023-09-07 | アクティム・セラピューティクス・インコーポレイテッド | 遺伝子操作された免疫刺激性細菌菌株およびその使用 |
US20210301020A1 (en) | 2018-07-24 | 2021-09-30 | Amgen Inc. | Combination of lilrb1/2 pathway inhibitors and pd-1 pathway inhibitors |
WO2020031107A1 (en) | 2018-08-08 | 2020-02-13 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds |
WO2020044206A1 (en) | 2018-08-29 | 2020-03-05 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors for use in the treatment cancer |
CN113164466A (zh) | 2018-09-11 | 2021-07-23 | 柯瑞斯公司 | 使用具有锌结合部分的磷酸肌醇3-激酶抑制剂的联合治疗 |
CN113286614A (zh) | 2018-09-26 | 2021-08-20 | 默克专利股份有限公司 | 用于治疗癌症的pd-1拮抗剂、atr抑制剂和铂化物质的组合 |
IL282317B2 (en) | 2018-10-17 | 2024-04-01 | Biolinerx Ltd | Treatment of metastatic adenocarcinoma of the pancreas |
WO2020086476A1 (en) | 2018-10-22 | 2020-04-30 | Glaxosmithkline Intellectual Property Development Limited | Dosing |
KR20210084546A (ko) | 2018-10-29 | 2021-07-07 | 메르사나 테라퓨틱스, 인코포레이티드 | 펩티드 함유 링커를 갖는 시스테인 조작된 항체-약물 접합체 |
US20210395240A1 (en) | 2018-11-01 | 2021-12-23 | Merck Sharp & Dohme Corp. | Novel substituted pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors |
US20210403469A1 (en) | 2018-11-06 | 2021-12-30 | Merck Sharp & Dohme Corp. | Novel substituted tricyclic compounds as indoleamine 2,3-dioxygenase inhibitors |
CA3119563A1 (en) * | 2018-11-14 | 2020-05-22 | Bayer Aktiengesellschaft | Pharmaceutical combination of anti-ceacam6 and either anti-pd-1 or anti-pd-l1 antibodies for the treatment of cancer |
CN113301899A (zh) | 2018-11-16 | 2021-08-24 | 艾科尔公司 | 用于治疗癌症的药物组合 |
EP3883576A4 (en) | 2018-11-20 | 2022-06-22 | Merck Sharp & Dohme Corp. | SUBSTITUTED AMINOTRIAZOLOPYRIMIDINES AND AMINO-TRIAZOLOPYRAZINE ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE |
AU2019383948A1 (en) | 2018-11-20 | 2021-05-20 | Merck Sharp & Dohme Llc | Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use |
EP3886842A1 (en) | 2018-11-26 | 2021-10-06 | Debiopharm International SA | Combination treatment of hiv infections |
US20230008022A1 (en) | 2018-11-28 | 2023-01-12 | Merck Sharp & Dohme Corp. | Novel substituted piperazine amide compounds as indoleamine 2,3-dioxygenase (ido) inhibitors |
JP7241871B2 (ja) | 2018-11-30 | 2023-03-17 | メルク・シャープ・アンド・ドーム・エルエルシー | アデノシン受容体拮抗薬としての9-置換されたアミノトリアゾロキナゾリン誘導体、医薬組成物及びそれらの使用 |
TWI824069B (zh) | 2018-11-30 | 2023-12-01 | 英商葛蘭素史密斯克藍智慧財產發展有限公司 | 用於hiv治療之化合物 |
JP2022511112A (ja) | 2018-12-11 | 2022-01-28 | セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー | Alk5阻害剤としてのナフチリジンおよびキノリン誘導体 |
KR20210106437A (ko) | 2018-12-20 | 2021-08-30 | 노파르티스 아게 | 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물 |
WO2020128893A1 (en) | 2018-12-21 | 2020-06-25 | Pfizer Inc. | Combination treatments of cancer comprising a tlr agonist |
MX2021009763A (es) | 2019-02-15 | 2021-09-08 | Novartis Ag | Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina -2,6-diona y usos de los mismos. |
CA3123519A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
CN109879855B (zh) * | 2019-03-26 | 2021-01-05 | 中国医学科学院医药生物技术研究所 | 靶向肿瘤细胞表面pd-l1分子的抑制剂及其应用 |
US20220177465A1 (en) | 2019-04-04 | 2022-06-09 | Merck Sharp & Dohme Corp. | Inhibitors of histone deacetylase-3 useful for the treatment of cancer, inflammation, neurodegeneration diseases and diabetes |
US11591395B2 (en) | 2019-04-19 | 2023-02-28 | Janssen Biotech, Inc. | Methods of treating prostate cancer with an anti-PSMA/CD3 antibody |
SG11202111106WA (en) | 2019-04-23 | 2021-11-29 | Innate Pharma | Cd73 blocking antibodies |
JP2022533194A (ja) | 2019-05-16 | 2022-07-21 | スティングセラ インコーポレイテッド | ベンゾ[b][1,8]ナフチリジン酢酸誘導体および使用方法 |
WO2020232375A1 (en) | 2019-05-16 | 2020-11-19 | Silicon Swat, Inc. | Oxoacridinyl acetic acid derivatives and methods of use |
AU2020281535A1 (en) | 2019-05-24 | 2022-01-27 | Merck Patent Gmbh | Combination therapies using CDK inhibitors |
EP3990635A1 (en) | 2019-06-27 | 2022-05-04 | Rigontec GmbH | Design method for optimized rig-i ligands |
GB201910304D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
GB201910305D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
CN114269780B (zh) * | 2019-07-19 | 2024-01-19 | 北京先通生物医药技术有限公司 | 一种新型抗pd-l1抗体及其用途 |
US11083705B2 (en) | 2019-07-26 | 2021-08-10 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
JP2022543086A (ja) | 2019-08-02 | 2022-10-07 | メルサナ セラピューティクス インコーポレイテッド | がんの処置用のSTING(インターフェロン遺伝子刺激因子)アゴニストとしてのビス-[N-((5-カルバモイル)-1H-ベンゾ[d]イミダゾール-2-イル)-ピラゾール-5-カルボキサミド]誘導体および関連化合物 |
WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
EP4013512B1 (en) | 2019-09-18 | 2024-02-14 | LamKap Bio alpha AG | Bispecific antibodies against ceacam5 and cd3 |
MX2022002883A (es) | 2019-09-20 | 2022-03-25 | Transgene | Combinacion de un poxvirus que codifica para polipeptidos de virus de papiloma humano (vph) e interleucina 2 (il-2) con un anticuerpo anti ligando 1 de muerte programada (pd-l1). |
JP7280387B2 (ja) | 2019-09-27 | 2023-05-23 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | 抗原結合タンパク質 |
CN114829357A (zh) | 2019-10-28 | 2022-07-29 | 中国科学院上海药物研究所 | 五元杂环氧代羧酸类化合物及其医药用途 |
KR20220092540A (ko) | 2019-10-29 | 2022-07-01 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 암을 치료하기 위한 pd-1 길항제, vegfr/fgfr/ret 티로신 키나제 억제제 및 cbp/베타-카테닌 억제제의 조합물 |
AU2020385400A1 (en) | 2019-11-22 | 2022-06-09 | Theravance Biopharma R&D Ip, Llc | Substituted 1,5-naphthyridines or quinolines as ALK5 inhibitors |
EP3831849A1 (en) | 2019-12-02 | 2021-06-09 | LamKap Bio beta AG | Bispecific antibodies against ceacam5 and cd47 |
EP4069683A1 (en) | 2019-12-06 | 2022-10-12 | Mersana Therapeutics, Inc. | Dimeric compounds as sting agonists |
JP2023507190A (ja) | 2019-12-20 | 2023-02-21 | ノバルティス アーゲー | 増殖性疾患を治療するための抗TGFβ抗体及びチェックポイント阻害薬の使用 |
TW202204339A (zh) | 2020-03-31 | 2022-02-01 | 美商施萬生物製藥研發 Ip有限責任公司 | 經取代的嘧啶及使用方法 |
US20230149543A1 (en) | 2020-04-14 | 2023-05-18 | Glaxosmithkline Intellectual Property Development Limited | Combination treatment for cancer based upon an icos antbody and a pd-l1 antibody tgf-bets-receptor fusion protein |
TW202206100A (zh) | 2020-04-27 | 2022-02-16 | 美商西健公司 | 癌症之治療 |
CA3177442A1 (en) | 2020-05-06 | 2021-11-11 | Brandon D. Cash | Il4i1 inhibitors and methods of use |
US20210387983A1 (en) | 2020-06-10 | 2021-12-16 | Theravance Biopharma R&D Ip, Llc | Crystalline alk5 inhibitors and uses thereof |
WO2021249969A1 (en) | 2020-06-10 | 2021-12-16 | Merck Patent Gmbh | Combination product for the treatment of cancer diseases |
CR20220637A (es) | 2020-06-19 | 2023-01-31 | Hoffmann La Roche | Anticuerpos que se unen a cd3 y cd19 |
WO2021260528A1 (en) | 2020-06-23 | 2021-12-30 | Novartis Ag | Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
US20230293530A1 (en) | 2020-06-24 | 2023-09-21 | Yeda Research And Development Co. Ltd. | Agents for sensitizing solid tumors to treatment |
US20230250173A1 (en) | 2020-07-01 | 2023-08-10 | Pfizer Inc. | Biomarkers for pd-1 axis binding antagonist therapy |
MX2023000197A (es) | 2020-07-07 | 2023-02-22 | BioNTech SE | Arn terapeutico para el cancer positivo para vph. |
WO2022049526A1 (en) | 2020-09-02 | 2022-03-10 | Pharmabcine Inc. | Combination therapy of a pd-1 antagonist and an antagonist for vegfr-2 for treating patients with cancer |
AU2021400227A1 (en) | 2020-12-18 | 2023-04-27 | Lamkap Bio Beta Ltd | Bispecific antibodies against ceacam5 and cd47 |
WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性rna |
WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
AU2022214491A1 (en) | 2021-01-28 | 2023-09-14 | Janssen Biotech, Inc. | Psma binding proteins and uses thereof |
EP4288434A1 (en) | 2021-02-02 | 2023-12-13 | Les Laboratoires Servier | Selective bcl-xl protac compounds and methods of use |
EP4301733A1 (en) | 2021-03-02 | 2024-01-10 | GlaxoSmithKline Intellectual Property Development Limited | Substituted pyridines as dnmt1 inhibitors |
JP2024511373A (ja) | 2021-03-18 | 2024-03-13 | ノバルティス アーゲー | がんのためのバイオマーカーおよびその使用 |
TW202304506A (zh) | 2021-03-25 | 2023-02-01 | 日商安斯泰來製藥公司 | 涉及抗claudin 18.2抗體的組合治療以治療癌症 |
US20240166747A1 (en) | 2021-03-31 | 2024-05-23 | Glazosmithkline Intellectual Property Development Limited | Antigen binding proteins and combinations thereof |
TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途 |
CA3214729A1 (en) | 2021-04-08 | 2022-10-13 | Marilena GALLOTTA | Combination therapies with cbl-b inhibitor compounds |
WO2022214652A1 (en) | 2021-04-09 | 2022-10-13 | Ose Immunotherapeutics | Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains |
IL307419A (en) | 2021-04-09 | 2023-12-01 | Ose Immunotherapeutics | A new scaffold for bifunctional molecules with improved properties |
WO2022227015A1 (en) | 2021-04-30 | 2022-11-03 | Merck Sharp & Dohme Corp. | Il4i1 inhibitors and methods of use |
AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
WO2022251359A1 (en) | 2021-05-26 | 2022-12-01 | Theravance Biopharma R&D Ip, Llc | Bicyclic inhibitors of alk5 and methods of use |
CA3218590A1 (en) | 2021-06-07 | 2022-12-15 | Providence Health & Services - Oregon | Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use |
EP4370552A1 (en) | 2021-07-13 | 2024-05-22 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
CA3227386A1 (en) * | 2021-07-28 | 2023-02-02 | Jianing Huang | Interleukin-2 muteins, fusion proteins, pharmaceutical compositions, and therapeutic applications |
EP4377348A1 (en) | 2021-07-30 | 2024-06-05 | Seagen Inc. | Treatment for cancer |
WO2023039583A1 (en) * | 2021-09-10 | 2023-03-16 | Trustees Of Tufts College | Anti-pd-1 immunoglobulin polypeptides and uses thereof |
WO2023051926A1 (en) | 2021-09-30 | 2023-04-06 | BioNTech SE | Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists |
TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
WO2023079428A1 (en) | 2021-11-03 | 2023-05-11 | Pfizer Inc. | Combination therapies using tlr7/8 agonist |
WO2023083439A1 (en) | 2021-11-09 | 2023-05-19 | BioNTech SE | Tlr7 agonist and combinations for cancer treatment |
US20240117030A1 (en) | 2022-03-03 | 2024-04-11 | Pfizer Inc. | Multispecific antibodies and uses thereof |
WO2023172643A1 (en) * | 2022-03-08 | 2023-09-14 | Whitehead Institute For Biomedical Research | The combination of macrophage-directed immunotherapy and targeted agents for treatment of cancer |
WO2023225320A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
WO2023225336A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
WO2023230541A1 (en) | 2022-05-27 | 2023-11-30 | Viiv Healthcare Company | Piperazine derivatives useful in hiv therapy |
WO2023242351A1 (en) | 2022-06-16 | 2023-12-21 | Lamkap Bio Beta Ag | Combination therapy of bispecific antibodies against ceacam5 and cd47 and bispecific antibodies against ceacam5 and cd3 |
WO2024115725A1 (en) | 2022-12-01 | 2024-06-06 | BioNTech SE | Multispecific antibody against cd40 and cd137 in combination therapy with anti-pd1 ab and chemotherapy |
WO2024126457A1 (en) | 2022-12-14 | 2024-06-20 | Astellas Pharma Europe Bv | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003077914A1 (en) * | 2002-03-13 | 2003-09-25 | Array Biopharma, Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
WO2005121142A1 (en) * | 2004-06-11 | 2005-12-22 | Japan Tobacco Inc. | 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyrido’2,3-d! pyrimidine derivatives and related compounds for the treatment of cancer |
WO2006045514A1 (en) * | 2004-10-20 | 2006-05-04 | Applied Research Systems Ars Holding N.V. | 3-arylamino pyridine derivatives |
WO2007044515A1 (en) * | 2005-10-07 | 2007-04-19 | Exelixis, Inc. | Azetidines as mek inhibitors for the treatment of proliferative diseases |
WO2008024725A1 (en) * | 2006-08-21 | 2008-02-28 | Genentech, Inc. | Aza-benzofuranyl compounds and methods of use |
WO2010077634A1 (en) * | 2008-12-09 | 2010-07-08 | Genentech, Inc. | Anti-pd-l1 antibodies and their use to enhance t-cell function |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4708871A (en) | 1983-03-08 | 1987-11-24 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
WO1984003506A1 (en) | 1983-03-08 | 1984-09-13 | Commw Serum Lab Commission | Antigenically active amino acid sequences |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
NZ215865A (en) | 1985-04-22 | 1988-10-28 | Commw Serum Lab Commission | Method of determining the active site of a receptor-binding analogue |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
US5571689A (en) | 1988-06-16 | 1996-11-05 | Washington University | Method of N-acylating peptide and proteins with diheteroatom substituted analogs of myristic acid |
US5663143A (en) | 1988-09-02 | 1997-09-02 | Dyax Corp. | Engineered human-derived kunitz domains that inhibit human neutrophil elastase |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5750373A (en) | 1990-12-03 | 1998-05-12 | Genentech, Inc. | Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants |
US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
DK0463151T3 (da) | 1990-01-12 | 1996-07-01 | Cell Genesys Inc | Frembringelse af xenogene antistoffer |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
DK0533838T3 (da) | 1990-06-11 | 1998-02-23 | Nexstar Pharmaceuticals Inc | Nukleinsyreligander |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
DE69133476T2 (de) | 1990-08-29 | 2006-01-05 | GenPharm International, Inc., Palo Alto | Transgene Mäuse fähig zur Produktion heterologer Antikörper |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
AU668347B2 (en) | 1990-11-21 | 1996-05-02 | Torrey Pines Institute For Molecular Studies | Synthesis of equimolar multiple oligomer mixtures, especially of oligopeptide mixtures |
ATE207080T1 (de) | 1991-11-25 | 2001-11-15 | Enzon Inc | Multivalente antigen-bindende proteine |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
EP1978033A3 (en) | 1995-04-27 | 2008-12-24 | Amgen Fremont Inc. | Human antibodies derived from immunized xenomice |
WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
JP4215172B2 (ja) | 1996-12-03 | 2009-01-28 | アムジェン フレモント インク. | 複数のV▲下H▼およびV▲下κ▼領域を含むヒトIg遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体 |
ES2375931T3 (es) | 1997-12-05 | 2012-03-07 | The Scripps Research Institute | Humanización de anticuerpo murino. |
AU8856201A (en) * | 2000-09-01 | 2002-03-13 | Andel Inst Van | Inhibition of mitogen-activated protein kinase (mapk) pathway: a selective therapeutic strategy against melanoma |
IL149462A0 (en) | 2001-05-09 | 2002-11-10 | Warner Lambert Co | Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor |
US20040209930A1 (en) | 2002-10-02 | 2004-10-21 | Carboni Joan M. | Synergistic methods and compositions for treating cancer |
US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
AU2003301882A1 (en) | 2002-11-01 | 2004-06-07 | The Regents Of The University Of Colorado, A Body Corporate | Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry |
CA2506085A1 (en) | 2002-11-15 | 2004-06-03 | Ronald Lynn Merriman | Combination chemotherapy comprising a mek inhibitor and capecitabine for treating cancer |
TW200639163A (en) | 2005-02-04 | 2006-11-16 | Genentech Inc | RAF inhibitor compounds and methods |
KR101339628B1 (ko) | 2005-05-09 | 2013-12-09 | 메다렉스, 인코포레이티드 | 예정 사멸 인자 1(pd-1)에 대한 인간 모노클로날 항체, 및 항-pd-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법 |
CN102603581B (zh) | 2005-06-22 | 2015-06-24 | 普莱希科公司 | 作为蛋白质激酶抑制剂的吡咯并[2,3-b]吡啶衍生物 |
KR101888321B1 (ko) | 2005-07-01 | 2018-08-13 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
US7612212B2 (en) | 2006-02-22 | 2009-11-03 | Hoffmann-La Roche Inc. | Substituted hydantoins |
WO2008101840A1 (en) | 2007-02-23 | 2008-08-28 | F. Hoffmann-La Roche Ag | Combination of erlotinib and mek-inhibitors for inhibiting proliferation of tumor cells |
US7919033B2 (en) * | 2007-07-18 | 2011-04-05 | Ngk Insulators, Ltd. | Method of manufacturing honeycomb structure and manufacturing apparatus thereof |
CA2695956A1 (en) | 2007-08-16 | 2009-02-19 | F. Hoffmann-La Roche Ag | Substituted hydantoins |
WO2009064675A1 (en) | 2007-11-12 | 2009-05-22 | Takeda Pharmaceutical Company Limited | Mapk/erk kinase inhibitors |
CA2706926A1 (en) | 2007-11-30 | 2009-06-11 | Bristol-Myers Squibb Company | Anti-b7h4 monoclonal antibody-drug conjugate and methods of use |
MX2010006800A (es) | 2007-12-19 | 2010-10-05 | Genentech Inc | 5-anilinoimidazopiridinas y metodos de uso de las mismas. |
CN101970499B (zh) | 2008-02-11 | 2014-12-31 | 治疗科技公司 | 用于肿瘤治疗的单克隆抗体 |
EP2265609B1 (en) | 2008-02-29 | 2012-09-05 | Array Biopharma, Inc. | Imdizo [4. 5-b] pyridine derivatives used as raf inhibitors |
WO2009111279A1 (en) | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | Pyrazole [3, 4-b] pyridine raf inhibitors |
CA2716949A1 (en) | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer |
PE20091561A1 (es) | 2008-02-29 | 2009-10-30 | Array Biopharma Inc | Compuestos inhibidores de raf y metodos para su uso |
EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
CN102089007B (zh) | 2008-07-11 | 2013-05-15 | 诺瓦提斯公司 | (a)磷酸肌醇3-激酶抑制剂和(b)ras/raf/mek通路调节剂的组合产品 |
PL2350129T3 (pl) | 2008-08-25 | 2015-12-31 | Amplimmune Inc | Kompozycje antagonistów PD-1 i sposoby stosowania |
CA2735006A1 (en) * | 2008-08-25 | 2010-03-11 | Amplimmune, Inc. | Pd-1 antagonists and methods of use thereof |
WO2010056735A1 (en) * | 2008-11-11 | 2010-05-20 | The Trustees Of The University Of Pennsylvania | Compositions and methods for inhibiting an oncogenic protein to enhance immunogenicity |
AU2010314287A1 (en) * | 2009-10-12 | 2012-05-03 | F. Hoffmann-La Roche Ag | Combinations of a PI3K inhibitor and a MEK inhibitor |
WO2011057222A1 (en) | 2009-11-06 | 2011-05-12 | Infinity Pharmaceuticals, Inc. | Oral formulations of a hedgehog pathway inhibitor |
US20110118298A1 (en) | 2009-11-13 | 2011-05-19 | Infinity Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer |
US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
WO2011066389A1 (en) | 2009-11-24 | 2011-06-03 | Medimmmune, Limited | Targeted binding agents against b7-h1 |
PE20170779A1 (es) | 2010-03-04 | 2017-07-04 | Macrogenics Inc | Anticuerpos reactivos con b7-h3, fragmentos inmunologicamente activos de los mismos y usos de los mismos |
EP2580255B1 (en) | 2010-06-11 | 2016-09-07 | The Government of the United States of America as represented by the Secretary of the Navy | Polyarylacetylenes containing siloxane, silane, and carborane moieties |
PE20141693A1 (es) | 2011-08-01 | 2014-11-24 | Genentech Inc | Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1e inhibidores de mek |
AR088509A1 (es) | 2011-10-28 | 2014-06-11 | Genentech Inc | Combinaciones terapeuticas y metodos para tratar el melanoma |
MX2015010777A (es) | 2013-03-14 | 2016-04-25 | Genentech Inc | Anticuerpos e inmunoconjugados anti-b7-h4. |
US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
MA38643A1 (fr) | 2013-06-03 | 2017-10-31 | Novartis Ag | Combinaisons d'un anticorps anti-pd-l1 et d'un inhibiteur de mek et/ou d'un inhibiteur de braf |
BR112017000672A2 (pt) | 2014-07-15 | 2017-11-14 | Genentech Inc | composições para tratamento de câncer utilizando antagonistas de ligação de eixo pd-1 e inibidores de mek |
-
2012
- 2012-08-01 PE PE2014000157A patent/PE20141693A1/es active IP Right Grant
- 2012-08-01 JP JP2014524059A patent/JP6238459B2/ja active Active
- 2012-08-01 AR ARP120102796A patent/AR087405A1/es not_active Application Discontinuation
- 2012-08-01 BR BR122022000334-6A patent/BR122022000334B1/pt active IP Right Grant
- 2012-08-01 EP EP12748808.8A patent/EP2739358B1/en active Active
- 2012-08-01 WO PCT/US2012/049233 patent/WO2013019906A1/en active Application Filing
- 2012-08-01 TW TW109132965A patent/TW202114735A/zh unknown
- 2012-08-01 CA CA2843595A patent/CA2843595C/en active Active
- 2012-08-01 TR TR2018/20873T patent/TR201820873T4/tr unknown
- 2012-08-01 TW TW101127823A patent/TWI654994B/zh active
- 2012-08-01 PE PE2018003248A patent/PE20190262A1/es unknown
- 2012-08-01 PL PL12748808T patent/PL2739358T3/pl unknown
- 2012-08-01 CN CN201280048398.5A patent/CN103842030B/zh active Active
- 2012-08-01 TW TW111100455A patent/TWI835048B/zh active
- 2012-08-01 EA EA201490369A patent/EA026924B1/ru not_active IP Right Cessation
- 2012-08-01 MY MYPI2014000238A patent/MY170117A/en unknown
- 2012-08-01 KR KR1020147005070A patent/KR102049817B1/ko active IP Right Grant
- 2012-08-01 TW TW107113740A patent/TW201840336A/zh unknown
- 2012-08-01 UA UAA201402084A patent/UA117220C2/uk unknown
- 2012-08-01 KR KR1020197034417A patent/KR20190133790A/ko not_active Application Discontinuation
- 2012-08-01 ES ES12748808T patent/ES2708669T3/es active Active
- 2012-08-01 SG SG10201606284UA patent/SG10201606284UA/en unknown
- 2012-08-01 AU AU2012290121A patent/AU2012290121B2/en active Active
- 2012-08-01 BR BR112014002353-0A patent/BR112014002353B1/pt active IP Right Grant
- 2012-08-01 US US14/236,064 patent/US9724413B2/en active Active
- 2012-08-01 MX MX2014001319A patent/MX368257B/es active IP Right Grant
- 2012-08-01 MY MYPI2017001198A patent/MY193562A/en unknown
-
2014
- 2014-01-23 CR CR20140034A patent/CR20140034A/es unknown
- 2014-01-24 ZA ZA2014/00612A patent/ZA201400612B/en unknown
- 2014-01-26 IL IL230647A patent/IL230647B/en active IP Right Grant
- 2014-01-31 MX MX2019011424A patent/MX2019011424A/es unknown
- 2014-02-28 MA MA36788A patent/MA35366B1/fr unknown
- 2014-02-28 CO CO14043469A patent/CO6900118A2/es unknown
- 2014-02-28 EC ECSP14013223 patent/ECSP14013223A/es unknown
-
2016
- 2016-02-22 AU AU2016201086A patent/AU2016201086B2/en active Active
-
2017
- 2017-06-28 US US15/635,920 patent/US10646567B2/en active Active
- 2017-07-14 JP JP2017137983A patent/JP6762274B2/ja active Active
-
2018
- 2018-01-24 AU AU2018200559A patent/AU2018200559B2/en active Active
- 2018-02-15 PH PH12018500365A patent/PH12018500365A1/en unknown
-
2019
- 2019-06-12 JP JP2019109305A patent/JP2019196357A/ja active Pending
- 2019-07-18 AU AU2019206076A patent/AU2019206076A1/en not_active Abandoned
-
2020
- 2020-04-20 IL IL274059A patent/IL274059B/en unknown
-
2021
- 2021-06-25 AR ARP210101755A patent/AR122743A2/es unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003077914A1 (en) * | 2002-03-13 | 2003-09-25 | Array Biopharma, Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
WO2005121142A1 (en) * | 2004-06-11 | 2005-12-22 | Japan Tobacco Inc. | 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyrido’2,3-d! pyrimidine derivatives and related compounds for the treatment of cancer |
WO2006045514A1 (en) * | 2004-10-20 | 2006-05-04 | Applied Research Systems Ars Holding N.V. | 3-arylamino pyridine derivatives |
WO2007044515A1 (en) * | 2005-10-07 | 2007-04-19 | Exelixis, Inc. | Azetidines as mek inhibitors for the treatment of proliferative diseases |
WO2008024725A1 (en) * | 2006-08-21 | 2008-02-28 | Genentech, Inc. | Aza-benzofuranyl compounds and methods of use |
WO2010077634A1 (en) * | 2008-12-09 | 2010-07-08 | Genentech, Inc. | Anti-pd-l1 antibodies and their use to enhance t-cell function |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI835048B (zh) | 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法 | |
US20220105180A1 (en) | Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors | |
NZ620411B2 (en) | Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors |